<SEC-DOCUMENT>0001493152-21-028506.txt : 20211115
<SEC-HEADER>0001493152-21-028506.hdr.sgml : 20211115
<ACCEPTANCE-DATETIME>20211115150037
ACCESSION NUMBER:		0001493152-21-028506
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		56
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211115
DATE AS OF CHANGE:		20211115

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		211409459

	BUSINESS ADDRESS:	
		STREET 1:		1330 AVENUE OF THE AMERICAS, 33RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		646-813-4701

	MAIL ADDRESS:	
		STREET 1:		1330 AVENUE OF THE AMERICAS, 33RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10-q.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:abeo="http://abeonatherapeutics.com/20210930">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_039_abeo_abeonatherapeutics.com_20210930 -->
<!-- Field: Set; Name: xdx; ID: xdx_04B_20210101_20210930 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000318306 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DDocumentFiscalPeriodFocus_Q3 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_070_XDX_form10%2Dq.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityCentralIndexKey">0000318306</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-09-30" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:DocumentFiscalPeriodFocus">Q3</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:LoansPayableCurrent" contextRef="AsOf2021-09-30" id="xdx2ixbrl0091" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermLoansPayable" contextRef="AsOf2021-09-30" id="xdx2ixbrl0103" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DueToRelatedPartiesNoncurrent" contextRef="AsOf2020-12-31" id="xdx2ixbrl0107" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2021-09-30" id="xdx2ixbrl0115" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2020-12-31" id="xdx2ixbrl0116" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-07-012021-09-30" id="xdx2ixbrl0155" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-01to2021-09-30" id="xdx2ixbrl0157" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2021-07-012021-09-30" id="xdx2ixbrl0180" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2020-07-012020-09-30" id="xdx2ixbrl0181" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2021-01-01to2021-09-30" id="xdx2ixbrl0182" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="abeo:GainOnSettlementOfRelatedParty" contextRef="From2020-07-012020-09-30" id="xdx2ixbrl0196" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="abeo:GainOnSettlementOfRelatedParty" contextRef="From2020-01-012020-09-30" id="xdx2ixbrl0198" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="abeo:PppLoanPayableForgivenessIncome" contextRef="From2020-07-012020-09-30" id="xdx2ixbrl0201" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="abeo:PppLoanPayableForgivenessIncome" contextRef="From2020-01-012020-09-30" id="xdx2ixbrl0203" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2020-07-012020-09-30" id="xdx2ixbrl0241" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2020-01-012020-09-30" id="xdx2ixbrl0243" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0258" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0260" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-07-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0261" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0264" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2021-07-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-07-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" contextRef="From2021-07-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" contextRef="From2021-07-012021-09-30" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-07-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-07-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0340" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2020-07-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="abeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod" contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="abeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod" contextRef="From2020-07-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0349" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="abeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod" contextRef="From2020-07-012020-09-30" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0360" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" contextRef="From2021-01-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" contextRef="From2021-01-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" contextRef="From2021-01-01to2021-09-30" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0423" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-01-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-01-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0440" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0445" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0447" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0448" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0451" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2020-01-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0453" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2020-01-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0454" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0459" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0460" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" contextRef="From2020-01-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0467" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" contextRef="From2020-01-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0468" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" contextRef="From2020-01-012020-09-30" id="xdx2ixbrl0469" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0473" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0474" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0476" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0479" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-01-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0480" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-01-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0481" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-01-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0486" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-01-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0487" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2021-01-01to2021-09-30" id="xdx2ixbrl0508" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="abeo:GainOnSettlementOfRelatedParty" contextRef="From2020-01-012020-09-30" id="xdx2ixbrl0512" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="abeo:PppLoanPayableForgivenessIncome" contextRef="From2020-01-012020-09-30" id="xdx2ixbrl0515" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestExpenseOther" contextRef="From2021-01-01to2021-09-30" id="xdx2ixbrl0517" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInReceivables" contextRef="From2021-01-01to2021-09-30" id="xdx2ixbrl0538" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromShortTermDebt" contextRef="From2021-01-01to2021-09-30" id="xdx2ixbrl0574" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2020-01-012020-09-30" id="xdx2ixbrl0578" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2021-01-01to2021-09-30" id="xdx2ixbrl0607" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2020-01-012020-09-30" id="xdx2ixbrl0608" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-01-01to2021-09-30" id="xdx2ixbrl0610" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2020-01-012020-09-30" id="xdx2ixbrl0611" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-09-30_custom_ShortTermInvestmentMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0778" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-09-30_custom_ShortTermInvestmentMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0782" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="abeo:FairValueDisclosureOfGainLoss" contextRef="AsOf2021-09-30_custom_ShortTermInvestmentMember_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0784" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-09-30_custom_LicensedTechnologyNetMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsNonrecurringMember" id="xdx2ixbrl0788" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-09-30_custom_LicensedTechnologyNetMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsNonrecurringMember" id="xdx2ixbrl0790" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="abeo:FairValueDisclosureOfGainLoss" contextRef="AsOf2021-09-30_custom_LicensedTechnologyNetMember_us-gaap_FairValueMeasurementsNonrecurringMember" id="xdx2ixbrl0794" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-09-30_us-gaap_GoodwillMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsNonrecurringMember" id="xdx2ixbrl0798" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-09-30_us-gaap_GoodwillMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsNonrecurringMember" id="xdx2ixbrl0800" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="abeo:FairValueDisclosureOfGainLoss" contextRef="AsOf2021-09-30_us-gaap_GoodwillMember_us-gaap_FairValueMeasurementsNonrecurringMember" id="xdx2ixbrl0804" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_custom_ShortTermInvestmentMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0808" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_custom_ShortTermInvestmentMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0812" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="abeo:FairValueDisclosureOfGainLoss" contextRef="AsOf2020-12-31_custom_ShortTermInvestmentMember_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0814" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_custom_LicensedTechnologyNetMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsNonrecurringMember" id="xdx2ixbrl0818" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_custom_LicensedTechnologyNetMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsNonrecurringMember" id="xdx2ixbrl0820" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_GoodwillMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsNonrecurringMember" id="xdx2ixbrl0828" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_GoodwillMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsNonrecurringMember" id="xdx2ixbrl0830" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="abeo:FairValueDisclosureOfGainLoss" contextRef="AsOf2020-12-31_us-gaap_GoodwillMember_us-gaap_FairValueMeasurementsNonrecurringMember" id="xdx2ixbrl0834" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2020-07-012020-09-30_us-gaap_RestrictedStockMember16575765" id="xdx2ixbrl0949" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-07-012020-09-30_us-gaap_RestrictedStockMember16575765" id="xdx2ixbrl0964" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="abeo-20210930.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-01-01to2021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-10-31_custom_PreFundedWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abeo:PreFundedWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abeo:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abeo:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abeo:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abeo:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-11-032018-11-04_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-11-03</xbrli:startDate>
        <xbrli:endDate>2018-11-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-11-04_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-11-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-11-04_srt_MaximumMember_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-11-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-032020-11-04_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-03</xbrli:startDate>
        <xbrli:endDate>2020-11-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-04_custom_OriginalLicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abeo:OriginalLicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-04_custom_AmendedAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abeo:AmendedAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-04_custom_AprilOneTwentyTwentyMember_custom_AmendedAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">abeo:AprilOneTwentyTwentyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abeo:AmendedAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-292020-04-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-03-29</xbrli:startDate>
        <xbrli:endDate>2020-04-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-032020-11-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-03</xbrli:startDate>
        <xbrli:endDate>2020-11-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-302020-04-02_custom_REGENXBIOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-03-30</xbrli:startDate>
        <xbrli:endDate>2020-04-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-242020-05-25_custom_REGENXBIOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-24</xbrli:startDate>
        <xbrli:endDate>2020-05-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-122020-07-13_custom_REGENXBIOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-12</xbrli:startDate>
        <xbrli:endDate>2020-07-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-12_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_custom_REGENXBIOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abeo:SettlementAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-12_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_custom_REGENXBIOMember_custom_OneBusinessDayMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abeo:SettlementAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">abeo:OneBusinessDayMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-12_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_custom_REGENXBIOMember_custom_FirstAnniversaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abeo:SettlementAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">abeo:FirstAnniversaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-12_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_custom_REGENXBIOMember_custom_ThirdAnniversaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abeo:SettlementAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">abeo:ThirdAnniversaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-05-142015-05-15_custom_AbeonaTherapeuticsLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abeo:AbeonaTherapeuticsLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-05-14</xbrli:startDate>
        <xbrli:endDate>2015-05-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-012020-05-02_custom_PaycheckProtectionProgramMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abeo:PaycheckProtectionProgramMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-01</xbrli:startDate>
        <xbrli:endDate>2020-05-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_ShortTermInvestmentMember_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:ShortTermInvestmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_ShortTermInvestmentMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:ShortTermInvestmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_ShortTermInvestmentMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:ShortTermInvestmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_ShortTermInvestmentMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:ShortTermInvestmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_LicensedTechnologyNetMember_us-gaap_FairValueMeasurementsNonrecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:LicensedTechnologyNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_LicensedTechnologyNetMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsNonrecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:LicensedTechnologyNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_LicensedTechnologyNetMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsNonrecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:LicensedTechnologyNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_LicensedTechnologyNetMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsNonrecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:LicensedTechnologyNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_GoodwillMember_us-gaap_FairValueMeasurementsNonrecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_GoodwillMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsNonrecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_GoodwillMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsNonrecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_GoodwillMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsNonrecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ShortTermInvestmentMember_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:ShortTermInvestmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ShortTermInvestmentMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:ShortTermInvestmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ShortTermInvestmentMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:ShortTermInvestmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ShortTermInvestmentMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:ShortTermInvestmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_LicensedTechnologyNetMember_us-gaap_FairValueMeasurementsNonrecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:LicensedTechnologyNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_LicensedTechnologyNetMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsNonrecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:LicensedTechnologyNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_LicensedTechnologyNetMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsNonrecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:LicensedTechnologyNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_LicensedTechnologyNetMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsNonrecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:LicensedTechnologyNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_GoodwillMember_us-gaap_FairValueMeasurementsNonrecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_GoodwillMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsNonrecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_GoodwillMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsNonrecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_GoodwillMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsNonrecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_EmployeeStockOptionMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abeo:StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_EmployeeStockOptionMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abeo:StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abeo:StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abeo:StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_RestrictedStockMember16575609">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_RestrictedStockMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_RestrictedStockMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_RestrictedStockMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_RestrictedStockMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_RestrictedStockMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_RestrictedStockMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_RestrictedStockMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_RestrictedStockMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_RestrictedStockMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abeo:StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_RestrictedStockMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abeo:StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_RestrictedStockMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abeo:StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_RestrictedStockMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abeo:StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_RestrictedStockMember16575765">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-09-30_us-gaap_RestrictedStockMember16575765">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-09-30_us-gaap_RestrictedStockMember16575781">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000318306</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b>Washington,
DC 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif">FORM
<span id="xdx_908_edei--DocumentType_c20210101__20210930_zsXjVUtsvwp3"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:DocumentType">10-Q</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">(Mark
one)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; layout-grid-mode: line"><span id="xdx_90F_edei--DocumentQuarterlyReport_c20210101__20210930_zARZCRupvn2i"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For
    the quarterly period ended <span id="xdx_907_edei--DocumentPeriodEndDate_c20210101__20210930_z1z2HmdfNMa8"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September 30, <span id="xdx_902_edei--DocumentFiscalYearFocus_c20210101__20210930_z7BdCP1Ir5ee"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:DocumentFiscalYearFocus">2021</ix:nonNumeric></span></ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>or</b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span id="xdx_90B_edei--DocumentTransitionReport_c20210101__20210930_zljBEEs5TkVb"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif"><b>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For
the transition period from ____________ to ____________</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Commission
file number <b><span id="xdx_909_edei--EntityFileNumber_c20210101__20210930_zYlWKNuVcK3b"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityFileNumber">001-15771</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_907_edei--EntityRegistrantName_c20210101__20210930_zkPTQkPbkhR7"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityRegistrantName">ABEONA
THERAPEUTICS INC.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; layout-grid-mode: line; width: 49%; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20210101__20210930_zGfS4VNvqSsc"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; layout-grid-mode: line; width: 2%; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; layout-grid-mode: line; width: 49%; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_904_edei--EntityTaxIdentificationNumber_c20210101__20210930_zS4rMguqtbv6"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityTaxIdentificationNumber">83-0221517</ix:nonNumeric></span>
    </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; layout-grid-mode: line; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">(State
    or other jurisdiction of</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; layout-grid-mode: line; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; layout-grid-mode: line; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">(I.R.S.
    Employer I.D. No.)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; layout-grid-mode: line; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;incorporation
    or organization)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; layout-grid-mode: line; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; layout-grid-mode: line; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_903_edei--EntityAddressAddressLine1_c20210101__20210930_zmzyBRVMPdNe"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityAddressAddressLine1">1330
Avenue of the Americas</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressAddressLine2_c20210101__20210930_zvZpEudntpx4"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityAddressAddressLine2">33rd Floor</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressCityOrTown_c20210101__20210930_zJ9xAdRgYWtg"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressStateOrProvince_c20210101__20210930_zb4OJb6AgHGk"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_907_edei--EntityAddressPostalZipCode_c20210101__20210930_z0JJC3wKnz0j"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityAddressPostalZipCode">10019</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Address
of principal executive offices, zip code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">(<span id="xdx_90F_edei--CityAreaCode_c20210101__20210930_zUG3tMm50ZL1"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:CityAreaCode">646</ix:nonNumeric></span>)
<span id="xdx_903_edei--LocalPhoneNumber_c20210101__20210930_zBZEHH7K6Xqk"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:LocalPhoneNumber">813-4701</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 95%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 36%; layout-grid-mode: line; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; width: 2%; layout-grid-mode: line; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 24%; layout-grid-mode: line; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Trading
    Symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; width: 2%; layout-grid-mode: line; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 36%; layout-grid-mode: line; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; layout-grid-mode: line; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_edei--Security12bTitle_c20210101__20210930_zziRdLsel2ah"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:Security12bTitle">Common
    Stock, $0.01 par value</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; layout-grid-mode: line; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; layout-grid-mode: line; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_edei--TradingSymbol_c20210101__20210930_zzwV1ERqBMMa"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:TradingSymbol">ABEO</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; layout-grid-mode: line; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; layout-grid-mode: line; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_edei--SecurityExchangeName_c20210101__20210930_zklbVuX4If39"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Markets</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_edei--EntityCurrentReportingStatus_c20210101__20210930_zfhKZ2vFJIsi"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>
&#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_902_edei--EntityInteractiveDataCurrent_c20210101__20210930_zclyKs8MUxUf"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 34%; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 33%; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 33%; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">Accelerated
    filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_edei--EntityFilerCategory_c20210101__20210930_zbHdJXDZzO21"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> &#9746; </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">Smaller
    reporting company <span id="xdx_901_edei--EntitySmallBusiness_c20210101__20210930_zUyjflvzTBd1"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Emerging
growth company <span id="xdx_909_edei--EntityEmergingGrowthCompany_c20210101__20210930_zWPiPeTcXzld"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; <span id="xdx_90F_edei--EntityShellCompany_c20210101__20210930_zGjqSSMNPb9i"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
number of shares outstanding of the registrant&#8217;s common stock as of November 8, 2021 was <span id="xdx_909_edei--EntityCommonStockSharesOutstanding_iI_c20211108_zviEigsTeCc2" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2021-11-08" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">101,917,914</ix:nonFraction></span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: double">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: double"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-underline-style: double">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ABEONA
THERAPEUTICS INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">INDEX</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; layout-grid-mode: line">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; layout-grid-mode: line">Page
No.</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; layout-grid-mode: line">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: center; layout-grid-mode: line">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#pri_001">PART I - FINANCIAL INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; width: 0.15in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; width: 0.75in">Item
    1. </td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><a href="#pri_002">Financial Statements:</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line; width: 0.75in">3</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#pri_003">Condensed Consolidated Balance Sheets at September 30, 2021 (Unaudited) and December 31, 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><a href="#pri_004">Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) for the three and nine months ended September 30, 2021 and 2020</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><a href="#pri_005">Condensed Consolidated Statements of Stockholders&#8217; Equity (Unaudited) for the three and nine months ended September 30, 2021 and 2020</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><a href="#pri_006">Condensed Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2021 and 2020</a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#pri_007">Notes to Condensed Consolidated Financial Statements (Unaudited)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#ar_001">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line">14</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#ar_002">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">19</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#ar_003">Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">19</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#ar_004">PART II - OTHER INFORMATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#ar_005">Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">20</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#ar_006">Risk Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">20</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#ar_007">Exhibits</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">22</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#ar_008">SIGNATURES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">23</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>FORWARD-LOOKING
STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>This
Form 10-Q contains statements that express management&#8217;s opinions, expectations, beliefs, plans, objectives, assumptions or projections
regarding future events or future results and therefore are, or may be deemed to be, &#8220;forward-looking statements&#8221; within
the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Words such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221;
&#8220;would,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; and variations of such words and similar expressions, and the negatives
thereof, are intended to identify such forward-looking statements. Such &#8220;forward-looking statements&#8221; speak only as of the
date made and are not guarantees of future performance and involve certain risks, uncertainties, estimates, and assumptions by management
that are difficult to predict. Various factors, some of which are beyond the Company&#8217;s control, could cause actual results to differ
materially from those expressed in, or implied by, such forward-looking statements. In addition, we disclaim any obligation to update
any forward-looking statements to reflect events or circumstances after the date of this report, except as may otherwise be required
by the federal securities laws.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Forward-looking
statements necessarily involve risks and uncertainties, and our actual results could differ materially from those anticipated in forward-looking
statements due to a number of factors. These statements include statements about: the potential impacts of the COVID-19 pandemic on our
business, operations, and financial condition; the achievement of or expected timing, progress and results of clinical development, clinical
trials and potential regulatory approvals; our Phase 3 clinical trial (VIITAL&#8482;) for patients with recessive dystrophic epidermolysis
bullosa (&#8220;RDEB&#8221;) and our beliefs relating thereto; our ability to identify and enroll patients in the Phase 3 clinical trial;
our pipeline of product candidates; our belief that we have sufficient resources on hand, access to additional financial resources and/or
financial flexibility to fund operations for at least the next 12 months from the date of filing of this report;  our belief that EB-101 could potentially benefit patients with RDEB; our belief
that adeno-associated virus (&#8220;AAV&#8221;) gene therapy could potentially benefit patients with Sanfilippo syndrome type A (&#8220;MPS
IIIA&#8221;) and Sanfilippo syndrome type B (&#8220;MPS IIIB&#8221;); our ability to develop our novel AAV-based gene therapy platform
technology; our belief in the adequacy of the data from clinical trials, including VIITAL&#8482; and our Phase 1/2 clinical trials in
ABO-102 (AAV-SGSH) for MPS IIIA and ABO-101 (AAV-NAGLU) for MPS IIIB, together with the data generated in the program to date, to support
regulatory approvals; the existence of intellectual property, a license to which might be required to market MPS IIIA and MPS IIIB; our
dependence upon our third-party and related-party customers and vendors and their compliance with regulatory bodies; our intellectual
property position and our ability to obtain, maintain and enforce intellectual property protection and exclusivity for our proprietary
assets; our estimates regarding the size of the potential markets for our product candidates, the strength of our commercialization strategies
and our ability to serve and supply those markets; and future economic conditions or performance.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Important
factors that could affect performance and cause results to differ materially from management&#8217;s expectations are described in the
sections entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results
of Operations&#8221; in the Company&#8217;s Form 10-K for the fiscal year ended December 31, 2020, as updated from time to time in the
Company&#8217;s Securities and Exchange Commission filings, including this Form 10-Q. These factors include: the impact of the COVID-19
pandemic on our business, operations (including our clinical trials), and financial condition, and on our ability to access the capital
markets; our ability to access our existing at-the-market sale agreement and any dilution that may result from accessing such sales agreement;
our estimates regarding expenses, future revenues, capital requirements, and needs for additional financing; our ability to raise capital;
our ability to fund our operating expenses and capital expenditure requirements for at least the next 12 months given our existing cash,
cash equivalents and short-term investments, our ability to access additional financial resources and/or our financial flexibility to
reduce operating expenses if required; our ability to obtain additional equity funding from current or new stockholders, out-licensing
technology and/or other assets, deferring and/or eliminating planned expenditures, restructuring operations and/or reducing headcount,
and sales of assets; the dilutive effect that raising additional funds by selling additional equity securities would have on the relative
equity ownership of our existing investors, including under our existing at-the-market sale agreement; our ability to continue to develop our novel AAV-based gene therapy platform technology; the outcome of any interactions
with the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory agencies relating to any of our products or product
candidates; our ability to execute a Phase 3 clinical trial for patients with RDEB; our ability to complete enrollment of patients into
clinical trials to secure sufficient data to assess efficacy and safety; our ability to identify additional patients for our Phase 1/2
clinical trial for patients with MPS IIIA and MPS IIIB; our ability to continue to secure and maintain regulatory designations for our
product candidates; our ability to develop manufacturing capabilities compliant with current good manufacturing practices for our product
candidates; our ability to manufacture gene and cell therapy products and produce an adequate product supply to support clinical trials
and potentially future commercialization; the rate and degree of market acceptance of our product candidates for any indication once
approved; and our ability to meet our obligations contained in license agreements to which we are party.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="pri_001"></span>PART
I &#8211; FINANCIAL INFORMATION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="pri_002"></span>ITEM
1. FINANCIAL STATEMENTS</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="pri_003"></span>Abeona
Therapeutics Inc. and Subsidiaries</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Condensed
Consolidated Balance Sheets</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_111_zxrlrpTlODC6" summary="xdx: Statement - Condensed Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20210930_zy6SozsKCUTg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20201231_zLgZOM0Ejuxi" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AssetsAbstract_iB_zVcUiD4WbXzg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetsCurrentAbstract_i01B_zLQ7VVUtVLm8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzwQ7_zYVXAqBfOiAj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,781,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,596,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShortTermInvestments_i02I_maCzwQ7_zimvo5H491G9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,217,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,438,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzwQ7_zeYcScdPU5Ea" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">907,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,708,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsCurrent_i02TI_mtCzwQ7_maCzTlu_zUvoFUe5TUni" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,905,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">97,742,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCzTlu_zcw9NQjhyLjb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,869,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,322,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maCzTlu_ziOqP9vdX6Zb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use lease assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,207,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,032,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_i01I_maCzTlu_zmBWZ0DHuk68" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Licensed technology, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,413,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Goodwill_i01I_maCzTlu_zdjkDTRqEnng" style="vertical-align: bottom; background-color: White">
    <td>Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,466,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,466,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--OtherAssetsAndRestrictedCash_i01I_maCzTlu_zxgeWSQGgktk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other assets and restricted cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="abeo:OtherAssetsAndRestrictedCash" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,159,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="abeo:OtherAssetsAndRestrictedCash" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,136,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--Assets_i01TI_mtCzTlu_zr4yTdb6fZld" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119,019,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,198,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrentAbstract_i01B_zvvDrrRK3iHk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_i02I_maCzwPh_maLCzo9g_zlr7Pwb9nLpl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,861,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,695,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzwPh_maLCzo9g_zXu6LRBzTVE1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,593,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,410,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCzwPh_maLCzo9g_zFv9UhKP4W7e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Current portion of lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,723,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,713,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LoansPayableCurrent_i02I_pp0p0_maLCzo9g_zfWw9pqbmYU" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Current portion of PPP loan payable</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0091">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LoansPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">330,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DueToRelatedPartiesCurrent_i02I_maCzwPh_maLCzo9g_zLtKNmTaqGKe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Current portion of payable to licensor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,515,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredRevenueCurrent_i02I_maCzwPh_maLCzo9g_zRzM91Mhlwph" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Contract liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">296,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">296,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesCurrent_i02TI_maCzxlH_mtLCzo9g_zktFk2x05EU7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,473,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,959,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LongTermLoansPayable_i01I_maCzxlH_zqwFF7KkaE3d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">PPP loan payable</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0103">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermLoansPayable" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,428,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DueToRelatedPartiesNoncurrent_i01I_maCzxlH_z4b2Y9jIqUmk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Payable to licensor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:DueToRelatedPartiesNoncurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,360,000</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0107">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maCzxlH_zHUBK5iKtsXk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Long-term lease liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,442,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,260,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Liabilities_i01TI_mtCzxlH_maCzqQF_maLASEzX3q_zToGokT7S2Ze" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,275,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,647,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommitmentsAndContingencies_i01I_maCzqQF_zzl0ai23YSsk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Commitments and contingencies</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0115">&#160;</span></td><td style="display: none; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0116">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif; display: none">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CommonStockValue_i02I_maCzVDy_maSEzFyR_zkG90sGmm1Li" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock - $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20210930_pdd" title="Common stock, par value"><span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_c20201231_pdd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></ix:nonFraction></span></span> par value; authorized <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_c20210930_pdd" title="Common stock, shares authorized"><span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_c20201231_pdd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000,000</ix:nonFraction></ix:nonFraction></span></span> shares; &#160;issued and outstanding <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_c20210930_pdd" title="Common stock, shares issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_c20210930_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">101,867,539</ix:nonFraction></ix:nonFraction></span></span> at September 30, 2021; issued and outstanding <span id="xdx_900_eus-gaap--CommonStockSharesIssued_c20201231_pdd" title="Common stock, shares issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_c20201231_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,131,678</ix:nonFraction></ix:nonFraction></span></span> at December 31, 2020;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,019,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">961,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AdditionalPaidInCapitalCommonStock_i02I_maCzVDy_maSEzFyR_zi75BNU20S21" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">687,691,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">672,304,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCzVDy_maSEzFyR_zIsD5A0veQff" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">608,957,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">570,704,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_maCzVDy_maSEzFyR_z3M8tHXQrRYj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Accumulated other comprehensive loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--StockholdersEquity_i02TI_pp0p0_mtSEzFyR_maLASEzX3q_zp6aAC01aLXh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">79,744,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">102,551,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzX3q_ziTxVlxIVQvb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">119,019,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">151,198,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying notes are an integral part of these condensed consolidated statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="pri_004"></span>Abeona
Therapeutics Inc. and Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.05in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Condensed
Consolidated Statements of Operations and Comprehensive Loss</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.05in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.05in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_113_z8LG57gT858e" summary="xdx: Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_498_20210701__20210930_zo71IIp7hAu2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_498_20200701__20200930_zbvJCj87nPxg">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_494_20210101__20210930_zXfR1Lj7kfsi">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_498_20200101__20200930_zXoDjcFao65">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended<br />
 September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the nine months ended<br />
 September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maCz3hB_zhcqa0hGQyGf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold; padding-bottom: 1pt">Revenues</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0155">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0157">-</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingExpensesAbstract_iB_zorZjyEkHWj3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_i01_maCz16i_zhwQLy5E1mQj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,978,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,969,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,624,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,896,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_i01_maCz16i_zUeiO9pxdUk5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,092,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,432,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,117,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,382,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DepreciationDepletionAndAmortization_i01_maCz16i_zsrcAtC38ev9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">802,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">847,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,443,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,746,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherCostAndExpenseOperating_i01_maCz16i_z9Vgv4n5eIC8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Licensed technology impairment charge</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0180">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0181">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0182">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,916,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingExpenses_i01T_mtCz16i_msCz3hB_zglYxQWfhXli" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,872,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,248,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,184,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,940,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingIncomeLoss_iT_mtCz3hB_maCz7EJ_maNILz7Xk_z42saUBHv26h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,872,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,248,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">43,184,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">66,940,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--GainOnSettlementOfRelatedParty_maNILz7Xk_zwTs4XnOr0Sh" style="vertical-align: bottom; background-color: White">
    <td><p style="margin: 0">Gain on settlement with licensor</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="abeo:GainOnSettlementOfRelatedParty" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,743,000</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0196">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="abeo:GainOnSettlementOfRelatedParty" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,743,000</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0198">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--PppLoanPayableForgivenessIncome_maNILz7Xk_zHWKhBwpY0vk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">PPP loan payable forgiveness income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="abeo:PppLoanPayableForgivenessIncome" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,758,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0201">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="abeo:PppLoanPayableForgivenessIncome" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,758,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0203">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--InterestAndMiscellaneousIncome_maCz7EJ_maNILz7Xk_zO9pxTG6FHo9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest and miscellaneous income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="abeo:InterestAndMiscellaneousIncome" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="abeo:InterestAndMiscellaneousIncome" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">338,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="abeo:InterestAndMiscellaneousIncome" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="abeo:InterestAndMiscellaneousIncome" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,261,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InterestExpense_iN_di_msCz7EJ_msNILz7Xk_zrjU41FS2ZJ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Interest expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">683,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,327,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,603,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,727,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_iT_mtNILz7Xk_maCINOTzuZ6_maCINOTzz5z_z5iTY9NL7Ie1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,044,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,237,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">38,253,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">68,406,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EarningsPerShareBasicAndDiluted_zUGJAX9CI8r3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted loss per common share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.07</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.08</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.40</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.74</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_i_pdd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted average number of common shares outstanding &#8211; basic and
    diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">97,990,338</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">92,714,983</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,258,681</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">92,594,339</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherComprehensiveIncomeLossTaxAbstract_iB_z3IiaoEi2sZc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other comprehensive income/(loss):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_i01_pp0p0_maCINOTzz5z_zVDjvg4MhWt2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in unrealized gains/(losses) related to available-for-sale debt securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">116,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_i01_msCINOTzuZ6_maCINOTzz5z_zm550Kw590a9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0241">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0243">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ComprehensiveIncomeNetOfTax_i01_mtCINOTzz5z_zNlY0VmdOEs7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Comprehensive loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,052,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,353,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">38,252,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">68,389,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.05in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying notes are an integral part of these condensed consolidated statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.05in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="pri_005"></span>Abeona
Therapeutics Inc. and Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Condensed
Consolidated Statements of Stockholders&#8217; Equity</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_114_zuOtXuvipYg2" summary="xdx: Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zze99Yhvasb2" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zWLsEoPd0CZf" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zb4qQFobIb13" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_z4lT8jFtyVX9" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B5_zXXJKwcgYRrg" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Paid-in</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Comprehensive</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Stockholders&#8217;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Income/(Loss)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">For the three months ended September 30, 2021</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_43A_c20210701__20210930_eus-gaap--StockholdersEquity_iS_zvwsnJVGjAie" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Balance, June 30, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRGu0kuVgEFj" title="Beginning balance, shares" style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">101,251,023</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,013,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">684,987,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">601,913,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,086,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zZtFPtRdZLLg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock option-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0258">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,387,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0260">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0261">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,387,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_zCNgtcbMDr4g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0264">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,150,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0266">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0267">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,150,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod_z3nMulu2686j" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cancellation of restricted share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited_zDZC4POhvqK1" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cancellation of restricted share awards, shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zrYx2oYF24Je" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock issued for cash exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpgdGtvBRgG1" title="Common stock issued for cash exercise of options, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">121,950</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0284">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0285">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">140,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations_zFLrlUsbxg98" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock in connection with restricted share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQ8mMfZGO5lf" title="Issuance of common stock in connection with restricted share awards, shares" style="text-align: right"><ix:nonFraction name="abeo:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">474,825</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0292">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0293">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0294">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueOther_z9oo6AEjVKC1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock issued for cash under open market sale agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesOther_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjFD2HbnYeVk" title="Common stock issued for cash under open market sale agreement, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,741</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0298">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0300">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0301">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zhb1HdjV5zi8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0306">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,044,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0309">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,044,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_z4FOHv2LhPee" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other comprehensive loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0312">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0313">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0314">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-07-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_431_c20210701__20210930_eus-gaap--StockholdersEquity_iE_zFr4pJO0Az69" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Balance, September 30, 2021</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_c20210701__20210930_zhOygiaTxrye" title="Ending balance, shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">101,867,539</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,019,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">687,691,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">608,957,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,744,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">For the three months ended September 30, 2020</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43B_c20200701__20200930_eus-gaap--StockholdersEquity_iS_zSakTosURK69" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, June 30, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_c20200701__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwdV1gVXb454" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">84,781,241</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">848,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">667,712,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">547,639,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">133,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,054,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zMOJJbLjF7u8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock option-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,249,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,249,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_zT9BDM8n7Ymh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0340">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0342">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0343">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod_zffkc2AnWAab" style="vertical-align: bottom; background-color: White">
    <td>Cancellation of restricted share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited_c20200701__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEMyANe3pGaf" title="Cancellation of restricted share awards, shares" style="text-align: right">(<ix:nonFraction name="abeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">265,080</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="abeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod" contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="abeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod" contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0348">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0349">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0350">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zr8KhYy4Ymdk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0354">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0355">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,237,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,237,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_zO0QCqry3Jn3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other comprehensive loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0360">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0361">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0362">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-07-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">116,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">116,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43B_c20200701__20200930_eus-gaap--StockholdersEquity_iE_zIENhkHkP108" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Balance, September 30, 2020</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_c20200701__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRGnotTca2Hk" title="Ending balance, shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">84,516,161</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">845,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">669,125,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">554,876,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115,111,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">For the nine months ended September 30, 2021</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20210101__20210930_eus-gaap--StockholdersEquity_iS_zytmFgWmcg66" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCHz7VFxjbAb" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">96,131,678</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">961,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">672,304,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">570,704,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,551,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zsyYs0MiOplj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock option-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0381">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,797,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0384">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,797,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_z3jYXpfougsi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0387">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2021-01-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,118,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0389">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0390">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,118,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zlHqlUm4nIJf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock issued for cash exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvRae7StTToe" title="Common stock issued for cash exercise of options, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">630,675</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">825,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0395">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0396">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">831,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations_zBrrAhQk7s53" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock in connection with restricted share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWya4Iud0z72" title="Issuance of common stock in connection with restricted share awards, shares" style="text-align: right"><ix:nonFraction name="abeo:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,021,900</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" contextRef="From2021-01-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0404">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0405">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueOther_zebJNirHylH6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock issued for cash under open market sale agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesOther_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFDvf3Cql7Fl" title="Common stock issued for cash under open market sale agreement, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,083,286</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,667,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0411">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0412">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,699,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zShnGBQb0zZh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0417">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0418">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">38,253,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0420">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">38,253,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_zMyV4D2ltTC9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other comprehensive income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0423">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0425">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-01-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43B_c20210101__20210930_eus-gaap--StockholdersEquity_iE_zrXIZqU8PyC3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Balance, September 30, 2021</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_c20210101__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zf2GHhcREo1g" title="Ending balance, shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">101,867,539</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,019,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">687,691,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">608,957,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">79,744,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">For the nine months ended September 30, 2020</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43B_c20200101__20200930_eus-gaap--StockholdersEquity_iS_zQ3SEThaoF22" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, December 31, 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20200101__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlp4O5FvgLDg" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">83,622,135</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">836,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">664,064,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">486,470,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0440">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,430,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zsfGrykRd1Ld" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock option-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0445">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,083,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0447">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0448">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,083,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_zmPmy4PjexT1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0451">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2020-01-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">812,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0453">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0454">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">812,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zEyj92y5KAta" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Common stock issued for cash exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20200101__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0hWEgSuMb0i" title="Common stock issued for cash exercise of options, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,793</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">174,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0459">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0460">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations_zIxlGDt1PCmi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock in connection with restricted share awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations_c20200101__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zk6XCpIn0MLj" title="Issuance of common stock in connection with restricted share awards, shares" style="text-align: right"><ix:nonFraction name="abeo:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">818,233</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" contextRef="From2020-01-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0467">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0468">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0469">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zAj4jBx1bqkc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0473">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0474">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">68,406,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0476">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">68,406,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_zhAXXImElI5i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other comprehensive income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0479">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0480">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0481">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-01-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_ziITSDCQHhul" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Other comprehensive income (loss)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0486">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0487">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-01-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_43A_c20200101__20200930_eus-gaap--StockholdersEquity_iE_zyh6Ji0caJMg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Balance, September 30, 2020</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_c20200101__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zy6Vd8gD12k8" title="Ending balance, shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">84,516,161</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">845,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">669,125,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">554,876,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115,111,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying notes are an integral part of these condensed consolidated statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="pri_006"></span>Abeona
Therapeutics Inc. and Subsidiaries</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Condensed
Consolidated Statements of Cash Flows</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_112_z6VkoKqcPBP8" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_499_20210101__20210930_zaPHHXnVRu0d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_499_20200101__20200930_zDagkJ82MjUe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the nine months ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">September 30,</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zapU7NXHtt76" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_i01_maCzIDf_maNCPBUzcwK_zVlYxGHkmmd" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">38,253,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">68,406,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zglUMpKpBXec" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherCostAndExpenseOperating_i02_maCzIDf_maNCPBUzcwK_zm9mv9rBmti4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Non-cash licensed technology impairment charge</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0508">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,916,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--GainOnSettlementOfRelatedParty_i02N_di_msNCPBUzcwK_zqm2Fl255B86" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Non-cash gain on settlement with licensor</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">(<ix:nonFraction name="abeo:GainOnSettlementOfRelatedParty" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,743,000</ix:nonFraction></p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0512">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--PppLoanPayableForgivenessIncome_i02N_di_msNCPBUzcwK_zlLLOpQ3gOrb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Non-cash PPP loan payable forgiveness income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">(<ix:nonFraction name="abeo:PppLoanPayableForgivenessIncome" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,758,000</ix:nonFraction></p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0515">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InterestExpenseOther_i02_pp0p0_maNCPBUzcwK_zRi9anWVida9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Non-cash interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0517">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:InterestExpenseOther" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">600,000</ix:nonFraction></p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DepreciationDepletionAndAmortization_i02_maCzIDf_maNCPBUzcwK_z4r4cKdlt0D8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,443,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,746,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_i02_maCzIDf_maNCPBUzcwK_zb3MyGrDXDw2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock option-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,797,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,083,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AllocatedShareBasedCompensationExpenseRestrictedStock_i02_maCzIDf_maNCPBUzcwK_zs92vgyfWaY7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Restricted stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="abeo:AllocatedShareBasedCompensationExpenseRestrictedStock" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,118,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="abeo:AllocatedShareBasedCompensationExpenseRestrictedStock" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">812,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AccretionAndInterestOnShorttermInvestments_i02N_di_msCzIDf_msNCPBUzcwK_zT2DVv4alDT1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accretion and interest on short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="abeo:AccretionAndInterestOnShorttermInvestments" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">256,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="abeo:AccretionAndInterestOnShorttermInvestments" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">237,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_i02_maCzIDf_maNCPBUzcwK_zTvvvQYtn6Fj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Amortization of right-of-use lease assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">825,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">752,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zmVrkoZeDix6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">Change in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInReceivables_i03N_di_msNCPBUzcwK_zJsjmobnvT5d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0538">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInReceivables" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msCzIDf_msNCPBUzcwK_z7IeAwnTS1G" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,801,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,443,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInOtherNoncurrentAssets_i03N_di_msCzIDf_msNCPBUzcwK_zPsGjZ5o6V6b" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities_i03N_di_msCzIDf_msNCPBUzcwK_zaWS7C4BPgH3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable, accrued expenses and lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="abeo:IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,459,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="abeo:IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,183,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--IncreaseDecreaseInPayableToLicensor_i03_maCzIDf_maNCPBUzcwK_zPyLIimyB6Qi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Change in payable to licensor</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="abeo:IncreaseDecreaseInPayableToLicensor" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,588,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="abeo:IncreaseDecreaseInPayableToLicensor" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,127,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_maCzLar_mtNCPBUzcwK_zcVQg8r7sIY7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Net cash used in operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">35,408,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,409,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zVNmfQokdpQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCzBdS_z5gHlMaFlpM6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Capital expenditures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">903,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,303,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PaymentsToAcquireShortTermInvestments_i01N_di_msCzBdS_zidLQbXjilB9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Purchases of short-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,164,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,230,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_i01_maCzBdS_z1H1UO6uvP49" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Proceeds from maturities of short-term investments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,130,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,037,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzBdS_maCzLar_zBbUePqLNrGl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Net cash provided by (used in)/investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,063,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">89,496,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zRicub84e8l5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProceedsFromShortTermDebt_i01_maCzUDW_zbeXHC9htjWk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from loan payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0574">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromShortTermDebt" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,758,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCzUDW_zuj71H7uBm37" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from open market sales of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,699,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0578">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromStockOptionsExercised_i01_maCzUDW_zhqatrbr4Tm3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Proceeds from exercise of stock options</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">831,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzUDW_maCzLar_zkoJKAsxeUki" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,530,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,933,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCzLar_zPl15wbchoFe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net increase/(decrease) in cash, cash equivalents and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,185,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">120,972,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_z8lNbOasrGca" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Cash, cash equivalents and restricted cash at beginning of period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,571,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130,368,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_z3M9btPnZDq4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash, cash equivalents and restricted cash at end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,756,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,396,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zf7dX3fmOp75" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Supplemental cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01E_zYtuBWU7zBgj" style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">Cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,781,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,424,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RestrictedCashAndCashEquivalents_i01E_zJUnBe6mvbJc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left; padding-bottom: 1pt">Restricted cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">975,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">972,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_i01E_ziV8ddTWYIz4" style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left; padding-bottom: 2.5pt">Total cash, cash equivalents and restricted cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,756,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,396,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InterestPaidNet_zmNcATp6sau5" style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left; padding-bottom: 2.5pt">Cash paid for interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0607">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0608">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxesPaidNet_ziCcIlKEdmqk" style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left; padding-bottom: 2.5pt">Cash paid for taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0610">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0611">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying notes are an integral part of these condensed consolidated statements.</span></p>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.05in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.05in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="pri_007"></span>ABEONA
THERAPEUTICS INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Notes
to Condensed Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"><p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zo7ANL6wddX5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
1 &#8211; <span id="xdx_820_z51qNbYu0ihj">NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="abeo:BackgroundPolicyTextBlock"><p id="xdx_844_ecustom--BackgroundPolicyTextBlock_zKzhqIm7jPz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86C_zcRrEZIaYKAk">Background</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Abeona
Therapeutics Inc. (together with our subsidiaries, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;Abeona&#8221; or the &#8220;Company&#8221;),
a Delaware corporation, is a clinical-stage biopharmaceutical company developing gene and cell therapies for life-threatening rare genetic
diseases. Our lead clinical programs consist of: (i) EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis
bullosa (&#8220;RDEB&#8221;), (ii) ABO-102, an adeno-associated virus (&#8220;AAV&#8221;)-based gene therapy for Sanfilippo syndrome
type A (&#8220;MPS IIIA&#8221;), and (iii) ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B (&#8220;MPS IIIB&#8221;).
We continue to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases, next-generation AAV-based
gene therapies using the novel AIM&#8482; capsid platform that we have exclusively licensed from the University of North Carolina at
Chapel Hill, and internal AAV vector research programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:BasisOfAccounting"><p id="xdx_843_eus-gaap--BasisOfAccounting_ziYBhQQ0QEv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86B_zpfYEzZH7Ezl">Basis
of Presentation</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
condensed consolidated balance sheet as of September 30, 2021, the condensed consolidated statements of operations and comprehensive
loss and stockholders&#8217; equity for the three and nine months ended September 30, 2021 and 2020, and the condensed consolidated statement
of cash flows for the nine months ended September 30, 2021 were prepared by management without audit. In the opinion of management, all
adjustments, consisting only of normal recurring adjustments, except as otherwise disclosed, necessary for the fair presentation of the
financial position, results of operations, and changes in financial position for such periods, have been made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Certain
information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally
accepted in the United States of America (&#8220;U.S. GAAP&#8221;) have been condensed or omitted. These interim financial statements
should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended
December 31, 2020. The results of operations for the period ended September 30, 2021 are not necessarily indicative of the operating
results that may be expected for a full year. The condensed consolidated balance sheet as of December 31, 2020 contains financial information
taken from the audited Abeona consolidated financial statements as of that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"><p id="xdx_84E_eus-gaap--CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_zEUpvfbSxsSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86A_zWLxmc3Owes7">Uses
and Sources of Liquidity</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
financial statements have been prepared on the going concern basis, which assumes the Company will have sufficient cash to pay its operating
expenses, as and when they become payable, for a period of at least 12 months from the date the financial report was issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2021, we had cash, cash equivalents and short-term investments of $<span id="xdx_907_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn5n6_c20210930_zZoJmyOIxkAg"><ix:nonFraction name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">67.0</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million and net assets of $<span id="xdx_90F_eus-gaap--AssetsNet_iI_pn5n6_c20210930_zn8YIc938426"><ix:nonFraction name="us-gaap:AssetsNet" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">79.7</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million. For the nine months ended September
30, 2021, we had cash outflows from operations of $<span id="xdx_903_ecustom--NetCashProvidedByUsedInOperatingActivity_pn5n6_c20210101__20210930_zeSaXZywvPTc"><ix:nonFraction name="abeo:NetCashProvidedByUsedInOperatingActivity" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">35.4</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million. We have not generated significant product
revenues and have not achieved profitable operations. There is no assurance that profitable operations will ever be achieved, and, if
achieved, could be sustained on a continuing basis. In addition, development activities, clinical and nonclinical testing, and commercialization
of our products will require significant additional financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
are subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful
discovery and development of product candidates, obtaining the necessary regulatory approval to market our product candidates, raising
additional capital to continue to fund our operations, development of competing drugs and therapies, protection of proprietary technology
and market acceptance of our products. As a result of these and other risks and the related uncertainties, there can be no assurance
of our future success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Based
on our existing cash, cash equivalents and short-term investments, our ability to access additional financial resources and/or our financial
flexibility to reduce operating expenses if required, we believe that we have sufficient resources to fund operations through at least
the next 12 months. We will need to secure additional funding in the future to carry out all of our planned research and development
activities. If we are unable to obtain additional financing or generate license or product revenue, the lack of liquidity and sufficient
capital resources could have a material adverse effect on our future prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_84D_eus-gaap--UseOfEstimates_zy5YlErp0Wff" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_863_zfJPSrLcRyi1">Use
of Estimates</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amount of assets and disclosure of contingent assets and liabilities at the date of the consolidated financial statements
and the reported amounts of revenue and expenses during the reported period. Actual results could differ from these estimates and assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zSQ0m0O8NET8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86C_zfinpwbrcCf4">Cash
and Cash Equivalents</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. We maintain deposits
primarily in financial institutions, which may at times exceed amounts covered by insurance provided by the U.S. Federal Deposit Insurance
Corporation (&#8220;FDIC&#8221;). We have not experienced any losses related to amounts in excess of FDIC limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:EquityMethodInvestmentsPolicy"><p id="xdx_849_eus-gaap--EquityMethodInvestmentsPolicy_zXhQvH2OjMS4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86E_ziGgthm8AcU1">Short-term
Investments</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Short-term
investments consist of investments in U.S. government, U.S. agency and U.S. treasury securities. We determine the appropriate classification
of the securities at the time they are acquired and evaluate the appropriateness of such classifications at each balance sheet date.
We classify our short-term investments as available-for-sale pursuant to Accounting Standards Codification (&#8220;ASC&#8221;) 320, <i>Investments
&#8211; Debt and Equity Securities</i>. Investments classified as current have maturities of less than one year. We review our short-term
investments for other-than-temporary impairment whenever the fair value of a marketable security is less than the amortized cost and
evidence indicates that a short-term investment&#8217;s carrying amount is not recoverable within a reasonable period of time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_84D_eus-gaap--LesseeLeasesPolicyTextBlock_zeDZ1lKkmWUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86E_zTvcJjVfRLBg">Leases</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">We
account for leases in accordance with ASC 842, <i>Leases</i>. Right-of-use lease assets represent our right to use an underlying asset
for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. The measurement of lease
liabilities is based on the present value of future lease payments over the lease term. As our leases do not provide an implicit rate,
we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value
of future lease payments. The right-of-use asset is based on the measurement of the lease liability and includes any lease payments made
prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. Rent expense for our
operating leases is recognized on a straight-line basis over the lease term. We do not have any leases classified as finance leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Our
leases do not have significant rent escalation, holidays, concessions, material residual value guarantees, material restrictive covenants
or contingent rent provisions. Our leases include both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease
components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component as we have elected the
practical expedient to group lease and non-lease components for all leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Most
leases include one or more options to renew. The exercise of lease renewal options is typically at our sole discretion; therefore, the
majority of renewals to extend the lease terms are not included in our right-of-use assets and lease liabilities as they are not reasonably
certain of exercise. We regularly evaluate the renewal options and when they are reasonably certain of exercise, we include the renewal
period in our lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Additional
information and disclosures required under ASC 842 are included in Note 7.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"><p id="xdx_84B_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zOdn5KLQjuTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_862_z5DzEwHQw0c1">Restricted
Cash</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Restricted
cash, which is recorded within other assets and restricted cash in the accompanying consolidated balance sheets and is included as a
component of cash, cash equivalents and restricted cash on our consolidated statements of cash flows, consists of cash and cash equivalents
held as collateral for a corporate credit card and office space in New York. As such, the cash and cash equivalents are restricted in
use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zIFTyweu3N44" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86B_z9oBtVlfjEva">Loss
Per Common Share</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">We
have presented basic and diluted loss per common share on the statement of operations and comprehensive loss. Basic and diluted net loss
per share is computed by dividing net loss by the weighted-average number of shares of common stock and shares underlying &#8220;pre-funded&#8221;
warrants outstanding during the period. The &#8220;pre-funded&#8221; warrants were included in the computation of basic net loss per
share as the exercise price was negligible and the warrants were fully vested and exercisable. In October 2020, all of the <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20201031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreFundedWarrantMember_pdd" title="Warrants converted to shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-10-31_custom_PreFundedWarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,017,055</ix:nonFraction></span>
&#8220;pre-funded&#8221; warrants were exercised and converted into shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zIjsTejJ69Xf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">We
do not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive.
Potential dilutive securities result from outstanding stock options, restricted stock and &#8220;non-pre-funded&#8221; warrants. We did
not include the following potentially dilutive securities in the computation of diluted net loss per common share during the periods
presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B0_zGpTDclD53Ef" style="display: none">SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the three months ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">September 30,</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the nine months ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">September 30,</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zGmT3TiyFHH" title="Total" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-07-012021-09-30_custom_StockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,755,196</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zVPZetACBmpj" title="Total" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-07-012020-09-30_custom_StockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,431,183</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zZEyPRPu13fh" title="Total" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-09-30_custom_StockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,755,196</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zElmds4z2HWd" title="Total" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-09-30_custom_StockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,431,183</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Restricted stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z0JAkd7JW7Dk" title="Total" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-07-012021-09-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,989,224</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zT0Jq02nK7s9" title="Total" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-07-012020-09-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">818,233</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zNbTYrZy4096" title="Total" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-09-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,989,224</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zq5ETfqCi4h9" title="Total" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">818,233</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930_z1yadaQyohHk" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,744,420</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200701__20200930_zk1Er6zMGrg4" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,249,416</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930_zVBezYMakOW9" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,744,420</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20200930_zMFXm5NhwoUc" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,249,416</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_z4wrP32YLEKl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"><p id="xdx_80E_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zdpp23stxiI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
2 &#8211; <span id="xdx_822_zHihvzzsYH16">SHORT-TERM INVESTMENTS</span></b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock"><p id="xdx_891_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zjbZsQZKxH7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
following table summarizes the available-for-sale investments held:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B8_zHdGAqPcpEZ3" style="display: none">SCHEDULE OF AVAILABLE-FOR-SALE INVESTMENTS HELD</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">September 30,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2021</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2020</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">U.S. government and agency securities and treasuries</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20210930_zNCwvQn3mAxh" title="U.S. government and agency securities and treasuries" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,217,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20201231_zK0VDqxmHNC3" title="U.S. government and agency securities and treasuries" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">82,438,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zKuy9IgcjIyb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
amortized cost of the available-for-sale debt securities, which is adjusted for amortization of premiums and accretion of discounts to
maturity, was $<span id="xdx_904_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20210930_zgbhmyqR9gek" title="Amortized cost of available-for-sale debt securities"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,217,000</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20201231_z3Y9j1wvEv62" title="Amortized cost of available-for-sale debt securities"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">82,448,000</ix:nonFraction></span> as of September 30, 2021 and December 31, 2020, respectively. There were <span id="xdx_908_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_do_c20210101__20210930_zSEWabXEfFJ8" title="Realized gains or losses on sale or maturity of available-for-sale debt securities"><span id="xdx_90D_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_do_c20200101__20200930_zzILk9FaHlk4" title="Realized gains or losses on sale or maturity of available-for-sale debt securities"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" contextRef="From2021-01-01to2021-09-30" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" contextRef="From2020-01-012020-09-30" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> significant realized
gains or losses recognized on the sale or maturity of available-for-sale debt securities during the nine months ended September 30, 2021
or 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_80B_eus-gaap--IntangibleAssetsDisclosureTextBlock_z5ziRi9Akllk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
3 &#8211; <span id="xdx_82A_zImVBkbtTvz3">LICENSED TECHNOLOGY</span></b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">On
November 4, 2018, we entered into a license agreement with REGENXBIO Inc. (&#8220;REGENXBIO&#8221;) to obtain rights to an exclusive
worldwide license (subject to certain non-exclusive rights previously granted for MPS IIIA), with rights to sublicense, to REGENXBIO&#8217;s
NAV AAV9 vector for gene therapies for treating MPS IIIA, MPS IIIB, CLN1 Disease and CLN3 Disease. Consideration for the rights granted
under the original agreement included fees totaling $<span id="xdx_909_eus-gaap--RoyaltyExpense_pn6n6_c20181103__20181104__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_z2GLLZSFK9J7" title="Royalty fees"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2018-11-032018-11-04_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">180</ix:nonFraction></span> million and a running royalty on net sales, including: (i) an initial fee of
$<span id="xdx_90D_eus-gaap--PaymentsForRoyalties_pn6n6_c20181103__20181104__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zCdCdWEzsam8" title="Royalties payments"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2018-11-032018-11-04_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">20</ix:nonFraction></span> million, $<span id="xdx_90D_ecustom--PaymentForExecutionOfContracts_iI_pn6n6_c20181104__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zOYyE6enaFr9" title="Payment on execution of contracts"><ix:nonFraction name="abeo:PaymentForExecutionOfContracts" contextRef="AsOf2018-11-04_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">10</ix:nonFraction></span> million of which was due to REGENXBIO shortly after the effective date of the agreement, and $<span id="xdx_904_eus-gaap--DueToRelatedPartiesCurrent_iI_pn6n6_c20181104__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zWqysz5KNsAb" title="Due to licensor current"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="AsOf2018-11-04_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">10</ix:nonFraction></span> million of which was
to be due on the first anniversary of the effective date of the agreement in November 2019, (ii) annual fees totaling up to $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20181104__srt--RangeAxis__srt--MaximumMember__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zQcynVfbUZEa" title="Annual fees"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2018-11-04_srt_MaximumMember_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">100</ix:nonFraction></span> million,
payable in $<span id="xdx_900_eus-gaap--PaymentsForRoyalties_pn6n6_c20201103__20201104__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_z5JQaYEbk40g"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2020-11-032020-11-04_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">20</ix:nonFraction></span> million annual installments beginning on the second anniversary of the effective date (the first of which was to remain
payable if the agreement were terminated before the second anniversary in November 2020), (iii) sales milestone payments totaling $<span id="xdx_906_ecustom--PaymentsForMilestone_pn6n6_c20181103__20181104__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zuENpTJjpxy5" title="Milestone payment"><ix:nonFraction name="abeo:PaymentsForMilestone" contextRef="From2018-11-032018-11-04_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">60</ix:nonFraction></span>
million, and (iv) royalties payable in the low double digits to low teens on net sales of products covered under the agreement. The license
was being amortized over the life of the patent of <span title="Finite-lived intangible asset, useful life::XDX::8"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dc_c20181103__20181104__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zzKOWzVxHZ6d" title="Finite-lived intangible asset, useful life"><ix:nonNumeric contextRef="From2018-11-032018-11-04_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">eight years</ix:nonNumeric></span></span>. On November 1, 2019, we entered into an amendment of the original license
agreement. The amended agreement replaced the $<span id="xdx_906_eus-gaap--ProgramRightsObligationsCurrent_iI_pn6n6_c20191104__us-gaap--TypeOfArrangementAxis__custom--OriginalLicenseAgreementMember_zS1MGwA152Ne" title="License to be paid"><ix:nonFraction name="us-gaap:ProgramRightsObligationsCurrent" contextRef="AsOf2019-11-04_custom_OriginalLicenseAgreementMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">10</ix:nonFraction></span> million payment due on November 4, 2019 with a $<span id="xdx_90A_eus-gaap--ProgramRightsObligationsCurrent_iI_pn6n6_c20191104__us-gaap--TypeOfArrangementAxis__custom--AmendedAgreementMember_zVJ320nawWld" title="License to be paid"><ix:nonFraction name="us-gaap:ProgramRightsObligationsCurrent" contextRef="AsOf2019-11-04_custom_AmendedAgreementMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">3</ix:nonFraction></span> million payment due on November 4,
2019 and an additional $<span id="xdx_90C_eus-gaap--ProgramRightsObligationsCurrent_iI_pn6n6_c20191104__us-gaap--AwardDateAxis__custom--AprilOneTwentyTwentyMember__us-gaap--TypeOfArrangementAxis__custom--AmendedAgreementMember_zg0YWHRunq5h" title="License to be paid"><ix:nonFraction name="us-gaap:ProgramRightsObligationsCurrent" contextRef="AsOf2019-11-04_custom_AprilOneTwentyTwentyMember_custom_AmendedAgreementMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">8</ix:nonFraction></span> million payment (which included $<span id="xdx_901_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn6n6_c20191104_z8XsMDVVTKJe" title="Interest payable"><ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="AsOf2019-11-04" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">1</ix:nonFraction></span> million of interest) that would have been due no later than April 1, 2020.
That $<span id="xdx_902_eus-gaap--PaymentsForRoyalties_pn6n6_c20200329__20200402_zAJkw6BcViqk" title="Royalties payments"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2020-03-292020-04-02" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">8</ix:nonFraction></span> million payment that had been scheduled to be paid by April 1, 2020 and the $<span id="xdx_901_eus-gaap--PaymentsForRoyalties_pn6n6_c20201103__20201104_zf7sLiE8eb37" title="Royalties payments"><ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="From2020-11-032020-11-04" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">20</ix:nonFraction></span> million that had been due to be paid on November
4, 2020 are both recorded as payable to licensor on the consolidated balance sheet. The Company disputed that it was responsible for
the $<span id="xdx_900_eus-gaap--LossContingencyAccrualAtCarryingValue_iI_pn6n6_c20201231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zdr1xbWgcbvd" title="Loss contingency accrual"><ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="AsOf2020-12-31_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">8</ix:nonFraction> </span>million and $<span id="xdx_900_eus-gaap--PaymentsForLegalSettlements_pn6n6_c20200101__20201231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zTkqgsAnGPk7" title="Payments for legal settlements"><ix:nonFraction name="us-gaap:PaymentsForLegalSettlements" contextRef="From2020-01-012020-12-31_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">20</ix:nonFraction></span> million payments, and those payments were the subject of an arbitration between the Company and REGENXBIO as noted
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">Prior to the
April 1, 2020 deadline, <span id="xdx_908_eus-gaap--LossContingencySettlementAgreementTerms_c20200330__20200402__dei--LegalEntityAxis__custom--REGENXBIOMember_zYpOuWx7UX5b" title="Settlement agreement financial terms, description"><ix:nonNumeric contextRef="From2020-03-302020-04-02_custom_REGENXBIOMember" name="us-gaap:LossContingencySettlementAgreementTerms">we engaged REGENXBIO in discussions in an attempt to renegotiate the financial terms of the agreement, but we
were unable to reach an agreement, and we did not make the $8 million payment due by April 1, 2020. On April 17, 2020, REGENXBIO sent
us a written demand for the $8 million fee, payable within a 15-day cure period after receipt of the demand letter. The license terminated
on May 2, 2020, when the 15-day period expired. We considered the status of our discussions with REGENXBIO in March 2020 as a potential
indicator of impairment in accordance with ASC 360-10-35-21.</ix:nonNumeric></span> Our impairment test indicated that the carrying value of the license agreement
exceeded its fair value and we recorded a $<span id="xdx_90D_eus-gaap--OtherCostAndExpenseOperating_pn5n6_c20210101__20210331_zlRwJIRWxsf7" title="Non-cash licensed technology impairment charge"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">32.9</ix:nonFraction></span> million non-cash impairment charge during the three months ended March 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;<span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></span></p>


<ix:exclude><!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">On May 25, 2020,
we filed an arbitration claim with the American Arbitration Association (&#8220;AAA&#8221;) alleging that REGENXBIO materially breached
the license agreement prior to termination and seeking, among other things, a declaration that as a result of REGENXBIO&#8217;s material
breach, we were not responsible for payments totaling $<span id="xdx_902_eus-gaap--GainLossRelatedToLitigationSettlement_pn6n6_c20200524__20200525__dei--LegalEntityAxis__custom--REGENXBIOMember_zYwBxXV89bDg" title="Gain loss on payments for settlement"><ix:nonFraction name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="From2020-05-242020-05-25_custom_REGENXBIOMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">28</ix:nonFraction></span> million (which would otherwise have been due in 2020) plus accrued interest.
REGENXBIO disputed our arbitration claim and filed a counterclaim seeking payment of the $<span id="xdx_909_eus-gaap--GainLossRelatedToLitigationSettlement_pn6n6_c20200524__20200525__dei--LegalEntityAxis__custom--REGENXBIOMember_zPUT0U4YIqLf"><ix:nonFraction name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="From2020-05-242020-05-25_custom_REGENXBIOMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">28</ix:nonFraction></span> million plus interest, which REGENXBIO argued
remained due. An arbitration hearing before a tribunal of three AAA arbitrators was held on March 8 and March 9, 2021. On July 13, 2021,
the tribunal found in favor of REGENXBIO in connection with the parties&#8217; arbitration claims and counterclaims. The tribunal awarded
REGENXBIO $<span id="xdx_908_eus-gaap--GainLossRelatedToLitigationSettlement_pn6n6_c20200712__20200713__dei--LegalEntityAxis__custom--REGENXBIOMember_zpcGhd9B3sQk"><ix:nonFraction name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="From2020-07-122020-07-13_custom_REGENXBIOMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">28</ix:nonFraction></span>.0 million plus interest. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">On August 9,
2021, we filed a second arbitration claim with the AAA asserting that a settlement had been reached before the tribunal&#8217;s award
in the first arbitration was issued. On September 14, 2021, REGENXBIO filed its answer, a counterclaim seeking attorney fees and costs,
and a request for permission to file a case dispositive motion. A preliminary hearing was held on November 1, 2021, during which the
AAA Tribunal set timetables for discovery and for REGENXBIO&#8217;s filing of its case dispositive motion. Those timetables were formalized
in a procedural order issued by the Tribunal on November 8, 2021. Under the schedule set by the Tribunal, REGENXBIO&#8217;s opening brief
in support of its case dispositive motion was filed on November 8, 2021, briefing was scheduled to be completed on December 29, 2021,
and oral argument was scheduled for January 14, 2022. REGENXBIO had also filed suit in the New York State Supreme Court Commercial Division
seeking enforcement of the original arbitration award, and we had requested that the Court stay that proceeding until the second arbitration
is complete. Oral argument on our request for a stay was set for March 10, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">On November
12, 2021, we entered into a settlement agreement (&#8220;Settlement Agreement&#8221;) with REGENXBIO to resolve all current disputes
between the parties including the aforementioned AAA arbitration and New York State Court action. In accordance with the Settlement Agreement,
we agreed to pay REGENXBIO a total of $<span id="xdx_90F_eus-gaap--SettlementLiabilitiesCurrent_iI_pn6n6_c20211112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zUOSsK0hrK88" title="Settlement amount"><ix:nonFraction name="us-gaap:SettlementLiabilitiesCurrent" contextRef="AsOf2021-11-12_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_custom_REGENXBIOMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">30</ix:nonFraction></span> million, payable as follows: (1) $<span id="xdx_905_eus-gaap--SettlementLiabilitiesCurrent_iI_pn6n6_c20211112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--REGENXBIOMember__srt--StatementScenarioAxis__custom--OneBusinessDayMember_z4zEM9DwHcEb"><ix:nonFraction name="us-gaap:SettlementLiabilitiesCurrent" contextRef="AsOf2021-11-12_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_custom_REGENXBIOMember_custom_OneBusinessDayMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">20</ix:nonFraction></span> million payable within one business day of the execution
of the Settlement Agreement, (2) $<span id="xdx_907_eus-gaap--SettlementLiabilitiesCurrent_iI_pn6n6_c20211112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--REGENXBIOMember__srt--StatementScenarioAxis__custom--FirstAnniversaryMember_zCzt974Dpwv2"><ix:nonFraction name="us-gaap:SettlementLiabilitiesCurrent" contextRef="AsOf2021-11-12_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_custom_REGENXBIOMember_custom_FirstAnniversaryMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million on the first anniversary of the effective date of the Settlement Agreement, and (3) $<span id="xdx_904_eus-gaap--SettlementLiabilitiesCurrent_iI_pn6n6_c20211112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--REGENXBIOMember__srt--StatementScenarioAxis__custom--ThirdAnniversaryMember_zy2VNSJSyD4"><ix:nonFraction name="us-gaap:SettlementLiabilitiesCurrent" contextRef="AsOf2021-11-12_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_custom_REGENXBIOMember_custom_ThirdAnniversaryMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million
upon the earlier of: (i) the third anniversary of the effective date of the Settlement Agreement or (ii) the closing of a Strategic Transaction,
as defined in the Settlement Agreement. Under the Settlement Agreement&#8217;s terms, the prior license agreement between the parties
was not reinstituted, and any future license agreement would need to be negotiated separately and require consideration in addition to
the consideration set forth in the Settlement Agreement. As of September 30, 2021, we have recorded the payable to licensor in the balance
sheet based on the present value of the payments due to REGENXBIO under the Settlement Agreement. The accounting for the Settlement Agreement
resulted in a $<span id="xdx_902_ecustom--GainOnSettlementOfRelatedParty_pn5n6_c20210101__20210930_zrhZWOInkWUj" title="Non-cash gain on settlement with licensor"><ix:nonFraction name="abeo:GainOnSettlementOfRelatedParty" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.7</ix:nonFraction></span> million gain on settlement with licensor in the statement of operations and comprehensive loss during the three and
nine months ended September 30, 2021 and a $<span id="xdx_907_ecustom--GainOnSettlementOfRelatedParty_pn5n6_c20210701__20210930_zRSG4WAcpFkj" title="Gain on settlement with licensor"><span id="xdx_90E_ecustom--GainOnSettlementOfRelatedParty_pn5n6_c20210101__20210930_zTFeMnIKbSM5" title="Gain on settlement with licensor"><ix:nonFraction name="abeo:GainOnSettlementOfRelatedParty" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="abeo:GainOnSettlementOfRelatedParty" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.7</ix:nonFraction></ix:nonFraction></span></span> million non-cash gain on settlement with licensor in the statement of cash flows during
the nine months ended September 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">On
May 15, 2015, we acquired Abeona Therapeutics LLC, which had an exclusive license through Nationwide Children&#8217;s Hospital to the
AB-101 and AB-102 patent portfolios for developing treatments for patients with Sanfilippo Syndrome Type A and Type B. The license is
amortized over the life of the license of <span title="Finite-lived intangible asset, useful life"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20150514__20150515__us-gaap--BusinessAcquisitionAxis__custom--AbeonaTherapeuticsLlcMember_z3uVg7quLRR1" title="Finite-lived intangible asset, useful life"><ix:nonNumeric contextRef="From2015-05-142015-05-15_custom_AbeonaTherapeuticsLlcMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">20</ix:nonNumeric></span></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z9UE8u2a6Jt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Licensed
technology consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BB_zRs7c9dsINs1" style="display: none">SCHEDULE OF LICENSED TECHNOLOGY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210930_zSCTNABmgGdj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,&#160;2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20201231_zX6IsieNFP07" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_maFLIANzlPQ_maFLIANzW7H_zhmnavrK8gw" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 54%; text-align: left">Licensed technology</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 19%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,156,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 19%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,156,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_msFLIANzlPQ_msFLIANzW7H_zLREEQbBP9F" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less accumulated amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">743,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">656,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzlPQ_mtFLIANzW7H_zauM9yRpWASd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Licensed technology, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,413,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,500,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_z89kyIfBWwa1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"><p id="xdx_898_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zTBwftYkHbEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
aggregate estimated amortization expense for intangible assets remaining as of September 30, 2021 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zfCXCDqoOfu8" style="display: none">SCHEDULE OF AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 30%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20210930_zTfOPHYYMC8e" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pp0p0_maFLIANznXj_maFLIANzM9M_zclkn8EHrLE" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: center">2021, remainder</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 44%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_maFLIANznXj_maFLIANzM9M_zDxGELT9MVz7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">117,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_maFLIANznXj_maFLIANzM9M_zfatiQ8z2Bl3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">117,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_maFLIANznXj_maFLIANzM9M_ztFFvH6slhoi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">117,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_maFLIANznXj_maFLIANzM9M_zP3Qx12frSd1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">117,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pp0p0_maFLIANznXj_maFLIANzM9M_zNwGMsa49kYe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">916,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANznXj_mtFLIANzM9M_zvXeRMuiKVXj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,413,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_z4qndAzFmivg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif; text-underline-style: double">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Amortization
on licensed technology was $<span id="xdx_90C_eus-gaap--AmortizationOfIntangibleAssets_c20210701__20210930_zcisbbBEgCZ9" title="Amortization of intangible assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,000</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20210930_zke4iL1pjElh" title="Amortization of intangible assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,000</ix:nonFraction></span> for the three and nine months ended September 30, 2021 and $<span id="xdx_90E_eus-gaap--AmortizationOfIntangibleAssets_c20200701__20200930_zBxNsuCGjkmd"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,000</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pn5n6_c20200101__20200930_zXyLGiJbZIM7" title="Amortization of intangible assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.4</ix:nonFraction></span> million for
the three and nine months ended September 30, 2020, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_800_eus-gaap--DebtDisclosureTextBlock_zZjdCfHwDAw1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
4 - <span id="xdx_829_zOZpT5Xrd8Wj">LOAN PAYABLE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
May 2, 2020, we received loan proceeds in the amount of approximately $<span id="xdx_90B_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20200501__20200502__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramMember_zvX7W6RWTlDj" title="Proceeds from loan"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2020-05-012020-05-02_custom_PaycheckProtectionProgramMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.8</ix:nonFraction></span> million (the &#8220;PPP Loan&#8221;) under the Paycheck Protection
Program (&#8220;PPP&#8221;). The PPP was established under the Coronavirus Aid, Relief and Economic Security Act, as amended (&#8220;CARES
Act&#8221;) and is administered by the U.S. Small Business Administration (&#8220;SBA&#8221;). Under the terms of the CARES Act, PPP
loan recipients can apply for loan forgiveness. The loan forgiveness for all or a portion of PPP loans was determined, subject to limitations,
based on the use of loan proceeds over the 24 weeks after the loan proceeds are disbursed. In July 2021, we received notice from the
SBA that our PPP loan has been forgiven. In the third quarter of 2021, the extinguishment of the PPP loan payable was recorded as PPP
loan payable forgiveness income in the statement of operations and comprehensive loss. The forgiveness of the PPP loan payable was recorded
as non-cash PPP loan payable forgiveness income in the statement of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_800_eus-gaap--FairValueDisclosuresTextBlock_zka8fLXsz7vd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
5 &#8211; <span id="xdx_823_z1OC8Uv6fiy3">FAIR VALUE MEASUREMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
calculate the fair value of our assets and liabilities that qualify as financial instruments and include additional information in the
notes to the consolidated financial statements when the fair value is different than the carrying value of these financial instruments.
The estimated fair value of prepaid expenses and other current assets, other assets, accounts payable, accrued expenses, loan payable,
payable to licensor and contract liability approximate their carrying amounts due to the relatively short maturity of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">U.S.
GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in
the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement
date. This guidance establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy
requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The lowest level fair value inputs
are used to assign a fair value level. The three levels of inputs used to measure fair value are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; layout-grid-mode: line; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    1 - Quoted prices in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    2 - Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active
    markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets
    and liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use
    significant unobservable inputs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
have segregated all financial assets and liabilities that are measured at fair value on a recurring basis (at least annually) into the
most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in
the table below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zy9jzHYcGQ7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Financial
assets and liabilities measured at fair value on a recurring and non-recurring basis as of September 30, 2021 and December 31, 2020 are
summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BF_zYsdQBF3Bs2a" style="display: none">SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Description</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">September
30,&#160;2021</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Gains/(Losses)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify">Recurring</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: justify">Short-term investments</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zXgJr5COOH9" title="Fair value disclosure of assets" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-09-30_custom_ShortTermInvestmentMember_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,217,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zpKsindg2PAc" title="Fair value disclosure of assets" style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0778">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zCIePP4gCDDf" title="Fair value disclosure of assets" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-09-30_custom_ShortTermInvestmentMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,217,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zIVmJtFdC7El" title="Fair value disclosure of assets" style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0782">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUmBb7HDRQJh" title="Fair value disclosure of assets" style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0784">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify">Non-recurring</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Licensed technology, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zCBSJxtCiGPi" title="Fair value disclosure of assets" style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-09-30_custom_LicensedTechnologyNetMember_us-gaap_FairValueMeasurementsNonrecurringMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,413,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zh5WLLypThL8" title="Fair value disclosure of assets" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0788">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_z8qzIY21wgv6" title="Fair value disclosure of assets" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0790">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_z3J6Afun9Bla" title="Fair value disclosure of assets" style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-09-30_custom_LicensedTechnologyNetMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsNonrecurringMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,413,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zB3PSIzLkd8g" title="Fair value disclosure of assets" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0794">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zc6MiCzs9hMg" title="Fair value disclosure of assets" style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-09-30_us-gaap_GoodwillMember_us-gaap_FairValueMeasurementsNonrecurringMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">32,466,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zvuYGx0DK9Wl" title="Fair value disclosure of assets" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0798">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zIl4ZPGNLQr3" title="Fair value disclosure of assets" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0800">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zXPePTJOBhRe" title="Fair value disclosure of assets" style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-09-30_us-gaap_GoodwillMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsNonrecurringMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">32,466,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zfSYe35hTNwe" title="Fair value disclosure of assets" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0804">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Description</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December
31,&#160;2020</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Gains/(Losses)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify">Recurring</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: justify">Short-term investments</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zcXn0nTmXfhd" title="Fair value disclosure of assets" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_custom_ShortTermInvestmentMember_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">82,438,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zvPylhnEA7R" title="Fair value disclosure of assets" style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0808">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxtpgDmCm5G2" title="Fair value disclosure of assets" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_custom_ShortTermInvestmentMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">82,438,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z5S6oy2RJ3yc" title="Fair value disclosure of assets" style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0812">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zK4YcvN9FZ34" title="Fair value disclosure of gain loss" style="width: 9%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0814">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify">Non-recurring</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Licensed technology, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zG7TKK9dokH9" title="Fair value disclosure of assets" style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_custom_LicensedTechnologyNetMember_us-gaap_FairValueMeasurementsNonrecurringMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_z5DAbHpfADdh" title="Fair value disclosure of assets" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0818">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_z0vvxhiAfeb4" title="Fair value disclosure of assets" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0820">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zgys0wMOkMSh" title="Fair value disclosure of assets" style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_custom_LicensedTechnologyNetMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsNonrecurringMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_z2oOXVuHir4e" title="Fair value disclosure of gain loss" style="text-align: right">(<ix:nonFraction name="abeo:FairValueDisclosureOfGainLoss" contextRef="AsOf2020-12-31_custom_LicensedTechnologyNetMember_us-gaap_FairValueMeasurementsNonrecurringMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">32,916,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zSKFMXFd51y5" title="Fair value disclosure of assets" style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_GoodwillMember_us-gaap_FairValueMeasurementsNonrecurringMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">32,466,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zir2urBeFoNh" title="Fair value disclosure of assets" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0828">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zgRfZXszhf79" title="Fair value disclosure of assets" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0830">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zA6JNTPYMid5" title="Fair value disclosure of assets" style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_GoodwillMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsNonrecurringMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">32,466,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zYvnQTSEOqHc" title="Fair value disclosure of gain loss" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0834">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zQLHL6oYFkGl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_807_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z8y1IWZi5l9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
6 &#8211; <span id="xdx_822_z3vc0rWceNO6">STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zeNE9WAF0w2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Stock
Options</i>: The following table summarizes stock option-based compensation for the three and nine months ended September 30, 2021 and
2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zhgHRbRE57u" style="display: none">SCHEDULE OF STOCK BASED COMPENSATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5vzLZ7mMNrd" title="Total stock-based compensation expense" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-07-012021-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">432,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zgx16oMVADmg" title="Total stock-based compensation expense" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-07-012020-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">765,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z6T2yur6qoU7" title="Total stock-based compensation expense" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,649,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zTILqnMQIvWe" title="Total stock-based compensation expense" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,380,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_z8EfdWkayT9j" title="Total stock-based compensation expense" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-07-012021-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">955,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zDpysH7Fa4Vl" title="Total stock-based compensation expense" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-07-012020-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">484,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_z48Hk68g8Lnd" title="Total stock-based compensation expense" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,148,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_ztcJTCgkkUW1" title="Total stock-based compensation expense" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,703,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock option-based compensation expense included in operating expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_z2mv0g5X8FNb" title="Total stock-based compensation expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-07-012021-09-30_us-gaap_EmployeeStockOptionMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,387,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_z2OI5eszwY6a" title="Total stock-based compensation expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-07-012020-09-30_us-gaap_EmployeeStockOptionMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,249,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_znZHQdfqMYIa" title="Total stock-based compensation expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,797,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_zfOM5lgJKL54" title="Total stock-based compensation expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,083,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><p id="xdx_8AD_zmRsHgVAOWQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">We
estimate the fair value of each option award on the date of grant using the Black-Scholes option valuation model. We then recognize the
grant date fair value of each option as compensation expense ratably using the straight-line attribution method over the service period
(generally the vesting period). The Black-Scholes model incorporates the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Expected
    volatility - we estimate the volatility of our share price at the date of grant using a &#8220;look-back&#8221; period which coincides
    with the expected term, defined below. We believe using a &#8220;look-back&#8221; period which coincides with the expected term is
    the most appropriate measure for determining expected volatility.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Expected
    term - we estimate the expected term using the &#8220;simplified&#8221; method, as outlined in Staff Accounting Bulletin No. 107,
    &#8220;Share-Based Payment.&#8221;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Risk-free
    interest rate - we estimate the risk-free interest rate using the U.S. Treasury yield curve for periods equal to the expected term
    of the options in effect at the time of grant.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Dividends
    - we use an expected dividend yield of zero because we have not declared or paid a cash dividend, nor do we have any plans to declare
    a dividend.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zmOzrQbauXUb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">We
used the following weighted-average assumptions to estimate the fair value of the options granted for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BE_z9vTJ4oi7gnd" style="display: none">SCHEDULE OF WEIGHTED-AVERAGE ASSUMPTIONS TO ESTIMATE THE FAIR VALUE OF THE OPTIONS GRANTED</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: justify">Expected volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210701__20210930_zwSBpvi10z9f" title="Expected volatility" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">92</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200701__20200930_zutH84DKe1Mi" title="Expected volatility" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">110</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210930_zgksPcwHzgd2" title="Expected volatility" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">97</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20200930_zddY1w2hz3Pl" title="Expected volatility" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">111</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210701__20210930_zwpxsh0F6KM5" title="Expected term"><ix:nonNumeric contextRef="From2021-07-012021-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.08</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200701__20200930_zOZToGJ7e7H3" title="Expected term"><ix:nonNumeric contextRef="From2020-07-012020-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.25</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930_zPNMWKfTQKkd" title="Expected term"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.97</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200930_zQ6T4jlsWTCa" title="Expected term"><ix:nonNumeric contextRef="From2020-01-012020-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.25</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210701__20210930_zrGMKD2M4uHc" title="Risk-free interest rate" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.97</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200701__20200930_zzocRiqjppDb" title="Risk-free interest rate" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.16</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210930_zkHTCGdpEd1i" title="Risk-free interest rate" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.98</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20200930_zbStsIJzRmgh" title="Risk-free interest rate" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.29</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210701__20210930_zYCr3zL3PVPg" title="Expected dividend yield" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200701__20200930_z5QhehHNzAtl" title="Expected dividend yield" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20210930_zshgLyGwuMx" title="Expected dividend yield" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20200930_zCTHltN2NDU2" title="Expected dividend yield" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zrkC2dldH4xi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zcDmRQ0OZzZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the options granted for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BA_zL7sPFqvKlN3" style="display: none">SCHEDULE OF OPTIONS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20210701__20210930_zxi79DAfrOad" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20200701__20200930_z1Ng8gXGbdjc" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20210930_zyqD3SuDpsXa" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20200101__20200930_zk3QNXRDBFw5" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_z3d42X4ijVSa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left">Options granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,028,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">342,100</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,383,308</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,415,146</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_zlrvW92nscca" style="vertical-align: bottom; background-color: White">
    <td>Weighted-average:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_zPFwpSYPHY5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.25</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.08</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.86</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_zqo0AiFkUskg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Grant date fair value</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.94</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.56</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.44</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.99</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_z78TTdMQYZHb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-012021-09-30_us-gaap_RestrictedStockMember16575609" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z7qGUTPJBeii" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Restricted
Common Stock</i>: The following table summarizes restricted common stock compensation expense for the three and nine months ended September
30, 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B7_zmxOinF77W7b" style="display: none">SCHEDULE OF STOCK BASED COMPENSATION</span><span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zuSkkw0JBdUc" title="Total stock-based compensation expense" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-07-012021-09-30_us-gaap_RestrictedStockMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">256,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zq5qyOdMmve4" title="Total stock-based compensation expense" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-07-012020-09-30_us-gaap_RestrictedStockMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">89,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z16OrbGmHlif" title="Total stock-based compensation expense" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-09-30_us-gaap_RestrictedStockMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,286,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zW4hkk3BjaEj" title="Total stock-based compensation expense" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">561,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zH1lLNUWHBIh" title="Total stock-based compensation expense" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-07-012021-09-30_us-gaap_RestrictedStockMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">894,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zHOBYHR1RS2b" title="Total stock-based compensation expense" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-07-012020-09-30_us-gaap_RestrictedStockMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">72,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zuaZ6snBlpdi" title="Total stock-based compensation expense" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-09-30_us-gaap_RestrictedStockMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,832,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zAA5M2f39fw7" title="Total stock-based compensation expense" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">251,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Restricted stock-based compensation expense included in operating expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_z66az17mTZr4" title="Total stock-based compensation expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-07-012021-09-30_us-gaap_RestrictedStockMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,150,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_zUi9HKJrfiMd" title="Total stock-based compensation expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-07-012020-09-30_us-gaap_RestrictedStockMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">161,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_z5FpDiF8Dhrl" title="Total stock-based compensation expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-09-30_us-gaap_RestrictedStockMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,118,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_zeufPMnGEovl" title="Total stock-based compensation expense" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">812,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zxHmrRmc9nea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zTBrOXitDuy" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the restricted common stock granted for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B7_zSwE6O0Yu767" style="display: none">SUMMARY OF RESTRICTED COMMON STOCK</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20210701__20210930_zW4rBtZApFic" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20200701__20200930_zOxJZK3nReA3" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20210101__20210930_zoftN5jipWK8" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20200101__20200930_z7rY7reo6kx2" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zWozfRO6RFwg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left">Restricted common stock granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2021-07-012021-09-30_us-gaap_RestrictedStockMember16575765" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">767,934</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0949">&#160;</span></td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2021-01-012021-09-30_us-gaap_RestrictedStockMember16575609" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,743,668</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember16575781" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,083,313</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z3j1UqswTnof" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted common stock forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2021-07-012021-09-30_us-gaap_RestrictedStockMember16575765" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">293,109</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2020-07-012020-09-30_us-gaap_RestrictedStockMember16575765" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">265,080</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2021-01-012021-09-30_us-gaap_RestrictedStockMember16575609" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">721,768</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember16575781" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">265,080</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_pid_ziM4EbnM7LN7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted-average:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z6f30tmPXUm5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Grant date fair value-granted awards</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-07-012021-09-30_us-gaap_RestrictedStockMember16575765" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.24</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0964">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-01-012021-09-30_us-gaap_RestrictedStockMember16575609" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.77</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember16575781" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.19</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z6gEnYUdCMFe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Grant date fair value-forfeited awards</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2021-07-012021-09-30_us-gaap_RestrictedStockMember16575765" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.93</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2020-07-012020-09-30_us-gaap_RestrictedStockMember16575765" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.18</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2021-01-012021-09-30_us-gaap_RestrictedStockMember16575609" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.90</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember16575781" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.18</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zYakx4IEhzwe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z7YvgbEMTim5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">NOTE
7 &#8211; <span id="xdx_82D_ztKGEtHWe4H2">COMMITMENTS AND CONTINGENCIES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Arbitration
Proceeding</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were engaged in an arbitration
proceeding with REGENXBIO regarding the former license agreement between us and REGENXBIO relating to use of the AAV9 capsid in our
MPS IIIA, MPS IIIB, CLN1 (which has now been sold to Taysha Gene Therapies), and CLN3 programs. <span style="font-weight: normal">The
license terminated on May 2, 2020, and on May 25, 2020, we filed an arbitration claim with the American Arbitration Association
(&#8220;AAA&#8221;) alleging that REGENXBIO materially breached the license agreement prior to termination and seeking, among other
things, a declaration that as a result of REGENXBIO&#8217;s material breach, we were not responsible for payments totaling $<span id="xdx_901_eus-gaap--GainLossRelatedToLitigationSettlement_pn6n6_c20200524__20200525__dei--LegalEntityAxis__custom--REGENXBIOMember_z6zno4I8x0Ya" title="Gain loss on payments for settlement"><ix:nonFraction name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="From2020-05-242020-05-25_custom_REGENXBIOMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">28</ix:nonFraction></span>
million (which would otherwise have been due in 2020) plus accrued interest. REGENXBIO disputed our arbitration claim and filed a
counterclaim seeking payment of the $<span id="xdx_90F_eus-gaap--GainLossRelatedToLitigationSettlement_pn6n6_c20200524__20200525__dei--LegalEntityAxis__custom--REGENXBIOMember_zO38o7snDLV4"><ix:nonFraction name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="From2020-05-242020-05-25_custom_REGENXBIOMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">28</ix:nonFraction></span> million plus interest, which REGENXBIO argued remained due. An arbitration hearing before a
tribunal of three AAA arbitrators was held on March 8 and March 9, 2021. On July 13, 2021, the tribunal found in favor of REGENXBIO
in connection with the parties&#8217; arbitration claims and counterclaims. The tribunal awarded REGENXBIO $<span id="xdx_903_eus-gaap--GainLossRelatedToLitigationSettlement_pn6n6_c20200712__20200713__dei--LegalEntityAxis__custom--REGENXBIOMember_zL2ZdWwNn0L"><ix:nonFraction name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="From2020-07-122020-07-13_custom_REGENXBIOMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">28</ix:nonFraction></span>.0 million plus
interest. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">On August 9,
2021, we filed a second arbitration claim with the AAA asserting that a settlement had been reached before the tribunal&#8217;s award
in the first arbitration was issued. On September 14, 2021, REGENXBIO filed its answer, a counterclaim seeking attorney fees and costs,
and a request for permission to file a case dispositive motion. A preliminary hearing was held on November 1, 2021, during which the
AAA Tribunal set timetables for discovery and for REGENXBIO&#8217;s filing of its case dispositive motion. Those timetables were formalized
in a procedural order issued by the Tribunal on November 8, 2021. Under the schedule set by the Tribunal, REGENXBIO&#8217;s opening brief
in support of its case dispositive motion was filed on November 8, 2021, briefing was scheduled to be completed on December 29, 2021,
and oral argument was scheduled for January 14, 2022. REGENXBIO had also filed suit in the New York State Supreme Court Commercial Division
seeking enforcement of the original arbitration award, and we had requested that the Court stay that proceeding until the second arbitration
is complete. Oral argument on our request for a stay was set for March 10, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">On November
12, 2021, we entered into a settlement agreement (&#8220;Settlement Agreement&#8221;) with REGENXBIO to resolve all current disputes
between the parties including the aforementioned AAA arbitration and New York State Court action. In accordance with the Settlement Agreement,
we agreed to pay REGENXBIO a total of $<span id="xdx_900_eus-gaap--SettlementLiabilitiesCurrent_iI_pn6n6_c20211112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zJ5YquSODEak" title="Settlement amount"><ix:nonFraction name="us-gaap:SettlementLiabilitiesCurrent" contextRef="AsOf2021-11-12_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_custom_REGENXBIOMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">30</ix:nonFraction></span> million, payable as follows: (1) $<span id="xdx_908_eus-gaap--SettlementLiabilitiesCurrent_iI_pn6n6_c20211112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--REGENXBIOMember__srt--StatementScenarioAxis__custom--OneBusinessDayMember_znSXizSwPtX1" title="Settlement amount"><ix:nonFraction name="us-gaap:SettlementLiabilitiesCurrent" contextRef="AsOf2021-11-12_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_custom_REGENXBIOMember_custom_OneBusinessDayMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">20</ix:nonFraction></span> million payable within one business day of the execution
of the Settlement Agreement, (2) $<span id="xdx_904_eus-gaap--SettlementLiabilitiesCurrent_iI_pn6n6_c20211112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--REGENXBIOMember__srt--StatementScenarioAxis__custom--FirstAnniversaryMember_zpW6RWHmuJPl" title="Settlement amount"><ix:nonFraction name="us-gaap:SettlementLiabilitiesCurrent" contextRef="AsOf2021-11-12_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_custom_REGENXBIOMember_custom_FirstAnniversaryMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million on the first anniversary of the effective date of the Settlement Agreement, and (3) $<span id="xdx_90F_eus-gaap--SettlementLiabilitiesCurrent_iI_pn6n6_c20211112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--REGENXBIOMember__srt--StatementScenarioAxis__custom--ThirdAnniversaryMember_zoQWVUvgpacj" title="Settlement amount"><ix:nonFraction name="us-gaap:SettlementLiabilitiesCurrent" contextRef="AsOf2021-11-12_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_custom_REGENXBIOMember_custom_ThirdAnniversaryMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million
upon the earlier of: (i) the third anniversary of the effective date of the Settlement Agreement or (ii) the closing of a Strategic Transaction,
as defined in the Settlement Agreement. Under the Settlement Agreement&#8217;s terms, the prior license agreement between the parties
was not reinstituted, and any future license agreement would need to be negotiated separately and require consideration in addition to
the consideration set forth in the Settlement Agreement. As of September 30, 2021, we have recorded the payable to licensor in the balance
sheet based on the present value of the payments due to REGENXBIO under the Settlement Agreement. The accounting for the Settlement Agreement
resulted in a $<span id="xdx_90A_ecustom--GainOnSettlementOfRelatedParty_pn5n6_c20210101__20210930_zj1LDjviZ8D7"><ix:nonFraction name="abeo:GainOnSettlementOfRelatedParty" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.7</ix:nonFraction></span> million gain on settlement with licensor in the statement of operations and comprehensive loss during the three and
nine months ended September 30, 2021 and a $<span id="xdx_90F_ecustom--GainOnSettlementOfRelatedParty_pn5n6_c20210701__20210930_znq4JCOg9Hkk"><span id="xdx_906_ecustom--GainOnSettlementOfRelatedParty_pn5n6_c20210101__20210930_ztdiYJM29xG2"><ix:nonFraction name="abeo:GainOnSettlementOfRelatedParty" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="abeo:GainOnSettlementOfRelatedParty" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.7</ix:nonFraction></ix:nonFraction></span></span> million non-cash gain on settlement with licensor in the statement of cash flows during
the nine months ended September 30, 2021.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Operating
Leases</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">We lease space
under operating leases for manufacturing and laboratory facilities and administrative offices in Cleveland, Ohio, as well as administrative
offices in New York, New York.</span><span style="font-weight: normal"> </span>We also lease office space in Madrid, Spain as well
as certain office equipment under operating leases, which have a non-cancelable lease term of less than one year and, therefore, we have
elected the practical expedient to exclude these short-term leases from our right-of-use assets and lease liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_895_eus-gaap--LeaseCostTableTextBlock_zZpb5PcItwUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Components
of lease cost are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B1_zBzypTUIghC3" style="display: none">SCHEDULE OF COMPONENTS OF LEASE COST</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20210701__20210930_zNujNpGJw8Df" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20200701__20200930_zNbZA6oGWHHk" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20210930_zRoqzCbnII9f" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20200101__20200930_zZeAdcvAV8tj" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseCost_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">434,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">434,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,302,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,302,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--VariableLeaseCost_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Variable lease cost</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">344,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">256,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShortTermLeaseCost_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Short-term lease cost</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2020-07-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2021-01-01to2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="From2020-01-012020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zzrBzH0LH1pi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-09-30" escape="true" name="abeo:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock"><p id="xdx_89A_ecustom--ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_zJ0ziEhp78gl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
following table presents information about the amount and timing of cash flows arising from operating leases as of September 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B0_z8hKq46Dpxe" style="display: none">SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20210930_zrs284mKV2ca">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1pt"><span style="text-decoration: underline">Maturity of lease liabilities:</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzoEX_maLOLLPzvfE_z0en0Rh81Pd9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">2021, remainder</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">429,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzvfE_zLpONmPcmVLg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,727,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzvfE_zZhc1j0uHIX2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,741,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzvfE_zJv2kQz1362l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,781,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzvfE_z0XKX1L55rJl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,799,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzvfE_z706LZog6hvi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_mtLOLLPzvfE_maOLLzUrS_zFTfFquNiLMk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total undiscounted operating lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,564,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pp0p0_maOLLzUrS_ze4bsotDBBYc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,399,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iTI_pp0p0_zwSzgtgoBaY1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,165,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Balance sheet classification:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_maOLLzHBA_zakll0xG9IA2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current portion of lease liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,723,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_maOLLzHBA_z2LIdWElG2Md" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Long-term lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,442,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiability_iTI_pp0p0_mtOLLzHBA_zFwDb5tXBPUh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,165,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; text-align: left">Other information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average remaining lease term for operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20210930_zCPuYwSooGwl" title="Weighted-average remaining lease term for operating leases"><ix:nonNumeric contextRef="AsOf2021-09-30" format="ixt-sec:durmonth" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">52</ix:nonNumeric></span> months</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted-average discount rate for operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20210930_zAB7llfmxoI" title="Weighted-average discount rate for operating leases"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.6</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric></ix:nonNumeric><p id="xdx_81F_zw1vK585d6i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>ITEM
    2.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="ar_001"></span>MANAGEMENT&#8217;S
    DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -60pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>OVERVIEW</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Abeona
Therapeutics Inc., a Delaware corporation (together with our subsidiaries, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;Abeona&#8221;
or the &#8220;Company&#8221;), is a clinical-stage biopharmaceutical company developing gene and cell therapies for life-threatening
rare genetic diseases. Our lead clinical programs consist of: (i) EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic
epidermolysis bullosa (&#8220;RDEB&#8221;), (ii) ABO-102, an adeno-associated virus (&#8220;AAV&#8221;)-based gene therapy for Sanfilippo
syndrome type A (&#8220;MPS IIIA&#8221;), and (iii) ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B (&#8220;MPS IIIB&#8221;).
We continue to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases, next-generation AAV-based
gene therapies using the novel AIM&#8482; capsid platform that we have exclusively licensed from the University of North Carolina at
Chapel Hill, and internal AAV vector research programs. A number of our product candidates are eligible for orphan drug designation,
breakthrough therapy designation, or other expedited review processes in the U.S., Europe, Japan, or other world markets. Our pipeline
includes three programs in clinical development&#8212;EB-101, ABO-101 and ABO-102&#8212;for which we hold several U.S. and European Union
(&#8220;EU&#8221;) regulatory designations, and a pipeline of additional earlier stage programs:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><img src="form10q_001.jpg" alt="" style="height: 253.5pt; width: 468pt" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
robust pipeline features early- and late-stage candidates with the potential to transform the treatment of devastating genetic diseases,
and we are conducting clinical trials in the U.S. and abroad.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Our
Mission and Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Abeona
is at the forefront of gene and cell therapy research and development. We are a fully-integrated company featuring therapies in clinical
development, in-house manufacturing facilities, a robust pipeline, and scientific and clinical leadership. We see our mission as working
to create, develop, manufacture, and deliver gene and cell therapies for people impacted by serious diseases. We partner with leading
academic researchers, patient advocacy organizations and caregivers to develop therapies that address the underlying cause of a broad
spectrum of rare genetic diseases for which no effective treatment options exist today.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Since
our last fiscal year, we have continued to make progress toward fulfilling our goal of harnessing the promise of genetic medicine to
transform the lives of people impacted by serious diseases and redefining the standard of care through gene and cell therapies. Our strategy
to achieve this goal consists of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Advancing
Our Clinical Gene and Cell Therapy Programs and Research and Development with a Focus on Rare and Orphan Diseases.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
have three programs in clinical development&#8212;EB-101, ABO-101 and ABO-102&#8212;and a pipeline of additional earlier stage programs.
Through our gene and cell therapy research and development expertise, we believe we are positioned to introduce efficacious and safe
therapeutics to transform the standard of care in devastating diseases and establish our leadership position in the field.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Applying
Novel Next Generation AAV Capsid Technology to Develop New In-Vivo Gene Therapies.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
are researching and developing next-generation AAV-based gene therapy using our novel capsids developed from the AIM&#8482; Capsid Technology
Platform and additional Company-invented AAV capsids. We plan to continue to develop chimeric AAV capsids capable of improved tissue
targeting for various indications and potentially evading immunity to wildtype AAV vectors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Establishing
Leadership Position in Commercial-Scale Gene and Cell-Therapy Manufacturing.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
established current Good Manufacturing Practice (&#8220;cGMP&#8221;), clinical-scale manufacturing capabilities for gene-corrected cell
therapy and AAV-based gene therapies in our state-of-the-art Cleveland facility. We believe that our platform provides us with distinct
advantages, including flexibility, scale, reliability, and the potential for reduced development risk, reduced cost, and faster times
to market. We have focused on establishing internal Chemistry, Manufacturing and Controls (&#8220;CMC&#8221;) capabilities that drive
value for our organization through process development, assay development and manufacturing. We have also deployed robust quality systems
governing all aspects of product lifecycle from preclinical through commercial stage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Establishing
Additional Gene and Cell Therapy Franchises and Adjacencies through In-Licensing and Strategic Partnerships.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
seek to be the partner of choice in gene therapy treatment and have closely collaborated with leading academic institutions, key opinion
leaders, patient foundations, and industry partners to generate novel intellectual property, accelerate research and development, and
understand the needs of patients and their families.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Maintaining
and Growing IP Portfolio.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
strive to have a leading intellectual property portfolio. To that end, we seek patent rights for various aspects of our programs, including
vector engineering and construct design, our production process, and all features of our clinical products including composition of matter
and method of administration and delivery. We expect to continue to expand our intellectual property portfolio by aggressively seeking
patent rights for promising aspects of our product engine and product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">IMPACT
OF COVID-19 PANDEMIC ON OUR BUSINESS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
continue to monitor the impact of the COVID-19 pandemic on our business and take appropriate actions to manage our spending activities
and preserve our cash resources. While there have been vaccines developed and administered, and the spread of COVID-19 may eventually
be contained or mitigated, we cannot predict the timing of vaccine adoption or roll-out globally or the efficacy of such vaccines, including
against variants that emerge, and we do not yet know how businesses and our partners will operate in a post COVID-19 environment. While
we are unable to determine or predict the extent, duration or scope of the overall impact the COVID-19 pandemic will have on our business,
operations, financial condition or liquidity, we believe it is important to keep our stakeholders informed about how our response to
COVID-19 is progressing and how our operations and financial condition may change.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
extent of the impact of the COVID-19 pandemic on our business, operations, and clinical trials continues to evolve and will depend on
certain developments, including: (i) the duration of the declared health emergencies; (ii) future actions taken by governmental authorities
and regulators with respect to the pandemic, including reinstituting state and local lockdowns; (iii) the impact on our partners, collaborators,
and suppliers; and (iv) actions being taken by us in response to this crisis. We remain dedicated to communicating regularly and openly
with our stakeholders as more information becomes available, including updates on material changes to prior guidance as we continue to
follow applicable government, regulatory and institutional guidelines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">RESULTS
OF OPERATIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Comparison
of Three Months Ended September 30, 2021 and September 30, 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">License
and other revenues for the third quarter of 2021 were nil, as compared to $7.0 million for the same period of 2020. The revenues in the
third quarter of 2020 were due to the sublicense and inventory purchase agreements we entered into with Taysha Gene Therapies (&#8220;Taysha&#8221;)
in August 2020 for ABO-202, an AAV gene therapy for CLN1 disease (also known as infantile Batten disease). The agreements grant to Taysha
worldwide exclusive rights to intellectual property developed by scientists at the University of North Carolina at Chapel Hill and us,
and our know-how relating to the research, development and manufacture of the gene therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Total
research and development spending was $8.0 million for each of the third quarters of 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Total
general and administrative spending was $6.1 million in the third quarter of 2021, as compared to $4.4 million for the same period of
2020, an increase of $1.7 million. The increase in expenses was primarily due to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; layout-grid-mode: line; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">increased
    stock-based compensation of $1.3 million; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">increased
    professional fees of $0.7 million; partially offset by</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">decreased
    salary and related costs of $0.3 million.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Depreciation
and amortization was $0.8 million in each of the third quarters of 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gain on settlement with licensor was $6.7
million in the third quarter of 2021, as compared to nil in the same period of 2020. On November 12, 2021, we entered into a Settlement
Agreement with REGENXBIO to resolve all current disputes between us and REGENXBIO. As of September 30, 2021, we have recorded the payable
to licensor in the balance sheet based on the present value of the payments due to REGENXBIO under the Settlement Agreement. The accounting
for the Settlement Agreement resulted in a $6.7 million gain on settlement with REGENXBIO in the third quarter of 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">PPP
loan payable forgiveness income was $1.8 million in the third quarter of 2021, as compared to nil in the same period of 2020. In July
2021, we received notice from the SBA that our PPP loan had been forgiven so the PPP loan payable was reversed in the third quarter of
2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Interest
and miscellaneous income was nil for the third quarter of 2021, as compared to $0.3 million for the same period in 2020. The decrease
resulted from lower earnings on short-term investments driven by lower interest rates and a lower average balance of short-term investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest expense was $0.7 million for the third
quarter of 2021, as compared to $1.3 million for the same period of 2020. The interest expense results from accrued interest under
the prior license agreement with REGENXBIO, which is discussed in Note 3 of our Notes to Condensed Consolidated Financial Statements.
The decrease results from a $0.6 million adjustment to accrued interest recorded in the third quarter of 2020 after it was determined
and ordered by the American Arbitration Association (&#8220;AAA&#8221;) tribunal that in accordance with the license agreement,
interest should be computed without compounding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Net
loss was $7.0 million for the third quarter of 2021, or a $0.07 basic and diluted loss per common share as compared to
a net loss of $7.2 million, or a $0.08 basic and diluted loss per common share, for the same period in 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Comparison
of Nine Months Ended September 30, 2021 and September 30, 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">License
and other revenues for the first nine months of 2021 were nil, as compared to $7.0 million for the same period of 2020. The decrease
in revenue was due to the aforementioned sublicense and inventory purchase agreements we entered into with Taysha in August 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Total
research and development spending was $22.6 million for the first nine months of 2021, as compared to $20.9 million for the same period
of 2020, an increase of $1.7 million. The increase in expenses was primarily due to increased clinical and development work for our gene
and cell therapy product candidates and other related costs of $1.7 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Total
general and administrative spending was $18.1 million for the first nine months of 2021, as compared to $16.4 million for the same period
of 2020, an increase of $1.7 million. The increase in expenses was primarily due to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; layout-grid-mode: line; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">increased
    stock-based compensation of $1.9 million; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">increased
    professional fees of $3.0 million; partially offset by</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">decreased
    salary and related costs of $3.1 million resulting from severance costs of $1.3 million recorded in the first nine months of 2020
    and lower compensation costs of $1.8 million due to reduced general and administrative headcount in the first nine months of 2021;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">decreased
    other costs of $0.1 million.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Depreciation
and amortization was $2.4 million for the first nine months of 2021, as compared to $3.7 million for the same period in 2020, a decrease
of $1.3 million. The decrease was driven by decreased amortization expense of $1.3 million on licensed technology in the first nine months
of 2021, as compared to the same period in 2020, due to the write-off of the REGENXBIO licensed technology in the first quarter of 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
license agreement with REGENXBIO terminated on May 2, 2020. Since our impairment testing indicated that the carrying value of the license
agreement with REGENXBIO exceeded its fair value, we recorded a $32.9 million non-cash impairment charge in the first six months of 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gain on settlement with licensor was $6.7
million in the first nine months of 2021, as compared to nil in the same period of 2020. On November 12, 2021, we entered into a Settlement
Agreement with REGENXBIO to resolve all current disputes between us and REGENXBIO. As of September 30, 2021, we have recorded the payable
to licensor in the balance sheet based on the present value of the payments due to REGENXBIO under the Settlement Agreement. The accounting
for the Settlement Agreement resulted in a $6.7 million gain on settlement with REGENXBIO in the first nine months of 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">PPP
loan payable forgiveness income was $1.8 million in the first nine months of 2021, as compared to nil in the same period of 2020. In
July 2021, we received notice from the SBA that our PPP loan had been forgiven so the PPP loan payable was reversed in the first nine
months of 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Interest
and miscellaneous income was nil for the first nine months of 2021, as compared to $1.3 million for the same period of 2020. The decrease
resulted from lower earnings on short-term investments driven by lower interest rates and a lower average balance of short-term investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Interest
expense was $3.6 million for the first nine months of 2021, as compared to $2.7 million for the same period of 2020. The increase results
primarily from accrued interest under the prior license agreement with REGENXBIO, which is discussed in Note 3 of our Notes to
Condensed Consolidated Financial Statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Net
loss was $38.3 million for the first nine months of 2021, or a $0.40 basic and diluted loss per common share as compared
to a net loss of $68.4 million, or a $0.74 basic and diluted loss per common share, for the same period in 2020. The decrease in the
net loss resulted primarily from a licensed technology impairment charge of $32.9 million in the first nine months of 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">LIQUIDITY
AND CAPITAL RESOURCES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
have historically funded our operations primarily through sale of common stock. The COVID-19 pandemic has negatively affected the global
economy and created significant volatility and disruption of financial markets. An extended period of economic disruption could negatively
affect our business, financial condition, and access to sources of liquidity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
principal source of liquidity is cash, cash equivalents and short-term investments. As of September 30, 2021 and December 31, 2020, our
cash, cash equivalents and short-term investments were $67.0 million and $95.0 million, respectively. Based on our existing cash, cash
equivalents and short-term investments, our ability to access additional financial resources and/or our financial flexibility to reduce
operating expenses if required, we believe that we have sufficient resources to fund operations through at least the next 12 months.
We will need to secure additional funding in the future to carry out all of our planned research and development activities. If we are
unable to obtain additional financing or generate license or product revenue, the lack of liquidity and sufficient capital resources
could have a material adverse effect on our future prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2021 and December 31, 2020, our working capital was $41.4 million and $55.8 million, respectively. The decrease
in working capital as of September 30, 2021 resulted primarily from $35.4 million of cash used for operating activities, partially offset
by $8.5 million of cash provided by financing activities and the positive impact on working capital of the Settlement Agreement with
REGENXBIO as described further below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
August 17, 2018, we entered into an open market sale agreement with Jefferies LLC (the &#8220;2018 ATM Agreement&#8221;). Pursuant to
the terms of the 2018 ATM Agreement, we were able to sell from time to time, through Jefferies LLC, shares of our common stock for an
aggregate sales price of up to $150 million. Any sales of shares pursuant to the 2018 ATM Agreement are made under an effective &#8220;shelf&#8221;
registration statement on Form S-3 that is on file with and has been declared effective by the SEC. We sold 3,083,286 shares of our common
stock under the 2018 ATM Agreement and received $7.7 million of net proceeds during the nine months ended September 30, 2021. Cumulatively,
as of September 30, 2021, we have sold an aggregate of 6,170,236 shares of our common stock under the 2018 ATM Agreement and received
$27.7 million of net proceeds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">License
Agreement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
November 4, 2018, we entered into a license agreement with REGENXBIO to obtain rights to an exclusive worldwide license (subject to certain
non-exclusive rights previously granted for MPS IIIA), with rights to sublicense, to REGENXBIO&#8217;s NAV AAV9 vector for gene therapies
for treating MPS IIIA, MPS IIIB, CLN1 Disease and CLN3 Disease. Consideration for the rights granted under the original agreement included
fees totaling $180 million and a running royalty on net sales, including: (i) an initial fee of $20 million, $10 million of which was
due to REGENXBIO shortly after the effective date of the agreement, and $10 million of which was to be due on the first anniversary of
the effective date of the agreement in November 2019, (ii) annual fees totaling up to $100 million, payable in $20 million annual installments
beginning on the second anniversary of the effective date (the first of which was to remain payable if the agreement were terminated
before the second anniversary in November 2020), (iii) sales milestone payments totaling $60 million, and (iv) royalties payable in the
low double digits to low teens on net sales of products covered under the agreement. The license was being amortized over the life of
the patent of eight years. On November 1, 2019, we entered into an amendment to the original license agreement. The amended agreement
replaced the $10 million payment due on November 4, 2019 with a $3 million payment due on November 4, 2019 and an additional $8 million
payment (which included $1 million of interest) that would have been due no later than April 1, 2020. That $8 million payment that had
been scheduled to be paid by April 1, 2020 and the $20 million that had been due to be paid on November 4, 2020 are both recorded as
payable to licensor on the consolidated balance sheet. The Company disputed that it was responsible for the $8 million and $20 million
payments, and those payments were the subject of an arbitration between the Company and REGENXBIO as noted below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">Prior to the
April 1, 2020 deadline, we engaged REGENXBIO in discussions in an attempt to renegotiate the financial terms of the agreement, but we
were unable to reach an agreement, and we did not make the $8 million payment due by April 1, 2020. On April 17, 2020, REGENXBIO sent
us a written demand for the $8 million fee, payable within a 15-day cure period after receipt of the demand letter. The license terminated
on May 2, 2020, when the 15-day period expired. There were no penalties for early termination of the license.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">On May 25, 2020,
we filed an arbitration claim with the American Arbitration Association (&#8220;AAA&#8221;) alleging that REGENXBIO materially breached
the license agreement prior to termination and seeking, among other things, a declaration that as a result of REGENXBIO&#8217;s material
breach, we were not responsible for payments totaling $28 million (which would otherwise have been due in 2020) plus accrued interest.
REGENXBIO disputed our arbitration claim and filed a counterclaim seeking payment of the $28 million plus interest, which REGENXBIO argued
remained due. An arbitration hearing before a tribunal of three AAA arbitrators was held on March 8 and March 9, 2021. On July 13, 2021,
the tribunal found in favor of REGENXBIO in connection with the parties&#8217; arbitration claims and counterclaims. The tribunal awarded
REGENXBIO $28.0 million plus interest. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">On August 9,
2021, we filed a second arbitration claim with the AAA asserting that a settlement had been reached before the tribunal&#8217;s award
in the first arbitration was issued. On September 14, 2021, REGENXBIO filed its answer, a counterclaim seeking attorney fees and costs,
and a request for permission to file a case dispositive motion. A preliminary hearing was held on November 1, 2021, during which the
AAA Tribunal set timetables for discovery and for REGENXBIO&#8217;s filing of its case dispositive motion. Those timetables were formalized
in a procedural order issued by the Tribunal on November 8, 2021. Under the schedule set by the Tribunal, REGENXBIO&#8217;s opening brief
in support of its case dispositive motion was filed on November 8, 2021, briefing was scheduled to be completed on December 29, 2021,
and oral argument was scheduled for January 14, 2022. REGENXBIO had also filed suit in the New York State Supreme Court Commercial Division
seeking enforcement of the original arbitration award, and we had requested that the Court stay that proceeding until the second arbitration
is complete. Oral argument on our request for a stay was set for March 10, 2022. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">On November
12, 2021, we entered into a settlement agreement (&#8220;Settlement Agreement&#8221;) with REGENXBIO to resolve all current disputes
between the parties including the aforementioned AAA arbitration and New York State Court action. In accordance with the Settlement Agreement,
we agreed to pay REGENXBIO a total of $30 million, payable as follows: (1) $20 million payable within one business day of the execution
of the Settlement Agreement, (2) $5 million on the first anniversary of the effective date of the Settlement Agreement, and (3) $5 million
upon the earlier of: (i) the third anniversary of the effective date of the Settlement Agreement or (ii) the closing of a Strategic Transaction,
as defined in the Settlement Agreement. Under the Settlement Agreement&#8217;s terms, the prior license agreement between the parties
was not reinstituted, and any future license agreement would need to be negotiated separately and require consideration in addition to
the consideration set forth in the Settlement Agreement. As of September 30, 2021, we have recorded the payable to licensor in the balance
sheet based on the present value of the payments due to REGENXBIO under the Settlement Agreement.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Since
our inception, we have incurred negative cash flows from operations and have expended, and expect to continue to expend, substantial
funds to complete our planned product development efforts. We have not been profitable since inception and to date have received limited
revenues from the sale of products. We expect to incur losses for the next several years as we continue to invest in product research
and development, preclinical studies, clinical trials, and regulatory compliance and cannot provide assurance that we will ever be able
to generate sufficient product sales or royalty revenue to achieve profitability on a sustained basis, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
we raise additional funds by selling additional equity securities, the relative equity ownership of our existing investors will be diluted,
and the new investors could obtain terms more favorable than previous investors. If we raise additional funds through collaborations,
strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future
revenue streams, research programs, or product candidates or grant licenses on terms that may not be favorable to us. If we are unable
to raise additional funds through equity or debt financing when needed, we may be required to delay, limit, or terminate our product
development programs or any future commercialization efforts or grant rights to develop and market product candidates to third parties
that we would otherwise prefer to develop and market ourselves.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">We
are carefully and continually reassessing key business activities and all associated spending decisions. Nonetheless, we are spending
necessary funds on manufacturing activities and preclinical studies and clinical trials of potential products, including research and
development with respect to our acquired and developed technology. Our future capital requirements and adequacy of available funds depend
on many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">the
    impact to our business, operations, and clinical programs from the COVID-19 pandemic and related effects on the U.S. and global economy;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">the
    successful development and commercialization of our gene and cell therapy and other product candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">the
    ability to establish and maintain collaborative arrangements with corporate partners for the research, development, and commercialization
    of products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">continued
    scientific progress in our research and development programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">the
    magnitude, scope and results of preclinical testing and clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">the
    costs involved in filing, prosecuting, and enforcing patent claims;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">the
    costs involved in conducting clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">competing
    technological developments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">the
    cost of manufacturing and scale-up;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">the
    ability to establish and maintain effective commercialization arrangements and activities; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">the
    successful outcome of our regulatory filings.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Due
to uncertainties and certain of the risks described above, including those relating to the COVID-19 pandemic, our ability to successfully
commercialize our product candidates, our ability to obtain applicable regulatory approval to market our product candidates, our ability
to obtain necessary additional capital to fund operations in the future, our ability to successfully manufacture our products and our
product candidates in clinical quantities or for commercial purposes, government regulation to which we are subject, the uncertainty
associated with preclinical and clinical testing, intense competition that we face, market acceptance of our products, the potential
necessity of licensing technology from third parties and protection of our intellectual property, it is not possible to reliably predict
future spending or time to completion by project or product category or the period in which material net cash inflows from significant
projects are expected to commence. If we are unable to timely complete a particular project, our research and development efforts could
be delayed or reduced, our business could suffer depending on the significance of the project and we might need to raise additional capital
to fund operations, as discussed in the risks above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
plan to continue our policy of investing any available funds in suitable certificates of deposit, money market funds, government securities
and investment-grade, interest-bearing securities. We do not invest in derivative financial instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>OFF-BALANCE
SHEET ARRANGEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable
SEC rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">ITEM
    3.</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif"><span id="ar_002"></span>QUANTITATIVE
    AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">ITEM
    4.</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif"><span id="ar_003"></span>CONTROLS
    AND PROCEDURES</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Evaluation
of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
the supervision and with the participation of our management and consultants, including the Chief Executive Officer (our principal executive
officer) and Chief Financial Officer (our principal financial officer), we have conducted an evaluation of the effectiveness of the design
and operation of our disclosure controls and procedures (&#8220;Disclosure Controls and Procedures&#8221;), as of September 30, 2021,
as such term is defined in Exchange Act Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
Act&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Conclusion
of Evaluation </b>&#8212; Based on this Disclosure Controls and Procedures evaluation, the Chief Executive Officer and Chief Financial
Officer concluded that our Disclosure Controls and Procedures as of September 30, 2021 were effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Changes
in Internal Control Over Financial Reporting &#8211;</b> There were no changes in our internal control over financial reporting that
occurred during the quarter ended September 30, 2021 that have materially affected, or are reasonably likely to materially affect, our
internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="ar_004"></span>PART
II &#8212; OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>ITEM
    1. </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="ar_005"></span>LEGAL
    PROCEEDINGS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">We
were engaged in an arbitration proceeding with REGENXBIO regarding the former license agreement between us and REGENXBIO relating to
use of the AAV9 capsid in our MPS IIIA, MPS IIIB, CLN1 (which has now been sold to Taysha Gene Therapies), and CLN3 programs. The
license terminated on May 2, 2020, and on May 25, 2020, we filed an arbitration claim with the American Arbitration Association (&#8220;AAA&#8221;)
alleging that REGENXBIO materially breached the license agreement prior to termination and seeking, among other things, a declaration
that as a result of REGENXBIO&#8217;s material breach, we were not responsible for payments totaling $28 million (which would otherwise
have been due in 2020) plus accrued interest. REGENXBIO disputed our arbitration claim and filed a counterclaim seeking payment of the
$28 million plus interest, which REGENXBIO argued remained due. An arbitration hearing before a tribunal of three AAA arbitrators was
held on March 8 and March 9, 2021. On July 13, 2021, the tribunal found in favor of REGENXBIO in connection with the parties&#8217; arbitration
claims and counterclaims. The tribunal awarded REGENXBIO $28.0 million plus interest. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">On August 9,
2021, we filed a second arbitration claim with the AAA asserting that a settlement had been reached before the tribunal&#8217;s award
in the first arbitration was issued. On September 14, 2021, REGENXBIO filed its answer, a counterclaim seeking attorney fees and costs,
and a request for permission to file a case dispositive motion. A preliminary hearing was held on November 1, 2021, during which the
AAA Tribunal set timetables for discovery and for REGENXBIO&#8217;s filing of its case dispositive motion. Those timetables were formalized
in a procedural order issued by the Tribunal on November 8, 2021. Under the schedule set by the Tribunal, REGENXBIO&#8217;s opening brief
in support of its case dispositive motion was filed on November 8, 2021, briefing was scheduled to be completed on December 29, 2021,
and oral argument was scheduled for January 14, 2022. REGENXBIO had also filed suit in the New York State Supreme Court Commercial Division
seeking enforcement of the original arbitration award, and we had requested that the Court stay that proceeding until the second arbitration
is complete. Oral argument on our request for a stay was set for March 10, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">On November
12, 2021, we entered into a settlement agreement (&#8220;Settlement Agreement&#8221;) with REGENXBIO to resolve all current disputes
between the parties including the aforementioned AAA arbitration and New York State Court action. In accordance with the Settlement Agreement,
we agreed to pay REGENXBIO a total of $30 million, payable as follows: (1) $20 million payable within one business day of the execution
of the Settlement Agreement, (2) $5 million on the first anniversary of the effective date of the Settlement Agreement, and (3) $5 million
upon the earlier of: (i) the third anniversary of the effective date of the Settlement Agreement or (ii) the closing of a Strategic Transaction,
as defined in the Settlement Agreement. Under the Settlement Agreement&#8217;s terms, the prior license agreement between the parties
was not reinstituted, and any future license agreement would need to be negotiated separately and require consideration in addition to
the consideration set forth in the Settlement Agreement. As of September 30, 2021, we have recorded the payable to licensor in the balance
sheet based on the present value of the payments due to REGENXBIO under the Settlement Agreement. The accounting for the Settlement Agreement
resulted in a $6.7 million gain on settlement with licensor in the statement of operations and comprehensive loss during the three and
nine months ended September 30, 2021 and a $6.7 million non-cash gain on settlement with licensor in the statement of cash flows during
the nine months ended September 30, 2021.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">ITEM
    1A.</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif"><span id="ar_006"></span>RISK
    FACTORS</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
business and financial results are subject to numerous risks and uncertainties. As a result, the risks and uncertainties discussed in
Part I, Item 1A. Risk Factors in our Form 10-K for the year ended December 31, 2020 should be carefully considered. The following updated
risk factor should be considered in addition to the risks and uncertainties discussed in Part I, Item 1A. Risk Factors in our Form 10-K
for the year ended December 31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our
rights to develop and commercialize our product candidates are subject to, in part, the terms and conditions of licenses granted to us
by others.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
rely upon licenses to certain patent rights and proprietary technology from third parties that are important or necessary to the development
of our technology and products, including technology related to our manufacturing process and our product candidates. These and other
licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories
in which we may wish to develop or commercialize our technology and products in the future. As a result, we may not be able to prevent
competitors from developing and commercializing competitive products in territories included in all of our licenses. These licenses may
also require us to grant back certain rights to licensors and to pay certain amounts relating to sublicensing patent and other rights
under the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
our licensors fail to maintain such patents, or lose rights to those patents or patent applications, the rights we have licensed may
be reduced or eliminated and our right to develop and commercialize any of our products that are the subject of such licensed rights
could be adversely affected. In certain circumstances, we have or may license technology from third parties on a non-exclusive basis.
In such instances, other licensees may have the right to enforce our licensed patents in their respective fields, without our oversight
or control. Those other licensees may choose to enforce our licensed patents in a way that harms our interest, for example, by advocating
for claim interpretations or agreeing on invalidity positions that conflict with our positions or our interest. In addition to the foregoing,
the risks associated with patent rights that we license from third parties will also apply to patent rights we may own in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Further,
in connection with our license agreements we may be responsible for bringing any actions against third parties for infringing claims
of the patents we have licensed. Certain of our license agreements also require us to meet development milestones to maintain the license,
including establishing a set timeline for developing and commercializing products and minimum yearly diligence obligations in developing
and commercializing the product. Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; layout-grid-mode: line; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    extent to which our technology and processes infringe intellectual property rights of the licensor that are not subject to the licensing
    agreement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    sublicensing of patent and other rights under our collaborative development relationships;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    inventorship or ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors
    and us and our partners; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    priority of invention of patented technology.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
any dispute over in-licensed intellectual property prevents or impairs our ability to maintain our current licensing arrangements on
acceptable terms, we may be unable to successfully commercialize the affected product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
we fail to comply with our obligations under these license agreements, or we are subject to a bankruptcy, the licensor may have the right
to terminate the license, in which event we may not be able to manufacture, or market products covered by the license or may face other
penalties. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having
to negotiate new or reinstated agreements with less favorable terms or cause us to lose our rights under these agreements, including
our rights to important intellectual property or technology. It is possible that such termination may occur even if we believe that we
have complied with our obligations under a license agreement, if a dispute arises between us and a licensor. Our license agreement with
REGENXBIO had granted us an exclusive worldwide license (subject to certain non-exclusive rights previously granted for MPS IIIA), with
rights to sublicense, to use REGENXBIO&#8217;s NAV AAV9 capsid in gene therapies for treating MPS IIIA, MPS IIIB, CLN1 Disease, and CLN3
Disease. (Our CLN1 program was sold to Taysha Gene Therapies in August 2020.) On May 2, 2020, REGENXBIO terminated the license agreement.
 On May 25, 2020, we filed an arbitration claim with the American
Arbitration Association (&#8220;AAA&#8221;) alleging that REGENXBIO materially breached the license agreement prior to termination and
seeking, among other things, a declaration that as a result of REGENXBIO&#8217;s material breach, we were not responsible for payments
totaling $28 million (which would otherwise have been due in 2020) plus accrued interest. REGENXBIO disputed our arbitration claim and
filed a counterclaim seeking payment of the $28 million plus interest, which REGENXBIO argued remained due. An arbitration hearing before
a tribunal of three AAA arbitrators was held on March 8 and March 9, 2021. On July 13, 2021, the tribunal found in favor of REGENXBIO
in connection with the parties&#8217; arbitration claims and counterclaims. The tribunal awarded REGENXBIO $28.0 million plus interest.
On August 9, 2021, we filed a second arbitration claim with the AAA asserting that a settlement had been reached before the tribunal&#8217;s
award in the first arbitration was issued. On September 14, 2021, REGENXBIO filed its answer, a counterclaim seeking attorney fees and
costs, and a request for permission to file a case dispositive motion. A preliminary hearing was held on November 1, 2021, during which
the AAA Tribunal set timetables for discovery and for REGENXBIO&#8217;s filing of its case dispositive motion. Those timetables were
formalized in a procedural order issued by the Tribunal on November 8, 2021. Under the schedule set by the Tribunal, REGENXBIO&#8217;s
opening brief in support of its case dispositive motion was filed on November 8, 2021, briefing was scheduled to be completed on December
29, 2021, and oral argument was scheduled for January 14, 2022. REGENXBIO had also filed suit in the New York State Supreme Court Commercial
Division seeking enforcement of the original arbitration award, and we had requested that the Court stay that proceeding until the second
arbitration is complete. Oral argument on our request for a stay was set for March 10, 2022. On November 12, 2021, we entered into a
settlement agreement (&#8220;Settlement Agreement&#8221;) with REGENXBIO to resolve all current disputes between the parties including
the aforementioned AAA arbitration and New York State Court action. In accordance with the Settlement Agreement, we agreed to pay REGENXBIO
a total of $30 million, payable as follows: (1) $20 million payable within one business day of the execution of the Settlement Agreement,
(2) $5 million on the first anniversary of the effective date of the Settlement Agreement, and (3) $5 million upon the earlier of: (i)
the third anniversary of the effective date of the Settlement Agreement or (ii) the closing of a Strategic Transaction, as defined in
the Settlement Agreement. Under the Settlement Agreement&#8217;s terms, the prior license agreement between the parties was not reinstituted,
and any future license agreement would need to be negotiated separately and require consideration in addition to the consideration set
forth in the Settlement Agreement. It is possible that REGENXBIO may in the future assert that our proposed products infringe one
or more of REGENXBIO&#8217;s AAV9 patent claims, and we still may ultimately need a license to use the AAV9 capsid in our proposed MPS
IIIA, MPS IIIB, or CLN3 products, if such a product is commercialized before the expiration of one or more REGENXBIO patent claims that
cover our commercial product. Absent such a license, if we are found to infringe a valid and enforceable REGENXBIO AAV9 patent claim
before the expiration of a relevant REGENXBIO patent, it is possible that a court may order us to pay a reasonable royalty to REGENXBIO
until relevant patents expire. Although courts generally impose a reasonable royalty and we believe it is very unlikely based on the
current state of the relevant law that a court would grant a permanent injunction to prevent the launch of one of our products, it is
possible that a court could enjoin us from commercializing our MPS IIIA, MPS IIIB, or CLN3 products until relevant AAV9 patents expire
if the court finds that any harm to REGENXBIO would not be compensable by money damages.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Furthermore,
to the extent that the research resulting in certain of our licensed patent rights and technology was funded by the U.S. government,
the government may have certain rights, or march-in rights, to such patent rights and technology. When new technologies are developed
with U.S. government funding, the U.S. government generally obtains certain rights in any resulting patents, including a non-exclusive,
royalty-free license authorizing the U.S. government, or a third party on its behalf, to use the invention for non-commercial purposes.
These rights may permit the government to disclose our confidential information to third parties and to exercise march-in rights to use
or allow third parties to use our licensed technology. The U.S. government can exercise its march-in rights if it determines that action
is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate
health or safety needs, to meet requirements of federal regulations or to give preference to U.S. industry. In addition, our rights in
such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any exercise
by the government, or a third party on its behalf, of such rights could harm our competitive position, business, financial condition,
results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>ITEM
    6.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="ar_007"></span>EXHIBITS</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -60pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -60pt"><span style="font: 10pt Times New Roman, Times, Serif">See
Exhibit Index below, which is incorporated by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -60pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: center; text-indent: -60pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Exhibit
Index</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -60pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Exhibits:</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: justify"></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><a href="ex10-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Letter Agreement, dated August 10, 2021, between the Company and Edward Carr.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">31.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex31-1.htm">Principal Executive Officer Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">31.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex31-2.htm">Principal Financial Officer Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">32*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex32.htm">Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">101</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">The
    following materials from Abeona&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, formatted in Inline
    XBRL (Extensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets at September 30, 2021 and December 31, 2020,
    (ii) Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2021
    and 2020, (iii) Condensed Consolidated Statements of Stockholders&#8217; Equity for the three and nine months ended September 30,
    2021 and 2020, (iv) Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2021 and 2020, and (v)
    Notes to Condensed Consolidated Financial Statements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-left: 0.75in; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">*
Pursuant to Item 601(b)(32)(ii) of Regulation S-K, this exhibit shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of
the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference
in any filings under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof
and irrespective of any general incorporation language in any filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -60pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="ar_008"></span>SIGNATURES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line"><span style="font: 10pt Times New Roman, Times, Serif">ABEONA
    THERAPEUTICS INC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Date:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">November
    15, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
    Vishwas Seshadri</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Vishwas
    Seshadri</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">President
    and Chief Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(Principal
    Executive Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Date:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">November
    15, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
    Edward Carr </i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Edward
    Carr</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(Principal
    Financial Officer)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 6.75pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.1</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 6.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 6.75pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex10-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 6.75pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">August
10, 2021</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Edward
Carr</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Edward:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
letter agreement sets forth the terms of your employment as SVP, Chief Financial Officer, effective August 10, 2021 (the &ldquo;<U>Effective
Date</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Duties;
                                            Best Efforts</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the SVP, Chief Financial Officer you shall have the duties, responsibilities and authority commensurate therewith, and shall report to
the Chief Executive Officer of the Company (the &ldquo;CEO&rdquo;). You shall perform all duties and accept all responsibilities incident
to such position as may be reasonably assigned to you. You represent you are not subject to or a party to any employment agreement, noncompetition
covenant, or other agreement that would be breached by, or prohibit you from executing, this letter agreement (&ldquo;<U>Agreement</U>&rdquo;)
and performing fully your duties and responsibilities hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
your employment, you will devote your best efforts and full time and attention to promote the business and affairs of the Company and
its affiliates, and shall be engaged in other business activities only to the extent that such activities do not materially interfere
or conflict with your obligations to the Company hereunder, including, without limitation, the obligations pursuant to Section 4 below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compensation
                                            and Benefits</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Base
Salary</U>. As of the Effective Date, you will receive an annual base salary of $400,000, as approved by the Compensation Committee
(the &ldquo;<U>Compensation Committee</U>&rdquo;) of the Board of Directors of the Company (the &ldquo;<U>Board</U>&rdquo;) and
payable in accordance with the regular payroll practices of the Company (&ldquo;<U>Base Salary</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Annual
Bonus</U>. During your employment, you may be considered for an annual discretionary bonus (&ldquo;<U>Annual Bonus</U>&rdquo;) in addition
to your Base Salary, with a target of 40% of your Base Salary (&ldquo;<U>Target Annual Bonus Opportunity</U>&rdquo;). Annual Bonus compensation
in any year, if any, will be determined in the Company&rsquo;s sole discretion, and shall be based on your performance and that of the
Company, as well as market factors. Except as provided below under Section 3, to be eligible to receive an Annual Bonus as described
above, you must be employed in good standing, and not have provided notice of resignation or been provided notice of termination, on
the date that the Annual Bonus is paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex10-1_002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Equity
Compensation. In connection with your employment, and subject to Compensation Committee discretion and approval, you will be entitled
to receive (i) stock option grants to purchase shares of Company common stock and (ii) other long-term equity compensation grants (collectively,
&ldquo;Equity Awards&rdquo;) under the Abeona Therapeutics Inc. 2015 Equity Incentive Plan (&ldquo;Plan&rdquo;), subject to the terms
and conditions of the Plan and the agreement memorializing the terms of the Equity Awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Sign-On Equity. As approved by the Compensation Committee, in connection with execution of this Agreement you will be granted 238,000
Restricted Stock Units (&ldquo;RSUs&rdquo;) and options under the Abeona Therapeutics 2015 Equity Incentive Plan to purchase 476,000
shares of the Company&rsquo;s Common Stock (the &ldquo;Option Shares&rdquo;) at an exercise price per share equal to the Fair Market
Value of a share of Common Stock (each term as defined in the Equity Incentive Plan) on the date of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.75pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9;The
Option Shares and RSUs will vest over a forty-eight (48) month period, with one quarter (25%) of vesting on the one-year anniversary
of the Effective Date and the remaining seventy-five percent (75%) of the Option Shares vesting in equal installments thereafter over
the remaining thirty-six (36) months &ndash; RSUs annually and Options monthly - commencing with the first such month following the first
anniversary of the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
vesting is subject to your continued employment with the Company and/or its Affiliates through the applicable vesting dates, and subject
to the terms and conditions of the Company&rsquo;s Equity Incentive Plan, except as provided below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) If
you remain continuously employed from the Effective Date through the date of a Change in Control (as defined below), notwithstanding
the terms of any equity incentive plan or award agreements, as applicable, all outstanding unvested stock options granted to you during
your employment with the Company shall become fully vested and exercisable and will remain exercisable for three (3) months following
the date of a Change in Control, and all outstanding long-term equity compensation awards, other than stock options, shall become fully
vested and the restrictions thereon shall lapse. Pursuant to the terms of the Plan, the exercise price of the stock options will be the
fair market value of the Company&rsquo;s common stock on the date that the stock options were granted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) Benefits.
During your employment, you will be eligible to participate in such health and other group insurance and other employee benefit plans
and programs of the Company as are in effect from time to time, on the same basis as those in commensurate positions of the Company.
Your participation will be subject to the terms of the applicable plan documents and generally applicable Company policies. The Company
reserves the right to amend or terminate any employee benefit plan, program and policy in its discretion at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) Paid
Time Off. You will be entitled to twenty (20) days of paid time off (vacation days plus sick time/personal time) per year, accrued at
a rate in accordance with the Company&rsquo;s policies from time to time in effect, in addition to holidays observed by the Company.
Paid Time Off may be taken at such times and intervals as you shall determine, subject to the business needs of the Company and the responsibilities
of your position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex10-1_002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Employment
                                            Termination</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Termination
of Employment; Accrued Amounts</U>. The Company may terminate your employment for any reason, and you may voluntarily terminate your
employment hereunder for any reason, in each case at any time upon written notice to the other party (the date on which your employment
terminates for any reason is herein referred to as the &ldquo;<U>Termination Date</U>&rdquo;). Upon the termination of your employment
for any reason, you (or your beneficiary or estate, as applicable, in the event of your death) will be entitled to (i) payment of any
Base Salary earned but unpaid through the Termination Date, (ii) any accrued unused vacation days, (iii) additional vested benefits (if
any) in accordance with the applicable terms of applicable Company arrangements, and (iv) any unreimbursed expenses in accordance with
the Company&rsquo;s business expense reimbursement policies (collectively, the &ldquo;<U>Accrued Amounts</U>&rdquo;), <U>provided</U>,
<U>however</U>, that if your employment hereunder is terminated (A) by the Company without Cause (as defined below) or (B) by you for
Good Reason (as defined below), then you will be eligible to receive any Annual Bonus awarded for a prior year, but not yet paid or due
to be paid as of the Termination Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#9;&#9;<U>Severance</U>.
If your employment is terminated (i) by the Company other than for Cause or (ii) by you for Good Reason (as defined below), in addition
to the Accrued Amounts and in lieu of any payments or benefits under any other Company separation policy or program, you will be entitled
to: (A) a payment equal to the sum of twelve (12) months of your Base Salary plus twelve (12) months of your Target Annual Bonus Opportunity
(the amount of such payment, the &ldquo;<U>Severance Amount</U>&rdquo;); and (B) a payment equal to the premiums that you would pay if
you elected continued health coverage under the Company&rsquo;s health plan for you and your eligible dependents for the twelve (12)
month period following the Termination Date, less the applicable active employee rate, which premiums will be calculated based on the
rate determined under the COBRA rate in effect on the Termination Date (&ldquo;<U>Medical Benefit Payment</U>&rdquo;); <U>provided that
</U>any delays in the settlement or payment of such awards that are set forth in the applicable award agreement and that are required
under Section 409A of the Internal Revenue Code, as amended (the &ldquo;<U>Code</U>&rdquo;), and the Treasury Regulations thereunder
(&ldquo;<U>Section 409A</U>&rdquo;) shall remain in effect. The Company&rsquo;s obligations to make the payments and provide the benefits
set forth in (A) and (B) in this Section 3(b) shall be conditioned upon your continued compliance with your obligations under Section
4 below and your execution and nonrevocation of a release of claims in favor of the Company and its affiliates in a form provided by
the Company (&ldquo;<U>Release</U>&rdquo;). Notwithstanding any provision to the contrary herein (other than the provisions of Section
7 below), and without limitation of any remedies to which the Company may be entitled, (I) the Severance Amount shall be paid in installments
in accordance with the Company&rsquo;s regular payroll practices during a twelve (12) month period commencing within sixty (60) days
following the Termination Date (with the first such payment to include all installment amounts from the Termination Date), and (II) the
Medical Benefit Payment shall be paid in a lump sum within sixty (60) days following the Termination Date; <U>provided that</U> the Release
is effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <U>Change
in Control Termination</U>. Notwithstanding any other provision contained herein, if your employment hereunder is terminated by you for
Good Reason (as defined below) or by the Company without Cause, in each case within twelve (12) months following a Change in Control,
in addition to the Accrued Amounts and in lieu of any payments or benefits under any other Company separation policy or program, you
will be entitled to receive (A) a payment equal to the sum of twelve (12) months of your Base Salary plus twelve (12) months of your
Target Annual Bonus Opportunity (such amount, the &ldquo;<U>CIC Severance Amount</U>&rdquo;); and (B) a payment equal to the premiums
that you would pay if you elected continued health coverage under the Company&rsquo;s health plan for you and your eligible dependents
for the twelve (12) month period following the Termination Date, less the applicable active employee rate, which premiums will be calculated
based on the rate determined under the COBRA rate in effect on the Termination Date (&ldquo;CIC <U>Medical Benefit Payment</U>&rdquo;).
If the Change in Control is a &ldquo;change in control event&rdquo; as defined under Section 409A, (I) the CIC Severance Amount shall
be paid in a lump sum within sixty (60) days following the Termination Date; and (II) the CIC Medical Benefit Payment shall be paid in
a lump sum within sixty (60) days following the Termination Date. The Company&rsquo;s obligations to provide the payments and benefits
described in this Section 3(c) shall be conditioned upon your continued compliance with your obligations under Section 4 below and your
execution and delivery to the Company of an effective Release.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex10-1_002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#9;&#9;<U>Resignation
of Positions</U>. Upon your termination of employment with the Company for any reason, you will be deemed to have resigned, as of the
Termination Date, from all positions you then hold with the Company and its affiliates, and you agree to execute all documents necessary
to effectuate the same. &#9;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) <U>Cooperation</U>.
Following the termination of your employment with the Company for any reason, you will reasonably cooperate with the Company upon request
of the CEO, General Counsel, or the Board, and be reasonably available to the Company (taking into account your other business endeavors)
with respect to matters arising out of your services to the Company and its subsidiaries, including, in connection with any legal proceeding,
providing testimony and affidavits; <U>provided</U>, <U>that</U>, the Company shall make reasonable efforts to minimize disruption of
your other activities. The Company shall reimburse you for reasonable expenses incurred in connection with such cooperation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#9;&#9;<U>Definitions</U>.
For purposes of this Agreement, the following terms have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) &ldquo;<U>Cause</U>&rdquo;
shall mean: (A) your substantial failure to perform your duties (other than any such failure resulting from incapacity due to physical
or mental disability) that continues for fifteen (15) calendar days after written notice from the Company; (B) your failure to comply
with any valid and legal directive of the CEO or the Board (as applicable) that continues for fifteen (15) calendar days after written
notice from the Company; (C) your engagement in dishonesty, illegal conduct, or misconduct (or the discovery of your having engaged in
such conduct in the past), which, in each case, materially harms or is reasonably likely to materially harm, reputationally, financially
or otherwise, the Company or its subsidiaries; (D) your embezzlement, misappropriation, or fraud, whether or not related to your employment
with the Company; (E) your conviction of or plea of guilty or nolo contendere to a crime that constitutes a felony; (F) your willful
violation of a material policy of the Company; (G) your willful or grossly negligent unauthorized disclosure of Confidential Information
(as defined below); or (H) your material breach of any material obligation under this Agreement or any other written agreement between
you and the Company that continues for fifteen (15) calendar days after written notice from the Company (if such breach is reasonably
curable); or (I) any willful material failure by you to comply with the Company&rsquo;s written policies or written rules, as they may
be in effect from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) &ldquo;<U>Change
in Control</U>&rdquo; shall have the meaning defined in subparagraph (ii) of the definition of such term under the Appendix in the Plan
as in effect on the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex10-1_002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) &ldquo;<U>Good
Reason</U>&rdquo; shall mean the occurrence of any of the following, in each case without your written consent: (A) a material reduction
of at least ten percent (10%) of your Base Salary other than a general reduction in Base Salary that affects all similarly situated executives;
(B) a material reduction of at least thirty percent (30%) of the Target Annual Bonus Opportunity other than a general reduction in the
Target Annual Bonus Opportunity that affects all similarly situated executives; (C) a permanent and material relocation of your principal
place of employment, which for purposes of this Agreement, means a relocation of more than fifty (50) miles; (D) any material breach
by the Company of any material provision of this Agreement; or (E) a material adverse change in your title, authority, duties, or responsibilities
(including the reporting structure applicable to you, other than temporarily while you are physically or mentally incapacitated); <U>provided</U>,
<U>however</U>, that you cannot terminate your employment for Good Reason unless you have provided written notice to the Company of the
existence of the circumstances providing grounds for termination for Good Reason within sixty (60) calendar days following the initial
existence of such grounds and the Company has had thirty (30) calendar days from the date on which such notice is provided to cure such
circumstances. If you do not terminate your employment for Good Reason within sixty (60) calendar days after expiration of the cure period
(in which the Company shall not have so cured such grounds), then you will be deemed to have waived your right to terminate for Good
Reason with respect to such grounds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Restrictive
                                            Covenants</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offer of employment is contingent on your signing the Company&rsquo;s Policy on Insider Trading, Whistle Blower Policy, Code of Ethics,
and the standard Employee Confidentiality, Non-competition and Proprietary Information Agreement attached hereto as <U>Exhibit A</U>,
the terms of which are incorporated herein by reference in its entirety.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Conditions
                                            of Employment</U></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.75pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offer of employment is contingent upon your providing an I-9 Employment Verification Form. You will be required to submit documentation
that establishes your identity and employment eligibility in accordance with the U.S. Immigration and Naturalization requirements, if
appropriate. The offer of employment contained in this Agreement, and your continued employment, are contingent upon and subject to a
satisfactory background and reference check (which you hereby authorize), including but not limited to confirmation of your stated credentials.
It will be in the Company&rsquo;s sole discretion at any time to determine the scope of the background and reference check, whether and
when to conduct or update such background check and reference check, and whether such check is satisfactory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>At-Will
                                            Employment</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
employment with the Company is at-will. This means that you will have the right to terminate your employment relationship with the Company
at any time for any reason. Similarly, the Company will have the right to terminate its employment relationship with you at any time
for any reason.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
                                            409A</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) To
the extent applicable, it is intended that this Agreement (including all amendments hereto, if any) either meets the requirements for
exclusion from coverage under Section 409A, or alternatively complies with the requirements of Section 409A, so that the income inclusion
provisions of Section 409A(a)(1) of the Code do not apply to you. This Agreement shall be interpreted and administered in a manner consistent
with this intent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) To
the extent that payment of amounts under this Agreement that are subject to Section 409A are payable upon termination of your employment,
such amounts shall only be payable if such termination also constitutes a &ldquo;separation from service,&rdquo; within the meaning of
Section 409A, from the Company and its affiliates. If you are deemed on the date of your separation from service to be a &ldquo;specified
employee&rdquo; (within the meaning of Section 409A(a)(2)(B) of the Code) of the Company, then, notwithstanding any other provision herein,
with regard to any payment that is &ldquo;nonqualified deferred compensation&rdquo; subject to Section 409A and that is payable on account
of your &ldquo;separation from service,&rdquo; such payment shall not be made prior to six (6) months from the date of your separation
from service, following which all payments so delayed shall be paid to you in a lump sum without interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex10-1_002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Any
taxable reimbursement of business or other expenses provided for under this Agreement that is subject to Section 409A shall be subject
to the following conditions: (i) the expenses eligible for reimbursement in one taxable year shall not affect the expenses eligible for
reimbursement in any other taxable year; (ii) the reimbursement of an eligible expense shall be made no later than the end of the year
after the year in which such expense was incurred; and (iii) the right to reimbursement shall not be subject to liquidation or exchange
for another benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) In
applying Section 409A to amounts paid pursuant to this Agreement, each payment shall be treated as a separate payment and any right to
a series of installment payments under this Agreement shall be treated as a right to a series of separate payments. Whenever a payment
under this Agreement specifies a payment period within a specified number of days, the actual date of payment within the specified period
shall be within the sole discretion of the Company. If the consideration and revocation period for the Release spans two taxable years
and any amount hereunder is &ldquo;nonqualified deferred compensation&rdquo; subject to Section 409A and payable on account of your separation
from service, such payment shall not be made or commence until the second taxable year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
                                            280G</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a change in ownership or control under Section 280G of the Code, if it shall be determined that any payment or distribution
in the nature of compensation (within the meaning of Section 280G(b)(2) of the Code) to or for your benefit, whether paid or payable
or distributed or distributable pursuant to the terms of this Agreement or otherwise (a &ldquo;<U>Payment</U>&rdquo;), would constitute
an &ldquo;excess parachute payment&rdquo; within the meaning of Section 280G of the Code, the aggregate present value of the Payments
under this Agreement shall be reduced (but not below zero) to the Reduced Amount (defined below) if and only if the Accounting Firm (described
below) determines that the reduction will provide you with a greater net after-tax benefit than would no reduction. No reduction shall
be made unless the reduction would provide you with a greater net after-tax benefit. The determinations under this Section 8 shall be
made as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 30.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) The
&ldquo;<U>Reduced Amount</U>&rdquo; shall be an amount expressed in present value which maximizes the aggregate present value of Payments
under this Agreement without causing any Payment under this Agreement to be subject to the Excise Tax (defined below), determined in
accordance with Section 280G(d)(4) of the Code. The term &ldquo;<U>Excise Tax</U>&rdquo; means the excise tax imposed under Section 4999
of the Code, together with any interest or penalties imposed with respect to such excise tax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.75pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 30.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) Payments
under this Agreement shall be reduced on a nondiscretionary basis in such a way as to minimize the reduction in the economic value deliverable
to you. Where more than one payment has the same value for this purpose and they are payable at different times, they will be reduced
on a pro-rata basis. Only amounts payable under the Agreement shall be reduced pursuant to this Section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 30.25pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex10-1_002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 30.25pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 30.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) All
determinations to be made under this Section shall be made by an independent certified public accounting firm selected by the Company
and agreed to by you immediately prior to the change in ownership or control transaction (the &ldquo;<U>Accounting Firm</U>&rdquo;).
The Accounting Firm shall provide its determinations and any supporting calculations both to the Company and you within ten (10) days
of the transaction. Any such determination by the Accounting Firm shall be binding upon the Company and you. All of the fees and expenses
of the Accounting Firm in performing the determinations referred to in this Section shall be borne solely by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Miscellaneous</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) All
amounts paid to you under this Agreement during or following your employment shall be subject to withholding and other employment taxes
imposed by applicable law, and the Company shall withhold from any payments under this Agreement all federal, state and local taxes that
the Company is required to withhold pursuant to any law or governmental rule or regulation. You shall be solely responsible for the payment
of all taxes imposed on you relating to the payment or provision of any amounts or benefits hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) This
Agreement may be executed by PDF or facsimile signatures in any number of counterparts, each of which shall be deemed an original, but
all such counterparts shall together constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) From
and after the Effective Date, this Agreement (including <U>Exhibit A</U> hereto) constitutes the entire agreement between you and the
Company, and supersedes all prior representations, agreements and understandings (including any prior course of dealings), both written
and oral, between you and the Company with respect to the subject matter hereof. In the event of any inconsistency between this Agreement
and any other plan, program, practice or agreement in which you are a participant or a party, this Agreement shall control unless such
other plan, program, practice or agreement is more favorable to you (term by term) or specifically refers to this Agreement as not controlling.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) This
Agreement and any of the provisions hereof may be amended, waived (either generally or in a particular instance and either retroactively
or prospectively), modified or supplemented, in whole or in part, only by written agreement signed by you and the Company. This Agreement
and your rights and obligations hereunder may not be assigned by you, and any purported assignment by you in violation hereof shall be
null and void. The Company is authorized to assign this Agreement to a successor to substantially all of its assets or business. Nothing
in this Agreement shall confer upon any person not a party hereto, or the legal representatives of such person, any rights or remedies
of any nature or kind whatsoever under or by reason of this Agreement, except the personal representative of the deceased. This Agreement
shall inure to the benefit of, and be binding on, the successors and assigns of each of the parties, including, without limitation, your
heirs and the personal representatives of your estate and any successor to all or substantially all of the business and/or assets of
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) No
remedy conferred upon a party by this Agreement is intended to be exclusive of any other remedy, and each and every such remedy shall
be cumulative and shall be in addition to any other remedy given under this Agreement or now or hereafter existing at law or in equity.
Except as explicitly provided herein, no delay or omission by a party in exercising any right, remedy or power under this Agreement or
existing at law or in equity shall be construed as a waiver thereof, and any such right, remedy or power may be exercised by such party
from time to time and as often as may be deemed expedient or necessary by such party in its sole discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex10-1_002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) This
Agreement shall be construed and enforced in accordance with the laws of the State of New York, without giving effect to the conflicts
of law principles thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) Any
reference to a Section of the Code shall be deemed to include any successor to such Section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h) This
Agreement and the compensation payable hereunder shall be subject to any applicable clawback or recoupment policies, share trading policies,
and other policies that may be implemented by the Board from time to time with respect to officers of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) Any
notices required or permitted hereunder or necessary or convenient in connection herewith shall be in writing and shall be deemed to
have been given (a) when hand delivered, (b) when emailed to the email address stated below, or (c) when actually received, if notice
is mailed by registered or certified mail to the physical address stated below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>If
                                            to Edward Carr</U>:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Edward
Carr</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
    </FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>If
                                            to Company</U>:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
    Therapeutics Inc.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o
    Chief Executive Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1330
    Avenue of the Americas, 33rd Floor</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, NY 10019</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
    <U>legalnotice@abeonatherapeutics.com</U></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j) Please
acknowledge your acceptance of this offer by returning a signed copy of this Agreement. If there are any other agreements of any type
that you are aware of that may impact or limit your ability to perform your job at the Company, please let us know as soon as possible.
In accepting this offer, you represent and warrant to the Company that you are not subject to any legal or contractual restrictions that
would in any way impair your ability to perform your duties and responsibilities to the Company, and that all information you provided
to the Company is accurate and complete in all respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael Amoroso</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Michael
    Amoroso</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief
    Executive Officer</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Abeona
    Therapeutics Inc.</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
accept this offer of employment with Abeona Therapeutics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Edward Carr</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    August 10, 2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Edward
    Carr</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex10-1_002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EMPLOYEE
CONFIDENTIALITY, NON-COMPETITION, AND</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROPRIETARY
INFORMATION AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
AGREEMENT, effective as of August 10, 2021 between Abeona Therapeutics Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
and Edward Carr (the &ldquo;<U>Employee</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. Employee
will make full and prompt disclosure to the Company of all inventions, improvements, modifications, discoveries, methods, technologies,
biological materials, and developments, and all other materials, items, techniques, and ideas related directly or indirectly to the business
of the Company (collectively, &ldquo;<U>Intellectual Property</U>&rdquo;), whether patentable or not, made or conceived by Employee or
under Employee&rsquo;s direction during Employee&rsquo;s employment with the Company, whether or not made or conceived during normal
working hours, or on the premises of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. Employee
agrees that all Intellectual Property, as defined above, shall be the sole property of the Company and its assigns, and the Company and
its assigns shall be the sole owner of all patents and other rights in connection therewith. Employee hereby assigns to the Company any
rights Employee may have or acquire in all Intellectual Property and all related patents, copyrights, trademarks, trade names, and other
industrial and intellectual property rights and applications therefore, in the United States and elsewhere. Employee further agrees that
with regard to all future developments of Intellectual Property, Employee will assist the Company in every way that may be reasonably
required by the Company (and at the Company&rsquo;s expense) to obtain and, from time to time, enforce patents on Intellectual Property
in any and all countries that the Company may require, and to that end, Employee will execute all documents for use in applying for and
obtaining such patents thereon and enforcing the same, as the Company may desire, together with any assignment thereof to the Company
or persons designated by the Company, and Employee hereby appoints the Company as Employee&rsquo;s attorney to execute and deliver any
such documents or assignments requested by the Company. Employee&rsquo;s obligation to assist the Company in obtaining and enforcing
patents for Intellectual Property in any and all countries shall continue beyond the termination of Employee&rsquo;s employment with
the Company, but the Company shall compensate Employee at a reasonable, standard hourly rate following such termination for time directly
spent by Employee at the Company&rsquo;s request for such assistance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. Employee
hereby represents that Employee has no continuing obligation to assign to any former employer or any other person, corporation, institution,
or firm any Intellectual Property as described above. Employee represents that Employee&rsquo;s performance of all the terms of this
Agreement and as an employee of the Company does not and will not breach any agreement to keep in confidence proprietary information
acquired by Employee, in confidence or in trust, prior to Employee&rsquo;s employment by the Company. Employee has not entered into,
and Employee agrees not to enter into, any agreement (either written or oral), which would put Employee in conflict with this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. Employee
agrees to assign to the Company any and all copyrights and reproduction rights to any material prepared by Employee in connection with
this Agreement and/or developed during the term of Employee&rsquo;s employment with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex10-1_002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5. Employee
understands and agrees that a condition of Employee&rsquo;s employment and continued employment with the Company is that Employee has
not brought and will not bring to the Company or use in the performance of Employee&rsquo;s duties at the Company any materials or documents
rightfully belonging to a former employer which are not generally available to the public.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6. Employee
recognizes that the services to be performed by Employee hereunder are special, unique, and extraordinary and that, by reason of Employee&rsquo;s
employment with the Company, Employee may acquire Confidential Information (as hereinafter defined) concerning the operation of the Company,
the use or disclosure of which would cause the Company substantial loss and damage which could not be readily calculated and for which
no remedy at law would be adequate. Accordingly, except as provided in the last Paragraph in this Section 6, Employee agrees that Employee
will not (directly or indirectly) at any time, whether during or after Employee&rsquo;s employment with the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">knowingly
    use for personal benefit or for any other reason not authorized by the Company any Confidential Information that Employee may acquire
    or has acquired by reason of Employee&rsquo;s employment with the Company, or;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose
    any such Confidential Information to any person or entity except (A) in the performance of Employee obligations to the Company hereunder,
    (B) as required by a court of competent jurisdiction or as permitted below, or (C) with the prior written consent of the Chief Executive
    Officer of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 77.75pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used herein, &ldquo;<U>Confidential Information</U>&rdquo; includes, for example and without limitation, information with respect to
the facilities and methods of the Company, reagents, chemical compounds, cell lines or subcellular constituents, organisms, or other
biological materials, trade secrets, and other Intellectual Property, systems, patents and patent applications, procedures, manuals,
confidential reports, financial information, business plans, prospects, or opportunities, personnel information, or lists of customers
and suppliers; <U>provided</U>, <U>however</U>, that Confidential Information shall not include any information that is known or becomes
generally known or available publicly (a) other than as a result of disclosure by Employee which is not permitted as described in clause
(ii) above, (b) as a result of wrongful conduct of a third party, or (c) because the Company discloses such Confidential Information
to others without obtaining an agreement of confidentiality.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex10-1_002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
in this Agreement shall prohibit or restrict Employee from lawfully (a) initiating communications directly with, cooperating with, providing
information to, causing information to be provided to, or otherwise assisting in an investigation by any governmental or regulatory agency,
entity, or officials, including, without limitation, the United States Food and Drug Administration (FDA), the United States Securities
and Exchange Commission (SEC), or the United States Equal Employment Opportunity Commission (EEOC) (collectively, &ldquo;<U>Governmental
Authorities</U>&rdquo;) regarding a possible violation of any law; (b) responding to any inquiry or legal process directed to Employee
individually (and not directed to the Company) from any such Governmental Authorities; (c) testifying, participating or otherwise assisting
in an action or proceeding by any such Governmental Authorities relating to a possible violation of law; or (d) making any other disclosures
that are protected under the whistleblower provisions of any applicable law. Notwithstanding the foregoing, Employee agrees that in making
any such disclosures or communications, Employee will take all reasonable precautions to prevent any unauthorized use or disclosure of
any information that may constitute Company Confidential Information to any parties other than any Governmental Authority. Employee further
understands that Employee is not permitted to disclose the Company&rsquo;s attorney-client privileged communications or attorney work
product unless required by applicable law. Additionally, pursuant to the federal Defend Trade Secrets Act of 2016, Employee shall not
be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (i) is made
(A) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (B) solely
for the purpose of reporting or investigating a suspected violation of law; or (ii) is made to Employee&rsquo;s attorney in relation
to a lawsuit for retaliation against Employee for reporting a suspected violation of law; or (iii) is made in a complaint or other document
filed in a lawsuit or other proceeding, if such filing is made under seal. Nor does this Agreement require Employee to obtain prior authorization
from the Company before engaging in any conduct described in this Paragraph, or to notify the Company that you have engaged in any such
conduct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7. During
the term of Employee&rsquo;s employment with the Company and for one (1) year thereafter (the &ldquo;<U>Restricted Period</U>&rdquo;),
the Employee shall not, without the Company&rsquo;s written consent, directly or indirectly, for Employee&rsquo;s own account or for
the account of others, act as an officer, director, stockholder (other than as the holder of less than 1% of the outstanding stock of
any publicly traded company), owner, partner, employee, promoter, investor, consultant, manager or otherwise participate in the promotion,
financing, ownership, operation, or management of, or assist in or carry on through proprietorship, a corporation, partnership, or other
form of business entity which is in competition with the Company, within the United States or any other country, in the fields of gene
and cell therapy (a) that the Company is engaged in or has engaged in within one (1) year prior to the Employee&rsquo;s separation from
the Company, or (b) in which the Company is actively seeking or planning to conduct Company Business as of the date of such termination
(the &ldquo;Company Business&rdquo;), and (c) about which the Employee possesses or has had access to Confidential Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the Restricted Period, the Employee shall not, whether for Employee&rsquo;s own account or for the account of any other person (excluding
the Company): (i) solicit or contact in an effort to do business with any person who was or is a customer or prospective customer (i.e.,
any individual or entity with whom the Company was actively engaged in soliciting to do business) of the Company, or any affiliate of
the Company, at the time of Employee&rsquo;s termination or at any time during the two (2) year period prior to Employee&rsquo;s termination,
if such solicitation or contact is for the purpose of competition with the Company; or (ii) solicit or induce any of the Company&rsquo;s
employees to leave their employment with the Company or accept employment with anyone else, or hire any such employees or persons who
were employed by the Company during the preceding twelve (12) months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
herein shall prohibit or preclude the Employee from performing any other types of services that are not precluded by this Section 7 for
any other person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex10-1_002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
has carefully read and considered the provisions of this Section 7 (including the Restricted Period, scope of activity to be restrained,
and the restriction&rsquo;s geographical scope) and concluded them to be fair, appropriate and reasonably required for the protection
of the legitimate business interests of the Company, its officers, directors, employees, creditors, and shareholders. Employee understands
that the restrictions contained in this Section 7 may limit Employee&rsquo;s ability to engage in a business similar to the Company&rsquo;s
business, but acknowledges that Employee will receive adequate and affluent remuneration and other benefits from the Company hereunder
to justify such restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Employee shall give prompt notice to the Company of the Employee&rsquo;s acceptance of employment or other fees for services relationship
during the Restricted Period, which notice shall include the name of, the business of, and the position that Employee shall hold with
such other employer. Employee also agrees to inform any prospective employer or business entity or person of the restrictions set forth
in this Agreement prior to accepting employment or entering into any business relationship.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8. In
the event that Employee&rsquo;s employment is transferred by the Company to a subsidiary, affiliated company, or acquiring company (as
the case may be), Employee&rsquo;s employment by such company will, for the purpose of this Agreement, be considered as continued employment
with the Company, unless Employee executes an agreement, substantially similar in substance to this Agreement, and until the effective
date of said agreement in any such company for which Employee becomes employed Employee agrees to be bound by and comply with Employee&rsquo;s
obligations under this Agreement. It is likewise agreed that no changes in Employee&rsquo;s position or title will operate to terminate
the provisions of this Agreement unless expressly agreed to in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9. Employee
confirms that all Confidential Information is the exclusive property of the Company. All business records, papers, documents and electronic
materials kept or made by Employee relating to the business of the Company which comprise Confidential Information shall be and remain
the property of the Company during the Employee&rsquo;s employment and at all times thereafter. Upon the termination, for any reason,
of Employee&rsquo;s employment with the Company, or upon the request of the Company at any time, Employee shall deliver to the Company,
and shall retain no copies of any written or electronic materials, records and documents made by Employee or coming into Employee&rsquo;s
possession concerning the business or affairs of the Company and which comprise Confidential Information. To the extent that, upon termination,
Employee has any Confidential Information or other proprietary material of the Company stored within any smart phone or personal computer,
email account, thumb drive or other storage device or cloud storage, Employee agrees to fully cooperate with the Company to return such
information and material and subsequently permanently delete and remove such information and material from such devices (subject to any
litigation preservation directive in effect), including, as necessary, providing access by the Company to such devices to ensure compliance
with this Paragraph. Employee further agrees, upon termination of Employee&rsquo;s employment for any reason, unless such employment
is transferred to a subsidiary, affiliated or acquiring company of the Company, Employee agrees to return to the Company all equipment,
tools or other devices owned by the Company, that are then in Employee&rsquo;s possession, however such items were obtained, and Employee
agrees not to reproduce or otherwise retain any document or data relating thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10. Subject
to Section 6 with respect to disclosure to Governmental Authorities, Employee agrees and covenants that s/he will not at any time make,
publish or communicate to any person or entity or in any public forum any defamatory or disparaging remarks, comments, or statements
concerning the Company or its businesses, or any of its employees, officers, and existing and prospective customers, suppliers, investors
and other associated third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex10-1_002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11. Employee&rsquo;s
obligations under this Agreement shall survive the termination of Employee&rsquo;s employment with the Company regardless of the manner
of, and reason for, such termination or resignation, and shall be binding upon Employee&rsquo;s heirs, executors, and administrators.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12. Prior
to entering the employ of the Company, Employee has lawfully terminated employment with all previous employers. Employee acknowledges
that this Agreement does not constitute a contract of employment for a term and does not otherwise imply that the Company will continue
his or her employment for any period of time, and the nature of Employee&rsquo;s employment with the Company is at-will.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13. Employee
agrees that there is no Intellectual Property relevant to the subject matter of Employee&rsquo;s employment with the Company, which has
been made or conceived or first reduced to practice by Employee alone or jointly with others prior to Employee&rsquo;s employment with
the Company, which Employee desires to exclude from Employee&rsquo;s obligations under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14. No
delay or omission by the Company in exercising any right under this Agreement will operate as a waiver of that or any other right. A
waiver or consent given by the Company on any one occasion is effective only in that instance and will not be construed as a bar to or
waiver of any right on any other occasion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15. Employee
agrees that in addition to any other rights and remedies available to the Company for any breach or threatened breach by Employee of
Employee&rsquo;s obligations hereunder, the Company shall be entitled to enforcement of Employee&rsquo;s obligations hereunder by whatever
means are at the Company&rsquo;s disposal, including court injunction, without having to post a bond or other security. In the event
of any such breach or threatened breach by Employee, the Company shall be entitled to recover all damages permitted by law in addition
to its reasonably incurred costs and attorney&rsquo;s fees in enforcing its rights hereunder, and the Restricted Period shall be extended
by the period of any such breach.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16. The
Company may assign this Agreement to any other corporation or entity which acquires (whether by purchase, merger, consolidation or otherwise)
all or substantially all of the business and/or assets of the Company. Employee shall have no rights of assignment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17. If
any provision of this Agreement shall be declared invalid, illegal, or unenforceable, then such provision shall be enforceable to the
extent that a court deems it reasonable to enforce such provision. If such provision shall be unreasonable to enforce to any extent,
such provision shall be severed and all remaining provisions shall continue in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18. Employee
hereby acknowledges receipt of the Company&rsquo;s Confidentiality Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex10-1_002.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19. This
Agreement shall be effective as of the date set forth below next to Employee&rsquo;s signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20. This
Agreement and the employment offer letter constitute the entire contract between the parties hereto with regard to the subject matter
hereof. They supersede any other agreements, representations or understandings (whether oral or written and whether express or implied)
which relate to the subject matter hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21. This
Agreement shall be governed in all respects by the laws of the State of New York. Each of the Company and Employee (a) hereby irrevocably
submits to the exclusive jurisdiction of the state courts of the State of New York or the United States District Court for the Southern
District of New York for the purpose of any action between the Company and Employee arising in whole or in part under or in connection
with this Agreement, (b) hereby waives, to the extent not prohibited by applicable law, and agrees not to assert, by way of motion, as
a defense or otherwise, in any such action, any claim that it is not subject personally to the jurisdiction of the above-named courts,
that its property is exempt or immune from attachment or execution, that any such action brought in one of the above-named courts should
be dismissed on grounds of forum non conveniens, should be transferred or removed to any court other than one of the above-named courts,
or should be stayed by reason of the pendency of some other proceeding in any other court other than one of the above-named courts, or
that this Agreement or the subject matter hereof may not be enforced in or by such court, and (c) hereby agrees not to commence any such
action other than before one of the above-named courts. Notwithstanding the previous sentence, the Company or Employee may commence any
action in a court other than the above-named courts solely for the purpose of enforcing an order or judgment issued by one of the above-named
courts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, Employee has executed this Agreement as of the date set forth above:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">EMPLOYEE</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Edward Carr</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Edward
Carr</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 293.75pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACCEPTED
    AND AGREED TO BY THE COMPANY:</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael Amoroso</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Michael
Amoroso</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-1_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>EXHIBIT
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>PRINCIPAL
EXECUTIVE OFFICER CERTIFICATION PURSUANT TO 18 U.S.C.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SECTION
1350, AS ADOPTED PURSUANT TO SECTION 302</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>OF
THE SARBANES-OXLEY ACT OF 2002</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Vishwas Seshadri, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this report on Form 10-Q of Abeona Therapeutics Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
    reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
    the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 5%; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 45%; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    15, 2021</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 3%; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Vishwas Seshadri</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vishwas
    Seshadri</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>PRINCIPAL
FINANCIAL OFFICER CERTIFICATION PURSUANT TO 18 U.S.C.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SECTION
1350, AS ADOPTED PURSUANT TO SECTION 302</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>OF
THE SARBANES-OXLEY ACT OF 2002</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Edward Carr, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this report on Form 10-Q of Abeona Therapeutics Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
    reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
    the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 5%; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 45%; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    15, 2021</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 3%; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Edward Carr </I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Edward
    Carr</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>5
<FILENAME>ex32.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
32</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>CERTIFICATION
PURSUANT TO 18 U.S.C.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SECTION
1350 AS ADOPTED PURSUANT TO SECTION 906</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>OF
THE SARBANES-OXLEY ACT OF 2002</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Quarterly Report of Abeona Therapeutics Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the three months ended
September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), we, Vishwas Seshadri,
President and Chief Executive Officer of the Company, and Edward Carr, Chief Financial Officer of the Company, certify, pursuant to 18
U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; layout-grid-mode: line"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
    of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 5%; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 45%; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    15, 2021</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 3%; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Vishwas Seshadri</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vishwas
    Seshadri</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    15, 2021</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Edward Carr </I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Edward
    Carr</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>form10q_001.jpg
<TEXT>
begin 644 form10q_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %K IX# 2(  A$! Q$!_\0
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M6HT+SI2=.LY7A^-?_#3W[37_ $<Q^T=_X?;XJ_\ S74?\-/?M-?]',?M'?\
MA]OBK_\ -=7V=_PZ(_;)_P"@=\+?_#B2_P#S.T?\.B/VR?\ H'?"W_PXDO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2^LZGI6F3WMEI2)([7<T4:,J%(CYTJQCS)I(8,3R1PO'%B1E)Z\0!0%5< 8
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M;/\ HW^:?^%&3?\ T1!_Q,?X+_\ 1P,I_P#"/./_ )T']+'VB'^__P".M_\
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M'_1L?Q._\+CPE_\ *ZC_ (EZ\;/^C?YI_P"%&3?_ $1!_P 3'^"__1P,I_\
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M]YM2DT.)M0U/]NOQO8ZK'%ID2IIOA?P,;98;BZU.YU3@_AA^W;\9/C)\+/\
M@G.= \.?#7P+\7/V[?#?Q"\5:AXG\4:7XK\1?"SX;Z7\+/!%[XX\0:5X?\)Z
M?XP\+>)?B!XY\71C2+;PGX/F^(OA9(?"MA\1?B+<ZSJ<'P_/A+Q( ?'_ .P1
M^TY^T'\1/!GP>U3]L3X^_M,> _VD=7\0?L+6/P_^"?A;X-:-)#\8/A3X^_9I
M^ /B'QYX_P#$'@EO@C<W'B#P=X[^)?C+XSZE^TU\8='U/0M,_9;U;P5+X6M]
M;^%4G@C4M'\7?T:5^!_@C_@JE\8=;\0/JWQ%T+]GWX3?!;X6?&3P_P#LZ?&O
MXG:MJ_B_QEX*U;XN:?\ ML?'']C[XCW@\5^#=>U/Q'^RUX3NX?A?X+^)WP$\
M0_M _![7OAE\6M>^)4/PBUOXU?#R[\+>(OB'9=)\'/\ @K#X^^)'[+?[2?Q4
MUWX-Z=X6^-G@KQ#\%;S]GKX5ZS#\0O"=CXX^%?[<OB;P_P"#?V#/&7Q+N?&&
MAZ/K?AYM<\:^)+SX??'F_P##-IK&C>'O$OPP^).H^"Y]4TR'28IP#]S**_G,
M^(W_  5Q_:2\'ZO\8-*T'P1\+O$=]X+\9_MF>&K;3]5^$GQL\%Z/X.\)_LR_
MM3^#/V9?#/Q,_P"%E^(/B'#X+_:,'B77O&OAC3_'OPV^"[Z+XB^%NN>./#=W
MXOUW1M-M0FN>[ZQ^WQ^U;!^V%??L2Z1H7PL\0^-/!NJ?%B3Q9\4_!'P<\:>-
M=(UK0?#WPE_9.^*_@N.U^%-Y^TOX#O/A_P"(M/A_:0U?0_'FG:G\7/'IETW1
MOAGXTT&WL(?BC)X9\' '[>45_/5XI_X*P?M(?#^+XI>+O%_PT^&\_P /_!VE
M_P#!47Q3X72?PKXS\"S>,K+_ ()B?M(Q^$O$GPZ\%^.7^*/CW3O&?Q)^,G[.
MGA3XO>,-)EUSP;\*-!\!>/\ P;+< ?$;PKH6NVK_ -!=C<17=G:W<$IF@NH(
M[B"8JZ&:"=1+#*4D5'C,D;*YC=%:,G8R@J10!:HHHH *_+K_ (+*?\HV?VGS
MD /I?PX"DD ,3\9?ANB@$X&2S  'W]*_46N.\:^!/!_Q(\,ZIX*^(/A#PMXZ
M\&Z[%#!KGA+QGH6D^*/#.KPVUW;:A;1ZIH&MV5]I>HI;W]G:7UNEU;.(+RUM
M[J(K/#'(OM<,YO'A[B7ASB">'J8N&19]D^<U,+1J4J57$T\LS'"8ZI0IU:_[
MFG4K4\-.E3G5]R-2<)23C&2?@<5Y-+B+ACB+((5X8:>>9%F^3PQ%2%2K3H5,
MTR_$X&G6J4Z/[Z=.C4Q$*M2-+WG3A-)IM,_R^< =S_W[F_\ C=&!ZG_OW-_\
M;K_2%_X82_8J_P"C/OV5_P#Q'?X/_P#S(4?\,)?L5?\ 1GW[*_\ XCO\'_\
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M_P#&Z_TA?^&$OV*O^C/OV5__ !'?X/\ _P R%'_#"7[%7_1GW[*__B._P?\
M_F0H_P")T^&_^B XD_\ #SD7_P Q!_Q)#Q+_ -%]PW_X9>(__F@_S>L#U/\
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M/_YH/\WK ]3_ -^YO_C=&!ZG_OW-_P#&Z_TA?^&$OV*O^C/OV5__ !'?X/\
M_P R%'_#"7[%7_1GW[*__B._P?\ _F0H_P")T^&_^B XD_\ #SD7_P Q!_Q)
M#Q+_ -%]PW_X9>(__F@_S>L#U/\ W[F_^-T8'J?^_<W_ ,;K_2%_X82_8J_Z
M,^_97_\ $=_@_P#_ #(4?\,)?L5?]&??LK_^([_!_P#^9"C_ (G3X;_Z(#B3
M_P /.1?_ #$'_$D/$O\ T7W#?_AEXC_^:#_-ZP/4_P#?N;_XW1@>I_[]S?\
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M644HJ*11113&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3%"A?M5\<1RQY-_>;B)6#%BYF+&1<8BE;+Q#Y8V4'@ TZ*S?[.Y.;N](/D'
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MI4I1HI49Q;=_.S'AWB#%<<<.\2X+C/,<LX;RK*^(<!G? U#*,EKY9Q3C<T6
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M_G,?TXT5_,=_Q$H>"_\ HTGQ7_X=O3/_ )WM'_$2AX+_ .C2?%?_ (=O3/\
MYWM'_$N?C3_T0N-_\.?#W_S\#_B8_P $O^B^R[_P@SW_ .<Q_3C17\QW_$2A
MX+_Z-)\5_P#AV],_^=[1_P 1*'@O_HTGQ7_X=O3/_G>T?\2Y^-/_ $0N-_\
M#GP]_P#/P/\ B8_P2_Z+[+O_  @SW_YS'].-%?S'?\1*'@O_ *-)\5_^';TS
M_P"=[1_Q$H>"_P#HTGQ7_P"';TS_ .=[1_Q+GXT_]$+C?_#GP]_\_ _XF/\
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M47>,DI1:LTXR5XR33:<9Q<:D))M3ISIU(MPJ0;****904444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% "-PK=1P>1C/3MD$9],@CU!K^?[XO\ [>OCS]G3]K?XUZC\
M1OC3X@^(7PB\!^,?BBN@?LR_"KP+X&N/%WAWP%\-_P!A6#XQC3OBKX#\;?!O
MP5^T'I>F>,/B[X<O#\*_VK?A-\:OCU\#O'_C7XD^!_@+J_@+P=KGBJPOO!O]
M #?=;/3:?Y?4?S'UK\</VH_^"H>N_L\:[X@U:T^$ND>(OA'\/?V\?@]^QM\3
M/%E]XRO-%UGP]X1U3]F2Y_:J_:2_:%M]/CTF>P_X1+X$_#O5M'==!O9[?5]?
MD\!_%:_DDM-//@Z;4SYM>C:_)H-.J3]4G^:=O56?9H^,= _;"_X*>>!- ^ O
MP5^(FC-XP_;1^'W[5AU'XZ?#O6OAY\)-%?\ :@_9B\:?L6_M+_M2:7X"^'T_
MPV\5ZS\/? .M6_CKX6?$C]G+X#?$O1_'NERZ[\2?V<? FN_'%$T#Q[\2-#N,
M;X:?ME_MR_&OX:_%GXN^#?C7XIC\(^!O^";]Q^U-H<][X1^$'@/4[CQ1K'QP
M_P""CFC>$]=NOA_XD_9%^(&K^+-<F\"_ _X(Z/JOP\?QY\';7P\FB/>7D6MZ
M_P"+-=O9?5M _P""RWQ-^*6M^.=/^%?P-TN70['X]?MB?#WX/:II_AGXS_'N
M_P#C9\-?V<?V?OV;?CE\'/B+H7@SX >'?$/BS3=&_:=MOC]8ZGH'BFWT;Q#9
M^$/ ]SX2UY_#7BK5]=CT.X^S?V<_VY_BW\4?BTWPY^-7PA\)_L]:]K/A?XS^
M(?#7PI\1^*?&^N>.W?X/:YX6T<+X2^,&A>#-3_9I_:!FU>RUG5M8^*_A+X:?
M$W1OB/\ LPW^GZ+X+\;^$O&&J:AXJU+P =;ZW]7OWLW)7[-)-=!M\V^ME97U
MLKW<4VVU%MMN*:3>K3>I^4OQ=_X*=?M)>'_V)-3\0^$_VD/#J?M7:7^T9_P4
M \/:AH5CX7^".I?$73?A+\'?V1/VX?B3\'+C4/A9/X)U 6>BZ+X_^&?P;URP
M\37/A&*X\42VVDZ7K>K:WH7BS4-+UOZ"\=>)/^"M;?']O@1X&^-GC'1KGXN?
MLY?M:?&+]F>/Q9H?['-[KOA#Q%\.;O\ X)Y^ OAOJ'[6GBSP_P# '5/ A^%V
MA_%'XH_'_5Y?"?[/VB^)/BIKGPI\1:(\^N:EXSMK*U^'&=X$_P""Z_B/6O!=
MIXT\8?!'P9H5E?\ ['_A[]H'2;.V^(>KQ3:]\4O'W[+G_!/'XR_#/X0V5[J&
M@QV5A;>-_B[^W3:_".T\1W\A73[#P]I7B2]AB6]UB*Q_0C]C#]OQ/VG_ !EX
M-\#:YX0\/>'==\2_ ?Q5\0O[0\'>-X/'/A^/XQ?L_?'+Q!^S7^V-\+K+4X88
MH]6\)_"WXCW/PNU?X4_$RW=;;XN^ _BA!KD&A>'+?1(+OQ2DDME%7=W:,8IM
M[MJ,8IM]6TV^K8KON_ODVO1N3:MTLU;H?*OA[]JK]HZ_^+OPUL)OC)>ZM\>-
M>_X*$_%+X"?$[_@G_P#\('\,H=(\!_LDZ'X]^(WACP]\<K>XA\#6_P"T)X6M
M-+^ /A'X9_M1V7QP\6?%37_@]\0_$7Q!D^&OA_1(H_B=\)?#W@[QK3OVM?VM
M+Z[_ &GH_#/[3<GQ&^(7PC\"_M.?M.:#X.T'X:?"X?!_3?!?[,_[4MM-H_[,
M/QD\/^(/@)\,?VI_V2/B;\6/@O<ZG\%&TSXCZ?\ '6_\36>FZO\ '?X,?&75
M+_X5^)=$^)7](13+%BS'.!MW';P.RC'.><G/\L1-;ASDR2_>5@ W0J21@$$#
M@X) #=&4AP&#_P K:75U?FUY7%/7JTWTNUH.[::>J>Z=W%WWO%OE??6,M4GN
MDU_,%\1?VU_^"C?P3N?&>J>*_&MOXX\*^)_V?_V'O%NN7'@CX1^$+T?LO_'#
M]M/]H?\ :-U+PK!X/O9/!NFW/CSX >'_  /X6\)?LD^+==^)OAWQ9\18-?7X
M-_'"2T\)1>*?C,]AQOB3]O+]L"V^%7PWU_X9_M7^+/BE\1?'NL?$O0?CMX,T
M/X=?LK:AK?[-%CH'_!1+X+?!/X:ZUHD^G?!>RTKP-XD\=> _&WB;X1Z3X5_:
M#MO&P\7PW\WQ5\/QZ--\'/B/K>H?U7"U48/F2E@6(<L"REB"=N00.!M)P25)
M#$CBG-#NQ^]E&""I##((&,],'/?<".JXVEU8_KK^K;_$7]?\#1)6^1_,+X:_
M;;_:KN[S]MO1/C?^U7XW_9=E^!.@?$B^_9/T?QA\(OV;O$?QN^+_ ,4-&\=?
M$VRU/X%?';0](^#^H_#WXR?$OP5:>$O@9K/@'X-_L:3>%O&7Q ^ '[67PMU2
MR^)?Q+\;>-O!WQ+TGQO2/^"F?_!2^2]L/A7XNT^?P9\4O%'_  4"^%WQ!U?6
ME^'O@_6_#/PL_8&;]L#PG^QC\=OV7[#6X/A\/"OB+XK^ _VB;G1/#%EXMU)-
M7\<:Q\$?C!I_Q%LO%JZOX6NM5L/ZW5M]H $LV!@ %R % 8!1MVG W<'.1M7!
MRN2@M@#DS3M@Y0%\*AP5^4*%XPQX.?087"@ _"7]D;]H+]H#XT?\$R/%WQG\
M2?M;V7BC]HFU_8V^'/QINM:^&?B[]F/XB>-_AM\19_@GJ?C_ %6P\7?"S2_V
M// ?ACX5:GXF\7:5?:1J?P]\9:-\6;JP70M7T;PSXDTJ_P! U+4-2D@\?_MX
MV7B']AKPGHO[2%[XF\'_ +6WP \*?&;XG^/_ !W\/?@MI_Q.^".K?L]>'_#7
MQ@^+>A_#32?!?P,T3X=>+[?]K73?B#X9^#FI0_$+P[:7OP%T/P[XG^(_@"[\
M2^*]7TS0]$_=<VX)#&25B.?F;(R"I4XQA0"B<+C<5W-N9G9FBT4;L2S#<<G#
M@,3G(RP 8E3T9BS<9))+%@#^6#X=_M3_ /!26W\&?\$X_B/\5_VH['P!\+OV
MP/@3\(?%^NZ[\:]7_9'^"NO7WQ77]C[QG\5_B[J5WXTT/]D+XI?#_P"%?P?\
M3^,M5^&%S\+?"&L>$/$?Q?OO$ND>/K7Q%JW@_P *R:#X5O?NS]H+]L_X^> O
MVM?A+??"Z36_%W[&7[-VE?!/0_VXO%?A[1/A/XD\->+=;_:_OE\+^#/$EYX]
MOYO#'C'PS#^R[H#_  U_:.\6S_!/P=K?A?QE\+_CA?\ _"7:9X3M-&TFXL_V
MV6 *S,)),L22=V>22V 2#\H)8JIRJ;F"!5.V@0;<8EEX&.6W'/3(9@3G&.^&
M(W2"1B20"5&+#G&064XZ94D' R2!D<9.<<\9IU1Q1B) BEB 6(W')P6)QGJ<
M9P"Q+MC<[.Y9VDH **** "ORW_X+'MN_X)K_ +3[221Q$Z7\-E+LRJJ%_C1\
M-T0LS$ #?G R,G'?&?U(KEO%7@KPGXZT#4/"OC7P[H7B_P +ZND4>K^&_%&C
MZ9X@T#58[>Y@O;>/4='U:UN].OH[>]MK:\@2ZMYEBNK>"X0":&-U]GAK-UP_
MQ-PWQ!+#RQ=/(L]RG.*F&A55"IB(99C\/CW0IU7&2I5*[PT:,:DE*--593E"
M7+8^?XKR:IQ'PUQ!D%.O##3SO(LYR>.(JPE5I4)YIEN)P-.O5HP<9U:=&>(]
MM.G3E"<U#EC)7U_R\\/V5_PBCQ^'%&)/[K_]^8O\*_TJ/^&/?V3/^C8?V>/_
M  R7PP_^96C_ (8]_9,_Z-A_9X_\,E\,/_F5K^Y/^)T<B_Z-UFW_ (>N'_\
MYWG\(_\ $DF?_P#1PLD_\,6>?_-Y_FKXD_NO_P!^8O\ "C$G]U_^_,7^%?Z5
M'_#'O[)G_1L/[/'_ (9+X8?_ #*T?\,>_LF?]&P_L\?^&2^&'_S*T_\ B='(
MO^C=9M_X>N'_ /YWA_Q))G__ $<+)/\ PQ9Y_P#-Y_FKXD_NO_WYB_PHQ)_=
M?_OS%_A7^E1_PQ[^R9_T;#^SQ_X9+X8?_,K1_P ,>_LF?]&P_L\?^&2^&'_S
M*T?\3HY%_P!&ZS;_ ,/7#_\ \[P_XDDS_P#Z.%DG_ABSS_YO/\U?$G]U_P#O
MS%_A1B3^Z_\ WYB_PK_2H_X8]_9,_P"C8?V>/_#)?##_ .96C_ACW]DS_HV'
M]GC_ ,,E\,/_ )E:/^)T<B_Z-UFW_AZX?_\ G>'_ !))G_\ T<+)/_#%GG_S
M>?YJ^)/[K_\ ?F+_  HQ)_=?_OS%_A7^E1_PQ[^R9_T;#^SQ_P"&2^&'_P R
MM'_#'O[)G_1L/[/'_ADOAA_\RM'_ !.CD7_1NLV_\/7#_P#\[P_XDDS_ /Z.
M%DG_ (8L\_\ F\_S5\2?W7_[\Q?X48D_NO\ ]^8O\*_TJ/\ ACW]DS_HV']G
MC_PR7PP_^96C_ACW]DS_ *-A_9X_\,E\,/\ YE:/^)T<B_Z-UFW_ (>N'_\
MYWA_Q))G_P#T<+)/_#%GG_S>?YJ^)/[K_P#?F+_"C$G]U_\ OS%_A7^E1_PQ
M[^R9_P!&P_L\?^&2^&'_ ,RM'_#'O[)G_1L/[/'_ (9+X8?_ #*T?\3HY%_T
M;K-O_#UP_P#_ #O#_B23/_\ HX62?^&+//\ YO/\U?$G]U_^_,7^%&)/[K_]
M^8O\*_TJ/^&/?V3/^C8?V>/_  R7PP_^96C_ (8]_9,_Z-A_9X_\,E\,/_F5
MH_XG1R+_ *-UFW_AZX?_ /G>'_$DF?\ _1PLD_\ #%GG_P WG^:OB3^Z_P#W
MYB_PHQ)_=?\ [\Q?X5_I4?\ #'O[)G_1L/[/'_ADOAA_\RM'_#'O[)G_ $;#
M^SQ_X9+X8?\ S*T?\3HY%_T;K-O_  ]</_\ SO#_ (DDS_\ Z.%DG_ABSS_Y
MO/\ -7Q)_=?_ +\Q?X48D_NO_P!^8O\ "O\ 2H_X8]_9,_Z-A_9X_P##)?##
M_P"96C_ACW]DS_HV']GC_P ,E\,/_F5H_P")T<B_Z-UFW_AZX?\ _G>'_$DF
M?_\ 1PLD_P##%GG_ ,WG^:OB3^Z__?F+_"C$G]U_^_,7^%?Z5'_#'O[)G_1L
M/[/'_ADOAA_\RM'_  Q[^R9_T;#^SQ_X9+X8?_,K1_Q.CD7_ $;K-O\ P]</
M_P#SO#_B23/_ /HX62?^&+//_F\_S5\/_=?_ +\Q?X5U'@OP=XM^(?BSP]X"
M\">'M>\6^,/%^KVF@>%_"V@VOV_6M?U:^?9!9V=LQ2W3""2XNKN[DCT[3[6&
M:]U.XL].@N;RW_T@/^&/?V3/^C8?V>/_  R7PP_^96NE\)?LY_ 3X?ZS%XD\
M ?!;X2^ _$<$%S:P^(O!7PU\$^%->AM;Q52ZM8=8T+0K#48K>YC41W,$=RL5
MS'^[N%D3Y:Y\5]-'+?JV(^H>'F.CCEA\2L$\9G>3K!K%SP\Z5"6,6$RYXFIA
M8SFI5J-'EG4C&T:D&U*/1A?H29FL10>/X_RRI@E7H_6X8/(LS6,EA?:1^L1P
MDL9C986GB)TE*%*K74HTI24U"3C9_-7_  3;_9M^+'[*7[*_@?X0?&+XF7_Q
M"\6Z5-/?)IKR0WWASX7:5J"6TEI\*_!.M36L6N:[X8\*.LRVNI:U=7:+=W-Y
M8^'XM(\*6>BZ-8??M1")00V22.A.,C/WAP "&ZGCC) P*EK^&LXS;&Y]G&:9
MWF"PZQV;X[$YCBUA,+AL%A5B<76J5:L<-A,+"G1P]!.2]G2A3C:\I2E4JSK5
M:O\ >.1Y/@^'\HRW),N6(6 RG X7+L'];QF(QV*>'PE"G1IRQ.*Q4JE:M7?+
M+VDY5))I0C35.E3I4J91117G'JA1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -+*
M#M) )4G!./E'4_09&3VS7R]J'['O[/>N^+?BOXL\5^!],\:V_P 8_&&D_$KQ
MEX0\9VNF^)/!O_"S+;X!WG[*^M_$'2=)U.PFN].UWQU^SC+I7P;\962ZC+X6
MU/P?H-JMEX>TW5]=\;:KXK^E[BQ@N7\R5KD,(I(0(;V\ME"R8W.%MIXE$Z[1
MY5SC[1!EQ!+&)) T1TNT.3NO<XA (U34P5\@[E9"+O*/(2?M+IM>\!*W;3*2
M" >&^!OV5OV;?ACK7A[Q%\//@O\ #OP7KGA.W:U\+ZEX=\-:?I=UH-K)\+OA
MA\%'M](:WA06L#?"/X*_"3X=&*%1$OA/X=^%-)55M])MP)?#/[+_ .SOX+\>
M:Y\4?"GPD\$>'_'7B*3QQ/J7B+3-(AMI%N_BAJFFZ[\4M0TJS3_B5>']4^*F
MOZ+I'B'XHZKX?LM,U/XC^(=,L->\;7>NZO:PWB^WC3;9760/>;EEFF7=J-^Z
M;YT".#$]RT31A0/*A9&B@;,D*1R,SE@TFT"A!)J 40&W'_$WU7?Y9D,F[S/M
MOF";<2/M ?[1L(C\WRPJ@ ^5](_8,_8OT#5/ >LZ-^S5\']-U?X7S^"I_A[?
MVO@[2TN/"%S\.?#7PG\(_#^716,3);2^#?#?P)^#&E^&B5<Z3#\+_ \MGY=S
MX=TZ:#K_  7^R_\ !CP!\?OBA^TKX5\/+IOQ.^+?ASP]X8\6W< LX=&6/0KJ
MZN=5UK3=-M;& 6?BCQX\/A:#XC>(IKBYU+Q?:_#7X:6>I3&W\&:5&GO9TNT+
M%LW@)ECEPNI:DJ QJ%6-8UNQ&ENP4&6U15MIV&^:*1R6*#2[4!5#WX55N5 &
MJ:F.+K=YF2+O)V!V%MS_ *$-HL_($<80 O[E[$$^@Y/?G SQP<'H:3S$/1@<
MDJ.>I R1]0.3Z51;2[5@07ON8X8OEU34D(2!MT>"MVO[PGB:;_77"Y2XDE4X
MIQTRU+ARUX6$KS8.I:B59G4J4=#=;'MU#$QVKJUM"Y,D4*/\U %SS$) # E@
M6 ')(! )&/0D ^A.*7>G]X<^O'IP<]#R.#@\]*SQI-H%VA[\?N'MRW]K:H9"
MDCJY=I&O"[SJ5"Q7+LUS#&6BBE2)W1G'3+8[COO?FD@E/_$SU'[]L$$6T_:L
MHA$:^=$A6*Z.YKE)F=B0"[O3(&X D%@#P<  DX.. ",^F1FCS$P3O7 4,3GC
M:> W^[[]*I#3+48^:].TSL,ZGJ1YGQO)!NR&*8'V<MDVG)M?)))+?[)LRI7=
M?8,*0Y_M75 X6,DB19/MF];ELD27BL+N93MEF=>* -#>O<XXSSD9Z],CD\'@
M9(I#(@!)8 *,L>=H SG+=.,'//&.:I_V=;[_ #-][N$YN #J.H&,2&-HL>2;
MDPF$(Q(MFC-L'Q)Y7F ,&?V5:A2@DU *89X?^0MJN[9<.[R,'^V>8LRL[>3<
M*PGMUVK;R1*D84 T"Z X+ 8QGGINZ9],]L]:-Z<_,#M.&QD[3Z-CI^.*H'2[
M0[OFO1N,+?)J>I(%,&-HC"7:B)7P/M"1!$NN?M*S9-+_ &9:@J0UZ-KS.JC4
MM1" SIY;J$%UM$2K_J(0!#;-\]O'$_S4 7MZ]B#GH!R2/4 9)'/7I[T@D0\A
ME/S;>#_$>0N.N2#G'6J!TJU*;/,OP!;I; KJNIJPB21)5.];L.9]Z+NNF)N7
M0M$\S1.Z,XZ9:LYD+7FXRI,1_:6HA"R1B,1E!=!#;%1E[0K]EDD+3/"TK,Y
M+OF)Q\P.[(&#G)'! QW!.".QX-+O3^\!CKDX(STR#TSVSC/:J TNU P'OLE)
MD+'5-39F6=MS;V:[+.R'/V=G+-:J2EL84)4ATJU*NN^^Q(MNC?\ $TU+=BU
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M3;"4),(1+'&Z,&E6@"C=?';')&"VJZH[$2L&+NS7A:2:,@?9[ART]J !;21
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MV%Q83^I_#O\ :/\ CCK'@WX[>']6^%=A\2_V@/@-\9-2^#=WX=^&-_I7P_\
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MHK\ ?^(BG]BW_HFW[4W_ (17P<_^?M1_Q$4_L6_]$V_:F_\ "*^#G_S]J/\
MB"/B[_T;OB?_ ,),'_\ /H/^(\>#?_1QN&?_  JQO_SC/W^HK\ ?^(BG]BW_
M *)M^U-_X17P<_\ G[4?\1%/[%O_ $3;]J;_ ,(KX.?_ #]J/^((^+O_ $;O
MB?\ \),'_P#/H/\ B/'@W_T<;AG_ ,*L;_\ .,_?ZBOP!_XB*?V+?^B;?M3?
M^$5\'/\ Y^U'_$13^Q;_ -$V_:F_\(KX.?\ S]J/^((^+O\ T;OB?_PDP?\
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MV<(SJU*5.I^GU%(.@Z]!UZ_CTYI:_/C]'"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@!K8VMD C:<@]",=#[>M?@=\8?^"D&H?LW?M6?&+_A;WQQT
M?6_@[\/O'?Q:TW3_ (*_#7PCX#U_7]%\"_"G]AQ/VA+W0?BUX9\22> ?VC/A
MU\6=>^(6B:_XA\$?&[PH?C9^R]X]^'WC/X6_"P>'O"/Q!^)V@^+M'_?(]#]#
MZ_T!/Y GV-?D)^TE_P %1M,_9Y\3ZO._P0NO%/PU\$_MU_!3]AGXA?$>3Q['
MX>O?"D/C+]GE?VG/C7\=DT&+P/XBCU/X6?L[_#O6?#<FO6]SXFT?4==OM&^+
MMW(GAFQ^'OAW5/B 7=FKZ/=='Z]Q-)M-I-Q=TVDVG>+NKIV=XQ=UK>,7O%-?
M$VC_ /!0#_@H%X0T/]G_ .&'Q-\&Z%XB_;,\$_M6A/VC?@I:>!O#^@:]\>OV
M8?&_[%/[1O[7VCZ!\$M T_7M:@LO'&CW/PH^(?P)^"WB2'Q3I^G_ !+^-O[+
MEW:^/]7\,>%?&OBUM.Q/A=_P4,_:A^/?PS^*GQE\"_&"ZN? OPZ_X)N7?[9'
MAK7/#GA?X-^&=#U?4M8^-?\ P46\/>"?$'COPG\1?A'XE\<:EX=UCP5^S;\*
MK$^&_#&L?#;5=&ELO$EUK9.K:S-'IWN>G_\ !:[4/&>K_$'3_AU^S/I>IV7A
MGXZ?MD?"#P!KGBWXO>,H(OC/X9_98^!_P$^-7@[X@>#/#GPQ_9T^*WBB^M_V
MD-,^.MO#\-M#TO0?$MW;^';#2/%NFS>,+WQK9^#[?Z__ &>_V[/B+\8/BL_P
MU^*?[-W_  SAJ%[X3^*_BWPUX.^*7Q#U_3?C/J\/PQUCP=:V\]CX0U+X.:%\
M,O'^B:WIGBF76_$NN? KXU?%\_!N8^%_#GQ-T_0/&7B:^T;PNK)[I/2VJ3TN
MW;6^EY2=MKMNVK!))MI)-N[:23;M&-VU9MVA!7;>D(+:,5'\H?BY_P %;_C?
MX7_8;U+XF^&_CC\)%_:(TS]H_P#;\\#WND_V;\.+W6['X<? /]D;]MSXO_#6
M>_\  <DTLMK'I'C3X-?"_4]2UF?3HFUFSM9K"[GFT[7Y9;GW3QS\9_\ @JS:
M_M I\"O FK>*H[[XA_L__M9_&G]ES1_'&G_L97/C[4=:^%@_X)\^"OAWJ_[8
MFL>%8V^&EK\"-.^-/QK^.D6OV7[,]VOQPU7X2:MX0N+: ^.='4-E:)_P7?U/
MQ%H_PRU[3/V0]/CU#XF^ _V9O&5G"?C-XAUJZTYOVD_"?_!,+Q+!H)T[P;^S
M?XD\7^)%\&S_ /!1UK!;?PKX>U3Q%XT/P6A_LCP[;ZC\3HM'\$?H-^QK_P %
M 9_VH/BGXG^$OBSX2#X5^(M&TSXQZKH#Q^,M5\3'Q+)\!_V@?$7P(^*&D:YX
M4\8_#/X4?$;X6:SH=A?? 'XH6/ASX@>#=&U[5/#'QZT)[>P.F:';Z_XG%&*V
M26K>B2U>K>B6K>K>[>K;>H]TD]4E9)ZI+LD[I+R22\CYB\-_MP?&F]^*'PQB
MF^*/A;5/BWXU_P""AGQ8_93\;_L 6F@>#?\ A)OA[^SIX(\>?$WPAIGQJMYX
M;5?C9I'B30_A)X.\"?M=Z_\ $[QMK5U\'/&7PL\=MX4\+> -)N/'OPP\6VGD
M>F?MY?M*7$_[1TN@?M!^ _B!X_\ A'X#_:4_:9M?AYX7\$?#W4?@_-\,/V4O
MVHK+3M7^!WB#Q++!X6_:*_9@^)?BSX%W-_\ !;QOH7[2?PM\0:B?CQ::U\4?
M@U\2-;\&?!SQ_P##GQC_ $5&W@9_,:"%I-BQ>88T+^6C^8D>XKNV+(!(J9VJ
M_P P ;FA;:W0R,EO"K2B,2LL4:F01+LB$A"@N(T^2,-G8ORK@<4N6.GNQT5E
M[JT7NZ+31>['167NQT]V-E9=EO?9;ZZ[;ZN[W=W=N[O_ ##_ !"_X*3?MS_
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M97G=(HU>9T)*-*RJ#(REB59R2I)P1DU22226B2226B22222Z))))+1))(?\
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M.-089>%AFWA)54"^<N<C/GE<AB"8<D1\4"SO 1_Q,&(#2G!MHLE7_P!4N00
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M+Y'.2I!F)_>'@4&SOR"!J6&,<:AOL</$BDF27&<'S1A1'PL?)!8T<L?Y8_\
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MR-F9L9Y\]25V\+#P4!P*7[)>9S_:!*^:7*_9HA^Z*;1"'!W#8WSB7[S?=8$
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M^GEN3U7["5:. KYI7PM2ABZ&'KT?1OC+\?OBEH'[37A?X ^ ]<^!_@?3=0^
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M'Z1TGXV?&7X9_&_X2_"+]H/0?ASJVD?'A_%6B_##XI_">/Q-X?TG3_B-X/\
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M>J*_#?\ XB /V!1_%\<!_P!TWMO_ )JJ/^(@#]@7^_\ '#_PV]M_\U5?H?\
MQ!OQ;_Z-OQ?_ .&F7_S:?FO_ !&[PB_Z./PC_P"'27_S"?N117X;_P#$0!^P
M+_?^.'_AM[;_ .:JC_B( _8%_O\ QP_\-O;?_-51_P 0;\6_^C;\7_\ AIE_
M\VA_Q&[PB_Z./PC_ .'27_S"?N117X;_ /$0!^P+_?\ CA_X;>V_^:JC_B(
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M>LO!VJ+#-X/^*W@?XP_$+Q#^SC+/HC>./#-U\'_']SJ^K_%F".SAT;'^'?\
MP4;_ &M/&'Q/_9@^!VH>++#Q?\1/C3X:^&?Q!\=Z5^S[X$_9PU?[1X7\??LO
M_M(_%"W\>?LS_&?Q1^T+XF^!_C/]G+Q]\2?@;<R?"+1/B_8^ OVG/#_PQ\.:
MYK'Q#T/Q!:_$3P3XHT'^AGPY\*?ACX.TN?1/"7P\\#^%M&NM8LO$5SI/AOPC
MX=T'3+CQ#IMQ9W>G:]/8:3IMG:RZUI]YIUA=V.J/$U]:75E:3V\\<MK;M%E:
MA\#/@OJ^EWVB:M\)/ACJFC:IXGOO&NI:3J/P_P#!][IFH>,M3C\G4?%M]87.
MBR6EWXFOX L%[KUQ#)JMW"JQW%W*!0!^#.M?\%3_ ([IXL^/>DZ-J_PF\.?#
M_P <:W'X%_86^)OQ:\$>(? .A>)=?_9\_: ^%?[-W[4=IXC^+>L7NA_L_P#Q
M0^)_QVUWX@>)O&W[&&F^"/$6G_#*.Y\"WDOQHUWPWX&:[UN'V7]D?]MGX^?M
M#_M3>.?@Y/XB^(&L>%/@AHGPS'C=/#_PK_9N^'VO>&/&VL?M1?MF?"GQKX,^
M/<_B/XY?$'2?%S^&/"WP"\">$;_QI^QYJ?BGPOX@\667Q#U_2++PAJ.K:5\.
M?"'[1R?#OP)-H.G>%9/!WA9_"^CV4^FZ/X9?P[HK^'M(T^[T;4/#=W8:7HDE
M@VF:?9W?AS5M6\/W5K:6L4$^B:KJ6ERQM97UU#+SC? KX*O=>$[U_A'\,9+W
MP"FG1^!+Q_A]X/:Z\%)H^HMJ^CIX1G.BF7PVFDZL[:GIB:,UDEEJ+-?VZI=N
M\S 'JM% &!CTXHH **** "BBB@ K\N_^"R0+?\$VOVH H+%M*^'.T*,EO^+R
M?#@?*!G.20.,\D=S7ZB5Y[\2?AEX!^,'@K7?AO\ %#P?HOCOP)XECLH?$'A/
MQ+I\6IZ'K$.GZC9ZO8QWUE,"DPM-5TW3]0@[Q7=G!*O*5[?#&;T^'^*.&L_K
M4*N)HY'G^39Q5P]&4(UL12RS,L'C:N'I2J>Y"K5I8>I"E.I^[C4<?:>ZVG\]
MQ;DU7B+A;B3(*-:GAJV=Y!G.44L35C*5'#U,SRW%8*E7JPA>I.E3K5Z<JD:2
M=1T^=Q5TC_,*VMZ'\C1@^A_(U_HD_P##LS]@3O\ LA_ O/\ V(VG?_$4?\.S
M/V _^C0_@7_X0VG?_$5_>/\ Q.EP;_T1/%O_ (7<.?\ R9_GY_Q)-QG_ -%I
MPO\ ^&_/_P#Y$_SML'T/Y&C!]#^1K_1)_P"'9G[ ?_1H?P+_ /"&T[_XBC_A
MV9^P'_T:'\"__"&T[_XBG_Q.EP;_ -$3Q;_X7<.__)A_Q)+QG_T6G"__ (;\
M_P#_ )$_SML'T/Y&C!]#^1K_ $2?^'9G[ ?_ $:'\"__  AM._\ B*/^'9G[
M ?\ T:'\"_\ PAM._P#B*/\ B=+@W_HB>+?_  NX=_\ DP_XDEXS_P"BTX7_
M /#?G_\ \B?YVV#Z'\C1@^A_(U_HD_\ #LS]@/\ Z-#^!?\ X0VG?_$4?\.S
M/V _^C0_@7_X0VG?_$4?\3I<&_\ 1$\6_P#A=P[_ /)A_P 22\9_]%IPO_X;
M\_\ _D3_ #ML'T/Y&C!]#^1K_1)_X=F?L!_]&A_ O_PAM._^(H_X=F?L!_\
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MY;YIV9VG$G-M<VL7[JD%K=@C_B97Y %UU32_F\_/E$XT]>;/@6P78#UO/MM
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MPS\3^*?&'AK0O!%YXBT71;CQMX6\7:)X/MYM*F\1_$F7P/\ $&?X<Z%XGM?
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MD>_Y'_"@!:*3(]_R/^%&1[_D?\* %HI,CW_(_P"%-WKN"_,"<XRK ' R<$@
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MQJN(R?#U,SP]"OC<3"EBZ&6YG5Q=/,LT]M56)J8.AB<%@ZV$J5:,OT_5@P#
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MHMGI0!VT_P"V?^PW8V&B:KK'Q&O_  WIOBBSO]1\)W_BSP1\>?"-KXPTO2]
M\<>)=2U;P;-XF\(Z2GB[2+'3?A[X@@NM5\-G5-.@UR^\$^%Y+I?$WQ,^&^D>
M*]G6/VK?V./#7B+P#X1\6^+]>\#^*/B=XZMOAIX*T#X@?#_X^^ -5U/QQJ&H
M^"-(TG0+ZT\:>$-"D\.3:]JGQ(\#Z?X<O/$XT;3/$5WXDL(-$O;]_/$/C/BK
M_@EI\-?B#HGP7\/>/?BU\3]7L?V=M-U[1O@Q<:-:^#_#FH^#[3Q%;ZM/>ZO-
M=+H.J+KOBQ?%,?PY\8Q:EJ$2Z FJ?"#PAIR^%TT#6O'VF>,O3OB7^P3X3^.W
MCOP+X]^/GQ(\8_%2;P6_Q,M9/"-_I/A#0_ >L>&OBEX+T7P/K?@V/1=*T;^V
M=%T&UL-&?6K6[M_$MYXG'BO6]:UR/Q#;HNB:=HP!Z=\*OC/^SA\;M7\0:+\+
M;SQ=XKF\*Z]J'A;Q#J</P_\ CMI7A72?$NEZ7I.MWN@7?C;7_"VE>#4UB/2M
M=T>]BTX:\UW=QZE:)9Q7$LR1GC[+]J7]C[5[1KSPYXMUSQFJ_%/XH_!06?@#
MP)\>/B#K,OQ.^#.EZAKGQ&\,0>'_  3X4U_7KC^Q="TV;7-.UN'37\.^+-%N
MM)U;P=J_B#3];TBXO>3_ &;_ -@30_V8HO%3>"_BEK/BCQ%XMM]2EO\ XI_$
M/P!X \0_&VWU^_\  .A>!_[:M?B9;:;IDTD/VGPYI_C&_P!#U#1;[3-6\47>
MN3W"1V6K-:6F=X._X)U>#OA/XD\#^)?@K\6/B5\/I_ ?ACP=HNF:;K,]C\3]
M-N?$WA'X,^*_@"WQ.N1XY%]J/_"<Z]\,-6\$Z'J@.JR^%/\ BT/PZ">%VM+;
MQ':>( #L[C]K?]B2W^'*_%M?BC87WP[D\'?&GX@0>)-'L/BGKL=WX._9[U72
MM"^*^O66F:+I&H:U>VFAZWX@\,:/H:VVFRW'Q U7Q=X-T_X<P^++OQ?X:AU2
M_??M3?L4Z9>^)[#4?BWX8LI/!GAWX*>,?%-U<ZAXX32=$\%_M$W=[9_!_P ;
M7NN>0=&7P5XJDTZ\FN_%\=_)X<\(6,#ZAXXU+PU9;9V\O\.?\$Q?@IX3U2TD
MT3QC\5(?"UC=_LX7=KX,'B'3K.UM9/V;1X0U33;C2O$6B:1HOBC0M5^*OCCX
M3_ ;Q]\8M9T?5;*\\6>(/@EX1BC%AI>I>)K'5> \3?\ !'_]G3QAX2E\"^(/
M%GQ0N_"R:OH.GZ;I]KK.EZ=?:?\ !+P^FI6&G?LWR>(H-(/B#5_A39>'SX+T
M;33JU_<^*].NOA5\-_$UOX@_X2?P\=6O0#Z:T3]HO]F'Q%XJT#P-I:?%9_&?
MB?1+GQ1HWA6\^!'[5.E>()_"EH?!D=QXNN])U;X;V5[I7A".Z\?^&-._X2O5
MH;'P\VKW&J:,FI-JOAKQ-9Z/8\)_M"_LN>.=+U'5_"VI^,]3M]/\%R?$:"U;
MX9?M"Z?K7B7P);ZZ_AK4/%?@'PYJG@VR\0_$K1-%UO['9^([WX>Z7XGC\-+K
M7AN\U_\ LZP\3^'KK4\75OV/]5\4?$GX<_%CQ]\9+WXI^+/AAX7UOP=X8L?B
M=\)_A;XA\':?8:[J7PXUG4?%NG>&],TC0)=)^*NIZQ\-=*U/4_'.GZS';K/J
M&H6V@^'O#^D+I^C:?I?"3]CK0OA@/#)O/B#XI\9M\/\ X(^-_P!G[X;1ZEIN
M@Z3%X2\ ?$CQ/X:\6>.;JZ_LNV6;Q+XN\2:EX%^'\%UK.HW$>E6&G^"-+AT+
MPYH]WJWBF_U\ BT[]I?]DG5/!LOC^#Q/KMMX5A\/_ OQ4]_K/@;X[>'KQO#W
M[2_CB_\ AQ\#M5AT+7O"NF^(+JV\?^,=-N],L?LNESRZ7;"WUOQ#'I&@7MGJ
MD^5>_M7_ +(6F>%/#?C?4]7^(>F^%?%GP]\1?%O1M8U#X*_M164#?"KPC:>
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M];:'JD.?*3(((R"&.6X8CDY;GUY/I4M%%,/P"OSX_P""H?PL^(GQL_85^/\
M\,/A/X3U#QQX_P#%NG^!X?#GA?2KC3+6^U633/B?X(UO45@GUC4-,TY#9Z3I
M6H7L@GO8B\=LT<(DF>*)_P!!ZKM"6X(0CN#SG\""I[=NU>CDV:XK(<ZR;/<%
M"C4Q>29ME^;X:GB(SGAZF(R[%T<90IUX4ITZKHSJT(*JZ=2,U!22=Y7CX_$&
M3T.(<CSC(,54K4L)G>59CE&*JX=TXXBEA\RPM7!UJM"5:,Z/MH4JTW356$H<
MUF_A:?\ GQ_\.E/^"CV,_P##*/CC_P *3X9Y_+_A.:Z[P'_P1P_X*&>,/&?A
M?PMK'P"U7X=Z3KVL6MAJOCGQCXC\#_\ ",^$=/D+/=ZWK,6A^+=2UJ]@M((Y
M##I^BV%[J6HWC6UA:QI)<B:+^^KR)?6/\V_PI_D<Y^4< 9&0>"#C( .../F/
M09R,BOZ?K?3&\2ZM"M2I9#P;A:TZ<X4<3# YO5GAYRA*,:T:5?/*E"K*FVIQ
MA5A*G*<(*<)TW4A/^5\-]#+PSIUZ-6MG/&>)I4ZM.<\-4QF5T:>(C"<92H5:
MM'*E6I4JL8N%2K1DJL(R:IN,W&</DK]C;]B_X2_L3_"/3/A9\+]-BN+IYK;5
MO''CS4K: >*/B)XJ2U2UN-?UJ2*/R[&WAB4VOA_P_92/I?AS3%CL;/S9WOM0
MO_KZBBOY=S/,\PSK,L?F^;8W$YCFF9XJKC,?CL74=;$XK$UFG.I5J-)NT5"G
M3@DJ=&C3HT*,*5"C1HTOZPRK*<MR/+L'E.3X+#Y=EN7X:CA,%@L)35+#X?#T
M(\M.G3IQT6\IU)MRJ5:LZM:M.K6JU:M0HHHKA/0"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "N)^)?_)./B!_V)/BO_TQ7]=M7$_$O_DG
M'Q _[$GQ7_Z8K^@#7N&"/,Q!.'Z*"QYVC@*"3UZ $^U9VEZUIFK6WVG2[ZTU
M*U6>:W>YT^ZMKRW2X@D99X6EM99D\V)\+)$"95R/D).!%XFT6V\2:+X@\.WK
MW,5EK^EZEHE[+97#6=['9ZK92V%W)97:*[VEXEO<2-:W2*SV]P(YE&Y!7B7P
M$_9YT3X#Z3K>FZ/KVK:\=?U&&^O+C4A;6D,0L[9K*UBM=-L8([6*00/(+NZ#
M>9=$6T:K!;V=K%%Z="AE4LIS'$XC,<11S>CB,##+<MAET\1A\=AZTJD<;6K8
MZ.)I+"2PL?9RA"5*K[2[>JO$^3S',>+Z'%W#F799PUEV/X.QN SJMQ-Q-7S^
ME@LPR',,+&C_ &'@<#P_+!5JV=4<WE4KK%8JGC<*LL^KPE*%6-2:GLZW^TQ^
MS[X:U?Q3H/B'XR_#K0]9\$MJ*>+-.U3Q/IUE<:%/H]KX:OM7LKX3RJHU'2;'
MQGX0O=3TV%I=0L+3Q3X?NKNUAAU:R>5L7[37[/L]G>W\7QD^'3V^FRV5MJ"C
MQ3I?VZRO]3\7>(OA_IFDW.DF<:O%K6H^.O"/BKP?9:(UA_:]QXE\.:UHJ6)U
M#3[F"/YP\<_L!^$?'EO^T1?ZGXNNX_&WQR^)4GCK0/%<D'BV\M_A)I=[HWP8
MT76]#\)^&5^(=EHT'B'7[3X/QV^I?$;PNG@3Q6]AX@^P"9H-*<:MQ'AC_@G7
MJ'@?XJ:9\6_"OQKMSX@\$_$4?$#X;Q>*OA[K_BJ2%[W7/VP4UW3_ (M>(+OX
MNV_BCXO:I<?#_P#;+\:^#='\:W.K^%O%-GJO@3X=^,?%%WXWN++7M&U[S#ZP
M^M]3_:P_9DT6VAOM8^/OPETO3YO#UGXK&J7WCC0K72(?#>I77BG3],UB^UB:
M[32]-L]3U/P/XRTG37U&\M7O]8\*^(='M8Y-4TB_M+<L/VK?V;=2DUV&V^-W
MPV2;POI7B?7/$L=_XGT_2F\/Z3X)\-Z)XR\97VL'59+)+"/PGX.\2^'/%WB2
M.X>.;1O"NOZ+XDOXX-$U6QOY_@;XC_\ !*>3XA>&?C#:/^T)>:9XL^,.G-+K
M5U)\/M>U'X8+XK\2?%#]J'XE_$+5M7^#B_&&PT3Q;HOV[]IR]OO@MIWB#6KK
MQ7\#?'WPV\"_$S2_'WBCQ#!?13_17BW]AG0O'%EXOLO%'BW2M<C\2_MB_!C]
MK&R_M3P(;J+18/A;X$^"7PY\0?#3[.WBX1ZC:_$CPC\*?$GA_7?$$K6^FKH/
MQ+UC0]4\$^(=-L;N'Q  ?1^J_M"? O0D\7RZW\7_ (<:.GP^O_AQI7CPZKXP
MT/3O^$+U/XP2Z3;_  JT[Q2M[>P/H5]\1;K7M"L_!5GJ26]SXGO-8TZST:&\
MN;E(JYQOVL?V:TT72/$LGQM^'L/AS7].U?6]#\07&N1VVBZQX?\ #^GZ5J^O
M>*-,U.X6*TOO"6AZ1KNB:KK'BRUEE\-Z7IVKZ9>7VJP6^HV<DWQ'^T!_P2WT
M_P".WQQ^)'QG/QJG\)K\5?%_@3Q?XU\&K\.EU_1_$MY\%O OPR\-?L^+X@GF
M\>:6+V?X*^+-$^-'Q&\-7NG6.BOJ&O\ QET^VU:&>#X9Z9/XB[3P'^PO\5_A
MOX>^">F^&OVB/"-QK?P3^"OQ$^#&DZQXO^$?Q2\>Z9J]C\0/"GPB\--K?_".
M^+_VJ-67PZFC3?".PU*U\'>'=5L? KIK5]I]IH&E^2+VZ /KW4OVE_V>]'>T
M35?C7\+M.-[?ZKIEN]UXW\/1P_;]%\;7'PTU*VGN#?\ V:T:W^)%I<_#X27D
MUO!-XWB?PK!++KH-@*,W[57[-<'AV?Q=)\>?A+_PC%MXBT[PA-KT?CSP[/IB
M>+-8^'.G_%_2?#'VF"^D1O$&J?"G5]+^(^G:.N;^^\$ZA9^)+2"?2YUN*^/?
M@3_P3J\1?LR^%]=\&?!?X_:?8Z'XK\&:=\-O$-YX]^#<?COQ(G@GPQ\9OC?\
M2?!@\/WY^)>@Z)9^*K#PI\=_$W@OQ+J_B?PWXRT#Q%XATK1OB#IOA+PPTFM>
M%-7\%U;_ ((V)/HOABV\/?M&GPWKNGZSX2U'QMJ-O\(KO^R/B5;_  [_ &9O
M#/[//PWDUW2]*^+^AZ_I7B?X?3:?XU\1^&/%^@^,K'4;?PW\3-?\!7-O<RZ#
MX,\8>'P#]6]'^/WP6U_Q/I7@G2/B=X/O/&.MN\.E>%?[6BM_$=]=II&K>(?[
M,@T2[$&I-K4GAO0=<\4PZ#]G_MN?PGHVJ^*HM/;PYIUYJD%&\_:1^ NGS:E;
MWOQ;\"02Z+X;U;QEKFW7[.Z@T+PEH-WXSL-9\3:W>V3W-CI&@Z?>_#KQ[:3Z
MOJ-U;:>9O!WB-8KB7^R;LQ^">#/V2_'_ (4^,GASXJ-\<=/L]-L/%)\1^--
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ME8$3QG(A($QQG@1$@2GI'GY]M1G3[0NTAMK4N\R7#.;:(NT\:>6D[.1EITC
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ML C/.-"OP>H!X;(_#-=S7$_$O_DG'Q _[$GQ7_Z8K^@#6N&*-,P&[:Q..1P
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M"TN?CG1_^"8 \)>)O@/XM\'?'SQ'::O\$O@]\$_A2/\ A)+;XM:S%XC?X0>
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M+XLTKQ]-IVH?%KQW:>);31;#X ^"?&/Q \+_  <^%OC3Q)I=[I]R?$6G^/\
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M2T#]C?5?@W\3/#>B:W^RUXHCT7XY6GQ5\/7DOB^WL_B?\=O ?AVZT?QEX?\
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M444 %%%% !51K@K\I"ASP"<A=QSMSDAN>. "QY(&,5;K\Y/^"K7CKQK\,/V
M_P!HCQU\._%GB+P/XU\.Z=X"ET/Q9X3U>^T#Q%I,E]\5O 6EWSZ=K&ES6M_8
MO>Z7?7FFW4EK/"\ME=W-NS%)I WIY)E.(S_/,ER'"5:5'%9YFV79/AJV(=3Z
MO1KYGCL-@Z5>NJ495)4:4JZE4C3_ 'CAS*%V>/Q#G%'AW(LYS_$TZM;#9'E6
M99QB:&'5-XBOA\LP6(QU2CA_;.-!5JRPZI0E6DH1YW)Z)M?HG]H'=&_-?\:/
MM _N-^:_XU_G%_\ #P+]NGM^V!^T=_X=[QN?U_MGFC_AX%^W3_T>!^T=_P"'
M>\;_ /RYK^LO^)+^,_\ HN.%/_#;Q'_D?R!_Q.UP9_T1/%G_ (<>'?\ (_T=
M/M _N-^:_P"- GR<!",]R1C]#FO\XO\ X>!?MT_]'@?M'?\ AWO&_P#\N:4?
M\% ?VZ2<?\-?_M'G/I\7_'"G\"-:&/\ #..:']##C-)O_7CA/1-ZY;Q&EHF]
M^5V];.V]G:SJ/TVN"W**?!7%B3:3;S'AUI)M7;5E=)7;5];6/]'/SP71 R;F
M8@C.6Q@MP,Y'"DY((P"?K8K^&S]@S_@LE\>_V?OBS$?VC?B!\1/CQ\$/%TEA
M9^,H?&'B/6?&?C/X>R0,T,'C3P'=:O>7%]/;V2W#?\))X/%RT/B"S,,NE01:
MU:J\W]LG@GQGH7Q \+>%_&_A+5K#7_"7C/0=*\4>&->TWS&L-:\.Z[I]OJNB
MZM9/*5D^RZCI]W;W<'G11RB*51+%%+OC7\(\3O"3BSPHS6AE_$,<-C,'CZ<J
MN5Y[EL<5_9>8>RA2EB:%..,C#$X;%X;VL'5PM:,I2HRABH3=*HHP_H#PM\8.
M%/%C+,3C<AEBL%C\!4C#,LAS/ZLLTP$*TIK#8F;PDIX?$X/%*#]CB:,DHU5+
M#5*:JPO/KZ***_,3]5"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *XGXE_\DX^('_8D^*__ $Q7]=M7$_$O_DG'Q _[$GQ7_P"F*_H U;J6.$SR
MRNL4499Y97*K'%&JAGED9F55CC4%W=V5$169V5 S#D?!/Q"\$?$/2IM9\!^,
MO"?C;2;:_N-,N-3\(Z]I?B+3X=2M@);C3YKK2KR[A2]AAFMY9+?S#*%F0K&P
MECJWX[\*Z9X[\(^,O VM/>1Z-XU\-^(/".L/I]PUI?KI7B72+K1M1-C=HKO:
M7GV*]G^S72*SVT_ES*I* 5\O_L??L;>$?V0-!\7Z3X:\7>(O&5YXWUBQU/5-
M2UNVT_3DCMM%M+NRT73[;3--B-M$UM;WUXUY?"=I[^XE0-%:V=K964%+EL[V
MOK9W=TTM-+6=WY_\'Z3!8/A:IPOG^.S#/LQPG%F$Q^2TN'N'J&2_6LMS?+L3
M.M#.L;CL[6(C++*^7)4?JN&EAJM/%J4WS<Z3H>C:I^U#\(M$L_C?JNKZIXCT
M[0/V=(?$C_%[Q/<>!/&I\-^&;KPIX0\/^.=9TBRUB+06M/%NN1>&_%.A7EEH
M_A!];O-7N;XZ3I"W^KVEY8PYD/[77P.OY_!-KH&O>)O%]Q\0?AY\/?BSX9B\
M$_#;XC^,G?X<_%C59]!^&WBO7(_#GA749O"NF^,M;M+[3=*;Q+'I<MK-IFJR
M:Y%I-IIE]=VW,Z]^Q+\&_$5U\4=0O'\1V6K_ !D^-W@GXV?$#Q%H<V@:#XOU
M9_ =Q\+=0TCX8Q>-=(\/6?BZR^%]WJWP@\(:GJNCV^M)KES+_:EO!XAM;.\2
M"#E;+]@;X<Z:WP[LK'XD_%R/PQ\*_','CGP+X:N]0\"ZK-X5EL_CK>_'JT\.
M^%O'.J> KOXF>%O#L^I7B_#/Q-#H/C*RU'QS\%[#2_ /C'4=9&GV^K"3YL]"
MB_;%^#$OPZTKXKJ/B8? FM?$NR^#^G:LOP<^*;74WQ$U'XF6/P:T_0)-&3P@
M^M6L5_\ %74;7P)9:U=:9%HEQKAD4:@ME')>Q\UXE_;Z_9B\&:+XS\1>+_&?
MB7PQHO@72/BMK6LZCK'PJ^*D-OJ$'P,^*6@_!7XLZ?X/2'P?/-X[UWPC\5?$
M_A_P&=!\')K6LZ]KVLZ?'X9T_6;:4W%=O:_LM^!K3X/^'_@K'K_C$^&?#GQP
M\+_'NRU-KO0/^$@F\5>$OVH+']J_3]&NIU\.KI;>&+CQY81>';VW@TJWU=O!
M326EOK-OX@*^(D\<;_@G-\"3X_T7XAP:W\2=,U2'XI?$GXL>.K#P_KF@>&+3
MXQ:YXW^-&O\ [0'A#3/BAJWAOPOI/B_5='^!GQ0U^36OA"VA^)O#^M6-IIVE
M:+XSUCQGI%K]C< ]2\9_MF?L^^!+3QGJ>M>+->U'0?AWH^FZWX\\6^"OAQ\2
M/B+X,\&6VM^!!\3=%M/$OBOP)X4\0:%I6LZGX"GTGQ=:Z+=ZA#?KH/BOP)=7
MD=F?B!X+&N]3;_M,_!J[T"P\56GBU[OPWK/C[Q'\,_#>NVOAWQ1=:5XP\6^#
MO#?BCQ=XJC\%WD&BM'XM\/:'X=\#^-M1O?&/A_\ M#PF8_!_B9;/6[Z?2)8)
M/FJS_P"";_P\T7X0_$CX"^%OC9\?O"OPG^+7AVW\+^/O#6EZS\.;R]UO2=)^
M&&G_  0\,VG_  E.O_#;6?$UK:Z'\&?"GPN^&=U9PZF(/%OA[X2^$YO&*ZWJ
M_B+XK:E\1NVO?V+?"NAVGPRT/X>>(=2\-> OAK\6OB7XVT+X?26FF'0/ _P^
M^+WP9\>_"GQA\*_A,FE:1;OX2\.Z-KOCJX^)7@.PU2U\40>&+I-0^'>B'1?A
MO/H&C>$@#?/[<G[/D6GZ;J][JWC_ $O1=4^&^D_&)=:U;X-_%G3](TGX3ZW>
M65C8?$CQ/?S>#?*\*^#?/OEEU#6_$ T^+0],M=4UW7X=*T'1M4U*V[/P1^U7
M\"_B+XMUKP/X/\;C6/$GA[XS>.OV?-6M1X<\66-E!\8OAMX4E\;^,/!,&L:I
MH=AH]]>Z?X7LM=U&UU&PO[K0=6G\)^,]'TG5[[7/!OB/3K#Q*;_@G?\ !VW\
M*6?@/PIXG\:_#_P5/^SSIO[,GC;P[X*TGX6:3:_$CX:P3PMX@F\3RO\ #FXE
MM/%GCNP2ZT3QEXD\.G1KJ]TK4;HZ5'HVJQ:?JMCD>#/^"?'@?X7_ !'^ WC#
MP#XZ^(#6'PP7PW<_$*#QOXAO/&.K?%G7_ 'A3XXZ3X/\9:C?W%M;IX=\9ZIX
MH_:(^)?B[Q]>^&I-'\+>(WU'^R$\"PPS6.H^'0#]#J*!T%% !1110 4444 %
M%%% !1110 4444 %%%% !7-Z1_R4'Q1_V)/@'_U(/B;725S>D?\ )0?%'_8D
M^ ?_ %(/B;0!WE%%% !1110 4444 %%%% !1110 C?=;MP>3TZ5^:F@_M0_&
MSXA?$OX\2>&M<_9N^%_PD_9__:V\%_L@ZUHWQM7QCIGCSQCXC\5>#_@]?KXN
MTSQSIWC+3/#7A?Q+XH\7?'SP-I'P,^"%[X!\0ZC\:+.R\,QP_%/P9?\ QKT9
MOAS^EA&01Z\<$@_F.1]1S7C&I?LX_L^:S\4]/^.>L? OX.ZM\;=(;27TKXQZ
MI\,?!&H_%737T#2O$.A:&]A\0[W0I_%]H^C:+XN\5Z1I3P:Q&VG:7XF\0:?9
MF"SUK4H;DMJGU5[?-6?WK_@6#?1[/3Y/?[S\F_#?[?'[;?C/PU=FT_9]^%/@
MWQ/X9_:$\*?L;^*]-U'6-/\ %?B+Q7\=/AYX>^*7CW]KKXH?LZ?"^\^,WPMU
M/XY_!KPSX*\$Z#JGP?\ AM:>,_"O[0OB'P@/C'\3]9\*WMI\&K3P/\2N,^+7
M_!2?]I7PO\*H/B[\/?$7[*_C+P]%_P $U_VQ/VVKRTM_A#\?8+>Z^(G['6H_
M!CP3XA^&T6I>,_BI\+?&_A;3O%OCWXC>)4U:T\;_  DT/QS\)G\+2^!]:T;Q
M9KMIJ>NI^S/B+]G3X >+_#6M^#/%OP1^$?BKP?XE\<1_$_Q'X4\2_#;P7KWA
MOQ!\3(M1L]9B^(VN:%JNB7>EZQX^CUG3K#6$\9:E:W7B,:I9VM]_:7VFWAD2
MO/\ LT_LZW7AG3/!5U\!?@Q=>#-$^$GB+X Z-X0NOA;X%N/"^D? CQ=%X9@\
M5_!/2] ET%]*T[X1^)H/!?A"'Q!\-K*U@\&:U%X6\.1ZGHMTNA:2+-.*>ZO[
MREJV_>3DU+63M).4FFK--^EERQ5[))./*TDDN77W;*WNZMV5E=MV3;;^0?V<
M/VG_ (M?&=_!7Q=UC5_V<_!WP;^*OQ@_:=^#_@[X4>()_%7A?]H:TO\ X!>*
M_B]X5T>TM/%-_P"+-8\)_%'XHWD'P(\<^+?BO\%]/^'W@"[^$>@R>*8D\=>,
MO^%-:QJ7C[\[_'7_  5?_; ^'G[!7[,_[7.L_#KX2W?BC]I3X9^+/B%I'A34
MOA;XK\):!HAT#_@G;^T+^V/96WAZXL_VF/'>J>/=*U#QW\*_"_@^TU/6G^%>
MHWOAB?6VFT'2-5U;3;[0OW3T+]G#]GKPO\2M<^,WACX$_!OPY\8/$[:Z_B7X
MK:#\+_ VC_$KQ"WBB+P]#XF;7/'>GZ#;^*=7/B*+PEX6CUXZAJMP=8C\-Z!'
MJ/VF/1M-2UK:_P#LQ_LX>*_ /@[X4^*?@#\%?$WPM^'>@W/A;X?_  S\0_"O
MP)K?P^\"^&KSP%K7PJN_#W@WP9J>@77ASPMH=W\+?$OB/X:7.D:#INGZ=/\
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M6= U>UL/#=O!J>B_%*U^'O@*V^(^EWT<]EXYMO!'A"V\40ZI!X8T..PDT_\
M91_9?TCQI!\2-)_9R^!&E_$.VTN'0[;Q[IWPA^'MEXUM]$M_!=G\-H-&@\5V
MWAV/7XM(A^'&G:?\/(M+34%L(O EC9^$([=?#]K!I\9*,96YE?E::3;:34H2
M3MS6NI4Z<EH[.":UO>?9PNY<D>9[RY5S:<Z6MDUI.:T:TG);-H_%C4_^"I'[
M7OA'QQX7^!>I_#[X!7W[0_B/P3#K^K?#K7='\2_!OQ3X-UCQ1XJ_9,\#^#=
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M77]GNZTU5G=75F?RZ?L+_P#!!'6_ 'Q?L_B%^VEJGPT\<>$_"4MCJ'@WX4^
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M9HO,D,4ERT9=RI8@'J-%%% !1110 4444 %%%% !7-Z1_P E!\4?]B3X!_\
M4@^)M=)7-Z1_R4'Q1_V)/@'_ -2#XFT =Y1110 4444 %%%% !1110 4444
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MR(G,<DIQT1)%9&)QA@0:O;%QC''3&3C'3&,XQ[=*3RT/..<@YR<Y  !Z]0
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MEI%UJ^M^*VT+Q,-"T'PEX=_M[QIKMVNA:C,VE^'KJVMX//N(67YNUC1_BO\
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M?"_A?PAX7\)^*=0UMM'\%>.-2DN+/1M+TFRU/5-?2QM.-L/VY4TW3X=2\?\
MPVU3P5IO@_\ :'F_9D_:$U*?Q;!K%C\#?&^H6.AW/P\\<7MZNB:8GBKX,?$9
M_&7PZCM?B"T7A*X\+1^/M#N_%?AG3H[/Q0GA[YAT/X#_ !:\+?&JV_:E\)_
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M*R\;*@\%-\0+::/7='T;Q_)X<MOB#'X-N_B#8?\ "2W?AV5KS5K/4_*_A_\
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M('Q#_P#//KOJ* .!_L?XA?\ 0T^"?_"!\0__ #SZ/['^(7_0T^"?_"!\0_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
A44 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex10-1_001.jpg
<TEXT>
begin 644 ex10-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !> 0P# 2(  A$! Q$!_\0
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M-1U.?5_%46A0KJ-I#"2;EGL5DM[E, E2S= 1D9[YKK(HHX(DBAC6.- %5$&
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MJ8JE"72]_N9R5JTG"SW2;?KH:WQ:UV_BU>ST^VNIH;7[.)CY3E?,8L1DD=0
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M^E?6XVC.K2Y8;_F9X"M"E5YI[?D?0%%8GAGQ-;>*-/:\M;:YA16VGSTP"?\
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B9W]D+_S_ %__ .!!H_LA?^?Z_P#_  (-%H]_P"\NWXG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex10-1_002.jpg
<TEXT>
begin 644 ex10-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% GL# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKX\927$=K-<Q++%]E4EUB$>/G)8, ISV*G-9L]GXO$VIN;>[6>X@C9WCN-R
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M9:HJK]DE_P"?^Y_*/_XFC[)+_P _]S^4?_Q-%EW"[+5%5?LDO_/_ '/Y1_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>abeo-20210930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWamLebP9z5Z8KekhvWB0bflKXyIve4OEjCvp3KjmUdsL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:abeo="http://abeonatherapeutics.com/20210930" elementFormDefault="qualified" targetNamespace="http://abeonatherapeutics.com/20210930">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
	  <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
	  <link:definition>00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPolicies" id="NatureOfOperationsAndSignificantAccountingPolicies">
	  <link:definition>00000007 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/Short-termInvestments" id="Short-termInvestments">
	  <link:definition>00000008 - Disclosure - SHORT-TERM INVESTMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/LicensedTechnology" id="LicensedTechnology">
	  <link:definition>00000009 - Disclosure - LICENSED TECHNOLOGY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/LoanPayable" id="LoanPayable">
	  <link:definition>00000010 - Disclosure - LOAN PAYABLE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/FairValueMeasurements" id="FairValueMeasurements">
	  <link:definition>00000011 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
	  <link:definition>00000012 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesPolicies" id="NatureOfOperationsAndSignificantAccountingPoliciesPolicies">
	  <link:definition>00000014 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesTables" id="NatureOfOperationsAndSignificantAccountingPoliciesTables">
	  <link:definition>00000015 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/Short-termInvestmentsTables" id="Short-termInvestmentsTables">
	  <link:definition>00000016 - Disclosure - SHORT-TERM INVESTMENTS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/LicensedTechnologyTables" id="LicensedTechnologyTables">
	  <link:definition>00000017 - Disclosure - LICENSED TECHNOLOGY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
	  <link:definition>00000018 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
	  <link:definition>00000019 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
	  <link:definition>00000021 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesDetailsNarrative" id="NatureOfOperationsAndSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000022 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfAvailable-for-saleInvestmentsHeldDetails" id="ScheduleOfAvailable-for-saleInvestmentsHeldDetails">
	  <link:definition>00000023 - Disclosure - SCHEDULE OF AVAILABLE-FOR-SALE INVESTMENTS HELD (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/Short-termInvestmentsDetailsNarrative" id="Short-termInvestmentsDetailsNarrative">
	  <link:definition>00000024 - Disclosure - SHORT-TERM INVESTMENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfLicensedTechnologyDetails" id="ScheduleOfLicensedTechnologyDetails">
	  <link:definition>00000025 - Disclosure - SCHEDULE OF LICENSED TECHNOLOGY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfAmortizationExpenseForIntangibleAssetsDetails" id="ScheduleOfAmortizationExpenseForIntangibleAssetsDetails">
	  <link:definition>00000026 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative" id="LicensedTechnologyDetailsNarrative">
	  <link:definition>00000027 - Disclosure - LICENSED TECHNOLOGY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/LoanPayableDetailsNarrative" id="LoanPayableDetailsNarrative">
	  <link:definition>00000028 - Disclosure - LOAN PAYABLE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails" id="ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails">
	  <link:definition>00000029 - Disclosure - SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails" id="ScheduleOfStockBasedCompensationDetails">
	  <link:definition>00000030 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfWeighted-averageAssumptionsToEstimateFairValueOfOptionsGrantedDetails" id="ScheduleOfWeighted-averageAssumptionsToEstimateFairValueOfOptionsGrantedDetails">
	  <link:definition>00000031 - Disclosure - SCHEDULE OF WEIGHTED-AVERAGE ASSUMPTIONS TO ESTIMATE THE FAIR VALUE OF THE OPTIONS GRANTED (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfOptionsActivityDetails" id="ScheduleOfOptionsActivityDetails">
	  <link:definition>00000032 - Disclosure - SCHEDULE OF OPTIONS ACTIVITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/SummaryOfRestrictedCommonStockDetails" id="SummaryOfRestrictedCommonStockDetails">
	  <link:definition>00000033 - Disclosure - SUMMARY OF RESTRICTED COMMON STOCK (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails" id="ScheduleOfComponentsOfLeaseCostDetails">
	  <link:definition>00000034 - Disclosure - SCHEDULE OF COMPONENTS OF LEASE COST (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" id="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails">
	  <link:definition>00000035 - Disclosure - SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="abeo-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="abeo-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="abeo-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="abeo-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
    <element id="abeo_PreFundedWarrantMember" name="PreFundedWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_StockOptionsMember" name="StockOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_REGENXBIOMember" name="REGENXBIOMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_OriginalLicenseAgreementMember" name="OriginalLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_AmendedAgreementMember" name="AmendedAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_AprilOneTwentyTwentyMember" name="AprilOneTwentyTwentyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_SettlementAgreementMember" name="SettlementAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_OneBusinessDayMember" name="OneBusinessDayMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_FirstAnniversaryMember" name="FirstAnniversaryMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_ThirdAnniversaryMember" name="ThirdAnniversaryMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_AbeonaTherapeuticsLlcMember" name="AbeonaTherapeuticsLlcMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_PaycheckProtectionProgramMember" name="PaycheckProtectionProgramMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_ShortTermInvestmentMember" name="ShortTermInvestmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_LicensedTechnologyNetMember" name="LicensedTechnologyNetMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember" name="StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_OtherAssetsAndRestrictedCash" name="OtherAssetsAndRestrictedCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_GainOnSettlementOfRelatedParty" name="GainOnSettlementOfRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_PppLoanPayableForgivenessIncome" name="PppLoanPayableForgivenessIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_InterestAndMiscellaneousIncome" name="InterestAndMiscellaneousIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" name="StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_AllocatedShareBasedCompensationExpenseRestrictedStock" name="AllocatedShareBasedCompensationExpenseRestrictedStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_AccretionAndInterestOnShorttermInvestments" name="AccretionAndInterestOnShorttermInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities" name="IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_IncreaseDecreaseInPayableToLicensor" name="IncreaseDecreaseInPayableToLicensor" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_BackgroundPolicyTextBlock" name="BackgroundPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" name="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_NetCashProvidedByUsedInOperatingActivity" name="NetCashProvidedByUsedInOperatingActivity" nillable="true" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_PaymentForExecutionOfContracts" name="PaymentForExecutionOfContracts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_PaymentsForMilestone" name="PaymentsForMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_FairValueDisclosureOfGainLoss" name="FairValueDisclosureOfGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_LicenseTerminationDate" name="LicenseTerminationDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_RDEBProductMember" name="RDEBProductMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_DebtInstrumentPeriodicRemainsDue" name="DebtInstrumentPeriodicRemainsDue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_NoncashInterestExpense" name="NoncashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="abeo_NoncashPppLoanPayableForgivenessIncome" name="NoncashPppLoanPayableForgivenessIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>abeo-20210930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Cover" xlink:href="abeo-20210930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/BalanceSheets" xlink:href="abeo-20210930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/BalanceSheetsParenthetical" xlink:href="abeo-20210930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="abeo-20210930.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity" xlink:href="abeo-20210930.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/StatementsOfCashFlows" xlink:href="abeo-20210930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPolicies" xlink:href="abeo-20210930.xsd#NatureOfOperationsAndSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Short-termInvestments" xlink:href="abeo-20210930.xsd#Short-termInvestments" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LicensedTechnology" xlink:href="abeo-20210930.xsd#LicensedTechnology" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LoanPayable" xlink:href="abeo-20210930.xsd#LoanPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/FairValueMeasurements" xlink:href="abeo-20210930.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Stock-basedCompensation" xlink:href="abeo-20210930.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/CommitmentsAndContingencies" xlink:href="abeo-20210930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesPolicies" xlink:href="abeo-20210930.xsd#NatureOfOperationsAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesTables" xlink:href="abeo-20210930.xsd#NatureOfOperationsAndSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Short-termInvestmentsTables" xlink:href="abeo-20210930.xsd#Short-termInvestmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LicensedTechnologyTables" xlink:href="abeo-20210930.xsd#LicensedTechnologyTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/FairValueMeasurementsTables" xlink:href="abeo-20210930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Stock-basedCompensationTables" xlink:href="abeo-20210930.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/CommitmentsAndContingenciesTables" xlink:href="abeo-20210930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="abeo-20210930.xsd#ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesDetailsNarrative" xlink:href="abeo-20210930.xsd#NatureOfOperationsAndSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfAvailable-for-saleInvestmentsHeldDetails" xlink:href="abeo-20210930.xsd#ScheduleOfAvailable-for-saleInvestmentsHeldDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Short-termInvestmentsDetailsNarrative" xlink:href="abeo-20210930.xsd#Short-termInvestmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfLicensedTechnologyDetails" xlink:href="abeo-20210930.xsd#ScheduleOfLicensedTechnologyDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfAmortizationExpenseForIntangibleAssetsDetails" xlink:href="abeo-20210930.xsd#ScheduleOfAmortizationExpenseForIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative" xlink:href="abeo-20210930.xsd#LicensedTechnologyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LoanPayableDetailsNarrative" xlink:href="abeo-20210930.xsd#LoanPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails" xlink:href="abeo-20210930.xsd#ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails" xlink:href="abeo-20210930.xsd#ScheduleOfStockBasedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfWeighted-averageAssumptionsToEstimateFairValueOfOptionsGrantedDetails" xlink:href="abeo-20210930.xsd#ScheduleOfWeighted-averageAssumptionsToEstimateFairValueOfOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfOptionsActivityDetails" xlink:href="abeo-20210930.xsd#ScheduleOfOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SummaryOfRestrictedCommonStockDetails" xlink:href="abeo-20210930.xsd#SummaryOfRestrictedCommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails" xlink:href="abeo-20210930.xsd#ScheduleOfComponentsOfLeaseCostDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:href="abeo-20210930.xsd#ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="abeo-20210930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_OtherAssetsAndRestrictedCash" xlink:label="loc_abeoOtherAssetsAndRestrictedCash" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_abeoOtherAssetsAndRestrictedCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaapLoansPayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLoansPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaapLongTermLoansPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermLoansPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:label="loc_us-gaapDueToRelatedPartiesNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDueToRelatedPartiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_GainOnSettlementOfRelatedParty" xlink:label="loc_abeoGainOnSettlementOfRelatedParty" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_abeoGainOnSettlementOfRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_PppLoanPayableForgivenessIncome" xlink:label="loc_abeoPppLoanPayableForgivenessIncome" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_abeoPppLoanPayableForgivenessIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_InterestAndMiscellaneousIncome" xlink:label="loc_abeoInterestAndMiscellaneousIncome" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_abeoInterestAndMiscellaneousIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_GainOnSettlementOfRelatedParty" xlink:label="loc_abeoGainOnSettlementOfRelatedParty" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_abeoGainOnSettlementOfRelatedParty" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_PppLoanPayableForgivenessIncome" xlink:label="loc_abeoPppLoanPayableForgivenessIncome" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_abeoPppLoanPayableForgivenessIncome" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaapInterestExpenseOther" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapInterestExpenseOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_AllocatedShareBasedCompensationExpenseRestrictedStock" xlink:label="loc_abeoAllocatedShareBasedCompensationExpenseRestrictedStock" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_abeoAllocatedShareBasedCompensationExpenseRestrictedStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_AccretionAndInterestOnShorttermInvestments" xlink:label="loc_abeoAccretionAndInterestOnShorttermInvestments" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_abeoAccretionAndInterestOnShorttermInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInReceivables" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInReceivables" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities" xlink:label="loc_abeoIncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_abeoIncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_IncreaseDecreaseInPayableToLicensor" xlink:label="loc_abeoIncreaseDecreaseInPayableToLicensor" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_abeoIncreaseDecreaseInPayableToLicensor" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaapPaymentsToAcquireShortTermInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireShortTermInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="loc_us-gaapProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaapProceedsFromShortTermDebt" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromShortTermDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Short-termInvestments" xlink:title="00000008 - Disclosure - SHORT-TERM INVESTMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LicensedTechnology" xlink:title="00000009 - Disclosure - LICENSED TECHNOLOGY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LoanPayable" xlink:title="00000010 - Disclosure - LOAN PAYABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/FairValueMeasurements" xlink:title="00000011 - Disclosure - FAIR VALUE MEASUREMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Stock-basedCompensation" xlink:title="00000012 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/CommitmentsAndContingencies" xlink:title="00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesPolicies" xlink:title="00000014 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesTables" xlink:title="00000015 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Short-termInvestmentsTables" xlink:title="00000016 - Disclosure - SHORT-TERM INVESTMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LicensedTechnologyTables" xlink:title="00000017 - Disclosure - LICENSED TECHNOLOGY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/FairValueMeasurementsTables" xlink:title="00000018 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Stock-basedCompensationTables" xlink:title="00000019 - Disclosure - STOCK-BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/CommitmentsAndContingenciesTables" xlink:title="00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000021 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000022 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfAvailable-for-saleInvestmentsHeldDetails" xlink:title="00000023 - Disclosure - SCHEDULE OF AVAILABLE-FOR-SALE INVESTMENTS HELD (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Short-termInvestmentsDetailsNarrative" xlink:title="00000024 - Disclosure - SHORT-TERM INVESTMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfLicensedTechnologyDetails" xlink:title="00000025 - Disclosure - SCHEDULE OF LICENSED TECHNOLOGY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfAmortizationExpenseForIntangibleAssetsDetails" xlink:title="00000026 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative" xlink:title="00000027 - Disclosure - LICENSED TECHNOLOGY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LoanPayableDetailsNarrative" xlink:title="00000028 - Disclosure - LOAN PAYABLE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails" xlink:title="00000029 - Disclosure - SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails" xlink:title="00000030 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfWeighted-averageAssumptionsToEstimateFairValueOfOptionsGrantedDetails" xlink:title="00000031 - Disclosure - SCHEDULE OF WEIGHTED-AVERAGE ASSUMPTIONS TO ESTIMATE THE FAIR VALUE OF THE OPTIONS GRANTED (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfOptionsActivityDetails" xlink:title="00000032 - Disclosure - SCHEDULE OF OPTIONS ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SummaryOfRestrictedCommonStockDetails" xlink:title="00000033 - Disclosure - SUMMARY OF RESTRICTED COMMON STOCK (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails" xlink:title="00000034 - Disclosure - SCHEDULE OF COMPONENTS OF LEASE COST (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:title="00000035 - Disclosure - SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>abeo-20210930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Cover" xlink:href="abeo-20210930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/BalanceSheets" xlink:href="abeo-20210930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/BalanceSheetsParenthetical" xlink:href="abeo-20210930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="abeo-20210930.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity" xlink:href="abeo-20210930.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/StatementsOfCashFlows" xlink:href="abeo-20210930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPolicies" xlink:href="abeo-20210930.xsd#NatureOfOperationsAndSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Short-termInvestments" xlink:href="abeo-20210930.xsd#Short-termInvestments" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LicensedTechnology" xlink:href="abeo-20210930.xsd#LicensedTechnology" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LoanPayable" xlink:href="abeo-20210930.xsd#LoanPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/FairValueMeasurements" xlink:href="abeo-20210930.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Stock-basedCompensation" xlink:href="abeo-20210930.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/CommitmentsAndContingencies" xlink:href="abeo-20210930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesPolicies" xlink:href="abeo-20210930.xsd#NatureOfOperationsAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesTables" xlink:href="abeo-20210930.xsd#NatureOfOperationsAndSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Short-termInvestmentsTables" xlink:href="abeo-20210930.xsd#Short-termInvestmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LicensedTechnologyTables" xlink:href="abeo-20210930.xsd#LicensedTechnologyTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/FairValueMeasurementsTables" xlink:href="abeo-20210930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Stock-basedCompensationTables" xlink:href="abeo-20210930.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/CommitmentsAndContingenciesTables" xlink:href="abeo-20210930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="abeo-20210930.xsd#ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesDetailsNarrative" xlink:href="abeo-20210930.xsd#NatureOfOperationsAndSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfAvailable-for-saleInvestmentsHeldDetails" xlink:href="abeo-20210930.xsd#ScheduleOfAvailable-for-saleInvestmentsHeldDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Short-termInvestmentsDetailsNarrative" xlink:href="abeo-20210930.xsd#Short-termInvestmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfLicensedTechnologyDetails" xlink:href="abeo-20210930.xsd#ScheduleOfLicensedTechnologyDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfAmortizationExpenseForIntangibleAssetsDetails" xlink:href="abeo-20210930.xsd#ScheduleOfAmortizationExpenseForIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative" xlink:href="abeo-20210930.xsd#LicensedTechnologyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LoanPayableDetailsNarrative" xlink:href="abeo-20210930.xsd#LoanPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails" xlink:href="abeo-20210930.xsd#ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails" xlink:href="abeo-20210930.xsd#ScheduleOfStockBasedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfWeighted-averageAssumptionsToEstimateFairValueOfOptionsGrantedDetails" xlink:href="abeo-20210930.xsd#ScheduleOfWeighted-averageAssumptionsToEstimateFairValueOfOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfOptionsActivityDetails" xlink:href="abeo-20210930.xsd#ScheduleOfOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SummaryOfRestrictedCommonStockDetails" xlink:href="abeo-20210930.xsd#SummaryOfRestrictedCommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails" xlink:href="abeo-20210930.xsd#ScheduleOfComponentsOfLeaseCostDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:href="abeo-20210930.xsd#ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="abeo-20210930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod" xlink:label="loc_abeoShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_abeoShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited" xlink:label="loc_abeoShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_abeoShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" xlink:label="loc_abeoStockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_abeoStockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" xlink:label="loc_abeoStockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_abeoStockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax_60" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Short-termInvestments" xlink:title="00000008 - Disclosure - SHORT-TERM INVESTMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LicensedTechnology" xlink:title="00000009 - Disclosure - LICENSED TECHNOLOGY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LoanPayable" xlink:title="00000010 - Disclosure - LOAN PAYABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/FairValueMeasurements" xlink:title="00000011 - Disclosure - FAIR VALUE MEASUREMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Stock-basedCompensation" xlink:title="00000012 - Disclosure - STOCK-BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/CommitmentsAndContingencies" xlink:title="00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesPolicies" xlink:title="00000014 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesTables" xlink:title="00000015 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Short-termInvestmentsTables" xlink:title="00000016 - Disclosure - SHORT-TERM INVESTMENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LicensedTechnologyTables" xlink:title="00000017 - Disclosure - LICENSED TECHNOLOGY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/FairValueMeasurementsTables" xlink:title="00000018 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Stock-basedCompensationTables" xlink:title="00000019 - Disclosure - STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/CommitmentsAndContingenciesTables" xlink:title="00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000021 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_StockOptionsMember" xlink:label="loc_abeoStockOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_abeoStockOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000022 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_PreFundedWarrantMember" xlink:label="loc_abeoPreFundedWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_abeoPreFundedWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaapCashCashEquivalentsAndShortTermInvestments_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapCashCashEquivalentsAndShortTermInvestments_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNet" xlink:label="loc_us-gaapAssetsNet_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAssetsNet_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_NetCashProvidedByUsedInOperatingActivity" xlink:label="loc_abeoNetCashProvidedByUsedInOperatingActivity_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_abeoNetCashProvidedByUsedInOperatingActivity_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfAvailable-for-saleInvestmentsHeldDetails" xlink:title="00000023 - Disclosure - SCHEDULE OF AVAILABLE-FOR-SALE INVESTMENTS HELD (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Short-termInvestmentsDetailsNarrative" xlink:title="00000024 - Disclosure - SHORT-TERM INVESTMENTS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfLicensedTechnologyDetails" xlink:title="00000025 - Disclosure - SCHEDULE OF LICENSED TECHNOLOGY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfAmortizationExpenseForIntangibleAssetsDetails" xlink:title="00000026 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative" xlink:title="00000027 - Disclosure - LICENSED TECHNOLOGY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaapLicensingAgreementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicensingAgreementsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_REGENXBIOMember" xlink:label="loc_abeoREGENXBIOMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_abeoREGENXBIOMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_OriginalLicenseAgreementMember" xlink:label="loc_abeoOriginalLicenseAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_abeoOriginalLicenseAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_AmendedAgreementMember" xlink:label="loc_abeoAmendedAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_abeoAmendedAgreementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_SettlementAgreementMember" xlink:label="loc_abeoSettlementAgreementMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_abeoSettlementAgreementMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_AprilOneTwentyTwentyMember" xlink:label="loc_abeoAprilOneTwentyTwentyMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_abeoAprilOneTwentyTwentyMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_OneBusinessDayMember" xlink:label="loc_abeoOneBusinessDayMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_abeoOneBusinessDayMember_170" xlink:type="arc" order="174" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_FirstAnniversaryMember" xlink:label="loc_abeoFirstAnniversaryMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_abeoFirstAnniversaryMember_180" xlink:type="arc" order="184" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_ThirdAnniversaryMember" xlink:label="loc_abeoThirdAnniversaryMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_abeoThirdAnniversaryMember_190" xlink:type="arc" order="194" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_AbeonaTherapeuticsLlcMember" xlink:label="loc_abeoAbeonaTherapeuticsLlcMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_abeoAbeonaTherapeuticsLlcMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapRoyaltyExpense_260" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties_260" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_PaymentForExecutionOfContracts" xlink:label="loc_abeoPaymentForExecutionOfContracts_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_abeoPaymentForExecutionOfContracts_260" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent_260" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_260" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_PaymentsForMilestone" xlink:label="loc_abeoPaymentsForMilestone_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_abeoPaymentsForMilestone_260" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_260" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProgramRightsObligationsCurrent" xlink:label="loc_us-gaapProgramRightsObligationsCurrent_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapProgramRightsObligationsCurrent_260" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent_260" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaapLossContingencyAccrualAtCarryingValue_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapLossContingencyAccrualAtCarryingValue_260" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaapPaymentsForLegalSettlements_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapPaymentsForLegalSettlements_260" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencySettlementAgreementTerms" xlink:label="loc_us-gaapLossContingencySettlementAgreementTerms_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapLossContingencySettlementAgreementTerms_260" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapOtherCostAndExpenseOperating_260" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaapGainLossRelatedToLitigationSettlement_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapGainLossRelatedToLitigationSettlement_260" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettlementLiabilitiesCurrent" xlink:label="loc_us-gaapSettlementLiabilitiesCurrent_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapSettlementLiabilitiesCurrent_260" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_GainOnSettlementOfRelatedParty" xlink:label="loc_abeoGainOnSettlementOfRelatedParty_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_abeoGainOnSettlementOfRelatedParty_260" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_260" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LoanPayableDetailsNarrative" xlink:title="00000028 - Disclosure - LOAN PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_PaycheckProtectionProgramMember" xlink:label="loc_abeoPaycheckProtectionProgramMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_abeoPaycheckProtectionProgramMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails" xlink:title="00000029 - Disclosure - SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaapFairValueByAssetClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByAssetClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_ShortTermInvestmentMember" xlink:label="loc_abeoShortTermInvestmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_abeoShortTermInvestmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_LicensedTechnologyNetMember" xlink:label="loc_abeoLicensedTechnologyNetMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_abeoLicensedTechnologyNetMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillMember" xlink:label="loc_us-gaapGoodwillMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapGoodwillMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsNonrecurringMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsNonrecurringMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure_250" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_FairValueDisclosureOfGainLoss" xlink:label="loc_abeoFairValueDisclosureOfGainLoss_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_abeoFairValueDisclosureOfGainLoss_250" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails" xlink:title="00000030 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember" xlink:label="loc_abeoStockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_abeoStockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_250" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfWeighted-averageAssumptionsToEstimateFairValueOfOptionsGrantedDetails" xlink:title="00000031 - Disclosure - SCHEDULE OF WEIGHTED-AVERAGE ASSUMPTIONS TO ESTIMATE THE FAIR VALUE OF THE OPTIONS GRANTED (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfOptionsActivityDetails" xlink:title="00000032 - Disclosure - SCHEDULE OF OPTIONS ACTIVITY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SummaryOfRestrictedCommonStockDetails" xlink:title="00000033 - Disclosure - SUMMARY OF RESTRICTED COMMON STOCK (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_90" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails" xlink:title="00000034 - Disclosure - SCHEDULE OF COMPONENTS OF LEASE COST (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:title="00000035 - Disclosure - SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_REGENXBIOMember" xlink:label="loc_abeoREGENXBIOMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_abeoREGENXBIOMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_SettlementAgreementMember" xlink:label="loc_abeoSettlementAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_abeoSettlementAgreementMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_OneBusinessDayMember" xlink:label="loc_abeoOneBusinessDayMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_abeoOneBusinessDayMember_30" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_FirstAnniversaryMember" xlink:label="loc_abeoFirstAnniversaryMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_abeoFirstAnniversaryMember_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_ThirdAnniversaryMember" xlink:label="loc_abeoThirdAnniversaryMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_abeoThirdAnniversaryMember_50" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaapGainLossRelatedToLitigationSettlement_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainLossRelatedToLitigationSettlement_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettlementLiabilitiesCurrent" xlink:label="loc_us-gaapSettlementLiabilitiesCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSettlementLiabilitiesCurrent_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_GainOnSettlementOfRelatedParty" xlink:label="loc_abeoGainOnSettlementOfRelatedParty_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_abeoGainOnSettlementOfRelatedParty_90" xlink:type="arc" order="2" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>abeo-20210930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_PreFundedWarrantMember" xlink:label="abeo_PreFundedWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_PreFundedWarrantMember" xlink:to="abeo_PreFundedWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_PreFundedWarrantMember_lbl" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_StockOptionsMember" xlink:label="abeo_StockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_StockOptionsMember" xlink:to="abeo_StockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_StockOptionsMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensingAgreementsMember" xlink:to="us-gaap_LicensingAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xml:lang="en-US">Licensing Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Series [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_REGENXBIOMember" xlink:label="abeo_REGENXBIOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_REGENXBIOMember" xlink:to="abeo_REGENXBIOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_REGENXBIOMember_lbl" xml:lang="en-US">REGENXBIO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_OriginalLicenseAgreementMember" xlink:label="abeo_OriginalLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_OriginalLicenseAgreementMember" xlink:to="abeo_OriginalLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_OriginalLicenseAgreementMember_lbl" xml:lang="en-US">Original License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_AmendedAgreementMember" xlink:label="abeo_AmendedAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_AmendedAgreementMember" xlink:to="abeo_AmendedAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_AmendedAgreementMember_lbl" xml:lang="en-US">Amended Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_AprilOneTwentyTwentyMember" xlink:label="abeo_AprilOneTwentyTwentyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_AprilOneTwentyTwentyMember" xlink:to="abeo_AprilOneTwentyTwentyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_AprilOneTwentyTwentyMember_lbl" xml:lang="en-US">April One Twenty Twenty [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_SettlementAgreementMember" xlink:label="abeo_SettlementAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_SettlementAgreementMember" xlink:to="abeo_SettlementAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_SettlementAgreementMember_lbl" xml:lang="en-US">Settlement Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_OneBusinessDayMember" xlink:label="abeo_OneBusinessDayMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_OneBusinessDayMember" xlink:to="abeo_OneBusinessDayMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_OneBusinessDayMember_lbl" xml:lang="en-US">One Business Day [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_FirstAnniversaryMember" xlink:label="abeo_FirstAnniversaryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_FirstAnniversaryMember" xlink:to="abeo_FirstAnniversaryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_FirstAnniversaryMember_lbl" xml:lang="en-US">First Anniversary [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_ThirdAnniversaryMember" xlink:label="abeo_ThirdAnniversaryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_ThirdAnniversaryMember" xlink:to="abeo_ThirdAnniversaryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_ThirdAnniversaryMember_lbl" xml:lang="en-US">Third Anniversary [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_AbeonaTherapeuticsLlcMember" xlink:label="abeo_AbeonaTherapeuticsLlcMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_AbeonaTherapeuticsLlcMember" xlink:to="abeo_AbeonaTherapeuticsLlcMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_AbeonaTherapeuticsLlcMember_lbl" xml:lang="en-US">Abeona Therapeutics LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_PaycheckProtectionProgramMember" xlink:label="abeo_PaycheckProtectionProgramMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_PaycheckProtectionProgramMember" xlink:to="abeo_PaycheckProtectionProgramMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_PaycheckProtectionProgramMember_lbl" xml:lang="en-US">Paycheck Protection Program [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_ShortTermInvestmentMember" xlink:label="abeo_ShortTermInvestmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_ShortTermInvestmentMember" xlink:to="abeo_ShortTermInvestmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_ShortTermInvestmentMember_lbl" xml:lang="en-US">Short Term Investment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_LicensedTechnologyNetMember" xlink:label="abeo_LicensedTechnologyNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_LicensedTechnologyNetMember" xlink:to="abeo_LicensedTechnologyNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_LicensedTechnologyNetMember_lbl" xml:lang="en-US">Licensed Technology Net [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillMember" xlink:label="us-gaap_GoodwillMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillMember" xlink:to="us-gaap_GoodwillMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillMember_lbl" xml:lang="en-US">Goodwill [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember" xlink:label="abeo_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember" xlink:to="abeo_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_lbl" xml:lang="en-US">Stock Option-Based Compensation Expense Included in Operating Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use lease assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Licensed technology, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_OtherAssetsAndRestrictedCash" xlink:label="abeo_OtherAssetsAndRestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_OtherAssetsAndRestrictedCash" xlink:to="abeo_OtherAssetsAndRestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_OtherAssetsAndRestrictedCash_lbl" xml:lang="en-US">Other assets and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableCurrent" xlink:to="us-gaap_LoansPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayableCurrent_lbl" xml:lang="en-US">Current portion of PPP loan payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Current portion of payable to licensor</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Contract liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US">PPP loan payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_lbl" xml:lang="en-US">Payable to licensor</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock - $0.01 par value; authorized 200,000,000 shares; &#160;issued and outstanding 101,867,539 at September 30, 2021; issued and outstanding 96,131,678 at December 31, 2020;</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="us-gaap_OtherCostAndExpenseOperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl" xml:lang="en-US">Licensed technology impairment charge</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_GainOnSettlementOfRelatedParty" xlink:label="abeo_GainOnSettlementOfRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_GainOnSettlementOfRelatedParty" xlink:to="abeo_GainOnSettlementOfRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_GainOnSettlementOfRelatedParty_lbl" xml:lang="en-US">Gain on settlement with licensor</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_PppLoanPayableForgivenessIncome" xlink:label="abeo_PppLoanPayableForgivenessIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_PppLoanPayableForgivenessIncome" xlink:to="abeo_PppLoanPayableForgivenessIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_PppLoanPayableForgivenessIncome_lbl" xml:lang="en-US">PPP loan payable forgiveness income</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_InterestAndMiscellaneousIncome" xlink:label="abeo_InterestAndMiscellaneousIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_InterestAndMiscellaneousIncome" xlink:to="abeo_InterestAndMiscellaneousIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_InterestAndMiscellaneousIncome_lbl" xml:lang="en-US">Interest and miscellaneous income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted loss per common share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of common shares outstanding &#8211; basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xml:lang="en-US">Other comprehensive income/(loss):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US">Change in unrealized gains/(losses) related to available-for-sale debt securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_lbl" xml:lang="en-US">Foreign currency translation adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock option-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Restricted stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod" xlink:label="abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod" xlink:to="abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod_lbl" xml:lang="en-US">Cancellation of restricted share awards</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited" xlink:label="abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited" xlink:to="abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited_lbl" xml:lang="en-US">Cancellation of restricted share awards, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Common stock issued for cash exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Common stock issued for cash exercise of options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" xlink:label="abeo_StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" xlink:to="abeo_StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations_lbl" xml:lang="en-US">Issuance of common stock in connection with restricted share awards</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" xlink:label="abeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" xlink:to="abeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations_lbl" xml:lang="en-US">Issuance of common stock in connection with restricted share awards, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Common stock issued for cash under open market sale agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Common stock issued for cash under open market sale agreement, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Other comprehensive income (loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherCostAndExpenseOperating_2_lbl" xml:lang="en-US">Non-cash licensed technology impairment charge</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_GainOnSettlementOfRelatedParty" xlink:to="abeo_GainOnSettlementOfRelatedParty_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="abeo_GainOnSettlementOfRelatedParty_2_lbl" xml:lang="en-US">Non-cash gain on settlement with licensor</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_PppLoanPayableForgivenessIncome" xlink:to="abeo_PppLoanPayableForgivenessIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="abeo_PppLoanPayableForgivenessIncome_2_lbl" xml:lang="en-US">Non-cash PPP loan payable forgiveness income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseOther" xlink:label="us-gaap_InterestExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOther_lbl" xml:lang="en-US">Non-cash interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock option-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_AllocatedShareBasedCompensationExpenseRestrictedStock" xlink:label="abeo_AllocatedShareBasedCompensationExpenseRestrictedStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_AllocatedShareBasedCompensationExpenseRestrictedStock" xlink:to="abeo_AllocatedShareBasedCompensationExpenseRestrictedStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abeo_AllocatedShareBasedCompensationExpenseRestrictedStock_lbl" xml:lang="en-US">Restricted stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_AccretionAndInterestOnShorttermInvestments" xlink:label="abeo_AccretionAndInterestOnShorttermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_AccretionAndInterestOnShorttermInvestments" xlink:to="abeo_AccretionAndInterestOnShorttermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="abeo_AccretionAndInterestOnShorttermInvestments_lbl" xml:lang="en-US">Accretion and interest on short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of right-of-use lease assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US">Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities" xlink:label="abeo_IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities" xlink:to="abeo_IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="abeo_IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities_lbl" xml:lang="en-US">Accounts payable, accrued expenses and lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_IncreaseDecreaseInPayableToLicensor" xlink:label="abeo_IncreaseDecreaseInPayableToLicensor" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_IncreaseDecreaseInPayableToLicensor" xlink:to="abeo_IncreaseDecreaseInPayableToLicensor_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_IncreaseDecreaseInPayableToLicensor_lbl" xml:lang="en-US">Change in payable to licensor</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Capital expenditures</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US">Purchases of short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xml:lang="en-US">Proceeds from maturities of short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in)/investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl" xml:lang="en-US">Proceeds from loan payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from open market sales of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase/(decrease) in cash, cash equivalents and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental cash flow information:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US">SHORT-TERM INVESTMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">LICENSED TECHNOLOGY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">LOAN PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_BackgroundPolicyTextBlock" xlink:label="abeo_BackgroundPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_BackgroundPolicyTextBlock" xlink:to="abeo_BackgroundPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_BackgroundPolicyTextBlock_lbl" xml:lang="en-US">Background</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:to="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_lbl" xml:lang="en-US">Uses and Sources of Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xml:lang="en-US">Short-term Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss Per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF AVAILABLE-FOR-SALE INVESTMENTS HELD</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF LICENSED TECHNOLOGY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WEIGHTED-AVERAGE ASSUMPTIONS TO ESTIMATE THE FAIR VALUE OF THE OPTIONS GRANTED</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OPTIONS ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">SUMMARY OF RESTRICTED COMMON STOCK</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF COMPONENTS OF LEASE COST</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:label="abeo_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:to="abeo_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNet" xlink:label="us-gaap_AssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNet" xlink:to="us-gaap_AssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNet_lbl" xml:lang="en-US">Net Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_NetCashProvidedByUsedInOperatingActivity" xlink:label="abeo_NetCashProvidedByUsedInOperatingActivity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_NetCashProvidedByUsedInOperatingActivity" xlink:to="abeo_NetCashProvidedByUsedInOperatingActivity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_NetCashProvidedByUsedInOperatingActivity_lbl" xml:lang="en-US">[custom:NetCashProvidedByUsedInOperatingActivity]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Warrants converted to shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US">U.S. government and agency securities and treasuries</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Amortized cost of available-for-sale debt securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xml:lang="en-US">Realized gains or losses on sale or maturity of available-for-sale debt securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Licensed technology</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Less accumulated amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Licensed technology, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xml:lang="en-US">2021, remainder</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xml:lang="en-US">Royalties payments</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_PaymentForExecutionOfContracts" xlink:label="abeo_PaymentForExecutionOfContracts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_PaymentForExecutionOfContracts" xlink:to="abeo_PaymentForExecutionOfContracts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_PaymentForExecutionOfContracts_lbl" xml:lang="en-US">Payment on execution of contracts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_2_lbl" xml:lang="en-US">Due to licensor current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Annual fees</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_PaymentsForMilestone" xlink:label="abeo_PaymentsForMilestone" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_PaymentsForMilestone" xlink:to="abeo_PaymentsForMilestone_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_PaymentsForMilestone_lbl" xml:lang="en-US">Milestone payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Finite-lived intangible asset, useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProgramRightsObligationsCurrent" xlink:label="us-gaap_ProgramRightsObligationsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProgramRightsObligationsCurrent" xlink:to="us-gaap_ProgramRightsObligationsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProgramRightsObligationsCurrent_lbl" xml:lang="en-US">License to be paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Interest payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xml:lang="en-US">Loss contingency accrual</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="us-gaap_PaymentsForLegalSettlements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLegalSettlements" xlink:to="us-gaap_PaymentsForLegalSettlements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForLegalSettlements_lbl" xml:lang="en-US">Payments for legal settlements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencySettlementAgreementTerms" xlink:label="us-gaap_LossContingencySettlementAgreementTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencySettlementAgreementTerms" xlink:to="us-gaap_LossContingencySettlementAgreementTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencySettlementAgreementTerms_lbl" xml:lang="en-US">Settlement agreement financial terms, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement_lbl" xml:lang="en-US">Gain loss on payments for settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettlementLiabilitiesCurrent" xlink:label="us-gaap_SettlementLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SettlementLiabilitiesCurrent" xlink:to="us-gaap_SettlementLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SettlementLiabilitiesCurrent_lbl" xml:lang="en-US">Settlement amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from loan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Fair value disclosure of assets</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_FairValueDisclosureOfGainLoss" xlink:label="abeo_FairValueDisclosureOfGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_FairValueDisclosureOfGainLoss" xlink:to="abeo_FairValueDisclosureOfGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_FairValueDisclosureOfGainLoss_lbl" xml:lang="en-US">Fair value disclosure of gain loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Total stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Weighted-average:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Grant date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Restricted common stock granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Restricted common stock forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">Weighted-average:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Grant date fair value-granted awards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Grant date fair value-forfeited awards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-term lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2021, remainder</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted operating lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Long-term lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term for operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate for operating leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_GainOnSettlementOfRelatedParty" xlink:to="abeo_GainOnSettlementOfRelatedParty_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abeo_GainOnSettlementOfRelatedParty_3_lbl" xml:lang="en-US">[custom:GainOnSettlementOfRelatedParty]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_BackgroundPolicyTextBlock" xlink:to="abeo_BackgroundPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_BackgroundPolicyTextBlock_doc" xml:lang="en-US">Background [PolicyText Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_OtherAssetsAndRestrictedCash" xlink:to="abeo_OtherAssetsAndRestrictedCash_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_OtherAssetsAndRestrictedCash_doc" xml:lang="en-US">Other assets and restricted cash.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_NetCashProvidedByUsedInOperatingActivity" xlink:to="abeo_NetCashProvidedByUsedInOperatingActivity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_NetCashProvidedByUsedInOperatingActivity_doc" xml:lang="en-US">Net cash provided by used in operating activities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_StockOptionsMember" xlink:to="abeo_StockOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_StockOptionsMember_doc" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_InterestAndMiscellaneousIncome" xlink:to="abeo_InterestAndMiscellaneousIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_InterestAndMiscellaneousIncome_doc" xml:lang="en-US">Interest and Miscellaneous Income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_REGENXBIOMember" xlink:to="abeo_REGENXBIOMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_REGENXBIOMember_doc" xml:lang="en-US">REGENXBIO [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_PaymentForExecutionOfContracts" xlink:to="abeo_PaymentForExecutionOfContracts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_PaymentForExecutionOfContracts_doc" xml:lang="en-US">Payment on Execution of Contracts.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_PaymentsForMilestone" xlink:to="abeo_PaymentsForMilestone_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_PaymentsForMilestone_doc" xml:lang="en-US">Payments for milestone.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_AmendedAgreementMember" xlink:to="abeo_AmendedAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_AmendedAgreementMember_doc" xml:lang="en-US">Amended Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_OriginalLicenseAgreementMember" xlink:to="abeo_OriginalLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_OriginalLicenseAgreementMember_doc" xml:lang="en-US">Original License Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_PppLoanPayableForgivenessIncome" xlink:to="abeo_PppLoanPayableForgivenessIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_PppLoanPayableForgivenessIncome_doc" xml:lang="en-US">Ppp Loan Payable Forgiveness Income.</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_LicenseTerminationDate" xlink:label="abeo_LicenseTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_LicenseTerminationDate" xlink:to="abeo_LicenseTerminationDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_LicenseTerminationDate_doc" xml:lang="en-US">License termination date.</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_RDEBProductMember" xlink:label="abeo_RDEBProductMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_RDEBProductMember" xlink:to="abeo_RDEBProductMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_RDEBProductMember_doc" xml:lang="en-US">RDEB Product [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_DebtInstrumentPeriodicRemainsDue" xlink:label="abeo_DebtInstrumentPeriodicRemainsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_DebtInstrumentPeriodicRemainsDue" xlink:to="abeo_DebtInstrumentPeriodicRemainsDue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_DebtInstrumentPeriodicRemainsDue_doc" xml:lang="en-US">Due remains value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_AbeonaTherapeuticsLlcMember" xlink:to="abeo_AbeonaTherapeuticsLlcMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_AbeonaTherapeuticsLlcMember_doc" xml:lang="en-US">Abeona Therapeutics Llc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" xlink:to="abeo_StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations_doc" xml:lang="en-US">Stock issued during period value share issuance of common stock in connection with restricted share awards net of cancellations.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod" xlink:to="abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options intrinsic value forfeited in Period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_PaycheckProtectionProgramMember" xlink:to="abeo_PaycheckProtectionProgramMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_PaycheckProtectionProgramMember_doc" xml:lang="en-US">Paycheck Protection Program [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" xlink:to="abeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations_doc" xml:lang="en-US">Stock issued during period Issuance of common stock in connection with restricted share awards, net of cancellations, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_ShortTermInvestmentMember" xlink:to="abeo_ShortTermInvestmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_ShortTermInvestmentMember_doc" xml:lang="en-US">Short Term Investment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_LicensedTechnologyNetMember" xlink:to="abeo_LicensedTechnologyNetMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_LicensedTechnologyNetMember_doc" xml:lang="en-US">Licensed Technology Net [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_FairValueDisclosureOfGainLoss" xlink:to="abeo_FairValueDisclosureOfGainLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_FairValueDisclosureOfGainLoss_doc" xml:lang="en-US">Fair value disclosure of gain loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_AllocatedShareBasedCompensationExpenseRestrictedStock" xlink:to="abeo_AllocatedShareBasedCompensationExpenseRestrictedStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_AllocatedShareBasedCompensationExpenseRestrictedStock_doc" xml:lang="en-US">Allocated share based compensation expense restricted stock.</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_NoncashInterestExpense" xlink:label="abeo_NoncashInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_NoncashInterestExpense" xlink:to="abeo_NoncashInterestExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_NoncashInterestExpense_doc" xml:lang="en-US">Non cash interest expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_AccretionAndInterestOnShorttermInvestments" xlink:to="abeo_AccretionAndInterestOnShorttermInvestments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_AccretionAndInterestOnShorttermInvestments_doc" xml:lang="en-US">Accretion and interest on short term investments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities" xlink:to="abeo_IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities_doc" xml:lang="en-US">Increase Decrease In accounts payable And accrued a nd lease liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_IncreaseDecreaseInPayableToLicensor" xlink:to="abeo_IncreaseDecreaseInPayableToLicensor_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_IncreaseDecreaseInPayableToLicensor_doc" xml:lang="en-US">Increase decrease in payable to licenser.</link:label>
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_NoncashPppLoanPayableForgivenessIncome" xlink:label="abeo_NoncashPppLoanPayableForgivenessIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_NoncashPppLoanPayableForgivenessIncome" xlink:to="abeo_NoncashPppLoanPayableForgivenessIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_NoncashPppLoanPayableForgivenessIncome_doc" xml:lang="en-US">Non cash Ppp laon payable forgiveness income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember" xlink:to="abeo_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_doc" xml:lang="en-US">Stock Option-Based Compensation Expense Included in Operating Expense [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:to="abeo_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_doc" xml:lang="en-US">Schedule of supplemental cash flow information related to leases [TableTextBlock]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited" xlink:to="abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited_doc" xml:lang="en-US">Cancellation of restricted shares awards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_PreFundedWarrantMember" xlink:to="abeo_PreFundedWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_PreFundedWarrantMember_doc" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_AprilOneTwentyTwentyMember" xlink:to="abeo_AprilOneTwentyTwentyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abeo_AprilOneTwentyTwentyMember_doc" xml:lang="en-US">April One Twenty Twenty [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_AllocatedShareBasedCompensationExpenseRestrictedStock" xlink:to="abeo_AllocatedShareBasedCompensationExpenseRestrictedStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_AllocatedShareBasedCompensationExpenseRestrictedStock_3_lbl" xml:lang="en-US">AllocatedShareBasedCompensationExpenseRestrictedStock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_AccretionAndInterestOnShorttermInvestments" xlink:to="abeo_AccretionAndInterestOnShorttermInvestments_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_AccretionAndInterestOnShorttermInvestments_3_lbl" xml:lang="en-US">AccretionAndInterestOnShorttermInvestments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInReceivables_2_lbl" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abeo_IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities" xlink:to="abeo_IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abeo_IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities_3_lbl" xml:lang="en-US">IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_2_lbl" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_2_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Operating Lease, Liability</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>abeo-20210930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Cover" xlink:href="abeo-20210930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/BalanceSheets" xlink:href="abeo-20210930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/BalanceSheetsParenthetical" xlink:href="abeo-20210930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="abeo-20210930.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity" xlink:href="abeo-20210930.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/StatementsOfCashFlows" xlink:href="abeo-20210930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPolicies" xlink:href="abeo-20210930.xsd#NatureOfOperationsAndSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Short-termInvestments" xlink:href="abeo-20210930.xsd#Short-termInvestments" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LicensedTechnology" xlink:href="abeo-20210930.xsd#LicensedTechnology" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LoanPayable" xlink:href="abeo-20210930.xsd#LoanPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/FairValueMeasurements" xlink:href="abeo-20210930.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Stock-basedCompensation" xlink:href="abeo-20210930.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/CommitmentsAndContingencies" xlink:href="abeo-20210930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesPolicies" xlink:href="abeo-20210930.xsd#NatureOfOperationsAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesTables" xlink:href="abeo-20210930.xsd#NatureOfOperationsAndSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Short-termInvestmentsTables" xlink:href="abeo-20210930.xsd#Short-termInvestmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LicensedTechnologyTables" xlink:href="abeo-20210930.xsd#LicensedTechnologyTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/FairValueMeasurementsTables" xlink:href="abeo-20210930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Stock-basedCompensationTables" xlink:href="abeo-20210930.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/CommitmentsAndContingenciesTables" xlink:href="abeo-20210930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="abeo-20210930.xsd#ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesDetailsNarrative" xlink:href="abeo-20210930.xsd#NatureOfOperationsAndSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfAvailable-for-saleInvestmentsHeldDetails" xlink:href="abeo-20210930.xsd#ScheduleOfAvailable-for-saleInvestmentsHeldDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/Short-termInvestmentsDetailsNarrative" xlink:href="abeo-20210930.xsd#Short-termInvestmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfLicensedTechnologyDetails" xlink:href="abeo-20210930.xsd#ScheduleOfLicensedTechnologyDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfAmortizationExpenseForIntangibleAssetsDetails" xlink:href="abeo-20210930.xsd#ScheduleOfAmortizationExpenseForIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative" xlink:href="abeo-20210930.xsd#LicensedTechnologyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/LoanPayableDetailsNarrative" xlink:href="abeo-20210930.xsd#LoanPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails" xlink:href="abeo-20210930.xsd#ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails" xlink:href="abeo-20210930.xsd#ScheduleOfStockBasedCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfWeighted-averageAssumptionsToEstimateFairValueOfOptionsGrantedDetails" xlink:href="abeo-20210930.xsd#ScheduleOfWeighted-averageAssumptionsToEstimateFairValueOfOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfOptionsActivityDetails" xlink:href="abeo-20210930.xsd#ScheduleOfOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/SummaryOfRestrictedCommonStockDetails" xlink:href="abeo-20210930.xsd#SummaryOfRestrictedCommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails" xlink:href="abeo-20210930.xsd#ScheduleOfComponentsOfLeaseCostDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:href="abeo-20210930.xsd#ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="abeo-20210930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_OtherAssetsAndRestrictedCash" xlink:label="loc_abeoOtherAssetsAndRestrictedCash" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_abeoOtherAssetsAndRestrictedCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaapLoansPayableCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLoansPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="loc_us-gaapLongTermLoansPayable" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLongTermLoansPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:label="loc_us-gaapDueToRelatedPartiesNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDueToRelatedPartiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_GainOnSettlementOfRelatedParty" xlink:label="loc_abeoGainOnSettlementOfRelatedParty" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_abeoGainOnSettlementOfRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_PppLoanPayableForgivenessIncome" xlink:label="loc_abeoPppLoanPayableForgivenessIncome" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_abeoPppLoanPayableForgivenessIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_InterestAndMiscellaneousIncome" xlink:label="loc_abeoInterestAndMiscellaneousIncome" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_abeoInterestAndMiscellaneousIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod" xlink:label="loc_abeoShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_abeoShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited" xlink:label="loc_abeoShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_abeoShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" xlink:label="loc_abeoStockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_abeoStockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" xlink:label="loc_abeoStockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_abeoStockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_GainOnSettlementOfRelatedParty" xlink:label="loc_abeoGainOnSettlementOfRelatedParty" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_abeoGainOnSettlementOfRelatedParty" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_PppLoanPayableForgivenessIncome" xlink:label="loc_abeoPppLoanPayableForgivenessIncome" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_abeoPppLoanPayableForgivenessIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaapInterestExpenseOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapInterestExpenseOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_AllocatedShareBasedCompensationExpenseRestrictedStock" xlink:label="loc_abeoAllocatedShareBasedCompensationExpenseRestrictedStock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_abeoAllocatedShareBasedCompensationExpenseRestrictedStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_AccretionAndInterestOnShorttermInvestments" xlink:label="loc_abeoAccretionAndInterestOnShorttermInvestments" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_abeoAccretionAndInterestOnShorttermInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInReceivables" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities" xlink:label="loc_abeoIncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_abeoIncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_IncreaseDecreaseInPayableToLicensor" xlink:label="loc_abeoIncreaseDecreaseInPayableToLicensor" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_abeoIncreaseDecreaseInPayableToLicensor" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaapPaymentsToAcquireShortTermInvestments" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireShortTermInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="loc_us-gaapProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaapProceedsFromShortTermDebt" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromShortTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPolicies" xlink:title="00000007 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Short-termInvestments" xlink:title="00000008 - Disclosure - SHORT-TERM INVESTMENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LicensedTechnology" xlink:title="00000009 - Disclosure - LICENSED TECHNOLOGY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LoanPayable" xlink:title="00000010 - Disclosure - LOAN PAYABLE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/FairValueMeasurements" xlink:title="00000011 - Disclosure - FAIR VALUE MEASUREMENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Stock-basedCompensation" xlink:title="00000012 - Disclosure - STOCK-BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/CommitmentsAndContingencies" xlink:title="00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesPolicies" xlink:title="00000014 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_BackgroundPolicyTextBlock" xlink:label="loc_abeoBackgroundPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_abeoBackgroundPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="loc_us-gaapBasisOfAccounting" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBasisOfAccounting" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:label="loc_us-gaapCostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaapEquityMethodInvestmentsPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapEquityMethodInvestmentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesTables" xlink:title="00000015 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Short-termInvestmentsTables" xlink:title="00000016 - Disclosure - SHORT-TERM INVESTMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LicensedTechnologyTables" xlink:title="00000017 - Disclosure - LICENSED TECHNOLOGY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/FairValueMeasurementsTables" xlink:title="00000018 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Stock-basedCompensationTables" xlink:title="00000019 - Disclosure - STOCK-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/CommitmentsAndContingenciesTables" xlink:title="00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:label="loc_abeoScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_abeoScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000021 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_StockOptionsMember" xlink:label="loc_abeoStockOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_abeoStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000022 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_PreFundedWarrantMember" xlink:label="loc_abeoPreFundedWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_abeoPreFundedWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaapCashCashEquivalentsAndShortTermInvestments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapCashCashEquivalentsAndShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNet" xlink:label="loc_us-gaapAssetsNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_NetCashProvidedByUsedInOperatingActivity" xlink:label="loc_abeoNetCashProvidedByUsedInOperatingActivity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_abeoNetCashProvidedByUsedInOperatingActivity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfAvailable-for-saleInvestmentsHeldDetails" xlink:title="00000023 - Disclosure - SCHEDULE OF AVAILABLE-FOR-SALE INVESTMENTS HELD (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/Short-termInvestmentsDetailsNarrative" xlink:title="00000024 - Disclosure - SHORT-TERM INVESTMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedGainLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfLicensedTechnologyDetails" xlink:title="00000025 - Disclosure - SCHEDULE OF LICENSED TECHNOLOGY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfAmortizationExpenseForIntangibleAssetsDetails" xlink:title="00000026 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative" xlink:title="00000027 - Disclosure - LICENSED TECHNOLOGY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaapLicensingAgreementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicensingAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_REGENXBIOMember" xlink:label="loc_abeoREGENXBIOMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_abeoREGENXBIOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_OriginalLicenseAgreementMember" xlink:label="loc_abeoOriginalLicenseAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_abeoOriginalLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_AmendedAgreementMember" xlink:label="loc_abeoAmendedAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_abeoAmendedAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_SettlementAgreementMember" xlink:label="loc_abeoSettlementAgreementMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_abeoSettlementAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapAwardDateAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_AprilOneTwentyTwentyMember" xlink:label="loc_abeoAprilOneTwentyTwentyMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_abeoAprilOneTwentyTwentyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_srtStatementScenarioAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_OneBusinessDayMember" xlink:label="loc_abeoOneBusinessDayMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_abeoOneBusinessDayMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_FirstAnniversaryMember" xlink:label="loc_abeoFirstAnniversaryMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_abeoFirstAnniversaryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_ThirdAnniversaryMember" xlink:label="loc_abeoThirdAnniversaryMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_abeoThirdAnniversaryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_AbeonaTherapeuticsLlcMember" xlink:label="loc_abeoAbeonaTherapeuticsLlcMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_abeoAbeonaTherapeuticsLlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_PaymentForExecutionOfContracts" xlink:label="loc_abeoPaymentForExecutionOfContracts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_abeoPaymentForExecutionOfContracts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_PaymentsForMilestone" xlink:label="loc_abeoPaymentsForMilestone" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_abeoPaymentsForMilestone" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProgramRightsObligationsCurrent" xlink:label="loc_us-gaapProgramRightsObligationsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapProgramRightsObligationsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaapLossContingencyAccrualAtCarryingValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapLossContingencyAccrualAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaapPaymentsForLegalSettlements" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapPaymentsForLegalSettlements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencySettlementAgreementTerms" xlink:label="loc_us-gaapLossContingencySettlementAgreementTerms" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapLossContingencySettlementAgreementTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaapGainLossRelatedToLitigationSettlement" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapGainLossRelatedToLitigationSettlement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettlementLiabilitiesCurrent" xlink:label="loc_us-gaapSettlementLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapSettlementLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_GainOnSettlementOfRelatedParty" xlink:label="loc_abeoGainOnSettlementOfRelatedParty" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_abeoGainOnSettlementOfRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/LoanPayableDetailsNarrative" xlink:title="00000028 - Disclosure - LOAN PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_PaycheckProtectionProgramMember" xlink:label="loc_abeoPaycheckProtectionProgramMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_abeoPaycheckProtectionProgramMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails" xlink:title="00000029 - Disclosure - SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaapFairValueByAssetClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByAssetClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByAssetClassAxis" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_ShortTermInvestmentMember" xlink:label="loc_abeoShortTermInvestmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_abeoShortTermInvestmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_LicensedTechnologyNetMember" xlink:label="loc_abeoLicensedTechnologyNetMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_abeoLicensedTechnologyNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillMember" xlink:label="loc_us-gaapGoodwillMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="loc_us-gaapGoodwillMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsNonrecurringMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsNonrecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_FairValueDisclosureOfGainLoss" xlink:label="loc_abeoFairValueDisclosureOfGainLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_abeoFairValueDisclosureOfGainLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails" xlink:title="00000030 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember" xlink:label="loc_abeoStockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_abeoStockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfWeighted-averageAssumptionsToEstimateFairValueOfOptionsGrantedDetails" xlink:title="00000031 - Disclosure - SCHEDULE OF WEIGHTED-AVERAGE ASSUMPTIONS TO ESTIMATE THE FAIR VALUE OF THE OPTIONS GRANTED (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfOptionsActivityDetails" xlink:title="00000032 - Disclosure - SCHEDULE OF OPTIONS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/SummaryOfRestrictedCommonStockDetails" xlink:title="00000033 - Disclosure - SUMMARY OF RESTRICTED COMMON STOCK (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails" xlink:title="00000034 - Disclosure - SCHEDULE OF COMPONENTS OF LEASE COST (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapVariableLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaapShortTermLeaseCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShortTermLeaseCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:title="00000035 - Disclosure - SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_REGENXBIOMember" xlink:label="loc_abeoREGENXBIOMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_abeoREGENXBIOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_SettlementAgreementMember" xlink:label="loc_abeoSettlementAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_abeoSettlementAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_OneBusinessDayMember" xlink:label="loc_abeoOneBusinessDayMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_abeoOneBusinessDayMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_FirstAnniversaryMember" xlink:label="loc_abeoFirstAnniversaryMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_abeoFirstAnniversaryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_ThirdAnniversaryMember" xlink:label="loc_abeoThirdAnniversaryMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_abeoThirdAnniversaryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaapGainLossRelatedToLitigationSettlement" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainLossRelatedToLitigationSettlement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettlementLiabilitiesCurrent" xlink:label="loc_us-gaapSettlementLiabilitiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSettlementLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="abeo-20210930.xsd#abeo_GainOnSettlementOfRelatedParty" xlink:label="loc_abeoGainOnSettlementOfRelatedParty" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_abeoGainOnSettlementOfRelatedParty" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>form10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:abeo="http://abeonatherapeutics.com/20210930"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="abeo-20210930.xsd" xlink:type="simple"/>
    <context id="From2021-01-01to2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <instant>2021-11-08</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-10-31_custom_PreFundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abeo:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abeo:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abeo:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abeo:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abeo:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2018-11-032018-11-04_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-03</startDate>
            <endDate>2018-11-04</endDate>
        </period>
    </context>
    <context id="AsOf2018-11-04_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-04</instant>
        </period>
    </context>
    <context id="AsOf2018-11-04_srt_MaximumMember_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-04</instant>
        </period>
    </context>
    <context id="From2020-11-032020-11-04_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-03</startDate>
            <endDate>2020-11-04</endDate>
        </period>
    </context>
    <context id="AsOf2019-11-04_custom_OriginalLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abeo:OriginalLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-04</instant>
        </period>
    </context>
    <context id="AsOf2019-11-04_custom_AmendedAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abeo:AmendedAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-04</instant>
        </period>
    </context>
    <context id="AsOf2019-11-04_custom_AprilOneTwentyTwentyMember_custom_AmendedAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">abeo:AprilOneTwentyTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abeo:AmendedAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-04</instant>
        </period>
    </context>
    <context id="AsOf2019-11-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <instant>2019-11-04</instant>
        </period>
    </context>
    <context id="From2020-03-292020-04-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <startDate>2020-03-29</startDate>
            <endDate>2020-04-02</endDate>
        </period>
    </context>
    <context id="From2020-11-032020-11-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <startDate>2020-11-03</startDate>
            <endDate>2020-11-04</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-03-302020-04-02_custom_REGENXBIOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-04-02</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-05-242020-05-25_custom_REGENXBIOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-24</startDate>
            <endDate>2020-05-25</endDate>
        </period>
    </context>
    <context id="From2020-07-122020-07-13_custom_REGENXBIOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-12</startDate>
            <endDate>2020-07-13</endDate>
        </period>
    </context>
    <context id="AsOf2021-11-12_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_custom_REGENXBIOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abeo:SettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-12</instant>
        </period>
    </context>
    <context id="AsOf2021-11-12_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_custom_REGENXBIOMember_custom_OneBusinessDayMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">abeo:OneBusinessDayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abeo:SettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-12</instant>
        </period>
    </context>
    <context id="AsOf2021-11-12_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_custom_REGENXBIOMember_custom_FirstAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">abeo:FirstAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abeo:SettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-12</instant>
        </period>
    </context>
    <context id="AsOf2021-11-12_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_custom_REGENXBIOMember_custom_ThirdAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">abeo:ThirdAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abeo:SettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abeo:REGENXBIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-12</instant>
        </period>
    </context>
    <context id="From2015-05-142015-05-15_custom_AbeonaTherapeuticsLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abeo:AbeonaTherapeuticsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-14</startDate>
            <endDate>2015-05-15</endDate>
        </period>
    </context>
    <context id="From2020-05-012020-05-02_custom_PaycheckProtectionProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abeo:PaycheckProtectionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-02</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_ShortTermInvestmentMember_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:ShortTermInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_ShortTermInvestmentMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:ShortTermInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_ShortTermInvestmentMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:ShortTermInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_ShortTermInvestmentMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:ShortTermInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_LicensedTechnologyNetMember_us-gaap_FairValueMeasurementsNonrecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:LicensedTechnologyNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_LicensedTechnologyNetMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsNonrecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:LicensedTechnologyNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_LicensedTechnologyNetMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsNonrecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:LicensedTechnologyNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_LicensedTechnologyNetMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsNonrecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:LicensedTechnologyNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_GoodwillMember_us-gaap_FairValueMeasurementsNonrecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_GoodwillMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsNonrecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_GoodwillMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsNonrecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_GoodwillMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsNonrecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ShortTermInvestmentMember_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:ShortTermInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ShortTermInvestmentMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:ShortTermInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ShortTermInvestmentMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:ShortTermInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ShortTermInvestmentMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:ShortTermInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_LicensedTechnologyNetMember_us-gaap_FairValueMeasurementsNonrecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:LicensedTechnologyNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_LicensedTechnologyNetMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsNonrecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:LicensedTechnologyNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_LicensedTechnologyNetMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsNonrecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:LicensedTechnologyNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_LicensedTechnologyNetMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsNonrecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abeo:LicensedTechnologyNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_GoodwillMember_us-gaap_FairValueMeasurementsNonrecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_GoodwillMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsNonrecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_GoodwillMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsNonrecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_GoodwillMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsNonrecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_EmployeeStockOptionMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abeo:StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_EmployeeStockOptionMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abeo:StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abeo:StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abeo:StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_RestrictedStockMember16575609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_RestrictedStockMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_RestrictedStockMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_RestrictedStockMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_RestrictedStockMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_RestrictedStockMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_RestrictedStockMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_RestrictedStockMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_RestrictedStockMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_RestrictedStockMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abeo:StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_RestrictedStockMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abeo:StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_RestrictedStockMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abeo:StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_RestrictedStockMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abeo:StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_RestrictedStockMember16575765">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-09-30_us-gaap_RestrictedStockMember16575765">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-09-30_us-gaap_RestrictedStockMember16575781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318306</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-01-01to2021-09-30">0000318306</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-01-01to2021-09-30">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2021-01-01to2021-09-30">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2021-01-01to2021-09-30">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2021-09-30"
      id="xdx2ixbrl0091"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermLoansPayable
      contextRef="AsOf2021-09-30"
      id="xdx2ixbrl0103"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0107"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2021-09-30"
      id="xdx2ixbrl0115"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0116"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-07-012021-09-30"
      id="xdx2ixbrl0155"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-01to2021-09-30"
      id="xdx2ixbrl0157"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2021-07-012021-09-30"
      id="xdx2ixbrl0180"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2020-07-012020-09-30"
      id="xdx2ixbrl0181"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2021-01-01to2021-09-30"
      id="xdx2ixbrl0182"
      unitRef="USD"
      xsi:nil="true"/>
    <abeo:GainOnSettlementOfRelatedParty
      contextRef="From2020-07-012020-09-30"
      id="xdx2ixbrl0196"
      unitRef="USD"
      xsi:nil="true"/>
    <abeo:GainOnSettlementOfRelatedParty
      contextRef="From2020-01-012020-09-30"
      id="xdx2ixbrl0198"
      unitRef="USD"
      xsi:nil="true"/>
    <abeo:PppLoanPayableForgivenessIncome
      contextRef="From2020-07-012020-09-30"
      id="xdx2ixbrl0201"
      unitRef="USD"
      xsi:nil="true"/>
    <abeo:PppLoanPayableForgivenessIncome
      contextRef="From2020-01-012020-09-30"
      id="xdx2ixbrl0203"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2020-07-012020-09-30"
      id="xdx2ixbrl0241"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2020-01-012020-09-30"
      id="xdx2ixbrl0243"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0258"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-07-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0261"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0264"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2021-07-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-07-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations
      contextRef="From2021-07-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations
      contextRef="From2021-07-012021-09-30"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-07-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-07-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0340"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2020-07-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <abeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod
      contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <abeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod
      contextRef="From2020-07-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <abeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod
      contextRef="From2020-07-012020-09-30"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations
      contextRef="From2021-01-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations
      contextRef="From2021-01-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations
      contextRef="From2021-01-01to2021-09-30"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2021-01-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2021-01-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0445"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0451"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2020-01-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0453"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2020-01-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0454"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0459"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0460"
      unitRef="USD"
      xsi:nil="true"/>
    <abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations
      contextRef="From2020-01-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0467"
      unitRef="USD"
      xsi:nil="true"/>
    <abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations
      contextRef="From2020-01-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations
      contextRef="From2020-01-012020-09-30"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0473"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0474"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0476"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0479"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-01-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-01-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0481"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-01-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0486"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-01-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2021-01-01to2021-09-30"
      id="xdx2ixbrl0508"
      unitRef="USD"
      xsi:nil="true"/>
    <abeo:GainOnSettlementOfRelatedParty
      contextRef="From2020-01-012020-09-30"
      id="xdx2ixbrl0512"
      unitRef="USD"
      xsi:nil="true"/>
    <abeo:PppLoanPayableForgivenessIncome
      contextRef="From2020-01-012020-09-30"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseOther
      contextRef="From2021-01-01to2021-09-30"
      id="xdx2ixbrl0517"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="From2021-01-01to2021-09-30"
      id="xdx2ixbrl0538"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="From2021-01-01to2021-09-30"
      id="xdx2ixbrl0574"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-01-012020-09-30"
      id="xdx2ixbrl0578"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2021-01-01to2021-09-30"
      id="xdx2ixbrl0607"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2020-01-012020-09-30"
      id="xdx2ixbrl0608"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-01-01to2021-09-30"
      id="xdx2ixbrl0610"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2020-01-012020-09-30"
      id="xdx2ixbrl0611"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-09-30_custom_ShortTermInvestmentMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0778"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-09-30_custom_ShortTermInvestmentMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0782"
      unitRef="USD"
      xsi:nil="true"/>
    <abeo:FairValueDisclosureOfGainLoss
      contextRef="AsOf2021-09-30_custom_ShortTermInvestmentMember_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0784"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-09-30_custom_LicensedTechnologyNetMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsNonrecurringMember"
      id="xdx2ixbrl0788"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-09-30_custom_LicensedTechnologyNetMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsNonrecurringMember"
      id="xdx2ixbrl0790"
      unitRef="USD"
      xsi:nil="true"/>
    <abeo:FairValueDisclosureOfGainLoss
      contextRef="AsOf2021-09-30_custom_LicensedTechnologyNetMember_us-gaap_FairValueMeasurementsNonrecurringMember"
      id="xdx2ixbrl0794"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-09-30_us-gaap_GoodwillMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsNonrecurringMember"
      id="xdx2ixbrl0798"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-09-30_us-gaap_GoodwillMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsNonrecurringMember"
      id="xdx2ixbrl0800"
      unitRef="USD"
      xsi:nil="true"/>
    <abeo:FairValueDisclosureOfGainLoss
      contextRef="AsOf2021-09-30_us-gaap_GoodwillMember_us-gaap_FairValueMeasurementsNonrecurringMember"
      id="xdx2ixbrl0804"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_custom_ShortTermInvestmentMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0808"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_custom_ShortTermInvestmentMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0812"
      unitRef="USD"
      xsi:nil="true"/>
    <abeo:FairValueDisclosureOfGainLoss
      contextRef="AsOf2020-12-31_custom_ShortTermInvestmentMember_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0814"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_custom_LicensedTechnologyNetMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsNonrecurringMember"
      id="xdx2ixbrl0818"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_custom_LicensedTechnologyNetMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsNonrecurringMember"
      id="xdx2ixbrl0820"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_GoodwillMember_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsNonrecurringMember"
      id="xdx2ixbrl0828"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_GoodwillMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsNonrecurringMember"
      id="xdx2ixbrl0830"
      unitRef="USD"
      xsi:nil="true"/>
    <abeo:FairValueDisclosureOfGainLoss
      contextRef="AsOf2020-12-31_us-gaap_GoodwillMember_us-gaap_FairValueMeasurementsNonrecurringMember"
      id="xdx2ixbrl0834"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2020-07-012020-09-30_us-gaap_RestrictedStockMember16575765"
      id="xdx2ixbrl0949"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-07-012020-09-30_us-gaap_RestrictedStockMember16575765"
      id="xdx2ixbrl0964"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2021-01-01to2021-09-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2021-01-01to2021-09-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2021-01-01to2021-09-30">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2021-01-01to2021-09-30">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2021-01-01to2021-09-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2021-01-01to2021-09-30">001-15771</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2021-01-01to2021-09-30">ABEONA THERAPEUTICS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-01-01to2021-09-30">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-01-01to2021-09-30">83-0221517</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-01-01to2021-09-30">1330 Avenue of the Americas</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-01-01to2021-09-30">33rd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-01-01to2021-09-30">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-01-01to2021-09-30">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-01-01to2021-09-30">10019</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-01-01to2021-09-30">646</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-01-01to2021-09-30">813-4701</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2021-01-01to2021-09-30">Common     Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-01-01to2021-09-30">ABEO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-01-01to2021-09-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2021-01-01to2021-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2021-01-01to2021-09-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2021-01-01to2021-09-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2021-01-01to2021-09-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-01-01to2021-09-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2021-01-01to2021-09-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2021-11-08" decimals="INF" unitRef="Shares">101917914</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">43781000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">12596000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">23217000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">82438000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">907000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2708000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">67905000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">97742000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">9869000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">11322000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">6207000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">7032000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1413000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">32466000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">32466000</us-gaap:Goodwill>
    <abeo:OtherAssetsAndRestrictedCash contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1159000</abeo:OtherAssetsAndRestrictedCash>
    <abeo:OtherAssetsAndRestrictedCash contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1136000</abeo:OtherAssetsAndRestrictedCash>
    <us-gaap:Assets contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">119019000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">151198000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1861000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">4695000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">2593000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">3410000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1723000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1713000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LoansPayableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">330000</us-gaap:LoansPayableCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">20000000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">31515000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">296000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">296000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">26473000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">41959000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermLoansPayable contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1428000</us-gaap:LongTermLoansPayable>
    <us-gaap:DueToRelatedPartiesNoncurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">8360000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">4442000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">5260000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">39275000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">48647000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-09-30"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">101867539</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">101867539</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">96131678</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">96131678</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1019000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">961000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">687691000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">672304000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">-608957000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-570704000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">-9000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-10000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">79744000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">102551000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">119019000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">151198000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">7978000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">7969000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">22624000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">20896000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">6092000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">4432000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">18117000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">16382000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">802000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">847000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">2443000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">3746000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">32916000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OperatingExpenses
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">14872000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">13248000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">43184000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">73940000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-14872000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-6248000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-43184000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-66940000</us-gaap:OperatingIncomeLoss>
    <abeo:GainOnSettlementOfRelatedParty
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">6743000</abeo:GainOnSettlementOfRelatedParty>
    <abeo:GainOnSettlementOfRelatedParty
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">6743000</abeo:GainOnSettlementOfRelatedParty>
    <abeo:PppLoanPayableForgivenessIncome
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">1758000</abeo:PppLoanPayableForgivenessIncome>
    <abeo:PppLoanPayableForgivenessIncome
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">1758000</abeo:PppLoanPayableForgivenessIncome>
    <abeo:InterestAndMiscellaneousIncome
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">10000</abeo:InterestAndMiscellaneousIncome>
    <abeo:InterestAndMiscellaneousIncome
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">338000</abeo:InterestAndMiscellaneousIncome>
    <abeo:InterestAndMiscellaneousIncome
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">33000</abeo:InterestAndMiscellaneousIncome>
    <abeo:InterestAndMiscellaneousIncome
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">1261000</abeo:InterestAndMiscellaneousIncome>
    <us-gaap:InterestExpense
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">683000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">1327000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">3603000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">2727000</us-gaap:InterestExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-7044000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-7237000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-38253000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-68406000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2021-07-012021-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.07</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-07-012020-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.08</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2021-01-01to2021-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.40</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-01-012020-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.74</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2021-07-012021-09-30"
      decimals="INF"
      unitRef="Shares">97990338</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-07-012020-09-30"
      decimals="INF"
      unitRef="Shares">92714983</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2021-01-01to2021-09-30"
      decimals="INF"
      unitRef="Shares">96258681</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-01-012020-09-30"
      decimals="INF"
      unitRef="Shares">92594339</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">1000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-116000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">10000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">17000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-9000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-9000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-7052000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-7353000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-38252000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-68389000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">101251023</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1013000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">684987000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-601913000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">84086000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1387000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">1387000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1150000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">1150000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">121950</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">139000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">140000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <abeo:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">474825</abeo:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations>
    <abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">5000</abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations>
    <abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-5000</abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">19741</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">33000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">33000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-7044000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-7044000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2021-07-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-8000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-8000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding contextRef="AsOf2021-09-30" decimals="INF" unitRef="Shares">101867539</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1019000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">687691000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-608957000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">79744000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">84781241</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">848000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">667712000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-547639000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">133000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">121054000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1249000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">1249000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">161000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">161000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <abeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">-265080</abeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited>
    <abeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod
      contextRef="From2020-07-012020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">-3000</abeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod>
    <abeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod
      contextRef="From2020-07-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3000</abeo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-012020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-7237000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-7237000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-07-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-116000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">-116000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">84516161</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">845000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">669125000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-554876000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">115111000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">96131678</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">961000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">672304000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-570704000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">102551000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3797000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">3797000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3118000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">3118000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">630675</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">825000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">831000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <abeo:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations
      contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2021900</abeo:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations>
    <abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations
      contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">20000</abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations>
    <abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations
      contextRef="From2021-01-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-20000</abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3083286</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">32000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">7667000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">7699000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-38253000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-38253000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2021-01-012021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">1000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">1000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">101867539</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1019000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">687691000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-608957000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">79744000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">83622135</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">836000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">664064000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-486470000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">178430000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">4083000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">4083000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2020-01-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">812000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">812000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">75793</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">174000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">175000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <abeo:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations
      contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">818233</abeo:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations>
    <abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations
      contextRef="From2020-01-012020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">8000</abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations>
    <abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations
      contextRef="From2020-01-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-8000</abeo:StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-68406000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-68406000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-01-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">17000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">17000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-01-012020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">17000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">17000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">84516161</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">845000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">669125000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-554876000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">115111000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-38253000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-68406000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">32916000</us-gaap:OtherCostAndExpenseOperating>
    <abeo:GainOnSettlementOfRelatedParty
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">6743000</abeo:GainOnSettlementOfRelatedParty>
    <abeo:PppLoanPayableForgivenessIncome
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">1758000</abeo:PppLoanPayableForgivenessIncome>
    <us-gaap:InterestExpenseOther
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">600000</us-gaap:InterestExpenseOther>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">2443000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">3746000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">3797000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">4083000</us-gaap:AllocatedShareBasedCompensationExpense>
    <abeo:AllocatedShareBasedCompensationExpenseRestrictedStock
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">3118000</abeo:AllocatedShareBasedCompensationExpenseRestrictedStock>
    <abeo:AllocatedShareBasedCompensationExpenseRestrictedStock
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">812000</abeo:AllocatedShareBasedCompensationExpenseRestrictedStock>
    <abeo:AccretionAndInterestOnShorttermInvestments
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-256000</abeo:AccretionAndInterestOnShorttermInvestments>
    <abeo:AccretionAndInterestOnShorttermInvestments
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">237000</abeo:AccretionAndInterestOnShorttermInvestments>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">825000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">752000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">7000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-1801000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-2443000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">23000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">62000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <abeo:IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">4459000</abeo:IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities>
    <abeo:IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">5183000</abeo:IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities>
    <abeo:IncreaseDecreaseInPayableToLicensor
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">3588000</abeo:IncreaseDecreaseInPayableToLicensor>
    <abeo:IncreaseDecreaseInPayableToLicensor
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">2127000</abeo:IncreaseDecreaseInPayableToLicensor>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">-35408000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-33409000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">903000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">1303000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">15164000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">139230000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">74130000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">51037000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">58063000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-89496000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">1758000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">7699000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">831000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">175000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">8530000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">1933000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">31185000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">-120972000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">13571000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">130368000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">44756000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">9396000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">43781000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">8424000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">975000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">972000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">44756000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">9396000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zo7ANL6wddX5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
1 &#x2013; &lt;span id="xdx_820_z51qNbYu0ihj"&gt;NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--BackgroundPolicyTextBlock_zKzhqIm7jPz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zcRrEZIaYKAk"&gt;Background&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Abeona
Therapeutics Inc. (together with our subsidiaries, &#x201c;we,&#x201d; &#x201c;our,&#x201d; &#x201c;Abeona&#x201d; or the &#x201c;Company&#x201d;),
a Delaware corporation, is a clinical-stage biopharmaceutical company developing gene and cell therapies for life-threatening rare genetic
diseases. Our lead clinical programs consist of: (i) EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis
bullosa (&#x201c;RDEB&#x201d;), (ii) ABO-102, an adeno-associated virus (&#x201c;AAV&#x201d;)-based gene therapy for Sanfilippo syndrome
type A (&#x201c;MPS IIIA&#x201d;), and (iii) ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B (&#x201c;MPS IIIB&#x201d;).
We continue to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases, next-generation AAV-based
gene therapies using the novel AIM&#x2122; capsid platform that we have exclusively licensed from the University of North Carolina at
Chapel Hill, and internal AAV vector research programs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--BasisOfAccounting_ziYBhQQ0QEv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zpfYEzZH7Ezl"&gt;Basis
of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
condensed consolidated balance sheet as of September 30, 2021, the condensed consolidated statements of operations and comprehensive
loss and stockholders&#x2019; equity for the three and nine months ended September 30, 2021 and 2020, and the condensed consolidated statement
of cash flows for the nine months ended September 30, 2021 were prepared by management without audit. In the opinion of management, all
adjustments, consisting only of normal recurring adjustments, except as otherwise disclosed, necessary for the fair presentation of the
financial position, results of operations, and changes in financial position for such periods, have been made.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Certain
information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally
accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) have been condensed or omitted. These interim financial statements
should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended
December 31, 2020. The results of operations for the period ended September 30, 2021 are not necessarily indicative of the operating
results that may be expected for a full year. The condensed consolidated balance sheet as of December 31, 2020 contains financial information
taken from the audited Abeona consolidated financial statements as of that date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_zEUpvfbSxsSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zWLxmc3Owes7"&gt;Uses
and Sources of Liquidity&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
financial statements have been prepared on the going concern basis, which assumes the Company will have sufficient cash to pay its operating
expenses, as and when they become payable, for a period of at least 12 months from the date the financial report was issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of September 30, 2021, we had cash, cash equivalents and short-term investments of $&lt;span id="xdx_907_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn5n6_c20210930_zZoJmyOIxkAg"&gt;67.0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million and net assets of $&lt;span id="xdx_90F_eus-gaap--AssetsNet_iI_pn5n6_c20210930_zn8YIc938426"&gt;79.7
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million. For the nine months ended September
30, 2021, we had cash outflows from operations of $&lt;span id="xdx_903_ecustom--NetCashProvidedByUsedInOperatingActivity_pn5n6_c20210101__20210930_zeSaXZywvPTc"&gt;35.4
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million. We have not generated significant product
revenues and have not achieved profitable operations. There is no assurance that profitable operations will ever be achieved, and, if
achieved, could be sustained on a continuing basis. In addition, development activities, clinical and nonclinical testing, and commercialization
of our products will require significant additional financing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
are subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful
discovery and development of product candidates, obtaining the necessary regulatory approval to market our product candidates, raising
additional capital to continue to fund our operations, development of competing drugs and therapies, protection of proprietary technology
and market acceptance of our products. As a result of these and other risks and the related uncertainties, there can be no assurance
of our future success.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Based
on our existing cash, cash equivalents and short-term investments, our ability to access additional financial resources and/or our financial
flexibility to reduce operating expenses if required, we believe that we have sufficient resources to fund operations through at least
the next 12 months. We will need to secure additional funding in the future to carry out all of our planned research and development
activities. If we are unable to obtain additional financing or generate license or product revenue, the lack of liquidity and sufficient
capital resources could have a material adverse effect on our future prospects.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--UseOfEstimates_zy5YlErp0Wff" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zfJPSrLcRyi1"&gt;Use
of Estimates&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amount of assets and disclosure of contingent assets and liabilities at the date of the consolidated financial statements
and the reported amounts of revenue and expenses during the reported period. Actual results could differ from these estimates and assumptions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zSQ0m0O8NET8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zfinpwbrcCf4"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. We maintain deposits
primarily in financial institutions, which may at times exceed amounts covered by insurance provided by the U.S. Federal Deposit Insurance
Corporation (&#x201c;FDIC&#x201d;). We have not experienced any losses related to amounts in excess of FDIC limits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--EquityMethodInvestmentsPolicy_zXhQvH2OjMS4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_ziGgthm8AcU1"&gt;Short-term
Investments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Short-term
investments consist of investments in U.S. government, U.S. agency and U.S. treasury securities. We determine the appropriate classification
of the securities at the time they are acquired and evaluate the appropriateness of such classifications at each balance sheet date.
We classify our short-term investments as available-for-sale pursuant to Accounting Standards Codification (&#x201c;ASC&#x201d;) 320, &lt;i&gt;Investments
&#x2013; Debt and Equity Securities&lt;/i&gt;. Investments classified as current have maturities of less than one year. We review our short-term
investments for other-than-temporary impairment whenever the fair value of a marketable security is less than the amortized cost and
evidence indicates that a short-term investment&#x2019;s carrying amount is not recoverable within a reasonable period of time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--LesseeLeasesPolicyTextBlock_zeDZ1lKkmWUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zTvcJjVfRLBg"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;We
account for leases in accordance with ASC 842, &lt;i&gt;Leases&lt;/i&gt;. Right-of-use lease assets represent our right to use an underlying asset
for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. The measurement of lease
liabilities is based on the present value of future lease payments over the lease term. As our leases do not provide an implicit rate,
we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value
of future lease payments. The right-of-use asset is based on the measurement of the lease liability and includes any lease payments made
prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. Rent expense for our
operating leases is recognized on a straight-line basis over the lease term. We do not have any leases classified as finance leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Our
leases do not have significant rent escalation, holidays, concessions, material residual value guarantees, material restrictive covenants
or contingent rent provisions. Our leases include both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease
components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component as we have elected the
practical expedient to group lease and non-lease components for all leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Most
leases include one or more options to renew. The exercise of lease renewal options is typically at our sole discretion; therefore, the
majority of renewals to extend the lease terms are not included in our right-of-use assets and lease liabilities as they are not reasonably
certain of exercise. We regularly evaluate the renewal options and when they are reasonably certain of exercise, we include the renewal
period in our lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Additional
information and disclosures required under ASC 842 are included in Note 7.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zOdn5KLQjuTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_z5DzEwHQw0c1"&gt;Restricted
Cash&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Restricted
cash, which is recorded within other assets and restricted cash in the accompanying consolidated balance sheets and is included as a
component of cash, cash equivalents and restricted cash on our consolidated statements of cash flows, consists of cash and cash equivalents
held as collateral for a corporate credit card and office space in New York. As such, the cash and cash equivalents are restricted in
use.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zIFTyweu3N44" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_z9oBtVlfjEva"&gt;Loss
Per Common Share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;We
have presented basic and diluted loss per common share on the statement of operations and comprehensive loss. Basic and diluted net loss
per share is computed by dividing net loss by the weighted-average number of shares of common stock and shares underlying &#x201c;pre-funded&#x201d;
warrants outstanding during the period. The &#x201c;pre-funded&#x201d; warrants were included in the computation of basic net loss per
share as the exercise price was negligible and the warrants were fully vested and exercisable. In October 2020, all of the &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20201031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreFundedWarrantMember_pdd" title="Warrants converted to shares"&gt;9,017,055&lt;/span&gt;
&#x201c;pre-funded&#x201d; warrants were exercised and converted into shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zIjsTejJ69Xf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;We
do not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive.
Potential dilutive securities result from outstanding stock options, restricted stock and &#x201c;non-pre-funded&#x201d; warrants. We did
not include the following potentially dilutive securities in the computation of diluted net loss per common share during the periods
presented:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B0_zGpTDclD53Ef" style="display: none"&gt;SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the three months ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the nine months ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;Stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zGmT3TiyFHH" style="width: 11%; text-align: right" title="Total"&gt;7,755,196&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zVPZetACBmpj" style="width: 11%; text-align: right" title="Total"&gt;6,431,183&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zZEyPRPu13fh" style="width: 11%; text-align: right" title="Total"&gt;7,755,196&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zElmds4z2HWd" style="width: 11%; text-align: right" title="Total"&gt;6,431,183&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Restricted stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z0JAkd7JW7Dk" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;2,989,224&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zT0Jq02nK7s9" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;818,233&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zNbTYrZy4096" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;2,989,224&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zq5ETfqCi4h9" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;818,233&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930_z1yadaQyohHk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;10,744,420&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200701__20200930_zk1Er6zMGrg4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;7,249,416&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930_zVBezYMakOW9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;10,744,420&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20200930_zMFXm5NhwoUc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;7,249,416&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_z4wrP32YLEKl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <abeo:BackgroundPolicyTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_844_ecustom--BackgroundPolicyTextBlock_zKzhqIm7jPz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zcRrEZIaYKAk"&gt;Background&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Abeona
Therapeutics Inc. (together with our subsidiaries, &#x201c;we,&#x201d; &#x201c;our,&#x201d; &#x201c;Abeona&#x201d; or the &#x201c;Company&#x201d;),
a Delaware corporation, is a clinical-stage biopharmaceutical company developing gene and cell therapies for life-threatening rare genetic
diseases. Our lead clinical programs consist of: (i) EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis
bullosa (&#x201c;RDEB&#x201d;), (ii) ABO-102, an adeno-associated virus (&#x201c;AAV&#x201d;)-based gene therapy for Sanfilippo syndrome
type A (&#x201c;MPS IIIA&#x201d;), and (iii) ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B (&#x201c;MPS IIIB&#x201d;).
We continue to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases, next-generation AAV-based
gene therapies using the novel AIM&#x2122; capsid platform that we have exclusively licensed from the University of North Carolina at
Chapel Hill, and internal AAV vector research programs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</abeo:BackgroundPolicyTextBlock>
    <us-gaap:BasisOfAccounting contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_843_eus-gaap--BasisOfAccounting_ziYBhQQ0QEv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_zpfYEzZH7Ezl"&gt;Basis
of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
condensed consolidated balance sheet as of September 30, 2021, the condensed consolidated statements of operations and comprehensive
loss and stockholders&#x2019; equity for the three and nine months ended September 30, 2021 and 2020, and the condensed consolidated statement
of cash flows for the nine months ended September 30, 2021 were prepared by management without audit. In the opinion of management, all
adjustments, consisting only of normal recurring adjustments, except as otherwise disclosed, necessary for the fair presentation of the
financial position, results of operations, and changes in financial position for such periods, have been made.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Certain
information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally
accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) have been condensed or omitted. These interim financial statements
should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended
December 31, 2020. The results of operations for the period ended September 30, 2021 are not necessarily indicative of the operating
results that may be expected for a full year. The condensed consolidated balance sheet as of December 31, 2020 contains financial information
taken from the audited Abeona consolidated financial statements as of that date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccounting>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_84E_eus-gaap--CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_zEUpvfbSxsSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zWLxmc3Owes7"&gt;Uses
and Sources of Liquidity&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
financial statements have been prepared on the going concern basis, which assumes the Company will have sufficient cash to pay its operating
expenses, as and when they become payable, for a period of at least 12 months from the date the financial report was issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of September 30, 2021, we had cash, cash equivalents and short-term investments of $&lt;span id="xdx_907_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn5n6_c20210930_zZoJmyOIxkAg"&gt;67.0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million and net assets of $&lt;span id="xdx_90F_eus-gaap--AssetsNet_iI_pn5n6_c20210930_zn8YIc938426"&gt;79.7
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million. For the nine months ended September
30, 2021, we had cash outflows from operations of $&lt;span id="xdx_903_ecustom--NetCashProvidedByUsedInOperatingActivity_pn5n6_c20210101__20210930_zeSaXZywvPTc"&gt;35.4
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million. We have not generated significant product
revenues and have not achieved profitable operations. There is no assurance that profitable operations will ever be achieved, and, if
achieved, could be sustained on a continuing basis. In addition, development activities, clinical and nonclinical testing, and commercialization
of our products will require significant additional financing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
are subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful
discovery and development of product candidates, obtaining the necessary regulatory approval to market our product candidates, raising
additional capital to continue to fund our operations, development of competing drugs and therapies, protection of proprietary technology
and market acceptance of our products. As a result of these and other risks and the related uncertainties, there can be no assurance
of our future success.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Based
on our existing cash, cash equivalents and short-term investments, our ability to access additional financial resources and/or our financial
flexibility to reduce operating expenses if required, we believe that we have sufficient resources to fund operations through at least
the next 12 months. We will need to secure additional funding in the future to carry out all of our planned research and development
activities. If we are unable to obtain additional financing or generate license or product revenue, the lack of liquidity and sufficient
capital resources could have a material adverse effect on our future prospects.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="AsOf2021-09-30" decimals="-5" unitRef="USD">67000000.0</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:AssetsNet contextRef="AsOf2021-09-30" decimals="-5" unitRef="USD">79700000</us-gaap:AssetsNet>
    <abeo:NetCashProvidedByUsedInOperatingActivity
      contextRef="From2021-01-01to2021-09-30"
      decimals="-5"
      unitRef="USD">35400000</abeo:NetCashProvidedByUsedInOperatingActivity>
    <us-gaap:UseOfEstimates contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_84D_eus-gaap--UseOfEstimates_zy5YlErp0Wff" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zfJPSrLcRyi1"&gt;Use
of Estimates&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amount of assets and disclosure of contingent assets and liabilities at the date of the consolidated financial statements
and the reported amounts of revenue and expenses during the reported period. Actual results could differ from these estimates and assumptions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zSQ0m0O8NET8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zfinpwbrcCf4"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. We maintain deposits
primarily in financial institutions, which may at times exceed amounts covered by insurance provided by the U.S. Federal Deposit Insurance
Corporation (&#x201c;FDIC&#x201d;). We have not experienced any losses related to amounts in excess of FDIC limits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_849_eus-gaap--EquityMethodInvestmentsPolicy_zXhQvH2OjMS4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_ziGgthm8AcU1"&gt;Short-term
Investments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Short-term
investments consist of investments in U.S. government, U.S. agency and U.S. treasury securities. We determine the appropriate classification
of the securities at the time they are acquired and evaluate the appropriateness of such classifications at each balance sheet date.
We classify our short-term investments as available-for-sale pursuant to Accounting Standards Codification (&#x201c;ASC&#x201d;) 320, &lt;i&gt;Investments
&#x2013; Debt and Equity Securities&lt;/i&gt;. Investments classified as current have maturities of less than one year. We review our short-term
investments for other-than-temporary impairment whenever the fair value of a marketable security is less than the amortized cost and
evidence indicates that a short-term investment&#x2019;s carrying amount is not recoverable within a reasonable period of time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_84D_eus-gaap--LesseeLeasesPolicyTextBlock_zeDZ1lKkmWUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zTvcJjVfRLBg"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;We
account for leases in accordance with ASC 842, &lt;i&gt;Leases&lt;/i&gt;. Right-of-use lease assets represent our right to use an underlying asset
for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. The measurement of lease
liabilities is based on the present value of future lease payments over the lease term. As our leases do not provide an implicit rate,
we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value
of future lease payments. The right-of-use asset is based on the measurement of the lease liability and includes any lease payments made
prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. Rent expense for our
operating leases is recognized on a straight-line basis over the lease term. We do not have any leases classified as finance leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Our
leases do not have significant rent escalation, holidays, concessions, material residual value guarantees, material restrictive covenants
or contingent rent provisions. Our leases include both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease
components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component as we have elected the
practical expedient to group lease and non-lease components for all leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Most
leases include one or more options to renew. The exercise of lease renewal options is typically at our sole discretion; therefore, the
majority of renewals to extend the lease terms are not included in our right-of-use assets and lease liabilities as they are not reasonably
certain of exercise. We regularly evaluate the renewal options and when they are reasonably certain of exercise, we include the renewal
period in our lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Additional
information and disclosures required under ASC 842 are included in Note 7.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_84B_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zOdn5KLQjuTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_z5DzEwHQw0c1"&gt;Restricted
Cash&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Restricted
cash, which is recorded within other assets and restricted cash in the accompanying consolidated balance sheets and is included as a
component of cash, cash equivalents and restricted cash on our consolidated statements of cash flows, consists of cash and cash equivalents
held as collateral for a corporate credit card and office space in New York. As such, the cash and cash equivalents are restricted in
use.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zIFTyweu3N44" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_z9oBtVlfjEva"&gt;Loss
Per Common Share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;We
have presented basic and diluted loss per common share on the statement of operations and comprehensive loss. Basic and diluted net loss
per share is computed by dividing net loss by the weighted-average number of shares of common stock and shares underlying &#x201c;pre-funded&#x201d;
warrants outstanding during the period. The &#x201c;pre-funded&#x201d; warrants were included in the computation of basic net loss per
share as the exercise price was negligible and the warrants were fully vested and exercisable. In October 2020, all of the &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20201031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreFundedWarrantMember_pdd" title="Warrants converted to shares"&gt;9,017,055&lt;/span&gt;
&#x201c;pre-funded&#x201d; warrants were exercised and converted into shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zIjsTejJ69Xf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;We
do not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive.
Potential dilutive securities result from outstanding stock options, restricted stock and &#x201c;non-pre-funded&#x201d; warrants. We did
not include the following potentially dilutive securities in the computation of diluted net loss per common share during the periods
presented:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B0_zGpTDclD53Ef" style="display: none"&gt;SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the three months ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the nine months ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;Stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zGmT3TiyFHH" style="width: 11%; text-align: right" title="Total"&gt;7,755,196&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zVPZetACBmpj" style="width: 11%; text-align: right" title="Total"&gt;6,431,183&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zZEyPRPu13fh" style="width: 11%; text-align: right" title="Total"&gt;7,755,196&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zElmds4z2HWd" style="width: 11%; text-align: right" title="Total"&gt;6,431,183&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Restricted stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z0JAkd7JW7Dk" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;2,989,224&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zT0Jq02nK7s9" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;818,233&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zNbTYrZy4096" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;2,989,224&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zq5ETfqCi4h9" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;818,233&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930_z1yadaQyohHk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;10,744,420&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200701__20200930_zk1Er6zMGrg4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;7,249,416&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930_zVBezYMakOW9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;10,744,420&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20200930_zMFXm5NhwoUc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;7,249,416&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_z4wrP32YLEKl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-10-31_custom_PreFundedWarrantMember"
      decimals="INF"
      unitRef="Shares">9017055</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zIjsTejJ69Xf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;We
do not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive.
Potential dilutive securities result from outstanding stock options, restricted stock and &#x201c;non-pre-funded&#x201d; warrants. We did
not include the following potentially dilutive securities in the computation of diluted net loss per common share during the periods
presented:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B0_zGpTDclD53Ef" style="display: none"&gt;SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the three months ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the nine months ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: justify"&gt;Stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zGmT3TiyFHH" style="width: 11%; text-align: right" title="Total"&gt;7,755,196&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zVPZetACBmpj" style="width: 11%; text-align: right" title="Total"&gt;6,431,183&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zZEyPRPu13fh" style="width: 11%; text-align: right" title="Total"&gt;7,755,196&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zElmds4z2HWd" style="width: 11%; text-align: right" title="Total"&gt;6,431,183&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Restricted stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z0JAkd7JW7Dk" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;2,989,224&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zT0Jq02nK7s9" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;818,233&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zNbTYrZy4096" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;2,989,224&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zq5ETfqCi4h9" style="border-bottom: Black 1pt solid; text-align: right" title="Total"&gt;818,233&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930_z1yadaQyohHk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;10,744,420&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200701__20200930_zk1Er6zMGrg4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;7,249,416&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930_zVBezYMakOW9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;10,744,420&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20200930_zMFXm5NhwoUc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;7,249,416&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-07-012021-09-30_custom_StockOptionsMember"
      decimals="INF"
      unitRef="Shares">7755196</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-07-012020-09-30_custom_StockOptionsMember"
      decimals="INF"
      unitRef="Shares">6431183</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-09-30_custom_StockOptionsMember"
      decimals="INF"
      unitRef="Shares">7755196</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-09-30_custom_StockOptionsMember"
      decimals="INF"
      unitRef="Shares">6431183</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-07-012021-09-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">2989224</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-07-012020-09-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">818233</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-09-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">2989224</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">818233</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-07-012021-09-30"
      decimals="INF"
      unitRef="Shares">10744420</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-07-012020-09-30"
      decimals="INF"
      unitRef="Shares">7249416</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-01to2021-09-30"
      decimals="INF"
      unitRef="Shares">10744420</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-09-30"
      decimals="INF"
      unitRef="Shares">7249416</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_80E_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zdpp23stxiI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
2 &#x2013; &lt;span id="xdx_822_zHihvzzsYH16"&gt;SHORT-TERM INVESTMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zjbZsQZKxH7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes the available-for-sale investments held:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B8_zHdGAqPcpEZ3" style="display: none"&gt;SCHEDULE OF AVAILABLE-FOR-SALE INVESTMENTS HELD&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;U.S. government and agency securities and treasuries&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20210930_zNCwvQn3mAxh" style="width: 16%; text-align: right" title="U.S. government and agency securities and treasuries"&gt;23,217,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20201231_zK0VDqxmHNC3" style="width: 16%; text-align: right" title="U.S. government and agency securities and treasuries"&gt;82,438,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zKuy9IgcjIyb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
amortized cost of the available-for-sale debt securities, which is adjusted for amortization of premiums and accretion of discounts to
maturity, was $&lt;span id="xdx_904_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20210930_zgbhmyqR9gek" title="Amortized cost of available-for-sale debt securities"&gt;23,217,000&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20201231_z3Y9j1wvEv62" title="Amortized cost of available-for-sale debt securities"&gt;82,448,000&lt;/span&gt; as of September 30, 2021 and December 31, 2020, respectively. There were &lt;span id="xdx_908_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_do_c20210101__20210930_zSEWabXEfFJ8" title="Realized gains or losses on sale or maturity of available-for-sale debt securities"&gt;&lt;span id="xdx_90D_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_do_c20200101__20200930_zzILk9FaHlk4" title="Realized gains or losses on sale or maturity of available-for-sale debt securities"&gt;no&lt;/span&gt;&lt;/span&gt; significant realized
gains or losses recognized on the sale or maturity of available-for-sale debt securities during the nine months ended September 30, 2021
or 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_891_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zjbZsQZKxH7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes the available-for-sale investments held:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B8_zHdGAqPcpEZ3" style="display: none"&gt;SCHEDULE OF AVAILABLE-FOR-SALE INVESTMENTS HELD&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;December 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;U.S. government and agency securities and treasuries&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20210930_zNCwvQn3mAxh" style="width: 16%; text-align: right" title="U.S. government and agency securities and treasuries"&gt;23,217,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20201231_zK0VDqxmHNC3" style="width: 16%; text-align: right" title="U.S. government and agency securities and treasuries"&gt;82,438,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">23217000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">82438000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">23217000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">82448000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_80B_eus-gaap--IntangibleAssetsDisclosureTextBlock_z5ziRi9Akllk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
3 &#x2013; &lt;span id="xdx_82A_zImVBkbtTvz3"&gt;LICENSED TECHNOLOGY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;On
November 4, 2018, we entered into a license agreement with REGENXBIO Inc. (&#x201c;REGENXBIO&#x201d;) to obtain rights to an exclusive
worldwide license (subject to certain non-exclusive rights previously granted for MPS IIIA), with rights to sublicense, to REGENXBIO&#x2019;s
NAV AAV9 vector for gene therapies for treating MPS IIIA, MPS IIIB, CLN1 Disease and CLN3 Disease. Consideration for the rights granted
under the original agreement included fees totaling $&lt;span id="xdx_909_eus-gaap--RoyaltyExpense_pn6n6_c20181103__20181104__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_z2GLLZSFK9J7" title="Royalty fees"&gt;180&lt;/span&gt; million and a running royalty on net sales, including: (i) an initial fee of
$&lt;span id="xdx_90D_eus-gaap--PaymentsForRoyalties_pn6n6_c20181103__20181104__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zCdCdWEzsam8" title="Royalties payments"&gt;20&lt;/span&gt; million, $&lt;span id="xdx_90D_ecustom--PaymentForExecutionOfContracts_iI_pn6n6_c20181104__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zOYyE6enaFr9" title="Payment on execution of contracts"&gt;10&lt;/span&gt; million of which was due to REGENXBIO shortly after the effective date of the agreement, and $&lt;span id="xdx_904_eus-gaap--DueToRelatedPartiesCurrent_iI_pn6n6_c20181104__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zWqysz5KNsAb" title="Due to licensor current"&gt;10&lt;/span&gt; million of which was
to be due on the first anniversary of the effective date of the agreement in November 2019, (ii) annual fees totaling up to $&lt;span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20181104__srt--RangeAxis__srt--MaximumMember__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zQcynVfbUZEa" title="Annual fees"&gt;100&lt;/span&gt; million,
payable in $&lt;span id="xdx_900_eus-gaap--PaymentsForRoyalties_pn6n6_c20201103__20201104__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_z5JQaYEbk40g"&gt;20&lt;/span&gt; million annual installments beginning on the second anniversary of the effective date (the first of which was to remain
payable if the agreement were terminated before the second anniversary in November 2020), (iii) sales milestone payments totaling $&lt;span id="xdx_906_ecustom--PaymentsForMilestone_pn6n6_c20181103__20181104__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zuENpTJjpxy5" title="Milestone payment"&gt;60&lt;/span&gt;
million, and (iv) royalties payable in the low double digits to low teens on net sales of products covered under the agreement. The license
was being amortized over the life of the patent of &lt;span title="Finite-lived intangible asset, useful life::XDX::8"&gt;&lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dc_c20181103__20181104__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zzKOWzVxHZ6d" title="Finite-lived intangible asset, useful life"&gt;eight years&lt;/span&gt;&lt;/span&gt;. On November 1, 2019, we entered into an amendment of the original license
agreement. The amended agreement replaced the $&lt;span id="xdx_906_eus-gaap--ProgramRightsObligationsCurrent_iI_pn6n6_c20191104__us-gaap--TypeOfArrangementAxis__custom--OriginalLicenseAgreementMember_zS1MGwA152Ne" title="License to be paid"&gt;10&lt;/span&gt; million payment due on November 4, 2019 with a $&lt;span id="xdx_90A_eus-gaap--ProgramRightsObligationsCurrent_iI_pn6n6_c20191104__us-gaap--TypeOfArrangementAxis__custom--AmendedAgreementMember_zVJ320nawWld" title="License to be paid"&gt;3&lt;/span&gt; million payment due on November 4,
2019 and an additional $&lt;span id="xdx_90C_eus-gaap--ProgramRightsObligationsCurrent_iI_pn6n6_c20191104__us-gaap--AwardDateAxis__custom--AprilOneTwentyTwentyMember__us-gaap--TypeOfArrangementAxis__custom--AmendedAgreementMember_zg0YWHRunq5h" title="License to be paid"&gt;8&lt;/span&gt; million payment (which included $&lt;span id="xdx_901_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn6n6_c20191104_z8XsMDVVTKJe" title="Interest payable"&gt;1&lt;/span&gt; million of interest) that would have been due no later than April 1, 2020.
That $&lt;span id="xdx_902_eus-gaap--PaymentsForRoyalties_pn6n6_c20200329__20200402_zAJkw6BcViqk" title="Royalties payments"&gt;8&lt;/span&gt; million payment that had been scheduled to be paid by April 1, 2020 and the $&lt;span id="xdx_901_eus-gaap--PaymentsForRoyalties_pn6n6_c20201103__20201104_zf7sLiE8eb37" title="Royalties payments"&gt;20&lt;/span&gt; million that had been due to be paid on November
4, 2020 are both recorded as payable to licensor on the consolidated balance sheet. The Company disputed that it was responsible for
the $&lt;span id="xdx_900_eus-gaap--LossContingencyAccrualAtCarryingValue_iI_pn6n6_c20201231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zdr1xbWgcbvd" title="Loss contingency accrual"&gt;8 &lt;/span&gt;million and $&lt;span id="xdx_900_eus-gaap--PaymentsForLegalSettlements_pn6n6_c20200101__20201231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zTkqgsAnGPk7" title="Payments for legal settlements"&gt;20&lt;/span&gt; million payments, and those payments were the subject of an arbitration between the Company and REGENXBIO as noted
below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;Prior to the
April 1, 2020 deadline, &lt;span id="xdx_908_eus-gaap--LossContingencySettlementAgreementTerms_c20200330__20200402__dei--LegalEntityAxis__custom--REGENXBIOMember_zYpOuWx7UX5b" title="Settlement agreement financial terms, description"&gt;we engaged REGENXBIO in discussions in an attempt to renegotiate the financial terms of the agreement, but we
were unable to reach an agreement, and we did not make the $8 million payment due by April 1, 2020. On April 17, 2020, REGENXBIO sent
us a written demand for the $8 million fee, payable within a 15-day cure period after receipt of the demand letter. The license terminated
on May 2, 2020, when the 15-day period expired. We considered the status of our discussions with REGENXBIO in March 2020 as a potential
indicator of impairment in accordance with ASC 360-10-35-21.&lt;/span&gt; Our impairment test indicated that the carrying value of the license agreement
exceeded its fair value and we recorded a $&lt;span id="xdx_90D_eus-gaap--OtherCostAndExpenseOperating_pn5n6_c20210101__20210331_zlRwJIRWxsf7" title="Non-cash licensed technology impairment charge"&gt;32.9&lt;/span&gt; million non-cash impairment charge during the three months ended March 31, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;On May 25, 2020,
we filed an arbitration claim with the American Arbitration Association (&#x201c;AAA&#x201d;) alleging that REGENXBIO materially breached
the license agreement prior to termination and seeking, among other things, a declaration that as a result of REGENXBIO&#x2019;s material
breach, we were not responsible for payments totaling $&lt;span id="xdx_902_eus-gaap--GainLossRelatedToLitigationSettlement_pn6n6_c20200524__20200525__dei--LegalEntityAxis__custom--REGENXBIOMember_zYwBxXV89bDg" title="Gain loss on payments for settlement"&gt;28&lt;/span&gt; million (which would otherwise have been due in 2020) plus accrued interest.
REGENXBIO disputed our arbitration claim and filed a counterclaim seeking payment of the $&lt;span id="xdx_909_eus-gaap--GainLossRelatedToLitigationSettlement_pn6n6_c20200524__20200525__dei--LegalEntityAxis__custom--REGENXBIOMember_zPUT0U4YIqLf"&gt;28&lt;/span&gt; million plus interest, which REGENXBIO argued
remained due. An arbitration hearing before a tribunal of three AAA arbitrators was held on March 8 and March 9, 2021. On July 13, 2021,
the tribunal found in favor of REGENXBIO in connection with the parties&#x2019; arbitration claims and counterclaims. The tribunal awarded
REGENXBIO $&lt;span id="xdx_908_eus-gaap--GainLossRelatedToLitigationSettlement_pn6n6_c20200712__20200713__dei--LegalEntityAxis__custom--REGENXBIOMember_zpcGhd9B3sQk"&gt;28&lt;/span&gt;.0 million plus interest. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;On August 9,
2021, we filed a second arbitration claim with the AAA asserting that a settlement had been reached before the tribunal&#x2019;s award
in the first arbitration was issued. On September 14, 2021, REGENXBIO filed its answer, a counterclaim seeking attorney fees and costs,
and a request for permission to file a case dispositive motion. A preliminary hearing was held on November 1, 2021, during which the
AAA Tribunal set timetables for discovery and for REGENXBIO&#x2019;s filing of its case dispositive motion. Those timetables were formalized
in a procedural order issued by the Tribunal on November 8, 2021. Under the schedule set by the Tribunal, REGENXBIO&#x2019;s opening brief
in support of its case dispositive motion was filed on November 8, 2021, briefing was scheduled to be completed on December 29, 2021,
and oral argument was scheduled for January 14, 2022. REGENXBIO had also filed suit in the New York State Supreme Court Commercial Division
seeking enforcement of the original arbitration award, and we had requested that the Court stay that proceeding until the second arbitration
is complete. Oral argument on our request for a stay was set for March 10, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;On November
12, 2021, we entered into a settlement agreement (&#x201c;Settlement Agreement&#x201d;) with REGENXBIO to resolve all current disputes
between the parties including the aforementioned AAA arbitration and New York State Court action. In accordance with the Settlement Agreement,
we agreed to pay REGENXBIO a total of $&lt;span id="xdx_90F_eus-gaap--SettlementLiabilitiesCurrent_iI_pn6n6_c20211112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zUOSsK0hrK88" title="Settlement amount"&gt;30&lt;/span&gt; million, payable as follows: (1) $&lt;span id="xdx_905_eus-gaap--SettlementLiabilitiesCurrent_iI_pn6n6_c20211112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--REGENXBIOMember__srt--StatementScenarioAxis__custom--OneBusinessDayMember_z4zEM9DwHcEb"&gt;20&lt;/span&gt; million payable within one business day of the execution
of the Settlement Agreement, (2) $&lt;span id="xdx_907_eus-gaap--SettlementLiabilitiesCurrent_iI_pn6n6_c20211112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--REGENXBIOMember__srt--StatementScenarioAxis__custom--FirstAnniversaryMember_zCzt974Dpwv2"&gt;5&lt;/span&gt; million on the first anniversary of the effective date of the Settlement Agreement, and (3) $&lt;span id="xdx_904_eus-gaap--SettlementLiabilitiesCurrent_iI_pn6n6_c20211112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--REGENXBIOMember__srt--StatementScenarioAxis__custom--ThirdAnniversaryMember_zy2VNSJSyD4"&gt;5&lt;/span&gt; million
upon the earlier of: (i) the third anniversary of the effective date of the Settlement Agreement or (ii) the closing of a Strategic Transaction,
as defined in the Settlement Agreement. Under the Settlement Agreement&#x2019;s terms, the prior license agreement between the parties
was not reinstituted, and any future license agreement would need to be negotiated separately and require consideration in addition to
the consideration set forth in the Settlement Agreement. As of September 30, 2021, we have recorded the payable to licensor in the balance
sheet based on the present value of the payments due to REGENXBIO under the Settlement Agreement. The accounting for the Settlement Agreement
resulted in a $&lt;span id="xdx_902_ecustom--GainOnSettlementOfRelatedParty_pn5n6_c20210101__20210930_zrhZWOInkWUj" title="Non-cash gain on settlement with licensor"&gt;6.7&lt;/span&gt; million gain on settlement with licensor in the statement of operations and comprehensive loss during the three and
nine months ended September 30, 2021 and a $&lt;span id="xdx_907_ecustom--GainOnSettlementOfRelatedParty_pn5n6_c20210701__20210930_zRSG4WAcpFkj" title="Gain on settlement with licensor"&gt;&lt;span id="xdx_90E_ecustom--GainOnSettlementOfRelatedParty_pn5n6_c20210101__20210930_zTFeMnIKbSM5" title="Gain on settlement with licensor"&gt;6.7&lt;/span&gt;&lt;/span&gt; million non-cash gain on settlement with licensor in the statement of cash flows during
the nine months ended September 30, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;On
May 15, 2015, we acquired Abeona Therapeutics LLC, which had an exclusive license through Nationwide Children&#x2019;s Hospital to the
AB-101 and AB-102 patent portfolios for developing treatments for patients with Sanfilippo Syndrome Type A and Type B. The license is
amortized over the life of the license of &lt;span title="Finite-lived intangible asset, useful life"&gt;&lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20150514__20150515__us-gaap--BusinessAcquisitionAxis__custom--AbeonaTherapeuticsLlcMember_z3uVg7quLRR1" title="Finite-lived intangible asset, useful life"&gt;20&lt;/span&gt;&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z9UE8u2a6Jt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Licensed
technology consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BB_zRs7c9dsINs1" style="display: none"&gt;SCHEDULE OF LICENSED TECHNOLOGY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210930_zSCTNABmgGdj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&#160;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20201231_zX6IsieNFP07" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_maFLIANzlPQ_maFLIANzW7H_zhmnavrK8gw" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 54%; text-align: left"&gt;Licensed technology&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;2,156,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;2,156,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_msFLIANzlPQ_msFLIANzW7H_zLREEQbBP9F" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;743,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;656,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzlPQ_mtFLIANzW7H_zauM9yRpWASd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Licensed technology, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,413,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,500,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_z89kyIfBWwa1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zTBwftYkHbEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
aggregate estimated amortization expense for intangible assets remaining as of September 30, 2021 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_zfCXCDqoOfu8" style="display: none"&gt;SCHEDULE OF AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 30%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20210930_zTfOPHYYMC8e" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pp0p0_maFLIANznXj_maFLIANzM9M_zclkn8EHrLE" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: center"&gt;2021, remainder&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 44%; text-align: right"&gt;29,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_maFLIANznXj_maFLIANzM9M_zDxGELT9MVz7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_maFLIANznXj_maFLIANzM9M_zfatiQ8z2Bl3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_maFLIANznXj_maFLIANzM9M_ztFFvH6slhoi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_maFLIANznXj_maFLIANzM9M_zP3Qx12frSd1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pp0p0_maFLIANznXj_maFLIANzM9M_zNwGMsa49kYe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;916,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANznXj_mtFLIANzM9M_zvXeRMuiKVXj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,413,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_z4qndAzFmivg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif; text-underline-style: double"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Amortization
on licensed technology was $&lt;span id="xdx_90C_eus-gaap--AmortizationOfIntangibleAssets_c20210701__20210930_zcisbbBEgCZ9" title="Amortization of intangible assets"&gt;29,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20210930_zke4iL1pjElh" title="Amortization of intangible assets"&gt;87,000&lt;/span&gt; for the three and nine months ended September 30, 2021 and $&lt;span id="xdx_90E_eus-gaap--AmortizationOfIntangibleAssets_c20200701__20200930_zBxNsuCGjkmd"&gt;43,000&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pn5n6_c20200101__20200930_zXyLGiJbZIM7" title="Amortization of intangible assets"&gt;1.4&lt;/span&gt; million for
the three and nine months ended September 30, 2020, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:RoyaltyExpense
      contextRef="From2018-11-032018-11-04_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember"
      decimals="-6"
      unitRef="USD">180000000</us-gaap:RoyaltyExpense>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2018-11-032018-11-04_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember"
      decimals="-6"
      unitRef="USD">20000000</us-gaap:PaymentsForRoyalties>
    <abeo:PaymentForExecutionOfContracts
      contextRef="AsOf2018-11-04_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember"
      decimals="-6"
      unitRef="USD">10000000</abeo:PaymentForExecutionOfContracts>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="AsOf2018-11-04_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember"
      decimals="-6"
      unitRef="USD">10000000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2018-11-04_srt_MaximumMember_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember"
      decimals="-6"
      unitRef="USD">100000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2020-11-032020-11-04_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember"
      decimals="-6"
      unitRef="USD">20000000</us-gaap:PaymentsForRoyalties>
    <abeo:PaymentsForMilestone
      contextRef="From2018-11-032018-11-04_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember"
      decimals="-6"
      unitRef="USD">60000000</abeo:PaymentsForMilestone>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2018-11-032018-11-04_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ProgramRightsObligationsCurrent
      contextRef="AsOf2019-11-04_custom_OriginalLicenseAgreementMember"
      decimals="-6"
      unitRef="USD">10000000</us-gaap:ProgramRightsObligationsCurrent>
    <us-gaap:ProgramRightsObligationsCurrent
      contextRef="AsOf2019-11-04_custom_AmendedAgreementMember"
      decimals="-6"
      unitRef="USD">3000000</us-gaap:ProgramRightsObligationsCurrent>
    <us-gaap:ProgramRightsObligationsCurrent
      contextRef="AsOf2019-11-04_custom_AprilOneTwentyTwentyMember_custom_AmendedAgreementMember"
      decimals="-6"
      unitRef="USD">8000000</us-gaap:ProgramRightsObligationsCurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="AsOf2019-11-04" decimals="-6" unitRef="USD">1000000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2020-03-292020-04-02"
      decimals="-6"
      unitRef="USD">8000000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="From2020-11-032020-11-04"
      decimals="-6"
      unitRef="USD">20000000</us-gaap:PaymentsForRoyalties>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="AsOf2020-12-31_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember"
      decimals="-6"
      unitRef="USD">8000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="From2020-01-012020-12-31_us-gaap_LicensingAgreementsMember_custom_REGENXBIOMember"
      decimals="-6"
      unitRef="USD">20000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:LossContingencySettlementAgreementTerms contextRef="From2020-03-302020-04-02_custom_REGENXBIOMember">we engaged REGENXBIO in discussions in an attempt to renegotiate the financial terms of the agreement, but we
were unable to reach an agreement, and we did not make the $8 million payment due by April 1, 2020. On April 17, 2020, REGENXBIO sent
us a written demand for the $8 million fee, payable within a 15-day cure period after receipt of the demand letter. The license terminated
on May 2, 2020, when the 15-day period expired. We considered the status of our discussions with REGENXBIO in March 2020 as a potential
indicator of impairment in accordance with ASC 360-10-35-21.</us-gaap:LossContingencySettlementAgreementTerms>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="From2021-01-012021-03-31"
      decimals="-5"
      unitRef="USD">32900000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="From2020-05-242020-05-25_custom_REGENXBIOMember"
      decimals="-6"
      unitRef="USD">28000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="From2020-05-242020-05-25_custom_REGENXBIOMember"
      decimals="-6"
      unitRef="USD">28000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="From2020-07-122020-07-13_custom_REGENXBIOMember"
      decimals="-6"
      unitRef="USD">28000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:SettlementLiabilitiesCurrent
      contextRef="AsOf2021-11-12_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_custom_REGENXBIOMember"
      decimals="-6"
      unitRef="USD">30000000</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:SettlementLiabilitiesCurrent
      contextRef="AsOf2021-11-12_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_custom_REGENXBIOMember_custom_OneBusinessDayMember"
      decimals="-6"
      unitRef="USD">20000000</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:SettlementLiabilitiesCurrent
      contextRef="AsOf2021-11-12_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_custom_REGENXBIOMember_custom_FirstAnniversaryMember"
      decimals="-6"
      unitRef="USD">5000000</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:SettlementLiabilitiesCurrent
      contextRef="AsOf2021-11-12_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_custom_REGENXBIOMember_custom_ThirdAnniversaryMember"
      decimals="-6"
      unitRef="USD">5000000</us-gaap:SettlementLiabilitiesCurrent>
    <abeo:GainOnSettlementOfRelatedParty
      contextRef="From2021-01-01to2021-09-30"
      decimals="-5"
      unitRef="USD">6700000</abeo:GainOnSettlementOfRelatedParty>
    <abeo:GainOnSettlementOfRelatedParty
      contextRef="From2021-07-012021-09-30"
      decimals="-5"
      unitRef="USD">6700000</abeo:GainOnSettlementOfRelatedParty>
    <abeo:GainOnSettlementOfRelatedParty
      contextRef="From2021-01-01to2021-09-30"
      decimals="-5"
      unitRef="USD">6700000</abeo:GainOnSettlementOfRelatedParty>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2015-05-142015-05-15_custom_AbeonaTherapeuticsLlcMember">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_898_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z9UE8u2a6Jt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Licensed
technology consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BB_zRs7c9dsINs1" style="display: none"&gt;SCHEDULE OF LICENSED TECHNOLOGY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210930_zSCTNABmgGdj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&#160;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20201231_zX6IsieNFP07" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_maFLIANzlPQ_maFLIANzW7H_zhmnavrK8gw" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 54%; text-align: left"&gt;Licensed technology&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;2,156,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;2,156,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_msFLIANzlPQ_msFLIANzW7H_zLREEQbBP9F" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;743,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;656,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzlPQ_mtFLIANzW7H_zauM9yRpWASd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Licensed technology, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,413,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,500,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">2156000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2156000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">743000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">656000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1413000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_898_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zTBwftYkHbEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
aggregate estimated amortization expense for intangible assets remaining as of September 30, 2021 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_zfCXCDqoOfu8" style="display: none"&gt;SCHEDULE OF AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 30%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20210930_zTfOPHYYMC8e" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pp0p0_maFLIANznXj_maFLIANzM9M_zclkn8EHrLE" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: center"&gt;2021, remainder&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 44%; text-align: right"&gt;29,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_maFLIANznXj_maFLIANzM9M_zDxGELT9MVz7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_maFLIANznXj_maFLIANzM9M_zfatiQ8z2Bl3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_maFLIANznXj_maFLIANzM9M_ztFFvH6slhoi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_maFLIANznXj_maFLIANzM9M_zP3Qx12frSd1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;117,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pp0p0_maFLIANznXj_maFLIANzM9M_zNwGMsa49kYe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;916,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANznXj_mtFLIANzM9M_zvXeRMuiKVXj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,413,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">29000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">117000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">117000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">117000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">117000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">916000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1413000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">29000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">87000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">43000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-01-012020-09-30"
      decimals="-5"
      unitRef="USD">1400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_800_eus-gaap--DebtDisclosureTextBlock_zZjdCfHwDAw1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
4 - &lt;span id="xdx_829_zOZpT5Xrd8Wj"&gt;LOAN PAYABLE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
May 2, 2020, we received loan proceeds in the amount of approximately $&lt;span id="xdx_90B_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20200501__20200502__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramMember_zvX7W6RWTlDj" title="Proceeds from loan"&gt;1.8&lt;/span&gt; million (the &#x201c;PPP Loan&#x201d;) under the Paycheck Protection
Program (&#x201c;PPP&#x201d;). The PPP was established under the Coronavirus Aid, Relief and Economic Security Act, as amended (&#x201c;CARES
Act&#x201d;) and is administered by the U.S. Small Business Administration (&#x201c;SBA&#x201d;). Under the terms of the CARES Act, PPP
loan recipients can apply for loan forgiveness. The loan forgiveness for all or a portion of PPP loans was determined, subject to limitations,
based on the use of loan proceeds over the 24 weeks after the loan proceeds are disbursed. In July 2021, we received notice from the
SBA that our PPP loan has been forgiven. In the third quarter of 2021, the extinguishment of the PPP loan payable was recorded as PPP
loan payable forgiveness income in the statement of operations and comprehensive loss. The forgiveness of the PPP loan payable was recorded
as non-cash PPP loan payable forgiveness income in the statement of cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2020-05-012020-05-02_custom_PaycheckProtectionProgramMember"
      decimals="-5"
      unitRef="USD">1800000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_800_eus-gaap--FairValueDisclosuresTextBlock_zka8fLXsz7vd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
5 &#x2013; &lt;span id="xdx_823_z1OC8Uv6fiy3"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
calculate the fair value of our assets and liabilities that qualify as financial instruments and include additional information in the
notes to the consolidated financial statements when the fair value is different than the carrying value of these financial instruments.
The estimated fair value of prepaid expenses and other current assets, other assets, accounts payable, accrued expenses, loan payable,
payable to licensor and contract liability approximate their carrying amounts due to the relatively short maturity of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;U.S.
GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in
the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement
date. This guidance establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy
requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The lowest level fair value inputs
are used to assign a fair value level. The three levels of inputs used to measure fair value are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; layout-grid-mode: line; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; layout-grid-mode: line; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    1 - Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    2 - Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active
    markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets
    and liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use
    significant unobservable inputs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;We
have segregated all financial assets and liabilities that are measured at fair value on a recurring basis (at least annually) into the
most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in
the table below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zy9jzHYcGQ7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Financial
assets and liabilities measured at fair value on a recurring and non-recurring basis as of September 30, 2021 and December 31, 2020 are
summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BF_zYsdQBF3Bs2a" style="display: none"&gt;SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;September
30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total Gains/(Losses)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: justify"&gt;Recurring&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: justify"&gt;Short-term investments&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zXgJr5COOH9" style="width: 16%; text-align: right" title="Fair value disclosure of assets"&gt;23,217,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zpKsindg2PAc" style="width: 9%; text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0778"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zCIePP4gCDDf" style="width: 9%; text-align: right" title="Fair value disclosure of assets"&gt;23,217,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zIVmJtFdC7El" style="width: 9%; text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0782"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUmBb7HDRQJh" style="width: 9%; text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0784"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: justify"&gt;Non-recurring&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Licensed technology, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zCBSJxtCiGPi" style="text-align: right" title="Fair value disclosure of assets"&gt;1,413,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zh5WLLypThL8" style="text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0788"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_z8qzIY21wgv6" style="text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0790"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_z3J6Afun9Bla" style="text-align: right" title="Fair value disclosure of assets"&gt;1,413,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zB3PSIzLkd8g" style="text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0794"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zc6MiCzs9hMg" style="text-align: right" title="Fair value disclosure of assets"&gt;32,466,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zvuYGx0DK9Wl" style="text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0798"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zIl4ZPGNLQr3" style="text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0800"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zXPePTJOBhRe" style="text-align: right" title="Fair value disclosure of assets"&gt;32,466,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zfSYe35hTNwe" style="text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0804"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;December
31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total Gains/(Losses)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: justify"&gt;Recurring&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: justify"&gt;Short-term investments&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zcXn0nTmXfhd" style="width: 16%; text-align: right" title="Fair value disclosure of assets"&gt;82,438,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zvPylhnEA7R" style="width: 9%; text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0808"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxtpgDmCm5G2" style="width: 9%; text-align: right" title="Fair value disclosure of assets"&gt;82,438,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z5S6oy2RJ3yc" style="width: 9%; text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0812"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zK4YcvN9FZ34" style="width: 9%; text-align: right" title="Fair value disclosure of gain loss"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0814"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: justify"&gt;Non-recurring&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Licensed technology, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zG7TKK9dokH9" style="text-align: right" title="Fair value disclosure of assets"&gt;1,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_z5DAbHpfADdh" style="text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0818"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_z0vvxhiAfeb4" style="text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0820"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zgys0wMOkMSh" style="text-align: right" title="Fair value disclosure of assets"&gt;1,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_z2oOXVuHir4e" style="text-align: right" title="Fair value disclosure of gain loss"&gt;(32,916,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zSKFMXFd51y5" style="text-align: right" title="Fair value disclosure of assets"&gt;32,466,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zir2urBeFoNh" style="text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0828"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zgRfZXszhf79" style="text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0830"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zA6JNTPYMid5" style="text-align: right" title="Fair value disclosure of assets"&gt;32,466,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zYvnQTSEOqHc" style="text-align: right" title="Fair value disclosure of gain loss"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0834"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zQLHL6oYFkGl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_898_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zy9jzHYcGQ7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Financial
assets and liabilities measured at fair value on a recurring and non-recurring basis as of September 30, 2021 and December 31, 2020 are
summarized below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BF_zYsdQBF3Bs2a" style="display: none"&gt;SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;September
30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total Gains/(Losses)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: justify"&gt;Recurring&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: justify"&gt;Short-term investments&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zXgJr5COOH9" style="width: 16%; text-align: right" title="Fair value disclosure of assets"&gt;23,217,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zpKsindg2PAc" style="width: 9%; text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0778"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zCIePP4gCDDf" style="width: 9%; text-align: right" title="Fair value disclosure of assets"&gt;23,217,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zIVmJtFdC7El" style="width: 9%; text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0782"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUmBb7HDRQJh" style="width: 9%; text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0784"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: justify"&gt;Non-recurring&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Licensed technology, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zCBSJxtCiGPi" style="text-align: right" title="Fair value disclosure of assets"&gt;1,413,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zh5WLLypThL8" style="text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0788"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_z8qzIY21wgv6" style="text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0790"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_z3J6Afun9Bla" style="text-align: right" title="Fair value disclosure of assets"&gt;1,413,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zB3PSIzLkd8g" style="text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0794"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zc6MiCzs9hMg" style="text-align: right" title="Fair value disclosure of assets"&gt;32,466,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zvuYGx0DK9Wl" style="text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0798"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zIl4ZPGNLQr3" style="text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0800"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zXPePTJOBhRe" style="text-align: right" title="Fair value disclosure of assets"&gt;32,466,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zfSYe35hTNwe" style="text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0804"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;December
31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total Gains/(Losses)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: justify"&gt;Recurring&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: justify"&gt;Short-term investments&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zcXn0nTmXfhd" style="width: 16%; text-align: right" title="Fair value disclosure of assets"&gt;82,438,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zvPylhnEA7R" style="width: 9%; text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0808"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxtpgDmCm5G2" style="width: 9%; text-align: right" title="Fair value disclosure of assets"&gt;82,438,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z5S6oy2RJ3yc" style="width: 9%; text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0812"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zK4YcvN9FZ34" style="width: 9%; text-align: right" title="Fair value disclosure of gain loss"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0814"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: justify"&gt;Non-recurring&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Licensed technology, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zG7TKK9dokH9" style="text-align: right" title="Fair value disclosure of assets"&gt;1,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_z5DAbHpfADdh" style="text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0818"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_z0vvxhiAfeb4" style="text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0820"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zgys0wMOkMSh" style="text-align: right" title="Fair value disclosure of assets"&gt;1,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_z2oOXVuHir4e" style="text-align: right" title="Fair value disclosure of gain loss"&gt;(32,916,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zSKFMXFd51y5" style="text-align: right" title="Fair value disclosure of assets"&gt;32,466,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zir2urBeFoNh" style="text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0828"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zgRfZXszhf79" style="text-align: right" title="Fair value disclosure of assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0830"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zA6JNTPYMid5" style="text-align: right" title="Fair value disclosure of assets"&gt;32,466,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zYvnQTSEOqHc" style="text-align: right" title="Fair value disclosure of gain loss"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0834"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-09-30_custom_ShortTermInvestmentMember_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      unitRef="USD">23217000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-09-30_custom_ShortTermInvestmentMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      unitRef="USD">23217000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-09-30_custom_LicensedTechnologyNetMember_us-gaap_FairValueMeasurementsNonrecurringMember"
      decimals="0"
      unitRef="USD">1413000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-09-30_custom_LicensedTechnologyNetMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsNonrecurringMember"
      decimals="0"
      unitRef="USD">1413000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-09-30_us-gaap_GoodwillMember_us-gaap_FairValueMeasurementsNonrecurringMember"
      decimals="0"
      unitRef="USD">32466000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-09-30_us-gaap_GoodwillMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsNonrecurringMember"
      decimals="0"
      unitRef="USD">32466000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_custom_ShortTermInvestmentMember_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      unitRef="USD">82438000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_custom_ShortTermInvestmentMember_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      unitRef="USD">82438000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_custom_LicensedTechnologyNetMember_us-gaap_FairValueMeasurementsNonrecurringMember"
      decimals="0"
      unitRef="USD">1500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_custom_LicensedTechnologyNetMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsNonrecurringMember"
      decimals="0"
      unitRef="USD">1500000</us-gaap:AssetsFairValueDisclosure>
    <abeo:FairValueDisclosureOfGainLoss
      contextRef="AsOf2020-12-31_custom_LicensedTechnologyNetMember_us-gaap_FairValueMeasurementsNonrecurringMember"
      decimals="0"
      unitRef="USD">-32916000</abeo:FairValueDisclosureOfGainLoss>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_GoodwillMember_us-gaap_FairValueMeasurementsNonrecurringMember"
      decimals="0"
      unitRef="USD">32466000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_GoodwillMember_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsNonrecurringMember"
      decimals="0"
      unitRef="USD">32466000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_807_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z8y1IWZi5l9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
6 &#x2013; &lt;span id="xdx_822_z3vc0rWceNO6"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zeNE9WAF0w2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Stock
Options&lt;/i&gt;: The following table summarizes stock option-based compensation for the three and nine months ended September 30, 2021 and
2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_zhgHRbRE57u" style="display: none"&gt;SCHEDULE OF STOCK BASED COMPENSATION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the three months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the nine months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5vzLZ7mMNrd" style="width: 10%; text-align: right" title="Total stock-based compensation expense"&gt;432,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zgx16oMVADmg" style="width: 10%; text-align: right" title="Total stock-based compensation expense"&gt;765,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z6T2yur6qoU7" style="width: 10%; text-align: right" title="Total stock-based compensation expense"&gt;1,649,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zTILqnMQIvWe" style="width: 10%; text-align: right" title="Total stock-based compensation expense"&gt;2,380,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_z8EfdWkayT9j" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense"&gt;955,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zDpysH7Fa4Vl" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense"&gt;484,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_z48Hk68g8Lnd" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense"&gt;2,148,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_ztcJTCgkkUW1" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense"&gt;1,703,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock option-based compensation expense included in operating expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_z2mv0g5X8FNb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense"&gt;1,387,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_z2OI5eszwY6a" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense"&gt;1,249,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_znZHQdfqMYIa" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense"&gt;3,797,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_zfOM5lgJKL54" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense"&gt;4,083,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8AD_zmRsHgVAOWQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;We
estimate the fair value of each option award on the date of grant using the Black-Scholes option valuation model. We then recognize the
grant date fair value of each option as compensation expense ratably using the straight-line attribution method over the service period
(generally the vesting period). The Black-Scholes model incorporates the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Expected
    volatility - we estimate the volatility of our share price at the date of grant using a &#x201c;look-back&#x201d; period which coincides
    with the expected term, defined below. We believe using a &#x201c;look-back&#x201d; period which coincides with the expected term is
    the most appropriate measure for determining expected volatility.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Expected
    term - we estimate the expected term using the &#x201c;simplified&#x201d; method, as outlined in Staff Accounting Bulletin No. 107,
    &#x201c;Share-Based Payment.&#x201d;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Risk-free
    interest rate - we estimate the risk-free interest rate using the U.S. Treasury yield curve for periods equal to the expected term
    of the options in effect at the time of grant.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Dividends
    - we use an expected dividend yield of zero because we have not declared or paid a cash dividend, nor do we have any plans to declare
    a dividend.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zmOzrQbauXUb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;We
used the following weighted-average assumptions to estimate the fair value of the options granted for the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BE_z9vTJ4oi7gnd" style="display: none"&gt;SCHEDULE OF WEIGHTED-AVERAGE ASSUMPTIONS TO ESTIMATE THE FAIR VALUE OF THE OPTIONS GRANTED&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the three months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the nine months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: justify"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210701__20210930_zwSBpvi10z9f" style="width: 10%; text-align: right" title="Expected volatility"&gt;92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200701__20200930_zutH84DKe1Mi" style="width: 10%; text-align: right" title="Expected volatility"&gt;110&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210930_zgksPcwHzgd2" style="width: 10%; text-align: right" title="Expected volatility"&gt;97&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20200930_zddY1w2hz3Pl" style="width: 10%; text-align: right" title="Expected volatility"&gt;111&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210701__20210930_zwpxsh0F6KM5" title="Expected term"&gt;6.08&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200701__20200930_zOZToGJ7e7H3" title="Expected term"&gt;6.25&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930_zPNMWKfTQKkd" title="Expected term"&gt;5.97&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200930_zQ6T4jlsWTCa" title="Expected term"&gt;6.25&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210701__20210930_zrGMKD2M4uHc" style="text-align: right" title="Risk-free interest rate"&gt;0.97&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200701__20200930_zzocRiqjppDb" style="text-align: right" title="Risk-free interest rate"&gt;0.16&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210930_zkHTCGdpEd1i" style="text-align: right" title="Risk-free interest rate"&gt;0.98&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20200930_zbStsIJzRmgh" style="text-align: right" title="Risk-free interest rate"&gt;0.29&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210701__20210930_zYCr3zL3PVPg" style="text-align: right" title="Expected dividend yield"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200701__20200930_z5QhehHNzAtl" style="text-align: right" title="Expected dividend yield"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20210930_zshgLyGwuMx" style="text-align: right" title="Expected dividend yield"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20200930_zCTHltN2NDU2" style="text-align: right" title="Expected dividend yield"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zrkC2dldH4xi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zcDmRQ0OZzZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes the options granted for the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BA_zL7sPFqvKlN3" style="display: none"&gt;SCHEDULE OF OPTIONS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20210701__20210930_zxi79DAfrOad" style="font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20200701__20200930_z1Ng8gXGbdjc" style="font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210101__20210930_zyqD3SuDpsXa" style="font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20200101__20200930_zk3QNXRDBFw5" style="font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the three months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the nine months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_z3d42X4ijVSa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Options granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,028,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;342,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;4,383,308&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;3,415,146&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_zlrvW92nscca" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Weighted-average:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_zPFwpSYPHY5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_zqo0AiFkUskg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Grant date fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.44&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_z78TTdMQYZHb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z7qGUTPJBeii" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Restricted
Common Stock&lt;/i&gt;: The following table summarizes restricted common stock compensation expense for the three and nine months ended September
30, 2021 and 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B7_zmxOinF77W7b" style="display: none"&gt;SCHEDULE OF STOCK BASED COMPENSATION&lt;/span&gt;&lt;span/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the three months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the nine months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zuSkkw0JBdUc" style="width: 10%; text-align: right" title="Total stock-based compensation expense"&gt;256,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zq5qyOdMmve4" style="width: 10%; text-align: right" title="Total stock-based compensation expense"&gt;89,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z16OrbGmHlif" style="width: 10%; text-align: right" title="Total stock-based compensation expense"&gt;1,286,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zW4hkk3BjaEj" style="width: 10%; text-align: right" title="Total stock-based compensation expense"&gt;561,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zH1lLNUWHBIh" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense"&gt;894,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zHOBYHR1RS2b" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense"&gt;72,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zuaZ6snBlpdi" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense"&gt;1,832,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zAA5M2f39fw7" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense"&gt;251,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Restricted stock-based compensation expense included in operating expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_z66az17mTZr4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense"&gt;1,150,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_zUi9HKJrfiMd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense"&gt;161,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_z5FpDiF8Dhrl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense"&gt;3,118,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_zeufPMnGEovl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense"&gt;812,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zxHmrRmc9nea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zTBrOXitDuy" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes the restricted common stock granted for the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B7_zSwE6O0Yu767" style="display: none"&gt;SUMMARY OF RESTRICTED COMMON STOCK&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20210701__20210930_zW4rBtZApFic" style="font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20200701__20200930_zOxJZK3nReA3" style="font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20210101__20210930_zoftN5jipWK8" style="font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20200101__20200930_z7rY7reo6kx2" style="font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the three months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the nine months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zWozfRO6RFwg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Restricted common stock granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;767,934&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0949"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;2,743,668&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,083,313&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z3j1UqswTnof" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted common stock forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(293,109&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(265,080&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(721,768&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(265,080&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_pid_ziM4EbnM7LN7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Weighted-average:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z6f30tmPXUm5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Grant date fair value-granted awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0964"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z6gEnYUdCMFe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Grant date fair value-forfeited awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zYakx4IEhzwe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_89D_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zeNE9WAF0w2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Stock
Options&lt;/i&gt;: The following table summarizes stock option-based compensation for the three and nine months ended September 30, 2021 and
2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_zhgHRbRE57u" style="display: none"&gt;SCHEDULE OF STOCK BASED COMPENSATION&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the three months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the nine months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5vzLZ7mMNrd" style="width: 10%; text-align: right" title="Total stock-based compensation expense"&gt;432,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zgx16oMVADmg" style="width: 10%; text-align: right" title="Total stock-based compensation expense"&gt;765,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z6T2yur6qoU7" style="width: 10%; text-align: right" title="Total stock-based compensation expense"&gt;1,649,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zTILqnMQIvWe" style="width: 10%; text-align: right" title="Total stock-based compensation expense"&gt;2,380,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_z8EfdWkayT9j" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense"&gt;955,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zDpysH7Fa4Vl" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense"&gt;484,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_z48Hk68g8Lnd" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense"&gt;2,148,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_ztcJTCgkkUW1" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense"&gt;1,703,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Stock option-based compensation expense included in operating expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_z2mv0g5X8FNb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense"&gt;1,387,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_z2OI5eszwY6a" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense"&gt;1,249,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_znZHQdfqMYIa" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense"&gt;3,797,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_zfOM5lgJKL54" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense"&gt;4,083,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-07-012021-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">432000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-07-012020-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">765000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">1649000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">2380000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-07-012021-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="0"
      unitRef="USD">955000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-07-012020-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="0"
      unitRef="USD">484000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="0"
      unitRef="USD">2148000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="0"
      unitRef="USD">1703000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-07-012021-09-30_us-gaap_EmployeeStockOptionMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember"
      decimals="0"
      unitRef="USD">1387000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-07-012020-09-30_us-gaap_EmployeeStockOptionMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember"
      decimals="0"
      unitRef="USD">1249000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember"
      decimals="0"
      unitRef="USD">3797000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-09-30_us-gaap_EmployeeStockOptionMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember"
      decimals="0"
      unitRef="USD">4083000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zmOzrQbauXUb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;We
used the following weighted-average assumptions to estimate the fair value of the options granted for the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BE_z9vTJ4oi7gnd" style="display: none"&gt;SCHEDULE OF WEIGHTED-AVERAGE ASSUMPTIONS TO ESTIMATE THE FAIR VALUE OF THE OPTIONS GRANTED&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the three months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the nine months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: justify"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210701__20210930_zwSBpvi10z9f" style="width: 10%; text-align: right" title="Expected volatility"&gt;92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200701__20200930_zutH84DKe1Mi" style="width: 10%; text-align: right" title="Expected volatility"&gt;110&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210930_zgksPcwHzgd2" style="width: 10%; text-align: right" title="Expected volatility"&gt;97&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20200930_zddY1w2hz3Pl" style="width: 10%; text-align: right" title="Expected volatility"&gt;111&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210701__20210930_zwpxsh0F6KM5" title="Expected term"&gt;6.08&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200701__20200930_zOZToGJ7e7H3" title="Expected term"&gt;6.25&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930_zPNMWKfTQKkd" title="Expected term"&gt;5.97&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200930_zQ6T4jlsWTCa" title="Expected term"&gt;6.25&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210701__20210930_zrGMKD2M4uHc" style="text-align: right" title="Risk-free interest rate"&gt;0.97&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200701__20200930_zzocRiqjppDb" style="text-align: right" title="Risk-free interest rate"&gt;0.16&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210930_zkHTCGdpEd1i" style="text-align: right" title="Risk-free interest rate"&gt;0.98&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20200930_zbStsIJzRmgh" style="text-align: right" title="Risk-free interest rate"&gt;0.29&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210701__20210930_zYCr3zL3PVPg" style="text-align: right" title="Expected dividend yield"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200701__20200930_z5QhehHNzAtl" style="text-align: right" title="Expected dividend yield"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20210930_zshgLyGwuMx" style="text-align: right" title="Expected dividend yield"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20200930_zCTHltN2NDU2" style="text-align: right" title="Expected dividend yield"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-07-012021-09-30"
      decimals="INF"
      unitRef="Pure">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-07-012020-09-30"
      decimals="INF"
      unitRef="Pure">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-01to2021-09-30"
      decimals="INF"
      unitRef="Pure">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-01-012020-09-30"
      decimals="INF"
      unitRef="Pure">1.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-07-012021-09-30">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-07-012020-09-30">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-01to2021-09-30">P5Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-012020-09-30">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-07-012021-09-30"
      decimals="INF"
      unitRef="Pure">0.0097</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-07-012020-09-30"
      decimals="INF"
      unitRef="Pure">0.0016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-01to2021-09-30"
      decimals="INF"
      unitRef="Pure">0.0098</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-01-012020-09-30"
      decimals="INF"
      unitRef="Pure">0.0029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-07-012021-09-30"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-07-012020-09-30"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-01to2021-09-30"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-01-012020-09-30"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zcDmRQ0OZzZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes the options granted for the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BA_zL7sPFqvKlN3" style="display: none"&gt;SCHEDULE OF OPTIONS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20210701__20210930_zxi79DAfrOad" style="font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20200701__20200930_z1Ng8gXGbdjc" style="font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210101__20210930_zyqD3SuDpsXa" style="font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20200101__20200930_zk3QNXRDBFw5" style="font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the three months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the nine months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_z3d42X4ijVSa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Options granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,028,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;342,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;4,383,308&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;3,415,146&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_zlrvW92nscca" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Weighted-average:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_zPFwpSYPHY5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_zqo0AiFkUskg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Grant date fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.44&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-07-012021-09-30"
      decimals="INF"
      unitRef="Shares">1028000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-07-012020-09-30"
      decimals="INF"
      unitRef="Shares">342100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-01to2021-09-30"
      decimals="INF"
      unitRef="Shares">4383308</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-01-012020-09-30"
      decimals="INF"
      unitRef="Shares">3415146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-07-012021-09-30"
      decimals="INF"
      unitRef="USDPShares">1.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-07-012020-09-30"
      decimals="INF"
      unitRef="USDPShares">3.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-01to2021-09-30"
      decimals="INF"
      unitRef="USDPShares">1.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-09-30"
      decimals="INF"
      unitRef="USDPShares">2.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-07-012021-09-30"
      decimals="INF"
      unitRef="USDPShares">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-07-012020-09-30"
      decimals="INF"
      unitRef="USDPShares">2.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-01-01to2021-09-30"
      decimals="INF"
      unitRef="USDPShares">1.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-09-30"
      decimals="INF"
      unitRef="USDPShares">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2021-01-012021-09-30_us-gaap_RestrictedStockMember16575609">&lt;p id="xdx_895_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z7qGUTPJBeii" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Restricted
Common Stock&lt;/i&gt;: The following table summarizes restricted common stock compensation expense for the three and nine months ended September
30, 2021 and 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B7_zmxOinF77W7b" style="display: none"&gt;SCHEDULE OF STOCK BASED COMPENSATION&lt;/span&gt;&lt;span/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the three months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the nine months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zuSkkw0JBdUc" style="width: 10%; text-align: right" title="Total stock-based compensation expense"&gt;256,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zq5qyOdMmve4" style="width: 10%; text-align: right" title="Total stock-based compensation expense"&gt;89,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z16OrbGmHlif" style="width: 10%; text-align: right" title="Total stock-based compensation expense"&gt;1,286,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zW4hkk3BjaEj" style="width: 10%; text-align: right" title="Total stock-based compensation expense"&gt;561,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zH1lLNUWHBIh" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense"&gt;894,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zHOBYHR1RS2b" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense"&gt;72,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zuaZ6snBlpdi" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense"&gt;1,832,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zAA5M2f39fw7" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense"&gt;251,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Restricted stock-based compensation expense included in operating expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_z66az17mTZr4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense"&gt;1,150,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_zUi9HKJrfiMd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense"&gt;161,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_z5FpDiF8Dhrl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense"&gt;3,118,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_zeufPMnGEovl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense"&gt;812,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-07-012021-09-30_us-gaap_RestrictedStockMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">256000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-07-012020-09-30_us-gaap_RestrictedStockMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">89000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-09-30_us-gaap_RestrictedStockMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">1286000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">561000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-07-012021-09-30_us-gaap_RestrictedStockMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="0"
      unitRef="USD">894000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-07-012020-09-30_us-gaap_RestrictedStockMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="0"
      unitRef="USD">72000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-09-30_us-gaap_RestrictedStockMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="0"
      unitRef="USD">1832000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="0"
      unitRef="USD">251000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-07-012021-09-30_us-gaap_RestrictedStockMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember"
      decimals="0"
      unitRef="USD">1150000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-07-012020-09-30_us-gaap_RestrictedStockMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember"
      decimals="0"
      unitRef="USD">161000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-09-30_us-gaap_RestrictedStockMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember"
      decimals="0"
      unitRef="USD">3118000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember_custom_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember"
      decimals="0"
      unitRef="USD">812000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_89D_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zTBrOXitDuy" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes the restricted common stock granted for the periods indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B7_zSwE6O0Yu767" style="display: none"&gt;SUMMARY OF RESTRICTED COMMON STOCK&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20210701__20210930_zW4rBtZApFic" style="font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20200701__20200930_zOxJZK3nReA3" style="font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20210101__20210930_zoftN5jipWK8" style="font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20200101__20200930_z7rY7reo6kx2" style="font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the three months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the nine months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zWozfRO6RFwg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Restricted common stock granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;767,934&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0949"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;2,743,668&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,083,313&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z3j1UqswTnof" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Restricted common stock forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(293,109&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(265,080&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(721,768&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(265,080&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_pid_ziM4EbnM7LN7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Weighted-average:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z6f30tmPXUm5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Grant date fair value-granted awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0964"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.77&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z6gEnYUdCMFe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Grant date fair value-forfeited awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.18&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2021-07-012021-09-30_us-gaap_RestrictedStockMember16575765"
      decimals="INF"
      unitRef="Shares">767934</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2021-01-012021-09-30_us-gaap_RestrictedStockMember16575609"
      decimals="INF"
      unitRef="Shares">2743668</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember16575781"
      decimals="INF"
      unitRef="Shares">1083313</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2021-07-012021-09-30_us-gaap_RestrictedStockMember16575765"
      decimals="INF"
      unitRef="Shares">293109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2020-07-012020-09-30_us-gaap_RestrictedStockMember16575765"
      decimals="INF"
      unitRef="Shares">265080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2021-01-012021-09-30_us-gaap_RestrictedStockMember16575609"
      decimals="INF"
      unitRef="Shares">721768</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember16575781"
      decimals="INF"
      unitRef="Shares">265080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-07-012021-09-30_us-gaap_RestrictedStockMember16575765"
      decimals="INF"
      unitRef="USDPShares">1.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-01-012021-09-30_us-gaap_RestrictedStockMember16575609"
      decimals="INF"
      unitRef="USDPShares">1.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember16575781"
      decimals="INF"
      unitRef="USDPShares">3.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2021-07-012021-09-30_us-gaap_RestrictedStockMember16575765"
      decimals="INF"
      unitRef="USDPShares">1.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2020-07-012020-09-30_us-gaap_RestrictedStockMember16575765"
      decimals="INF"
      unitRef="USDPShares">3.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2021-01-012021-09-30_us-gaap_RestrictedStockMember16575609"
      decimals="INF"
      unitRef="USDPShares">1.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2020-01-012020-09-30_us-gaap_RestrictedStockMember16575781"
      decimals="INF"
      unitRef="USDPShares">3.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z7YvgbEMTim5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;NOTE
7 &#x2013; &lt;span id="xdx_82D_ztKGEtHWe4H2"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Arbitration
Proceeding&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We were engaged in an arbitration
proceeding with REGENXBIO regarding the former license agreement between us and REGENXBIO relating to use of the AAV9 capsid in our
MPS IIIA, MPS IIIB, CLN1 (which has now been sold to Taysha Gene Therapies), and CLN3 programs. &lt;span style="font-weight: normal"&gt;The
license terminated on May 2, 2020, and on May 25, 2020, we filed an arbitration claim with the American Arbitration Association
(&#x201c;AAA&#x201d;) alleging that REGENXBIO materially breached the license agreement prior to termination and seeking, among other
things, a declaration that as a result of REGENXBIO&#x2019;s material breach, we were not responsible for payments totaling $&lt;span id="xdx_901_eus-gaap--GainLossRelatedToLitigationSettlement_pn6n6_c20200524__20200525__dei--LegalEntityAxis__custom--REGENXBIOMember_z6zno4I8x0Ya" title="Gain loss on payments for settlement"&gt;28&lt;/span&gt;
million (which would otherwise have been due in 2020) plus accrued interest. REGENXBIO disputed our arbitration claim and filed a
counterclaim seeking payment of the $&lt;span id="xdx_90F_eus-gaap--GainLossRelatedToLitigationSettlement_pn6n6_c20200524__20200525__dei--LegalEntityAxis__custom--REGENXBIOMember_zO38o7snDLV4"&gt;28&lt;/span&gt; million plus interest, which REGENXBIO argued remained due. An arbitration hearing before a
tribunal of three AAA arbitrators was held on March 8 and March 9, 2021. On July 13, 2021, the tribunal found in favor of REGENXBIO
in connection with the parties&#x2019; arbitration claims and counterclaims. The tribunal awarded REGENXBIO $&lt;span id="xdx_903_eus-gaap--GainLossRelatedToLitigationSettlement_pn6n6_c20200712__20200713__dei--LegalEntityAxis__custom--REGENXBIOMember_zL2ZdWwNn0L"&gt;28&lt;/span&gt;.0 million plus
interest. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;On August 9,
2021, we filed a second arbitration claim with the AAA asserting that a settlement had been reached before the tribunal&#x2019;s award
in the first arbitration was issued. On September 14, 2021, REGENXBIO filed its answer, a counterclaim seeking attorney fees and costs,
and a request for permission to file a case dispositive motion. A preliminary hearing was held on November 1, 2021, during which the
AAA Tribunal set timetables for discovery and for REGENXBIO&#x2019;s filing of its case dispositive motion. Those timetables were formalized
in a procedural order issued by the Tribunal on November 8, 2021. Under the schedule set by the Tribunal, REGENXBIO&#x2019;s opening brief
in support of its case dispositive motion was filed on November 8, 2021, briefing was scheduled to be completed on December 29, 2021,
and oral argument was scheduled for January 14, 2022. REGENXBIO had also filed suit in the New York State Supreme Court Commercial Division
seeking enforcement of the original arbitration award, and we had requested that the Court stay that proceeding until the second arbitration
is complete. Oral argument on our request for a stay was set for March 10, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;On November
12, 2021, we entered into a settlement agreement (&#x201c;Settlement Agreement&#x201d;) with REGENXBIO to resolve all current disputes
between the parties including the aforementioned AAA arbitration and New York State Court action. In accordance with the Settlement Agreement,
we agreed to pay REGENXBIO a total of $&lt;span id="xdx_900_eus-gaap--SettlementLiabilitiesCurrent_iI_pn6n6_c20211112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zJ5YquSODEak" title="Settlement amount"&gt;30&lt;/span&gt; million, payable as follows: (1) $&lt;span id="xdx_908_eus-gaap--SettlementLiabilitiesCurrent_iI_pn6n6_c20211112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--REGENXBIOMember__srt--StatementScenarioAxis__custom--OneBusinessDayMember_znSXizSwPtX1" title="Settlement amount"&gt;20&lt;/span&gt; million payable within one business day of the execution
of the Settlement Agreement, (2) $&lt;span id="xdx_904_eus-gaap--SettlementLiabilitiesCurrent_iI_pn6n6_c20211112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--REGENXBIOMember__srt--StatementScenarioAxis__custom--FirstAnniversaryMember_zpW6RWHmuJPl" title="Settlement amount"&gt;5&lt;/span&gt; million on the first anniversary of the effective date of the Settlement Agreement, and (3) $&lt;span id="xdx_90F_eus-gaap--SettlementLiabilitiesCurrent_iI_pn6n6_c20211112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--REGENXBIOMember__srt--StatementScenarioAxis__custom--ThirdAnniversaryMember_zoQWVUvgpacj" title="Settlement amount"&gt;5&lt;/span&gt; million
upon the earlier of: (i) the third anniversary of the effective date of the Settlement Agreement or (ii) the closing of a Strategic Transaction,
as defined in the Settlement Agreement. Under the Settlement Agreement&#x2019;s terms, the prior license agreement between the parties
was not reinstituted, and any future license agreement would need to be negotiated separately and require consideration in addition to
the consideration set forth in the Settlement Agreement. As of September 30, 2021, we have recorded the payable to licensor in the balance
sheet based on the present value of the payments due to REGENXBIO under the Settlement Agreement. The accounting for the Settlement Agreement
resulted in a $&lt;span id="xdx_90A_ecustom--GainOnSettlementOfRelatedParty_pn5n6_c20210101__20210930_zj1LDjviZ8D7"&gt;6.7&lt;/span&gt; million gain on settlement with licensor in the statement of operations and comprehensive loss during the three and
nine months ended September 30, 2021 and a $&lt;span id="xdx_90F_ecustom--GainOnSettlementOfRelatedParty_pn5n6_c20210701__20210930_znq4JCOg9Hkk"&gt;&lt;span id="xdx_906_ecustom--GainOnSettlementOfRelatedParty_pn5n6_c20210101__20210930_ztdiYJM29xG2"&gt;6.7&lt;/span&gt;&lt;/span&gt; million non-cash gain on settlement with licensor in the statement of cash flows during
the nine months ended September 30, 2021.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Operating
Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;We lease space
under operating leases for manufacturing and laboratory facilities and administrative offices in Cleveland, Ohio, as well as administrative
offices in New York, New York.&lt;/span&gt;&lt;span style="font-weight: normal"&gt; &lt;/span&gt;We also lease office space in Madrid, Spain as well
as certain office equipment under operating leases, which have a non-cancelable lease term of less than one year and, therefore, we have
elected the practical expedient to exclude these short-term leases from our right-of-use assets and lease liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--LeaseCostTableTextBlock_zZpb5PcItwUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Components
of lease cost are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B1_zBzypTUIghC3" style="display: none"&gt;SCHEDULE OF COMPONENTS OF LEASE COST&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20210701__20210930_zNujNpGJw8Df" style="font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20200701__20200930_zNbZA6oGWHHk" style="font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210101__20210930_zRoqzCbnII9f" style="font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20200101__20200930_zZeAdcvAV8tj" style="font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the three months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the nine months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseCost_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;434,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;434,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,302,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,302,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--VariableLeaseCost_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Variable lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;105,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;81,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;344,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;256,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShortTermLeaseCost_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Short-term lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;13,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;19,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;23,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;43,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zzrBzH0LH1pi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_ecustom--ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_zJ0ziEhp78gl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
following table presents information about the amount and timing of cash flows arising from operating leases as of September 30, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B0_z8hKq46Dpxe" style="display: none"&gt;SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20210930_zrs284mKV2ca"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="text-decoration: underline"&gt;Maturity of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzoEX_maLOLLPzvfE_z0en0Rh81Pd9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;2021, remainder&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;429,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzvfE_zLpONmPcmVLg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,727,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzvfE_zZhc1j0uHIX2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,741,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzvfE_zJv2kQz1362l" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,781,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzvfE_z0XKX1L55rJl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,799,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzvfE_z706LZog6hvi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;87,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_mtLOLLPzvfE_maOLLzUrS_zFTfFquNiLMk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total undiscounted operating lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,564,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pp0p0_maOLLzUrS_ze4bsotDBBYc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,399,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iTI_pp0p0_zwSzgtgoBaY1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,165,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Balance sheet classification:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_maOLLzHBA_zakll0xG9IA2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Current portion of lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,723,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_maOLLzHBA_z2LIdWElG2Md" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Long-term lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,442,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseLiability_iTI_pp0p0_mtOLLzHBA_zFwDb5tXBPUh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,165,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Other information:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average remaining lease term for operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20210930_zCPuYwSooGwl" title="Weighted-average remaining lease term for operating leases"&gt;52&lt;/span&gt; months&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average discount rate for operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20210930_zAB7llfmxoI" title="Weighted-average discount rate for operating leases"&gt;9.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="From2020-05-242020-05-25_custom_REGENXBIOMember"
      decimals="-6"
      unitRef="USD">28000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="From2020-05-242020-05-25_custom_REGENXBIOMember"
      decimals="-6"
      unitRef="USD">28000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="From2020-07-122020-07-13_custom_REGENXBIOMember"
      decimals="-6"
      unitRef="USD">28000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:SettlementLiabilitiesCurrent
      contextRef="AsOf2021-11-12_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_custom_REGENXBIOMember"
      decimals="-6"
      unitRef="USD">30000000</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:SettlementLiabilitiesCurrent
      contextRef="AsOf2021-11-12_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_custom_REGENXBIOMember_custom_OneBusinessDayMember"
      decimals="-6"
      unitRef="USD">20000000</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:SettlementLiabilitiesCurrent
      contextRef="AsOf2021-11-12_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_custom_REGENXBIOMember_custom_FirstAnniversaryMember"
      decimals="-6"
      unitRef="USD">5000000</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:SettlementLiabilitiesCurrent
      contextRef="AsOf2021-11-12_us-gaap_SubsequentEventMember_custom_SettlementAgreementMember_custom_REGENXBIOMember_custom_ThirdAnniversaryMember"
      decimals="-6"
      unitRef="USD">5000000</us-gaap:SettlementLiabilitiesCurrent>
    <abeo:GainOnSettlementOfRelatedParty
      contextRef="From2021-01-01to2021-09-30"
      decimals="-5"
      unitRef="USD">6700000</abeo:GainOnSettlementOfRelatedParty>
    <abeo:GainOnSettlementOfRelatedParty
      contextRef="From2021-07-012021-09-30"
      decimals="-5"
      unitRef="USD">6700000</abeo:GainOnSettlementOfRelatedParty>
    <abeo:GainOnSettlementOfRelatedParty
      contextRef="From2021-01-01to2021-09-30"
      decimals="-5"
      unitRef="USD">6700000</abeo:GainOnSettlementOfRelatedParty>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_895_eus-gaap--LeaseCostTableTextBlock_zZpb5PcItwUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Components
of lease cost are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B1_zBzypTUIghC3" style="display: none"&gt;SCHEDULE OF COMPONENTS OF LEASE COST&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20210701__20210930_zNujNpGJw8Df" style="font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20200701__20200930_zNbZA6oGWHHk" style="font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210101__20210930_zRoqzCbnII9f" style="font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20200101__20200930_zZeAdcvAV8tj" style="font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the three months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the nine months ended September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseCost_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;434,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;434,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,302,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,302,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--VariableLeaseCost_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Variable lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;105,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;81,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;344,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;256,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShortTermLeaseCost_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Short-term lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;13,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;19,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;23,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;43,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">434000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">434000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">1302000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">1302000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">105000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">81000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">344000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">256000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">13000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2020-07-012020-09-30"
      decimals="0"
      unitRef="USD">19000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">23000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="From2020-01-012020-09-30"
      decimals="0"
      unitRef="USD">43000</us-gaap:ShortTermLeaseCost>
    <abeo:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock contextRef="From2021-01-01to2021-09-30">&lt;p id="xdx_89A_ecustom--ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_zJ0ziEhp78gl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
following table presents information about the amount and timing of cash flows arising from operating leases as of September 30, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B0_z8hKq46Dpxe" style="display: none"&gt;SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20210930_zrs284mKV2ca"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="text-decoration: underline"&gt;Maturity of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzoEX_maLOLLPzvfE_z0en0Rh81Pd9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;2021, remainder&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;429,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzvfE_zLpONmPcmVLg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,727,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzvfE_zZhc1j0uHIX2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,741,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzvfE_zJv2kQz1362l" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,781,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzvfE_z0XKX1L55rJl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,799,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzvfE_z706LZog6hvi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;87,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_mtLOLLPzvfE_maOLLzUrS_zFTfFquNiLMk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total undiscounted operating lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,564,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pp0p0_maOLLzUrS_ze4bsotDBBYc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,399,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iTI_pp0p0_zwSzgtgoBaY1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Present value of operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,165,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Balance sheet classification:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_maOLLzHBA_zakll0xG9IA2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Current portion of lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,723,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_maOLLzHBA_z2LIdWElG2Md" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Long-term lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,442,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseLiability_iTI_pp0p0_mtOLLzHBA_zFwDb5tXBPUh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,165,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; text-align: left"&gt;Other information:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average remaining lease term for operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20210930_zCPuYwSooGwl" title="Weighted-average remaining lease term for operating leases"&gt;52&lt;/span&gt; months&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average discount rate for operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20210930_zAB7llfmxoI" title="Weighted-average discount rate for operating leases"&gt;9.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</abeo:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">429000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1727000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1741000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1781000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1799000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">87000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">7564000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1399000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">6165000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">1723000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">4442000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">6165000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2021-09-30">P52M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2021-09-30" decimals="INF" unitRef="Pure">0.096</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325114794552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Nov. 08, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-15771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ABEONA
THERAPEUTICS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000318306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-0221517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1330
Avenue of the Americas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">33rd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">813-4701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABEO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,917,914<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325198224280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 43,781,000<span></span>
</td>
<td class="nump">$ 12,596,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">23,217,000<span></span>
</td>
<td class="nump">82,438,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">907,000<span></span>
</td>
<td class="nump">2,708,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">67,905,000<span></span>
</td>
<td class="nump">97,742,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">9,869,000<span></span>
</td>
<td class="nump">11,322,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use lease assets</a></td>
<td class="nump">6,207,000<span></span>
</td>
<td class="nump">7,032,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Licensed technology, net</a></td>
<td class="nump">1,413,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">32,466,000<span></span>
</td>
<td class="nump">32,466,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_OtherAssetsAndRestrictedCash', window );">Other assets and restricted cash</a></td>
<td class="nump">1,159,000<span></span>
</td>
<td class="nump">1,136,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">119,019,000<span></span>
</td>
<td class="nump">151,198,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,861,000<span></span>
</td>
<td class="nump">4,695,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,593,000<span></span>
</td>
<td class="nump">3,410,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,723,000<span></span>
</td>
<td class="nump">1,713,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Current portion of PPP loan payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">330,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Current portion of payable to licensor</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">31,515,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Contract liability</a></td>
<td class="nump">296,000<span></span>
</td>
<td class="nump">296,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">26,473,000<span></span>
</td>
<td class="nump">41,959,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">PPP loan payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,428,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Payable to licensor</a></td>
<td class="nump">8,360,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">4,442,000<span></span>
</td>
<td class="nump">5,260,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">39,275,000<span></span>
</td>
<td class="nump">48,647,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $0.01 par value; authorized 200,000,000 shares; &#160;issued and outstanding 101,867,539 at September 30, 2021; issued and outstanding 96,131,678 at December 31, 2020;</a></td>
<td class="nump">1,019,000<span></span>
</td>
<td class="nump">961,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">687,691,000<span></span>
</td>
<td class="nump">672,304,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(608,957,000)<span></span>
</td>
<td class="num">(570,704,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(9,000)<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">79,744,000<span></span>
</td>
<td class="nump">102,551,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 119,019,000<span></span>
</td>
<td class="nump">$ 151,198,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abeo_OtherAssetsAndRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other assets and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abeo_OtherAssetsAndRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325197651768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">101,867,539<span></span>
</td>
<td class="nump">96,131,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">101,867,539<span></span>
</td>
<td class="nump">96,131,678<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325197548264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">7,978,000<span></span>
</td>
<td class="nump">7,969,000<span></span>
</td>
<td class="nump">22,624,000<span></span>
</td>
<td class="nump">20,896,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,092,000<span></span>
</td>
<td class="nump">4,432,000<span></span>
</td>
<td class="nump">18,117,000<span></span>
</td>
<td class="nump">16,382,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">802,000<span></span>
</td>
<td class="nump">847,000<span></span>
</td>
<td class="nump">2,443,000<span></span>
</td>
<td class="nump">3,746,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Licensed technology impairment charge</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">32,916,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total expenses</a></td>
<td class="nump">14,872,000<span></span>
</td>
<td class="nump">13,248,000<span></span>
</td>
<td class="nump">43,184,000<span></span>
</td>
<td class="nump">73,940,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(14,872,000)<span></span>
</td>
<td class="num">(6,248,000)<span></span>
</td>
<td class="num">(43,184,000)<span></span>
</td>
<td class="num">(66,940,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_GainOnSettlementOfRelatedParty', window );">Gain on settlement with licensor</a></td>
<td class="nump">6,743,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,743,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_PppLoanPayableForgivenessIncome', window );">PPP loan payable forgiveness income</a></td>
<td class="nump">1,758,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,758,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_InterestAndMiscellaneousIncome', window );">Interest and miscellaneous income</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">338,000<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="nump">1,261,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(683,000)<span></span>
</td>
<td class="num">(1,327,000)<span></span>
</td>
<td class="num">(3,603,000)<span></span>
</td>
<td class="num">(2,727,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,044,000)<span></span>
</td>
<td class="num">$ (7,237,000)<span></span>
</td>
<td class="num">$ (38,253,000)<span></span>
</td>
<td class="num">$ (68,406,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per common share</a></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding &#8211; basic and diluted</a></td>
<td class="nump">97,990,338<span></span>
</td>
<td class="nump">92,714,983<span></span>
</td>
<td class="nump">96,258,681<span></span>
</td>
<td class="nump">92,594,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive income/(loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Change in unrealized gains/(losses) related to available-for-sale debt securities</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="num">$ (116,000)<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(9,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(9,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (7,052,000)<span></span>
</td>
<td class="num">$ (7,353,000)<span></span>
</td>
<td class="num">$ (38,252,000)<span></span>
</td>
<td class="num">$ (68,389,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abeo_GainOnSettlementOfRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abeo_GainOnSettlementOfRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abeo_InterestAndMiscellaneousIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and Miscellaneous Income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abeo_InterestAndMiscellaneousIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abeo_PppLoanPayableForgivenessIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ppp Loan Payable Forgiveness Income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abeo_PppLoanPayableForgivenessIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325111041496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2019</a></td>
<td class="nump">$ 836,000<span></span>
</td>
<td class="nump">$ 664,064,000<span></span>
</td>
<td class="num">$ (486,470,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 178,430,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2019</a></td>
<td class="nump">83,622,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock option-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,083,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,083,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Restricted stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">812,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">812,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued for cash exercise of options</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">174,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">175,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued for cash exercise of options, shares</a></td>
<td class="nump">75,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations', window );">Issuance of common stock in connection with restricted share awards</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations', window );">Issuance of common stock in connection with restricted share awards, shares</a></td>
<td class="nump">818,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(68,406,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(68,406,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2020</a></td>
<td class="nump">$ 845,000<span></span>
</td>
<td class="nump">669,125,000<span></span>
</td>
<td class="num">(554,876,000)<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="nump">115,111,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2020</a></td>
<td class="nump">84,516,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Jun. 30, 2020</a></td>
<td class="nump">$ 848,000<span></span>
</td>
<td class="nump">667,712,000<span></span>
</td>
<td class="num">(547,639,000)<span></span>
</td>
<td class="nump">133,000<span></span>
</td>
<td class="nump">121,054,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Jun. 30, 2020</a></td>
<td class="nump">84,781,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock option-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,249,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,249,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Restricted stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">161,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">161,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod', window );">Cancellation of restricted share awards</a></td>
<td class="num">$ (3,000)<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited', window );">Cancellation of restricted share awards, shares</a></td>
<td class="num">(265,080)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,237,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,237,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(116,000)<span></span>
</td>
<td class="num">(116,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2020</a></td>
<td class="nump">$ 845,000<span></span>
</td>
<td class="nump">669,125,000<span></span>
</td>
<td class="num">(554,876,000)<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="nump">115,111,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2020</a></td>
<td class="nump">84,516,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 961,000<span></span>
</td>
<td class="nump">672,304,000<span></span>
</td>
<td class="num">(570,704,000)<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="nump">102,551,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="nump">96,131,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock option-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,797,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,797,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Restricted stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,118,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,118,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued for cash exercise of options</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">831,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued for cash exercise of options, shares</a></td>
<td class="nump">630,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations', window );">Issuance of common stock in connection with restricted share awards</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations', window );">Issuance of common stock in connection with restricted share awards, shares</a></td>
<td class="nump">2,021,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Common stock issued for cash under open market sale agreement</a></td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="nump">7,667,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,699,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock issued for cash under open market sale agreement, shares</a></td>
<td class="nump">3,083,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(38,253,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(38,253,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2021</a></td>
<td class="nump">$ 1,019,000<span></span>
</td>
<td class="nump">687,691,000<span></span>
</td>
<td class="num">(608,957,000)<span></span>
</td>
<td class="num">(9,000)<span></span>
</td>
<td class="nump">$ 79,744,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2021</a></td>
<td class="nump">101,867,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,867,539<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Jun. 30, 2021</a></td>
<td class="nump">$ 1,013,000<span></span>
</td>
<td class="nump">684,987,000<span></span>
</td>
<td class="num">(601,913,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">$ 84,086,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Jun. 30, 2021</a></td>
<td class="nump">101,251,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock option-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,387,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,387,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Restricted stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,150,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued for cash exercise of options</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">139,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">140,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued for cash exercise of options, shares</a></td>
<td class="nump">121,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations', window );">Issuance of common stock in connection with restricted share awards</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations', window );">Issuance of common stock in connection with restricted share awards, shares</a></td>
<td class="nump">474,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Common stock issued for cash under open market sale agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">33,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock issued for cash under open market sale agreement, shares</a></td>
<td class="nump">19,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,044,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,044,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2021</a></td>
<td class="nump">$ 1,019,000<span></span>
</td>
<td class="nump">$ 687,691,000<span></span>
</td>
<td class="num">$ (608,957,000)<span></span>
</td>
<td class="num">$ (9,000)<span></span>
</td>
<td class="nump">$ 79,744,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2021</a></td>
<td class="nump">101,867,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,867,539<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cancellation of restricted shares awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options intrinsic value forfeited in Period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period Issuance of common stock in connection with restricted share awards, net of cancellations, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abeo_StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value share issuance of common stock in connection with restricted share awards net of cancellations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abeo_StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325110981288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,044,000)<span></span>
</td>
<td class="num">$ (7,237,000)<span></span>
</td>
<td class="num">$ (38,253,000)<span></span>
</td>
<td class="num">$ (68,406,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Non-cash licensed technology impairment charge</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">32,916,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_GainOnSettlementOfRelatedParty', window );">Non-cash gain on settlement with licensor</a></td>
<td class="num">(6,743,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,743,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_PppLoanPayableForgivenessIncome', window );">Non-cash PPP loan payable forgiveness income</a></td>
<td class="num">(1,758,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,758,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">802,000<span></span>
</td>
<td class="nump">847,000<span></span>
</td>
<td class="nump">2,443,000<span></span>
</td>
<td class="nump">3,746,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock option-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,797,000<span></span>
</td>
<td class="nump">4,083,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_AllocatedShareBasedCompensationExpenseRestrictedStock', window );">Restricted stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,118,000<span></span>
</td>
<td class="nump">812,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_AccretionAndInterestOnShorttermInvestments', window );">Accretion and interest on short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256,000<span></span>
</td>
<td class="num">(237,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
<td class="nump">752,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,801,000<span></span>
</td>
<td class="nump">2,443,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,000)<span></span>
</td>
<td class="num">(62,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities', window );">Accounts payable, accrued expenses and lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,459,000)<span></span>
</td>
<td class="num">(5,183,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_IncreaseDecreaseInPayableToLicensor', window );">Change in payable to licensor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,588,000<span></span>
</td>
<td class="nump">2,127,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,408,000)<span></span>
</td>
<td class="num">(33,409,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(903,000)<span></span>
</td>
<td class="num">(1,303,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,164,000)<span></span>
</td>
<td class="num">(139,230,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Proceeds from maturities of short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,130,000<span></span>
</td>
<td class="nump">51,037,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in)/investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,063,000<span></span>
</td>
<td class="num">(89,496,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from loan payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,758,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from open market sales of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,699,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">831,000<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,530,000<span></span>
</td>
<td class="nump">1,933,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase/(decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,185,000<span></span>
</td>
<td class="num">(120,972,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,571,000<span></span>
</td>
<td class="nump">130,368,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">44,756,000<span></span>
</td>
<td class="nump">9,396,000<span></span>
</td>
<td class="nump">44,756,000<span></span>
</td>
<td class="nump">9,396,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">43,781,000<span></span>
</td>
<td class="nump">8,424,000<span></span>
</td>
<td class="nump">43,781,000<span></span>
</td>
<td class="nump">8,424,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">975,000<span></span>
</td>
<td class="nump">972,000<span></span>
</td>
<td class="nump">975,000<span></span>
</td>
<td class="nump">972,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 44,756,000<span></span>
</td>
<td class="nump">$ 9,396,000<span></span>
</td>
<td class="nump">44,756,000<span></span>
</td>
<td class="nump">9,396,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abeo_AccretionAndInterestOnShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion and interest on short term investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abeo_AccretionAndInterestOnShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abeo_AllocatedShareBasedCompensationExpenseRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allocated share based compensation expense restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abeo_AllocatedShareBasedCompensationExpenseRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abeo_GainOnSettlementOfRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abeo_GainOnSettlementOfRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abeo_IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In accounts payable And accrued a nd lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abeo_IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abeo_IncreaseDecreaseInPayableToLicensor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in payable to licenser.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abeo_IncreaseDecreaseInPayableToLicensor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abeo_PppLoanPayableForgivenessIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ppp Loan Payable Forgiveness Income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abeo_PppLoanPayableForgivenessIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325117834904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zo7ANL6wddX5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
1 &#8211; <span id="xdx_820_z51qNbYu0ihj">NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_844_ecustom--BackgroundPolicyTextBlock_zKzhqIm7jPz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86C_zcRrEZIaYKAk">Background</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Abeona
Therapeutics Inc. (together with our subsidiaries, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;Abeona&#8221; or the &#8220;Company&#8221;),
a Delaware corporation, is a clinical-stage biopharmaceutical company developing gene and cell therapies for life-threatening rare genetic
diseases. Our lead clinical programs consist of: (i) EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis
bullosa (&#8220;RDEB&#8221;), (ii) ABO-102, an adeno-associated virus (&#8220;AAV&#8221;)-based gene therapy for Sanfilippo syndrome
type A (&#8220;MPS IIIA&#8221;), and (iii) ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B (&#8220;MPS IIIB&#8221;).
We continue to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases, next-generation AAV-based
gene therapies using the novel AIM&#8482; capsid platform that we have exclusively licensed from the University of North Carolina at
Chapel Hill, and internal AAV vector research programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_843_eus-gaap--BasisOfAccounting_ziYBhQQ0QEv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86B_zpfYEzZH7Ezl">Basis
of Presentation</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
condensed consolidated balance sheet as of September 30, 2021, the condensed consolidated statements of operations and comprehensive
loss and stockholders&#8217; equity for the three and nine months ended September 30, 2021 and 2020, and the condensed consolidated statement
of cash flows for the nine months ended September 30, 2021 were prepared by management without audit. In the opinion of management, all
adjustments, consisting only of normal recurring adjustments, except as otherwise disclosed, necessary for the fair presentation of the
financial position, results of operations, and changes in financial position for such periods, have been made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Certain
information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally
accepted in the United States of America (&#8220;U.S. GAAP&#8221;) have been condensed or omitted. These interim financial statements
should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended
December 31, 2020. The results of operations for the period ended September 30, 2021 are not necessarily indicative of the operating
results that may be expected for a full year. The condensed consolidated balance sheet as of December 31, 2020 contains financial information
taken from the audited Abeona consolidated financial statements as of that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_84E_eus-gaap--CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_zEUpvfbSxsSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86A_zWLxmc3Owes7">Uses
and Sources of Liquidity</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
financial statements have been prepared on the going concern basis, which assumes the Company will have sufficient cash to pay its operating
expenses, as and when they become payable, for a period of at least 12 months from the date the financial report was issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2021, we had cash, cash equivalents and short-term investments of $<span id="xdx_907_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn5n6_c20210930_zZoJmyOIxkAg">67.0
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million and net assets of $<span id="xdx_90F_eus-gaap--AssetsNet_iI_pn5n6_c20210930_zn8YIc938426">79.7
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million. For the nine months ended September
30, 2021, we had cash outflows from operations of $<span id="xdx_903_ecustom--NetCashProvidedByUsedInOperatingActivity_pn5n6_c20210101__20210930_zeSaXZywvPTc">35.4
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million. We have not generated significant product
revenues and have not achieved profitable operations. There is no assurance that profitable operations will ever be achieved, and, if
achieved, could be sustained on a continuing basis. In addition, development activities, clinical and nonclinical testing, and commercialization
of our products will require significant additional financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
are subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful
discovery and development of product candidates, obtaining the necessary regulatory approval to market our product candidates, raising
additional capital to continue to fund our operations, development of competing drugs and therapies, protection of proprietary technology
and market acceptance of our products. As a result of these and other risks and the related uncertainties, there can be no assurance
of our future success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Based
on our existing cash, cash equivalents and short-term investments, our ability to access additional financial resources and/or our financial
flexibility to reduce operating expenses if required, we believe that we have sufficient resources to fund operations through at least
the next 12 months. We will need to secure additional funding in the future to carry out all of our planned research and development
activities. If we are unable to obtain additional financing or generate license or product revenue, the lack of liquidity and sufficient
capital resources could have a material adverse effect on our future prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_84D_eus-gaap--UseOfEstimates_zy5YlErp0Wff" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_863_zfJPSrLcRyi1">Use
of Estimates</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amount of assets and disclosure of contingent assets and liabilities at the date of the consolidated financial statements
and the reported amounts of revenue and expenses during the reported period. Actual results could differ from these estimates and assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zSQ0m0O8NET8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86C_zfinpwbrcCf4">Cash
and Cash Equivalents</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. We maintain deposits
primarily in financial institutions, which may at times exceed amounts covered by insurance provided by the U.S. Federal Deposit Insurance
Corporation (&#8220;FDIC&#8221;). We have not experienced any losses related to amounts in excess of FDIC limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_849_eus-gaap--EquityMethodInvestmentsPolicy_zXhQvH2OjMS4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86E_ziGgthm8AcU1">Short-term
Investments</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Short-term
investments consist of investments in U.S. government, U.S. agency and U.S. treasury securities. We determine the appropriate classification
of the securities at the time they are acquired and evaluate the appropriateness of such classifications at each balance sheet date.
We classify our short-term investments as available-for-sale pursuant to Accounting Standards Codification (&#8220;ASC&#8221;) 320, <i>Investments
&#8211; Debt and Equity Securities</i>. Investments classified as current have maturities of less than one year. We review our short-term
investments for other-than-temporary impairment whenever the fair value of a marketable security is less than the amortized cost and
evidence indicates that a short-term investment&#8217;s carrying amount is not recoverable within a reasonable period of time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_84D_eus-gaap--LesseeLeasesPolicyTextBlock_zeDZ1lKkmWUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86E_zTvcJjVfRLBg">Leases</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">We
account for leases in accordance with ASC 842, <i>Leases</i>. Right-of-use lease assets represent our right to use an underlying asset
for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. The measurement of lease
liabilities is based on the present value of future lease payments over the lease term. As our leases do not provide an implicit rate,
we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value
of future lease payments. The right-of-use asset is based on the measurement of the lease liability and includes any lease payments made
prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. Rent expense for our
operating leases is recognized on a straight-line basis over the lease term. We do not have any leases classified as finance leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Our
leases do not have significant rent escalation, holidays, concessions, material residual value guarantees, material restrictive covenants
or contingent rent provisions. Our leases include both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease
components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component as we have elected the
practical expedient to group lease and non-lease components for all leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Most
leases include one or more options to renew. The exercise of lease renewal options is typically at our sole discretion; therefore, the
majority of renewals to extend the lease terms are not included in our right-of-use assets and lease liabilities as they are not reasonably
certain of exercise. We regularly evaluate the renewal options and when they are reasonably certain of exercise, we include the renewal
period in our lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Additional
information and disclosures required under ASC 842 are included in Note 7.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_84B_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zOdn5KLQjuTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_862_z5DzEwHQw0c1">Restricted
Cash</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Restricted
cash, which is recorded within other assets and restricted cash in the accompanying consolidated balance sheets and is included as a
component of cash, cash equivalents and restricted cash on our consolidated statements of cash flows, consists of cash and cash equivalents
held as collateral for a corporate credit card and office space in New York. As such, the cash and cash equivalents are restricted in
use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zIFTyweu3N44" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86B_z9oBtVlfjEva">Loss
Per Common Share</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">We
have presented basic and diluted loss per common share on the statement of operations and comprehensive loss. Basic and diluted net loss
per share is computed by dividing net loss by the weighted-average number of shares of common stock and shares underlying &#8220;pre-funded&#8221;
warrants outstanding during the period. The &#8220;pre-funded&#8221; warrants were included in the computation of basic net loss per
share as the exercise price was negligible and the warrants were fully vested and exercisable. In October 2020, all of the <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20201031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreFundedWarrantMember_pdd" title="Warrants converted to shares">9,017,055</span>
&#8220;pre-funded&#8221; warrants were exercised and converted into shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zIjsTejJ69Xf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">We
do not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive.
Potential dilutive securities result from outstanding stock options, restricted stock and &#8220;non-pre-funded&#8221; warrants. We did
not include the following potentially dilutive securities in the computation of diluted net loss per common share during the periods
presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B0_zGpTDclD53Ef" style="display: none">SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the three months ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">September 30,</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the nine months ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">September 30,</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zGmT3TiyFHH" style="width: 11%; text-align: right" title="Total">7,755,196</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zVPZetACBmpj" style="width: 11%; text-align: right" title="Total">6,431,183</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zZEyPRPu13fh" style="width: 11%; text-align: right" title="Total">7,755,196</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zElmds4z2HWd" style="width: 11%; text-align: right" title="Total">6,431,183</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Restricted stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z0JAkd7JW7Dk" style="border-bottom: Black 1pt solid; text-align: right" title="Total">2,989,224</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zT0Jq02nK7s9" style="border-bottom: Black 1pt solid; text-align: right" title="Total">818,233</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zNbTYrZy4096" style="border-bottom: Black 1pt solid; text-align: right" title="Total">2,989,224</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zq5ETfqCi4h9" style="border-bottom: Black 1pt solid; text-align: right" title="Total">818,233</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930_z1yadaQyohHk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">10,744,420</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200701__20200930_zk1Er6zMGrg4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">7,249,416</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930_zVBezYMakOW9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">10,744,420</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20200930_zMFXm5NhwoUc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">7,249,416</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_z4wrP32YLEKl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325273811368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHORT-TERM INVESTMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">SHORT-TERM INVESTMENTS</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zdpp23stxiI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
2 &#8211; <span id="xdx_822_zHihvzzsYH16">SHORT-TERM INVESTMENTS</span></b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_891_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zjbZsQZKxH7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
following table summarizes the available-for-sale investments held:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B8_zHdGAqPcpEZ3" style="display: none">SCHEDULE OF AVAILABLE-FOR-SALE INVESTMENTS HELD</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">September 30,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2021</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2020</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">U.S. government and agency securities and treasuries</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20210930_zNCwvQn3mAxh" style="width: 16%; text-align: right" title="U.S. government and agency securities and treasuries">23,217,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20201231_zK0VDqxmHNC3" style="width: 16%; text-align: right" title="U.S. government and agency securities and treasuries">82,438,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zKuy9IgcjIyb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
amortized cost of the available-for-sale debt securities, which is adjusted for amortization of premiums and accretion of discounts to
maturity, was $<span id="xdx_904_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20210930_zgbhmyqR9gek" title="Amortized cost of available-for-sale debt securities">23,217,000</span> and $<span id="xdx_901_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_iI_pp0p0_c20201231_z3Y9j1wvEv62" title="Amortized cost of available-for-sale debt securities">82,448,000</span> as of September 30, 2021 and December 31, 2020, respectively. There were <span id="xdx_908_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_do_c20210101__20210930_zSEWabXEfFJ8" title="Realized gains or losses on sale or maturity of available-for-sale debt securities"><span id="xdx_90D_eus-gaap--DebtSecuritiesAvailableForSaleRealizedGainLoss_do_c20200101__20200930_zzILk9FaHlk4" title="Realized gains or losses on sale or maturity of available-for-sale debt securities">no</span></span> significant realized
gains or losses recognized on the sale or maturity of available-for-sale debt securities during the nine months ended September 30, 2021
or 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325114004344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSED TECHNOLOGY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">LICENSED TECHNOLOGY</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--IntangibleAssetsDisclosureTextBlock_z5ziRi9Akllk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
3 &#8211; <span id="xdx_82A_zImVBkbtTvz3">LICENSED TECHNOLOGY</span></b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">On
November 4, 2018, we entered into a license agreement with REGENXBIO Inc. (&#8220;REGENXBIO&#8221;) to obtain rights to an exclusive
worldwide license (subject to certain non-exclusive rights previously granted for MPS IIIA), with rights to sublicense, to REGENXBIO&#8217;s
NAV AAV9 vector for gene therapies for treating MPS IIIA, MPS IIIB, CLN1 Disease and CLN3 Disease. Consideration for the rights granted
under the original agreement included fees totaling $<span id="xdx_909_eus-gaap--RoyaltyExpense_pn6n6_c20181103__20181104__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_z2GLLZSFK9J7" title="Royalty fees">180</span> million and a running royalty on net sales, including: (i) an initial fee of
$<span id="xdx_90D_eus-gaap--PaymentsForRoyalties_pn6n6_c20181103__20181104__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zCdCdWEzsam8" title="Royalties payments">20</span> million, $<span id="xdx_90D_ecustom--PaymentForExecutionOfContracts_iI_pn6n6_c20181104__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zOYyE6enaFr9" title="Payment on execution of contracts">10</span> million of which was due to REGENXBIO shortly after the effective date of the agreement, and $<span id="xdx_904_eus-gaap--DueToRelatedPartiesCurrent_iI_pn6n6_c20181104__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zWqysz5KNsAb" title="Due to licensor current">10</span> million of which was
to be due on the first anniversary of the effective date of the agreement in November 2019, (ii) annual fees totaling up to $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20181104__srt--RangeAxis__srt--MaximumMember__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zQcynVfbUZEa" title="Annual fees">100</span> million,
payable in $<span id="xdx_900_eus-gaap--PaymentsForRoyalties_pn6n6_c20201103__20201104__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_z5JQaYEbk40g">20</span> million annual installments beginning on the second anniversary of the effective date (the first of which was to remain
payable if the agreement were terminated before the second anniversary in November 2020), (iii) sales milestone payments totaling $<span id="xdx_906_ecustom--PaymentsForMilestone_pn6n6_c20181103__20181104__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zuENpTJjpxy5" title="Milestone payment">60</span>
million, and (iv) royalties payable in the low double digits to low teens on net sales of products covered under the agreement. The license
was being amortized over the life of the patent of <span title="Finite-lived intangible asset, useful life::XDX::8"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dc_c20181103__20181104__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zzKOWzVxHZ6d" title="Finite-lived intangible asset, useful life">eight years</span></span>. On November 1, 2019, we entered into an amendment of the original license
agreement. The amended agreement replaced the $<span id="xdx_906_eus-gaap--ProgramRightsObligationsCurrent_iI_pn6n6_c20191104__us-gaap--TypeOfArrangementAxis__custom--OriginalLicenseAgreementMember_zS1MGwA152Ne" title="License to be paid">10</span> million payment due on November 4, 2019 with a $<span id="xdx_90A_eus-gaap--ProgramRightsObligationsCurrent_iI_pn6n6_c20191104__us-gaap--TypeOfArrangementAxis__custom--AmendedAgreementMember_zVJ320nawWld" title="License to be paid">3</span> million payment due on November 4,
2019 and an additional $<span id="xdx_90C_eus-gaap--ProgramRightsObligationsCurrent_iI_pn6n6_c20191104__us-gaap--AwardDateAxis__custom--AprilOneTwentyTwentyMember__us-gaap--TypeOfArrangementAxis__custom--AmendedAgreementMember_zg0YWHRunq5h" title="License to be paid">8</span> million payment (which included $<span id="xdx_901_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pn6n6_c20191104_z8XsMDVVTKJe" title="Interest payable">1</span> million of interest) that would have been due no later than April 1, 2020.
That $<span id="xdx_902_eus-gaap--PaymentsForRoyalties_pn6n6_c20200329__20200402_zAJkw6BcViqk" title="Royalties payments">8</span> million payment that had been scheduled to be paid by April 1, 2020 and the $<span id="xdx_901_eus-gaap--PaymentsForRoyalties_pn6n6_c20201103__20201104_zf7sLiE8eb37" title="Royalties payments">20</span> million that had been due to be paid on November
4, 2020 are both recorded as payable to licensor on the consolidated balance sheet. The Company disputed that it was responsible for
the $<span id="xdx_900_eus-gaap--LossContingencyAccrualAtCarryingValue_iI_pn6n6_c20201231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zdr1xbWgcbvd" title="Loss contingency accrual">8 </span>million and $<span id="xdx_900_eus-gaap--PaymentsForLegalSettlements_pn6n6_c20200101__20201231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zTkqgsAnGPk7" title="Payments for legal settlements">20</span> million payments, and those payments were the subject of an arbitration between the Company and REGENXBIO as noted
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">Prior to the
April 1, 2020 deadline, <span id="xdx_908_eus-gaap--LossContingencySettlementAgreementTerms_c20200330__20200402__dei--LegalEntityAxis__custom--REGENXBIOMember_zYpOuWx7UX5b" title="Settlement agreement financial terms, description">we engaged REGENXBIO in discussions in an attempt to renegotiate the financial terms of the agreement, but we
were unable to reach an agreement, and we did not make the $8 million payment due by April 1, 2020. On April 17, 2020, REGENXBIO sent
us a written demand for the $8 million fee, payable within a 15-day cure period after receipt of the demand letter. The license terminated
on May 2, 2020, when the 15-day period expired. We considered the status of our discussions with REGENXBIO in March 2020 as a potential
indicator of impairment in accordance with ASC 360-10-35-21.</span> Our impairment test indicated that the carrying value of the license agreement
exceeded its fair value and we recorded a $<span id="xdx_90D_eus-gaap--OtherCostAndExpenseOperating_pn5n6_c20210101__20210331_zlRwJIRWxsf7" title="Non-cash licensed technology impairment charge">32.9</span> million non-cash impairment charge during the three months ended March 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;<span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">On May 25, 2020,
we filed an arbitration claim with the American Arbitration Association (&#8220;AAA&#8221;) alleging that REGENXBIO materially breached
the license agreement prior to termination and seeking, among other things, a declaration that as a result of REGENXBIO&#8217;s material
breach, we were not responsible for payments totaling $<span id="xdx_902_eus-gaap--GainLossRelatedToLitigationSettlement_pn6n6_c20200524__20200525__dei--LegalEntityAxis__custom--REGENXBIOMember_zYwBxXV89bDg" title="Gain loss on payments for settlement">28</span> million (which would otherwise have been due in 2020) plus accrued interest.
REGENXBIO disputed our arbitration claim and filed a counterclaim seeking payment of the $<span id="xdx_909_eus-gaap--GainLossRelatedToLitigationSettlement_pn6n6_c20200524__20200525__dei--LegalEntityAxis__custom--REGENXBIOMember_zPUT0U4YIqLf">28</span> million plus interest, which REGENXBIO argued
remained due. An arbitration hearing before a tribunal of three AAA arbitrators was held on March 8 and March 9, 2021. On July 13, 2021,
the tribunal found in favor of REGENXBIO in connection with the parties&#8217; arbitration claims and counterclaims. The tribunal awarded
REGENXBIO $<span id="xdx_908_eus-gaap--GainLossRelatedToLitigationSettlement_pn6n6_c20200712__20200713__dei--LegalEntityAxis__custom--REGENXBIOMember_zpcGhd9B3sQk">28</span>.0 million plus interest. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">On August 9,
2021, we filed a second arbitration claim with the AAA asserting that a settlement had been reached before the tribunal&#8217;s award
in the first arbitration was issued. On September 14, 2021, REGENXBIO filed its answer, a counterclaim seeking attorney fees and costs,
and a request for permission to file a case dispositive motion. A preliminary hearing was held on November 1, 2021, during which the
AAA Tribunal set timetables for discovery and for REGENXBIO&#8217;s filing of its case dispositive motion. Those timetables were formalized
in a procedural order issued by the Tribunal on November 8, 2021. Under the schedule set by the Tribunal, REGENXBIO&#8217;s opening brief
in support of its case dispositive motion was filed on November 8, 2021, briefing was scheduled to be completed on December 29, 2021,
and oral argument was scheduled for January 14, 2022. REGENXBIO had also filed suit in the New York State Supreme Court Commercial Division
seeking enforcement of the original arbitration award, and we had requested that the Court stay that proceeding until the second arbitration
is complete. Oral argument on our request for a stay was set for March 10, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">On November
12, 2021, we entered into a settlement agreement (&#8220;Settlement Agreement&#8221;) with REGENXBIO to resolve all current disputes
between the parties including the aforementioned AAA arbitration and New York State Court action. In accordance with the Settlement Agreement,
we agreed to pay REGENXBIO a total of $<span id="xdx_90F_eus-gaap--SettlementLiabilitiesCurrent_iI_pn6n6_c20211112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zUOSsK0hrK88" title="Settlement amount">30</span> million, payable as follows: (1) $<span id="xdx_905_eus-gaap--SettlementLiabilitiesCurrent_iI_pn6n6_c20211112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--REGENXBIOMember__srt--StatementScenarioAxis__custom--OneBusinessDayMember_z4zEM9DwHcEb">20</span> million payable within one business day of the execution
of the Settlement Agreement, (2) $<span id="xdx_907_eus-gaap--SettlementLiabilitiesCurrent_iI_pn6n6_c20211112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--REGENXBIOMember__srt--StatementScenarioAxis__custom--FirstAnniversaryMember_zCzt974Dpwv2">5</span> million on the first anniversary of the effective date of the Settlement Agreement, and (3) $<span id="xdx_904_eus-gaap--SettlementLiabilitiesCurrent_iI_pn6n6_c20211112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--REGENXBIOMember__srt--StatementScenarioAxis__custom--ThirdAnniversaryMember_zy2VNSJSyD4">5</span> million
upon the earlier of: (i) the third anniversary of the effective date of the Settlement Agreement or (ii) the closing of a Strategic Transaction,
as defined in the Settlement Agreement. Under the Settlement Agreement&#8217;s terms, the prior license agreement between the parties
was not reinstituted, and any future license agreement would need to be negotiated separately and require consideration in addition to
the consideration set forth in the Settlement Agreement. As of September 30, 2021, we have recorded the payable to licensor in the balance
sheet based on the present value of the payments due to REGENXBIO under the Settlement Agreement. The accounting for the Settlement Agreement
resulted in a $<span id="xdx_902_ecustom--GainOnSettlementOfRelatedParty_pn5n6_c20210101__20210930_zrhZWOInkWUj" title="Non-cash gain on settlement with licensor">6.7</span> million gain on settlement with licensor in the statement of operations and comprehensive loss during the three and
nine months ended September 30, 2021 and a $<span id="xdx_907_ecustom--GainOnSettlementOfRelatedParty_pn5n6_c20210701__20210930_zRSG4WAcpFkj" title="Gain on settlement with licensor"><span id="xdx_90E_ecustom--GainOnSettlementOfRelatedParty_pn5n6_c20210101__20210930_zTFeMnIKbSM5" title="Gain on settlement with licensor">6.7</span></span> million non-cash gain on settlement with licensor in the statement of cash flows during
the nine months ended September 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">On
May 15, 2015, we acquired Abeona Therapeutics LLC, which had an exclusive license through Nationwide Children&#8217;s Hospital to the
AB-101 and AB-102 patent portfolios for developing treatments for patients with Sanfilippo Syndrome Type A and Type B. The license is
amortized over the life of the license of <span title="Finite-lived intangible asset, useful life"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20150514__20150515__us-gaap--BusinessAcquisitionAxis__custom--AbeonaTherapeuticsLlcMember_z3uVg7quLRR1" title="Finite-lived intangible asset, useful life">20</span></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z9UE8u2a6Jt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Licensed
technology consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BB_zRs7c9dsINs1" style="display: none">SCHEDULE OF LICENSED TECHNOLOGY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210930_zSCTNABmgGdj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,&#160;2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20201231_zX6IsieNFP07" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_maFLIANzlPQ_maFLIANzW7H_zhmnavrK8gw" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 54%; text-align: left">Licensed technology</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 19%; text-align: right">2,156,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 19%; text-align: right">2,156,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_msFLIANzlPQ_msFLIANzW7H_zLREEQbBP9F" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less accumulated amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">743,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">656,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzlPQ_mtFLIANzW7H_zauM9yRpWASd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Licensed technology, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,413,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,500,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_z89kyIfBWwa1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_898_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zTBwftYkHbEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
aggregate estimated amortization expense for intangible assets remaining as of September 30, 2021 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zfCXCDqoOfu8" style="display: none">SCHEDULE OF AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 30%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20210930_zTfOPHYYMC8e" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pp0p0_maFLIANznXj_maFLIANzM9M_zclkn8EHrLE" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: center">2021, remainder</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 44%; text-align: right">29,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_maFLIANznXj_maFLIANzM9M_zDxGELT9MVz7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_maFLIANznXj_maFLIANzM9M_zfatiQ8z2Bl3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_maFLIANznXj_maFLIANzM9M_ztFFvH6slhoi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_maFLIANznXj_maFLIANzM9M_zP3Qx12frSd1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pp0p0_maFLIANznXj_maFLIANzM9M_zNwGMsa49kYe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">916,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANznXj_mtFLIANzM9M_zvXeRMuiKVXj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,413,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_z4qndAzFmivg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif; text-underline-style: double">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Amortization
on licensed technology was $<span id="xdx_90C_eus-gaap--AmortizationOfIntangibleAssets_c20210701__20210930_zcisbbBEgCZ9" title="Amortization of intangible assets">29,000</span> and $<span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20210930_zke4iL1pjElh" title="Amortization of intangible assets">87,000</span> for the three and nine months ended September 30, 2021 and $<span id="xdx_90E_eus-gaap--AmortizationOfIntangibleAssets_c20200701__20200930_zBxNsuCGjkmd">43,000</span> and $<span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pn5n6_c20200101__20200930_zXyLGiJbZIM7" title="Amortization of intangible assets">1.4</span> million for
the three and nine months ended September 30, 2020, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325114575272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOAN PAYABLE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">LOAN PAYABLE</a></td>
<td class="text"><p id="xdx_800_eus-gaap--DebtDisclosureTextBlock_zZjdCfHwDAw1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
4 - <span id="xdx_829_zOZpT5Xrd8Wj">LOAN PAYABLE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
May 2, 2020, we received loan proceeds in the amount of approximately $<span id="xdx_90B_eus-gaap--ProceedsFromNotesPayable_pn5n6_c20200501__20200502__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramMember_zvX7W6RWTlDj" title="Proceeds from loan">1.8</span> million (the &#8220;PPP Loan&#8221;) under the Paycheck Protection
Program (&#8220;PPP&#8221;). The PPP was established under the Coronavirus Aid, Relief and Economic Security Act, as amended (&#8220;CARES
Act&#8221;) and is administered by the U.S. Small Business Administration (&#8220;SBA&#8221;). Under the terms of the CARES Act, PPP
loan recipients can apply for loan forgiveness. The loan forgiveness for all or a portion of PPP loans was determined, subject to limitations,
based on the use of loan proceeds over the 24 weeks after the loan proceeds are disbursed. In July 2021, we received notice from the
SBA that our PPP loan has been forgiven. In the third quarter of 2021, the extinguishment of the PPP loan payable was recorded as PPP
loan payable forgiveness income in the statement of operations and comprehensive loss. The forgiveness of the PPP loan payable was recorded
as non-cash PPP loan payable forgiveness income in the statement of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325114037304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p id="xdx_800_eus-gaap--FairValueDisclosuresTextBlock_zka8fLXsz7vd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
5 &#8211; <span id="xdx_823_z1OC8Uv6fiy3">FAIR VALUE MEASUREMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
calculate the fair value of our assets and liabilities that qualify as financial instruments and include additional information in the
notes to the consolidated financial statements when the fair value is different than the carrying value of these financial instruments.
The estimated fair value of prepaid expenses and other current assets, other assets, accounts payable, accrued expenses, loan payable,
payable to licensor and contract liability approximate their carrying amounts due to the relatively short maturity of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">U.S.
GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in
the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement
date. This guidance establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy
requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The lowest level fair value inputs
are used to assign a fair value level. The three levels of inputs used to measure fair value are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; layout-grid-mode: line; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    1 - Quoted prices in active markets for identical assets or liabilities.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    2 - Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active
    markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable
    or can be corroborated by observable market data.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; layout-grid-mode: line; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets
    and liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use
    significant unobservable inputs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
have segregated all financial assets and liabilities that are measured at fair value on a recurring basis (at least annually) into the
most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in
the table below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zy9jzHYcGQ7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Financial
assets and liabilities measured at fair value on a recurring and non-recurring basis as of September 30, 2021 and December 31, 2020 are
summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BF_zYsdQBF3Bs2a" style="display: none">SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Description</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">September
30,&#160;2021</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Gains/(Losses)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify">Recurring</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: justify">Short-term investments</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zXgJr5COOH9" style="width: 16%; text-align: right" title="Fair value disclosure of assets">23,217,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zpKsindg2PAc" style="width: 9%; text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0778">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zCIePP4gCDDf" style="width: 9%; text-align: right" title="Fair value disclosure of assets">23,217,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zIVmJtFdC7El" style="width: 9%; text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0782">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUmBb7HDRQJh" style="width: 9%; text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0784">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify">Non-recurring</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Licensed technology, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zCBSJxtCiGPi" style="text-align: right" title="Fair value disclosure of assets">1,413,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zh5WLLypThL8" style="text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0788">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_z8qzIY21wgv6" style="text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0790">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_z3J6Afun9Bla" style="text-align: right" title="Fair value disclosure of assets">1,413,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zB3PSIzLkd8g" style="text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0794">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zc6MiCzs9hMg" style="text-align: right" title="Fair value disclosure of assets">32,466,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zvuYGx0DK9Wl" style="text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0798">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zIl4ZPGNLQr3" style="text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0800">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zXPePTJOBhRe" style="text-align: right" title="Fair value disclosure of assets">32,466,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zfSYe35hTNwe" style="text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0804">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Description</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December
31,&#160;2020</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Gains/(Losses)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify">Recurring</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: justify">Short-term investments</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zcXn0nTmXfhd" style="width: 16%; text-align: right" title="Fair value disclosure of assets">82,438,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zvPylhnEA7R" style="width: 9%; text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0808">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxtpgDmCm5G2" style="width: 9%; text-align: right" title="Fair value disclosure of assets">82,438,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z5S6oy2RJ3yc" style="width: 9%; text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0812">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zK4YcvN9FZ34" style="width: 9%; text-align: right" title="Fair value disclosure of gain loss"><span style="-sec-ix-hidden: xdx2ixbrl0814">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify">Non-recurring</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Licensed technology, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zG7TKK9dokH9" style="text-align: right" title="Fair value disclosure of assets">1,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_z5DAbHpfADdh" style="text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0818">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_z0vvxhiAfeb4" style="text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0820">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zgys0wMOkMSh" style="text-align: right" title="Fair value disclosure of assets">1,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_z2oOXVuHir4e" style="text-align: right" title="Fair value disclosure of gain loss">(32,916,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zSKFMXFd51y5" style="text-align: right" title="Fair value disclosure of assets">32,466,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zir2urBeFoNh" style="text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0828">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zgRfZXszhf79" style="text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0830">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zA6JNTPYMid5" style="text-align: right" title="Fair value disclosure of assets">32,466,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zYvnQTSEOqHc" style="text-align: right" title="Fair value disclosure of gain loss"><span style="-sec-ix-hidden: xdx2ixbrl0834">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zQLHL6oYFkGl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325112766296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_807_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z8y1IWZi5l9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
6 &#8211; <span id="xdx_822_z3vc0rWceNO6">STOCK-BASED COMPENSATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zeNE9WAF0w2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Stock
Options</i>: The following table summarizes stock option-based compensation for the three and nine months ended September 30, 2021 and
2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zhgHRbRE57u" style="display: none">SCHEDULE OF STOCK BASED COMPENSATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5vzLZ7mMNrd" style="width: 10%; text-align: right" title="Total stock-based compensation expense">432,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zgx16oMVADmg" style="width: 10%; text-align: right" title="Total stock-based compensation expense">765,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z6T2yur6qoU7" style="width: 10%; text-align: right" title="Total stock-based compensation expense">1,649,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zTILqnMQIvWe" style="width: 10%; text-align: right" title="Total stock-based compensation expense">2,380,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_z8EfdWkayT9j" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense">955,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zDpysH7Fa4Vl" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense">484,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_z48Hk68g8Lnd" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense">2,148,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_ztcJTCgkkUW1" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense">1,703,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock option-based compensation expense included in operating expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_z2mv0g5X8FNb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">1,387,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_z2OI5eszwY6a" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">1,249,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_znZHQdfqMYIa" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">3,797,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_zfOM5lgJKL54" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">4,083,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8AD_zmRsHgVAOWQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">We
estimate the fair value of each option award on the date of grant using the Black-Scholes option valuation model. We then recognize the
grant date fair value of each option as compensation expense ratably using the straight-line attribution method over the service period
(generally the vesting period). The Black-Scholes model incorporates the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Expected
    volatility - we estimate the volatility of our share price at the date of grant using a &#8220;look-back&#8221; period which coincides
    with the expected term, defined below. We believe using a &#8220;look-back&#8221; period which coincides with the expected term is
    the most appropriate measure for determining expected volatility.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Expected
    term - we estimate the expected term using the &#8220;simplified&#8221; method, as outlined in Staff Accounting Bulletin No. 107,
    &#8220;Share-Based Payment.&#8221;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Risk-free
    interest rate - we estimate the risk-free interest rate using the U.S. Treasury yield curve for periods equal to the expected term
    of the options in effect at the time of grant.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Dividends
    - we use an expected dividend yield of zero because we have not declared or paid a cash dividend, nor do we have any plans to declare
    a dividend.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zmOzrQbauXUb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">We
used the following weighted-average assumptions to estimate the fair value of the options granted for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BE_z9vTJ4oi7gnd" style="display: none">SCHEDULE OF WEIGHTED-AVERAGE ASSUMPTIONS TO ESTIMATE THE FAIR VALUE OF THE OPTIONS GRANTED</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: justify">Expected volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210701__20210930_zwSBpvi10z9f" style="width: 10%; text-align: right" title="Expected volatility">92</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200701__20200930_zutH84DKe1Mi" style="width: 10%; text-align: right" title="Expected volatility">110</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210930_zgksPcwHzgd2" style="width: 10%; text-align: right" title="Expected volatility">97</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20200930_zddY1w2hz3Pl" style="width: 10%; text-align: right" title="Expected volatility">111</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210701__20210930_zwpxsh0F6KM5" title="Expected term">6.08</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200701__20200930_zOZToGJ7e7H3" title="Expected term">6.25</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930_zPNMWKfTQKkd" title="Expected term">5.97</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200930_zQ6T4jlsWTCa" title="Expected term">6.25</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210701__20210930_zrGMKD2M4uHc" style="text-align: right" title="Risk-free interest rate">0.97</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200701__20200930_zzocRiqjppDb" style="text-align: right" title="Risk-free interest rate">0.16</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210930_zkHTCGdpEd1i" style="text-align: right" title="Risk-free interest rate">0.98</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20200930_zbStsIJzRmgh" style="text-align: right" title="Risk-free interest rate">0.29</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210701__20210930_zYCr3zL3PVPg" style="text-align: right" title="Expected dividend yield">0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200701__20200930_z5QhehHNzAtl" style="text-align: right" title="Expected dividend yield">0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20210930_zshgLyGwuMx" style="text-align: right" title="Expected dividend yield">0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20200930_zCTHltN2NDU2" style="text-align: right" title="Expected dividend yield">0</td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A7_zrkC2dldH4xi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zcDmRQ0OZzZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the options granted for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BA_zL7sPFqvKlN3" style="display: none">SCHEDULE OF OPTIONS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20210701__20210930_zxi79DAfrOad" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20200701__20200930_z1Ng8gXGbdjc" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20210930_zyqD3SuDpsXa" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20200101__20200930_zk3QNXRDBFw5" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_z3d42X4ijVSa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left">Options granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">1,028,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">342,100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">4,383,308</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">3,415,146</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_zlrvW92nscca" style="vertical-align: bottom; background-color: White">
    <td>Weighted-average:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_zPFwpSYPHY5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.38</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_zqo0AiFkUskg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Grant date fair value</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.94</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.44</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.99</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_z78TTdMQYZHb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z7qGUTPJBeii" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Restricted
Common Stock</i>: The following table summarizes restricted common stock compensation expense for the three and nine months ended September
30, 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B7_zmxOinF77W7b" style="display: none">SCHEDULE OF STOCK BASED COMPENSATION</span><span/></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zuSkkw0JBdUc" style="width: 10%; text-align: right" title="Total stock-based compensation expense">256,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zq5qyOdMmve4" style="width: 10%; text-align: right" title="Total stock-based compensation expense">89,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z16OrbGmHlif" style="width: 10%; text-align: right" title="Total stock-based compensation expense">1,286,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zW4hkk3BjaEj" style="width: 10%; text-align: right" title="Total stock-based compensation expense">561,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zH1lLNUWHBIh" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense">894,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zHOBYHR1RS2b" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense">72,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zuaZ6snBlpdi" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense">1,832,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zAA5M2f39fw7" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense">251,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Restricted stock-based compensation expense included in operating expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_z66az17mTZr4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">1,150,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_zUi9HKJrfiMd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">161,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_z5FpDiF8Dhrl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">3,118,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_zeufPMnGEovl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">812,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zxHmrRmc9nea" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zTBrOXitDuy" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the restricted common stock granted for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B7_zSwE6O0Yu767" style="display: none">SUMMARY OF RESTRICTED COMMON STOCK</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20210701__20210930_zW4rBtZApFic" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20200701__20200930_zOxJZK3nReA3" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20210101__20210930_zoftN5jipWK8" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20200101__20200930_z7rY7reo6kx2" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zWozfRO6RFwg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left">Restricted common stock granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">767,934</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0949">&#160;</span></td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">2,743,668</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">1,083,313</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z3j1UqswTnof" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted common stock forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(293,109</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(265,080</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(721,768</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(265,080</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_pid_ziM4EbnM7LN7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted-average:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z6f30tmPXUm5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Grant date fair value-granted awards</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0964">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.77</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.19</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z6gEnYUdCMFe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Grant date fair value-forfeited awards</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.93</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.18</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zYakx4IEhzwe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325114057032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z7YvgbEMTim5" style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">NOTE
7 &#8211; <span id="xdx_82D_ztKGEtHWe4H2">COMMITMENTS AND CONTINGENCIES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Arbitration
Proceeding</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were engaged in an arbitration
proceeding with REGENXBIO regarding the former license agreement between us and REGENXBIO relating to use of the AAV9 capsid in our
MPS IIIA, MPS IIIB, CLN1 (which has now been sold to Taysha Gene Therapies), and CLN3 programs. <span style="font-weight: normal">The
license terminated on May 2, 2020, and on May 25, 2020, we filed an arbitration claim with the American Arbitration Association
(&#8220;AAA&#8221;) alleging that REGENXBIO materially breached the license agreement prior to termination and seeking, among other
things, a declaration that as a result of REGENXBIO&#8217;s material breach, we were not responsible for payments totaling $<span id="xdx_901_eus-gaap--GainLossRelatedToLitigationSettlement_pn6n6_c20200524__20200525__dei--LegalEntityAxis__custom--REGENXBIOMember_z6zno4I8x0Ya" title="Gain loss on payments for settlement">28</span>
million (which would otherwise have been due in 2020) plus accrued interest. REGENXBIO disputed our arbitration claim and filed a
counterclaim seeking payment of the $<span id="xdx_90F_eus-gaap--GainLossRelatedToLitigationSettlement_pn6n6_c20200524__20200525__dei--LegalEntityAxis__custom--REGENXBIOMember_zO38o7snDLV4">28</span> million plus interest, which REGENXBIO argued remained due. An arbitration hearing before a
tribunal of three AAA arbitrators was held on March 8 and March 9, 2021. On July 13, 2021, the tribunal found in favor of REGENXBIO
in connection with the parties&#8217; arbitration claims and counterclaims. The tribunal awarded REGENXBIO $<span id="xdx_903_eus-gaap--GainLossRelatedToLitigationSettlement_pn6n6_c20200712__20200713__dei--LegalEntityAxis__custom--REGENXBIOMember_zL2ZdWwNn0L">28</span>.0 million plus
interest. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">On August 9,
2021, we filed a second arbitration claim with the AAA asserting that a settlement had been reached before the tribunal&#8217;s award
in the first arbitration was issued. On September 14, 2021, REGENXBIO filed its answer, a counterclaim seeking attorney fees and costs,
and a request for permission to file a case dispositive motion. A preliminary hearing was held on November 1, 2021, during which the
AAA Tribunal set timetables for discovery and for REGENXBIO&#8217;s filing of its case dispositive motion. Those timetables were formalized
in a procedural order issued by the Tribunal on November 8, 2021. Under the schedule set by the Tribunal, REGENXBIO&#8217;s opening brief
in support of its case dispositive motion was filed on November 8, 2021, briefing was scheduled to be completed on December 29, 2021,
and oral argument was scheduled for January 14, 2022. REGENXBIO had also filed suit in the New York State Supreme Court Commercial Division
seeking enforcement of the original arbitration award, and we had requested that the Court stay that proceeding until the second arbitration
is complete. Oral argument on our request for a stay was set for March 10, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">On November
12, 2021, we entered into a settlement agreement (&#8220;Settlement Agreement&#8221;) with REGENXBIO to resolve all current disputes
between the parties including the aforementioned AAA arbitration and New York State Court action. In accordance with the Settlement Agreement,
we agreed to pay REGENXBIO a total of $<span id="xdx_900_eus-gaap--SettlementLiabilitiesCurrent_iI_pn6n6_c20211112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--REGENXBIOMember_zJ5YquSODEak" title="Settlement amount">30</span> million, payable as follows: (1) $<span id="xdx_908_eus-gaap--SettlementLiabilitiesCurrent_iI_pn6n6_c20211112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--REGENXBIOMember__srt--StatementScenarioAxis__custom--OneBusinessDayMember_znSXizSwPtX1" title="Settlement amount">20</span> million payable within one business day of the execution
of the Settlement Agreement, (2) $<span id="xdx_904_eus-gaap--SettlementLiabilitiesCurrent_iI_pn6n6_c20211112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--REGENXBIOMember__srt--StatementScenarioAxis__custom--FirstAnniversaryMember_zpW6RWHmuJPl" title="Settlement amount">5</span> million on the first anniversary of the effective date of the Settlement Agreement, and (3) $<span id="xdx_90F_eus-gaap--SettlementLiabilitiesCurrent_iI_pn6n6_c20211112__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember__dei--LegalEntityAxis__custom--REGENXBIOMember__srt--StatementScenarioAxis__custom--ThirdAnniversaryMember_zoQWVUvgpacj" title="Settlement amount">5</span> million
upon the earlier of: (i) the third anniversary of the effective date of the Settlement Agreement or (ii) the closing of a Strategic Transaction,
as defined in the Settlement Agreement. Under the Settlement Agreement&#8217;s terms, the prior license agreement between the parties
was not reinstituted, and any future license agreement would need to be negotiated separately and require consideration in addition to
the consideration set forth in the Settlement Agreement. As of September 30, 2021, we have recorded the payable to licensor in the balance
sheet based on the present value of the payments due to REGENXBIO under the Settlement Agreement. The accounting for the Settlement Agreement
resulted in a $<span id="xdx_90A_ecustom--GainOnSettlementOfRelatedParty_pn5n6_c20210101__20210930_zj1LDjviZ8D7">6.7</span> million gain on settlement with licensor in the statement of operations and comprehensive loss during the three and
nine months ended September 30, 2021 and a $<span id="xdx_90F_ecustom--GainOnSettlementOfRelatedParty_pn5n6_c20210701__20210930_znq4JCOg9Hkk"><span id="xdx_906_ecustom--GainOnSettlementOfRelatedParty_pn5n6_c20210101__20210930_ztdiYJM29xG2">6.7</span></span> million non-cash gain on settlement with licensor in the statement of cash flows during
the nine months ended September 30, 2021.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Operating
Leases</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-weight: normal">We lease space
under operating leases for manufacturing and laboratory facilities and administrative offices in Cleveland, Ohio, as well as administrative
offices in New York, New York.</span><span style="font-weight: normal"> </span>We also lease office space in Madrid, Spain as well
as certain office equipment under operating leases, which have a non-cancelable lease term of less than one year and, therefore, we have
elected the practical expedient to exclude these short-term leases from our right-of-use assets and lease liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_895_eus-gaap--LeaseCostTableTextBlock_zZpb5PcItwUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Components
of lease cost are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B1_zBzypTUIghC3" style="display: none">SCHEDULE OF COMPONENTS OF LEASE COST</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20210701__20210930_zNujNpGJw8Df" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20200701__20200930_zNbZA6oGWHHk" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20210930_zRoqzCbnII9f" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20200101__20200930_zZeAdcvAV8tj" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseCost_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">434,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">434,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,302,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,302,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--VariableLeaseCost_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Variable lease cost</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">105,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">81,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">344,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">256,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShortTermLeaseCost_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Short-term lease cost</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">19,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">23,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">43,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zzrBzH0LH1pi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89A_ecustom--ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_zJ0ziEhp78gl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
following table presents information about the amount and timing of cash flows arising from operating leases as of September 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B0_z8hKq46Dpxe" style="display: none">SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20210930_zrs284mKV2ca">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1pt"><span style="text-decoration: underline">Maturity of lease liabilities:</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzoEX_maLOLLPzvfE_z0en0Rh81Pd9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">2021, remainder</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">429,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzvfE_zLpONmPcmVLg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,727,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzvfE_zZhc1j0uHIX2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,741,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzvfE_zJv2kQz1362l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,781,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzvfE_z0XKX1L55rJl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,799,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzvfE_z706LZog6hvi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">87,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_mtLOLLPzvfE_maOLLzUrS_zFTfFquNiLMk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total undiscounted operating lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,564,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pp0p0_maOLLzUrS_ze4bsotDBBYc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,399,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iTI_pp0p0_zwSzgtgoBaY1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,165,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Balance sheet classification:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_maOLLzHBA_zakll0xG9IA2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current portion of lease liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,723,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_maOLLzHBA_z2LIdWElG2Md" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Long-term lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,442,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiability_iTI_pp0p0_mtOLLzHBA_zFwDb5tXBPUh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,165,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; text-align: left">Other information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average remaining lease term for operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20210930_zCPuYwSooGwl" title="Weighted-average remaining lease term for operating leases">52</span> months</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted-average discount rate for operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20210930_zAB7llfmxoI" title="Weighted-average discount rate for operating leases">9.6</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325114055448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_BackgroundPolicyTextBlock', window );">Background</a></td>
<td class="text"><p id="xdx_844_ecustom--BackgroundPolicyTextBlock_zKzhqIm7jPz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86C_zcRrEZIaYKAk">Background</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Abeona
Therapeutics Inc. (together with our subsidiaries, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;Abeona&#8221; or the &#8220;Company&#8221;),
a Delaware corporation, is a clinical-stage biopharmaceutical company developing gene and cell therapies for life-threatening rare genetic
diseases. Our lead clinical programs consist of: (i) EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis
bullosa (&#8220;RDEB&#8221;), (ii) ABO-102, an adeno-associated virus (&#8220;AAV&#8221;)-based gene therapy for Sanfilippo syndrome
type A (&#8220;MPS IIIA&#8221;), and (iii) ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B (&#8220;MPS IIIB&#8221;).
We continue to develop additional AAV-based gene therapies designed to treat ophthalmic and other diseases, next-generation AAV-based
gene therapies using the novel AIM&#8482; capsid platform that we have exclusively licensed from the University of North Carolina at
Chapel Hill, and internal AAV vector research programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_843_eus-gaap--BasisOfAccounting_ziYBhQQ0QEv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86B_zpfYEzZH7Ezl">Basis
of Presentation</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
condensed consolidated balance sheet as of September 30, 2021, the condensed consolidated statements of operations and comprehensive
loss and stockholders&#8217; equity for the three and nine months ended September 30, 2021 and 2020, and the condensed consolidated statement
of cash flows for the nine months ended September 30, 2021 were prepared by management without audit. In the opinion of management, all
adjustments, consisting only of normal recurring adjustments, except as otherwise disclosed, necessary for the fair presentation of the
financial position, results of operations, and changes in financial position for such periods, have been made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Certain
information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally
accepted in the United States of America (&#8220;U.S. GAAP&#8221;) have been condensed or omitted. These interim financial statements
should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended
December 31, 2020. The results of operations for the period ended September 30, 2021 are not necessarily indicative of the operating
results that may be expected for a full year. The condensed consolidated balance sheet as of December 31, 2020 contains financial information
taken from the audited Abeona consolidated financial statements as of that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock', window );">Uses and Sources of Liquidity</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_zEUpvfbSxsSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86A_zWLxmc3Owes7">Uses
and Sources of Liquidity</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
financial statements have been prepared on the going concern basis, which assumes the Company will have sufficient cash to pay its operating
expenses, as and when they become payable, for a period of at least 12 months from the date the financial report was issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2021, we had cash, cash equivalents and short-term investments of $<span id="xdx_907_eus-gaap--CashCashEquivalentsAndShortTermInvestments_iI_pn5n6_c20210930_zZoJmyOIxkAg">67.0
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million and net assets of $<span id="xdx_90F_eus-gaap--AssetsNet_iI_pn5n6_c20210930_zn8YIc938426">79.7
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million. For the nine months ended September
30, 2021, we had cash outflows from operations of $<span id="xdx_903_ecustom--NetCashProvidedByUsedInOperatingActivity_pn5n6_c20210101__20210930_zeSaXZywvPTc">35.4
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million. We have not generated significant product
revenues and have not achieved profitable operations. There is no assurance that profitable operations will ever be achieved, and, if
achieved, could be sustained on a continuing basis. In addition, development activities, clinical and nonclinical testing, and commercialization
of our products will require significant additional financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
are subject to a number of risks similar to other life science companies, including, but not limited to, risks related to the successful
discovery and development of product candidates, obtaining the necessary regulatory approval to market our product candidates, raising
additional capital to continue to fund our operations, development of competing drugs and therapies, protection of proprietary technology
and market acceptance of our products. As a result of these and other risks and the related uncertainties, there can be no assurance
of our future success.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Based
on our existing cash, cash equivalents and short-term investments, our ability to access additional financial resources and/or our financial
flexibility to reduce operating expenses if required, we believe that we have sufficient resources to fund operations through at least
the next 12 months. We will need to secure additional funding in the future to carry out all of our planned research and development
activities. If we are unable to obtain additional financing or generate license or product revenue, the lack of liquidity and sufficient
capital resources could have a material adverse effect on our future prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--UseOfEstimates_zy5YlErp0Wff" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_863_zfJPSrLcRyi1">Use
of Estimates</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amount of assets and disclosure of contingent assets and liabilities at the date of the consolidated financial statements
and the reported amounts of revenue and expenses during the reported period. Actual results could differ from these estimates and assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zSQ0m0O8NET8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86C_zfinpwbrcCf4">Cash
and Cash Equivalents</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. We maintain deposits
primarily in financial institutions, which may at times exceed amounts covered by insurance provided by the U.S. Federal Deposit Insurance
Corporation (&#8220;FDIC&#8221;). We have not experienced any losses related to amounts in excess of FDIC limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Short-term Investments</a></td>
<td class="text"><p id="xdx_849_eus-gaap--EquityMethodInvestmentsPolicy_zXhQvH2OjMS4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86E_ziGgthm8AcU1">Short-term
Investments</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Short-term
investments consist of investments in U.S. government, U.S. agency and U.S. treasury securities. We determine the appropriate classification
of the securities at the time they are acquired and evaluate the appropriateness of such classifications at each balance sheet date.
We classify our short-term investments as available-for-sale pursuant to Accounting Standards Codification (&#8220;ASC&#8221;) 320, <i>Investments
&#8211; Debt and Equity Securities</i>. Investments classified as current have maturities of less than one year. We review our short-term
investments for other-than-temporary impairment whenever the fair value of a marketable security is less than the amortized cost and
evidence indicates that a short-term investment&#8217;s carrying amount is not recoverable within a reasonable period of time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--LesseeLeasesPolicyTextBlock_zeDZ1lKkmWUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86E_zTvcJjVfRLBg">Leases</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">We
account for leases in accordance with ASC 842, <i>Leases</i>. Right-of-use lease assets represent our right to use an underlying asset
for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. The measurement of lease
liabilities is based on the present value of future lease payments over the lease term. As our leases do not provide an implicit rate,
we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value
of future lease payments. The right-of-use asset is based on the measurement of the lease liability and includes any lease payments made
prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. Rent expense for our
operating leases is recognized on a straight-line basis over the lease term. We do not have any leases classified as finance leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Our
leases do not have significant rent escalation, holidays, concessions, material residual value guarantees, material restrictive covenants
or contingent rent provisions. Our leases include both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease
components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component as we have elected the
practical expedient to group lease and non-lease components for all leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Most
leases include one or more options to renew. The exercise of lease renewal options is typically at our sole discretion; therefore, the
majority of renewals to extend the lease terms are not included in our right-of-use assets and lease liabilities as they are not reasonably
certain of exercise. We regularly evaluate the renewal options and when they are reasonably certain of exercise, we include the renewal
period in our lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Additional
information and disclosures required under ASC 842 are included in Note 7.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_zOdn5KLQjuTe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_862_z5DzEwHQw0c1">Restricted
Cash</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Restricted
cash, which is recorded within other assets and restricted cash in the accompanying consolidated balance sheets and is included as a
component of cash, cash equivalents and restricted cash on our consolidated statements of cash flows, consists of cash and cash equivalents
held as collateral for a corporate credit card and office space in New York. As such, the cash and cash equivalents are restricted in
use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Common Share</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zIFTyweu3N44" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86B_z9oBtVlfjEva">Loss
Per Common Share</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">We
have presented basic and diluted loss per common share on the statement of operations and comprehensive loss. Basic and diluted net loss
per share is computed by dividing net loss by the weighted-average number of shares of common stock and shares underlying &#8220;pre-funded&#8221;
warrants outstanding during the period. The &#8220;pre-funded&#8221; warrants were included in the computation of basic net loss per
share as the exercise price was negligible and the warrants were fully vested and exercisable. In October 2020, all of the <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20201031__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreFundedWarrantMember_pdd" title="Warrants converted to shares">9,017,055</span>
&#8220;pre-funded&#8221; warrants were exercised and converted into shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zIjsTejJ69Xf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">We
do not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive.
Potential dilutive securities result from outstanding stock options, restricted stock and &#8220;non-pre-funded&#8221; warrants. We did
not include the following potentially dilutive securities in the computation of diluted net loss per common share during the periods
presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B0_zGpTDclD53Ef" style="display: none">SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the three months ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">September 30,</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the nine months ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">September 30,</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zGmT3TiyFHH" style="width: 11%; text-align: right" title="Total">7,755,196</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zVPZetACBmpj" style="width: 11%; text-align: right" title="Total">6,431,183</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zZEyPRPu13fh" style="width: 11%; text-align: right" title="Total">7,755,196</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zElmds4z2HWd" style="width: 11%; text-align: right" title="Total">6,431,183</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Restricted stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z0JAkd7JW7Dk" style="border-bottom: Black 1pt solid; text-align: right" title="Total">2,989,224</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zT0Jq02nK7s9" style="border-bottom: Black 1pt solid; text-align: right" title="Total">818,233</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zNbTYrZy4096" style="border-bottom: Black 1pt solid; text-align: right" title="Total">2,989,224</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zq5ETfqCi4h9" style="border-bottom: Black 1pt solid; text-align: right" title="Total">818,233</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930_z1yadaQyohHk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">10,744,420</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200701__20200930_zk1Er6zMGrg4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">7,249,416</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930_zVBezYMakOW9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">10,744,420</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20200930_zMFXm5NhwoUc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">7,249,416</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_z4wrP32YLEKl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abeo_BackgroundPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Background [PolicyText Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abeo_BackgroundPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325112707112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zIjsTejJ69Xf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">We
do not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive.
Potential dilutive securities result from outstanding stock options, restricted stock and &#8220;non-pre-funded&#8221; warrants. We did
not include the following potentially dilutive securities in the computation of diluted net loss per common share during the periods
presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B0_zGpTDclD53Ef" style="display: none">SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the three months ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">September 30,</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the nine months ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">September 30,</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: justify">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zGmT3TiyFHH" style="width: 11%; text-align: right" title="Total">7,755,196</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zVPZetACBmpj" style="width: 11%; text-align: right" title="Total">6,431,183</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zZEyPRPu13fh" style="width: 11%; text-align: right" title="Total">7,755,196</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsMember_zElmds4z2HWd" style="width: 11%; text-align: right" title="Total">6,431,183</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Restricted stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z0JAkd7JW7Dk" style="border-bottom: Black 1pt solid; text-align: right" title="Total">2,989,224</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200701__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zT0Jq02nK7s9" style="border-bottom: Black 1pt solid; text-align: right" title="Total">818,233</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zNbTYrZy4096" style="border-bottom: Black 1pt solid; text-align: right" title="Total">2,989,224</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20200930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zq5ETfqCi4h9" style="border-bottom: Black 1pt solid; text-align: right" title="Total">818,233</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930_z1yadaQyohHk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">10,744,420</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200701__20200930_zk1Er6zMGrg4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">7,249,416</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930_zVBezYMakOW9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">10,744,420</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20200101__20200930_zMFXm5NhwoUc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">7,249,416</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325114313896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHORT-TERM INVESTMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">SCHEDULE OF AVAILABLE-FOR-SALE INVESTMENTS HELD</a></td>
<td class="text"><p id="xdx_891_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zjbZsQZKxH7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
following table summarizes the available-for-sale investments held:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B8_zHdGAqPcpEZ3" style="display: none">SCHEDULE OF AVAILABLE-FOR-SALE INVESTMENTS HELD</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">September 30,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2021</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2020</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">U.S. government and agency securities and treasuries</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20210930_zNCwvQn3mAxh" style="width: 16%; text-align: right" title="U.S. government and agency securities and treasuries">23,217,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20201231_zK0VDqxmHNC3" style="width: 16%; text-align: right" title="U.S. government and agency securities and treasuries">82,438,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325113967240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSED TECHNOLOGY (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">SCHEDULE OF LICENSED TECHNOLOGY</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_z9UE8u2a6Jt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Licensed
technology consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BB_zRs7c9dsINs1" style="display: none">SCHEDULE OF LICENSED TECHNOLOGY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210930_zSCTNABmgGdj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,&#160;2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20201231_zX6IsieNFP07" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_maFLIANzlPQ_maFLIANzW7H_zhmnavrK8gw" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 54%; text-align: left">Licensed technology</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 19%; text-align: right">2,156,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 19%; text-align: right">2,156,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pp0p0_msFLIANzlPQ_msFLIANzW7H_zLREEQbBP9F" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less accumulated amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">743,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">656,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzlPQ_mtFLIANzW7H_zauM9yRpWASd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Licensed technology, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,413,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,500,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">SCHEDULE OF AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_898_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_zTBwftYkHbEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
aggregate estimated amortization expense for intangible assets remaining as of September 30, 2021 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zfCXCDqoOfu8" style="display: none">SCHEDULE OF AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 30%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20210930_zTfOPHYYMC8e" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pp0p0_maFLIANznXj_maFLIANzM9M_zclkn8EHrLE" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: center">2021, remainder</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 44%; text-align: right">29,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_maFLIANznXj_maFLIANzM9M_zDxGELT9MVz7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_maFLIANznXj_maFLIANzM9M_zfatiQ8z2Bl3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_maFLIANznXj_maFLIANzM9M_ztFFvH6slhoi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_maFLIANznXj_maFLIANzM9M_zP3Qx12frSd1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pp0p0_maFLIANznXj_maFLIANzM9M_zNwGMsa49kYe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">916,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANznXj_mtFLIANzM9M_zvXeRMuiKVXj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,413,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325112587832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zy9jzHYcGQ7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Financial
assets and liabilities measured at fair value on a recurring and non-recurring basis as of September 30, 2021 and December 31, 2020 are
summarized below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BF_zYsdQBF3Bs2a" style="display: none">SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Description</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">September
30,&#160;2021</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Gains/(Losses)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify">Recurring</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: justify">Short-term investments</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zXgJr5COOH9" style="width: 16%; text-align: right" title="Fair value disclosure of assets">23,217,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zpKsindg2PAc" style="width: 9%; text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0778">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zCIePP4gCDDf" style="width: 9%; text-align: right" title="Fair value disclosure of assets">23,217,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zIVmJtFdC7El" style="width: 9%; text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0782">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zUmBb7HDRQJh" style="width: 9%; text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0784">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify">Non-recurring</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Licensed technology, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zCBSJxtCiGPi" style="text-align: right" title="Fair value disclosure of assets">1,413,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zh5WLLypThL8" style="text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0788">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_z8qzIY21wgv6" style="text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0790">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_z3J6Afun9Bla" style="text-align: right" title="Fair value disclosure of assets">1,413,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zB3PSIzLkd8g" style="text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0794">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zc6MiCzs9hMg" style="text-align: right" title="Fair value disclosure of assets">32,466,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zvuYGx0DK9Wl" style="text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0798">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zIl4ZPGNLQr3" style="text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0800">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zXPePTJOBhRe" style="text-align: right" title="Fair value disclosure of assets">32,466,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20210930__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zfSYe35hTNwe" style="text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0804">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify">Description</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December
31,&#160;2020</p></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total Gains/(Losses)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify">Recurring</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: justify">Short-term investments</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zcXn0nTmXfhd" style="width: 16%; text-align: right" title="Fair value disclosure of assets">82,438,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zvPylhnEA7R" style="width: 9%; text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0808">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxtpgDmCm5G2" style="width: 9%; text-align: right" title="Fair value disclosure of assets">82,438,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z5S6oy2RJ3yc" style="width: 9%; text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0812">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--ShortTermInvestmentMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zK4YcvN9FZ34" style="width: 9%; text-align: right" title="Fair value disclosure of gain loss"><span style="-sec-ix-hidden: xdx2ixbrl0814">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify">Non-recurring</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Licensed technology, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zG7TKK9dokH9" style="text-align: right" title="Fair value disclosure of assets">1,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_z5DAbHpfADdh" style="text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0818">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_z0vvxhiAfeb4" style="text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0820">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zgys0wMOkMSh" style="text-align: right" title="Fair value disclosure of assets">1,500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__custom--LicensedTechnologyNetMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_z2oOXVuHir4e" style="text-align: right" title="Fair value disclosure of gain loss">(32,916,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zSKFMXFd51y5" style="text-align: right" title="Fair value disclosure of assets">32,466,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zir2urBeFoNh" style="text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0828">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zgRfZXszhf79" style="text-align: right" title="Fair value disclosure of assets"><span style="-sec-ix-hidden: xdx2ixbrl0830">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zA6JNTPYMid5" style="text-align: right" title="Fair value disclosure of assets">32,466,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--FairValueDisclosureOfGainLoss_iI_pp0p0_c20201231__us-gaap--FairValueByAssetClassAxis__us-gaap--GoodwillMember__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zYvnQTSEOqHc" style="text-align: right" title="Fair value disclosure of gain loss"><span style="-sec-ix-hidden: xdx2ixbrl0834">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325112810440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">SCHEDULE OF STOCK BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zeNE9WAF0w2h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Stock
Options</i>: The following table summarizes stock option-based compensation for the three and nine months ended September 30, 2021 and
2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zhgHRbRE57u" style="display: none">SCHEDULE OF STOCK BASED COMPENSATION</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z5vzLZ7mMNrd" style="width: 10%; text-align: right" title="Total stock-based compensation expense">432,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zgx16oMVADmg" style="width: 10%; text-align: right" title="Total stock-based compensation expense">765,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z6T2yur6qoU7" style="width: 10%; text-align: right" title="Total stock-based compensation expense">1,649,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zTILqnMQIvWe" style="width: 10%; text-align: right" title="Total stock-based compensation expense">2,380,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_z8EfdWkayT9j" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense">955,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zDpysH7Fa4Vl" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense">484,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_z48Hk68g8Lnd" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense">2,148,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_ztcJTCgkkUW1" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense">1,703,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Stock option-based compensation expense included in operating expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_z2mv0g5X8FNb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">1,387,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_z2OI5eszwY6a" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">1,249,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_znZHQdfqMYIa" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">3,797,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_zfOM5lgJKL54" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">4,083,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF WEIGHTED-AVERAGE ASSUMPTIONS TO ESTIMATE THE FAIR VALUE OF THE OPTIONS GRANTED</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zmOzrQbauXUb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">We
used the following weighted-average assumptions to estimate the fair value of the options granted for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BE_z9vTJ4oi7gnd" style="display: none">SCHEDULE OF WEIGHTED-AVERAGE ASSUMPTIONS TO ESTIMATE THE FAIR VALUE OF THE OPTIONS GRANTED</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: justify">Expected volatility</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210701__20210930_zwSBpvi10z9f" style="width: 10%; text-align: right" title="Expected volatility">92</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200701__20200930_zutH84DKe1Mi" style="width: 10%; text-align: right" title="Expected volatility">110</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210930_zgksPcwHzgd2" style="width: 10%; text-align: right" title="Expected volatility">97</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20200930_zddY1w2hz3Pl" style="width: 10%; text-align: right" title="Expected volatility">111</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210701__20210930_zwpxsh0F6KM5" title="Expected term">6.08</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200701__20200930_zOZToGJ7e7H3" title="Expected term">6.25</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930_zPNMWKfTQKkd" title="Expected term">5.97</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200930_zQ6T4jlsWTCa" title="Expected term">6.25</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210701__20210930_zrGMKD2M4uHc" style="text-align: right" title="Risk-free interest rate">0.97</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200701__20200930_zzocRiqjppDb" style="text-align: right" title="Risk-free interest rate">0.16</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210930_zkHTCGdpEd1i" style="text-align: right" title="Risk-free interest rate">0.98</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20200930_zbStsIJzRmgh" style="text-align: right" title="Risk-free interest rate">0.29</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210701__20210930_zYCr3zL3PVPg" style="text-align: right" title="Expected dividend yield">0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200701__20200930_z5QhehHNzAtl" style="text-align: right" title="Expected dividend yield">0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20210930_zshgLyGwuMx" style="text-align: right" title="Expected dividend yield">0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20200930_zCTHltN2NDU2" style="text-align: right" title="Expected dividend yield">0</td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF OPTIONS ACTIVITY</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zcDmRQ0OZzZ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the options granted for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BA_zL7sPFqvKlN3" style="display: none">SCHEDULE OF OPTIONS ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20210701__20210930_zxi79DAfrOad" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20200701__20200930_z1Ng8gXGbdjc" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20210930_zyqD3SuDpsXa" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20200101__20200930_zk3QNXRDBFw5" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_z3d42X4ijVSa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left">Options granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">1,028,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">342,100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">4,383,308</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">3,415,146</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_zlrvW92nscca" style="vertical-align: bottom; background-color: White">
    <td>Weighted-average:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_zPFwpSYPHY5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.38</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_zqo0AiFkUskg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Grant date fair value</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.94</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.56</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.44</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.99</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">SUMMARY OF RESTRICTED COMMON STOCK</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zTBrOXitDuy" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the restricted common stock granted for the periods indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B7_zSwE6O0Yu767" style="display: none">SUMMARY OF RESTRICTED COMMON STOCK</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20210701__20210930_zW4rBtZApFic" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20200701__20200930_zOxJZK3nReA3" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20210101__20210930_zoftN5jipWK8" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20200101__20200930_z7rY7reo6kx2" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zWozfRO6RFwg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left">Restricted common stock granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">767,934</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0949">&#160;</span></td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">2,743,668</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">1,083,313</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z3j1UqswTnof" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Restricted common stock forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(293,109</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(265,080</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(721,768</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(265,080</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_pid_ziM4EbnM7LN7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted-average:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z6f30tmPXUm5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Grant date fair value-granted awards</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0964">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.77</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.19</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z6gEnYUdCMFe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Grant date fair value-forfeited awards</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.93</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.18</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.18</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">SCHEDULE OF STOCK BASED COMPENSATION</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z7qGUTPJBeii" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Restricted
Common Stock</i>: The following table summarizes restricted common stock compensation expense for the three and nine months ended September
30, 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B7_zmxOinF77W7b" style="display: none">SCHEDULE OF STOCK BASED COMPENSATION</span><span/></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zuSkkw0JBdUc" style="width: 10%; text-align: right" title="Total stock-based compensation expense">256,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zq5qyOdMmve4" style="width: 10%; text-align: right" title="Total stock-based compensation expense">89,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z16OrbGmHlif" style="width: 10%; text-align: right" title="Total stock-based compensation expense">1,286,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zW4hkk3BjaEj" style="width: 10%; text-align: right" title="Total stock-based compensation expense">561,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zH1lLNUWHBIh" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense">894,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zHOBYHR1RS2b" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense">72,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zuaZ6snBlpdi" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense">1,832,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zAA5M2f39fw7" style="border-bottom: Black 1pt solid; text-align: right" title="Total stock-based compensation expense">251,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Restricted stock-based compensation expense included in operating expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_z66az17mTZr4" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">1,150,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200701__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_zUi9HKJrfiMd" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">161,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_z5FpDiF8Dhrl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">3,118,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200101__20200930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--IncomeStatementLocationAxis__custom--StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember_zeufPMnGEovl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total stock-based compensation expense">812,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325114300728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">SCHEDULE OF COMPONENTS OF LEASE COST</a></td>
<td class="text"><p id="xdx_895_eus-gaap--LeaseCostTableTextBlock_zZpb5PcItwUe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Components
of lease cost are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B1_zBzypTUIghC3" style="display: none">SCHEDULE OF COMPONENTS OF LEASE COST</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20210701__20210930_zNujNpGJw8Df" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20200701__20200930_zNbZA6oGWHHk" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20210930_zRoqzCbnII9f" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20200101__20200930_zZeAdcvAV8tj" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the three months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the nine months ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseCost_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">434,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">434,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,302,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,302,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--VariableLeaseCost_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Variable lease cost</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">105,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">81,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">344,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">256,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShortTermLeaseCost_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Short-term lease cost</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">19,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">23,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">43,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock', window );">SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES</a></td>
<td class="text"><p id="xdx_89A_ecustom--ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_zJ0ziEhp78gl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
following table presents information about the amount and timing of cash flows arising from operating leases as of September 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B0_z8hKq46Dpxe" style="display: none">SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20210930_zrs284mKV2ca">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-bottom: 1pt"><span style="text-decoration: underline">Maturity of lease liabilities:</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPzoEX_maLOLLPzvfE_z0en0Rh81Pd9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">2021, remainder</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">429,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzvfE_zLpONmPcmVLg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,727,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzvfE_zZhc1j0uHIX2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,741,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzvfE_zJv2kQz1362l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,781,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzvfE_z0XKX1L55rJl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,799,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzvfE_z706LZog6hvi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">87,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_mtLOLLPzvfE_maOLLzUrS_zFTfFquNiLMk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total undiscounted operating lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,564,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_pp0p0_maOLLzUrS_ze4bsotDBBYc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,399,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iTI_pp0p0_zwSzgtgoBaY1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Present value of operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,165,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Balance sheet classification:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_maOLLzHBA_zakll0xG9IA2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current portion of lease liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,723,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_maOLLzHBA_z2LIdWElG2Md" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Long-term lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,442,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiability_iTI_pp0p0_mtOLLzHBA_zFwDb5tXBPUh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,165,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; text-align: left">Other information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average remaining lease term for operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20210930_zCPuYwSooGwl" title="Weighted-average remaining lease term for operating leases">52</span> months</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted-average discount rate for operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20210930_zAB7llfmxoI" title="Weighted-average discount rate for operating leases">9.6</span></td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abeo_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental cash flow information related to leases [TableTextBlock]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abeo_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325112466424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">10,744,420<span></span>
</td>
<td class="nump">7,249,416<span></span>
</td>
<td class="nump">10,744,420<span></span>
</td>
<td class="nump">7,249,416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=abeo_StockOptionsMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">7,755,196<span></span>
</td>
<td class="nump">6,431,183<span></span>
</td>
<td class="nump">7,755,196<span></span>
</td>
<td class="nump">6,431,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">2,989,224<span></span>
</td>
<td class="nump">818,233<span></span>
</td>
<td class="nump">2,989,224<span></span>
</td>
<td class="nump">818,233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=abeo_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=abeo_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325112504424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, Cash Equivalents, and Short-term Investments</a></td>
<td class="nump">$ 67.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNet', window );">Net Assets</a></td>
<td class="nump">79.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_NetCashProvidedByUsedInOperatingActivity', window );">[custom:NetCashProvidedByUsedInOperatingActivity]</a></td>
<td class="nump">$ 35.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=abeo_PreFundedWarrantMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants converted to shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,017,055<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abeo_NetCashProvidedByUsedInOperatingActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net cash provided by used in operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abeo_NetCashProvidedByUsedInOperatingActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net assets (liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77885760&amp;loc=SL35686385-199418<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 205<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118262037&amp;loc=d3e9915-115836<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874367-224272<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604008-122996<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874367-224272<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=abeo_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=abeo_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325114320136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF AVAILABLE-FOR-SALE INVESTMENTS HELD (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">U.S. government and agency securities and treasuries</a></td>
<td class="nump">$ 23,217,000<span></span>
</td>
<td class="nump">$ 82,438,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325114725080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHORT-TERM INVESTMENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost of available-for-sale debt securities</a></td>
<td class="nump">$ 23,217,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,448,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized gains or losses on sale or maturity of available-for-sale debt securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325117700456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF LICENSED TECHNOLOGY (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Licensed technology</a></td>
<td class="nump">$ 2,156,000<span></span>
</td>
<td class="nump">$ 2,156,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="nump">743,000<span></span>
</td>
<td class="nump">656,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Licensed technology, net</a></td>
<td class="nump">$ 1,413,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325197509784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2021, remainder</a></td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">117,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">117,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">117,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">117,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">916,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Licensed technology, net</a></td>
<td class="nump">$ 1,413,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325105658552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSED TECHNOLOGY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 04, 2020</div></th>
<th class="th"><div>Jul. 13, 2020</div></th>
<th class="th"><div>May 25, 2020</div></th>
<th class="th"><div>Apr. 02, 2020</div></th>
<th class="th"><div>Apr. 02, 2020</div></th>
<th class="th"><div>Nov. 04, 2018</div></th>
<th class="th"><div>May 15, 2015</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 12, 2021</div></th>
<th class="th"><div>Nov. 04, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalties payments</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to licensor current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,515,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Non-cash licensed technology impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 32,900,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 32,916,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_GainOnSettlementOfRelatedParty', window );">Gain on settlement with licensor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,743,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,743,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="nump">$ 87,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=abeo_AbeonaTherapeuticsLlcMember', window );">Abeona Therapeutics LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abeo_OriginalLicenseAgreementMember', window );">Original License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProgramRightsObligationsCurrent', window );">License to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abeo_AmendedAgreementMember', window );">Amended Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProgramRightsObligationsCurrent', window );">License to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abeo_AmendedAgreementMember', window );">Amended Agreements [Member] | April One Twenty Twenty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProgramRightsObligationsCurrent', window );">License to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=abeo_REGENXBIOMember', window );">REGENXBIO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencySettlementAgreementTerms', window );">Settlement agreement financial terms, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">we engaged REGENXBIO in discussions in an attempt to renegotiate the financial terms of the agreement, but we
were unable to reach an agreement, and we did not make the $8 million payment due by April 1, 2020. On April 17, 2020, REGENXBIO sent
us a written demand for the $8 million fee, payable within a 15-day cure period after receipt of the demand letter. The license terminated
on May 2, 2020, when the 15-day period expired. We considered the status of our discussions with REGENXBIO in March 2020 as a potential
indicator of impairment in accordance with ASC 360-10-35-21.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain loss on payments for settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=abeo_REGENXBIOMember', window );">REGENXBIO [Member] | Settlement Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SettlementLiabilitiesCurrent', window );">Settlement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=abeo_REGENXBIOMember', window );">REGENXBIO [Member] | Settlement Agreement [Member] | Subsequent Event [Member] | One Business Day [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SettlementLiabilitiesCurrent', window );">Settlement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=abeo_REGENXBIOMember', window );">REGENXBIO [Member] | Settlement Agreement [Member] | Subsequent Event [Member] | First Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SettlementLiabilitiesCurrent', window );">Settlement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=abeo_REGENXBIOMember', window );">REGENXBIO [Member] | Settlement Agreement [Member] | Subsequent Event [Member] | Third Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SettlementLiabilitiesCurrent', window );">Settlement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements [Member] | REGENXBIO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalties payments</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_PaymentForExecutionOfContracts', window );">Payment on execution of contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to licensor current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_PaymentsForMilestone', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements [Member] | REGENXBIO [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Annual fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abeo_GainOnSettlementOfRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abeo_GainOnSettlementOfRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abeo_PaymentForExecutionOfContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment on Execution of Contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abeo_PaymentForExecutionOfContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abeo_PaymentsForMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abeo_PaymentsForMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencySettlementAgreementTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the terms of a settlement agreement which resolved the legal matter, including the nature of the consideration, timing of payment, and the nature of rights obtained or lost (for example, but not limited to, patent, trademark, copyright, license and franchise rights).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencySettlementAgreementTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProgramRightsObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations related to rights to programming, including, but not limited to, feature films and episodic series, acquired under license agreements that will be paid within the next twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProgramRightsObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SettlementLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SettlementLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=abeo_AbeonaTherapeuticsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=abeo_AbeonaTherapeuticsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abeo_OriginalLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abeo_OriginalLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abeo_AmendedAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abeo_AmendedAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=abeo_AprilOneTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=abeo_AprilOneTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=abeo_REGENXBIOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=abeo_REGENXBIOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abeo_SettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abeo_SettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=abeo_OneBusinessDayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=abeo_OneBusinessDayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=abeo_FirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=abeo_FirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=abeo_ThirdAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=abeo_ThirdAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325112764600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LOAN PAYABLE (Details Narrative)<br> $ in Millions</strong></div></th>
<th class="th">
<div>May 02, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abeo_PaycheckProtectionProgramMember', window );">Paycheck Protection Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from loan</a></td>
<td class="nump">$ 1.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abeo_PaycheckProtectionProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abeo_PaycheckProtectionProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325117000648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=abeo_ShortTermInvestmentMember', window );">Short Term Investment [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value disclosure of assets</a></td>
<td class="nump">$ 23,217,000<span></span>
</td>
<td class="nump">$ 82,438,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_FairValueDisclosureOfGainLoss', window );">Fair value disclosure of gain loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=abeo_ShortTermInvestmentMember', window );">Short Term Investment [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value disclosure of assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=abeo_ShortTermInvestmentMember', window );">Short Term Investment [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value disclosure of assets</a></td>
<td class="nump">23,217,000<span></span>
</td>
<td class="nump">82,438,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=abeo_ShortTermInvestmentMember', window );">Short Term Investment [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value disclosure of assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=abeo_LicensedTechnologyNetMember', window );">Licensed Technology Net [Member] | Fair Value, Nonrecurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value disclosure of assets</a></td>
<td class="nump">1,413,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_FairValueDisclosureOfGainLoss', window );">Fair value disclosure of gain loss</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(32,916,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=abeo_LicensedTechnologyNetMember', window );">Licensed Technology Net [Member] | Fair Value, Nonrecurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value disclosure of assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=abeo_LicensedTechnologyNetMember', window );">Licensed Technology Net [Member] | Fair Value, Nonrecurring [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value disclosure of assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=abeo_LicensedTechnologyNetMember', window );">Licensed Technology Net [Member] | Fair Value, Nonrecurring [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value disclosure of assets</a></td>
<td class="nump">1,413,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_GoodwillMember', window );">Goodwill [Member] | Fair Value, Nonrecurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value disclosure of assets</a></td>
<td class="nump">32,466,000<span></span>
</td>
<td class="nump">32,466,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_FairValueDisclosureOfGainLoss', window );">Fair value disclosure of gain loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_GoodwillMember', window );">Goodwill [Member] | Fair Value, Nonrecurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value disclosure of assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_GoodwillMember', window );">Goodwill [Member] | Fair Value, Nonrecurring [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value disclosure of assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_GoodwillMember', window );">Goodwill [Member] | Fair Value, Nonrecurring [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value disclosure of assets</a></td>
<td class="nump">$ 32,466,000<span></span>
</td>
<td class="nump">$ 32,466,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abeo_FairValueDisclosureOfGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value disclosure of gain loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abeo_FairValueDisclosureOfGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=abeo_ShortTermInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=abeo_ShortTermInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=abeo_LicensedTechnologyNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=abeo_LicensedTechnologyNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325105618600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK BASED COMPENSATION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,797,000<span></span>
</td>
<td class="nump">$ 4,083,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 432,000<span></span>
</td>
<td class="nump">$ 765,000<span></span>
</td>
<td class="nump">1,649,000<span></span>
</td>
<td class="nump">2,380,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member] | Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">955,000<span></span>
</td>
<td class="nump">484,000<span></span>
</td>
<td class="nump">2,148,000<span></span>
</td>
<td class="nump">1,703,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member] | Stock Option-Based Compensation Expense Included in Operating Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,387,000<span></span>
</td>
<td class="nump">1,249,000<span></span>
</td>
<td class="nump">3,797,000<span></span>
</td>
<td class="nump">4,083,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">256,000<span></span>
</td>
<td class="nump">89,000<span></span>
</td>
<td class="nump">1,286,000<span></span>
</td>
<td class="nump">561,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">894,000<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="nump">1,832,000<span></span>
</td>
<td class="nump">251,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Stock Option-Based Compensation Expense Included in Operating Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,150,000<span></span>
</td>
<td class="nump">$ 161,000<span></span>
</td>
<td class="nump">$ 3,118,000<span></span>
</td>
<td class="nump">$ 812,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=abeo_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=abeo_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325117403272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WEIGHTED-AVERAGE ASSUMPTIONS TO ESTIMATE THE FAIR VALUE OF THE OPTIONS GRANTED (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">92.00%<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">111.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">5 years 11 months 19 days<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.97%<span></span>
</td>
<td class="nump">0.16%<span></span>
</td>
<td class="nump">0.98%<span></span>
</td>
<td class="nump">0.29%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325117890104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF OPTIONS ACTIVITY (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">1,028,000<span></span>
</td>
<td class="nump">342,100<span></span>
</td>
<td class="nump">4,383,308<span></span>
</td>
<td class="nump">3,415,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-average:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="nump">$ 3.08<span></span>
</td>
<td class="nump">$ 1.86<span></span>
</td>
<td class="nump">$ 2.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="nump">$ 0.94<span></span>
</td>
<td class="nump">$ 2.56<span></span>
</td>
<td class="nump">$ 1.44<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325114802312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF RESTRICTED COMMON STOCK (Details) - Restricted Stock [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted common stock granted</a></td>
<td class="nump">767,934<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,743,668<span></span>
</td>
<td class="nump">1,083,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted common stock forfeited</a></td>
<td class="num">(293,109)<span></span>
</td>
<td class="num">(265,080)<span></span>
</td>
<td class="num">(721,768)<span></span>
</td>
<td class="num">(265,080)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-average:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value-granted awards</a></td>
<td class="nump">$ 1.24<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1.77<span></span>
</td>
<td class="nump">$ 3.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Grant date fair value-forfeited awards</a></td>
<td class="nump">$ 1.93<span></span>
</td>
<td class="nump">$ 3.18<span></span>
</td>
<td class="nump">$ 1.90<span></span>
</td>
<td class="nump">$ 3.18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325117662456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF COMPONENTS OF LEASE COST (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 434,000<span></span>
</td>
<td class="nump">$ 434,000<span></span>
</td>
<td class="nump">$ 1,302,000<span></span>
</td>
<td class="nump">$ 1,302,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">105,000<span></span>
</td>
<td class="nump">81,000<span></span>
</td>
<td class="nump">344,000<span></span>
</td>
<td class="nump">256,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325116916680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021, remainder</a></td>
<td class="nump">$ 429,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">1,727,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">1,741,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">1,781,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">1,799,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">Thereafter</a></td>
<td class="nump">87,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted operating lease payments</a></td>
<td class="nump">7,564,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">1,399,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">6,165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,723,000<span></span>
</td>
<td class="nump">$ 1,713,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liability</a></td>
<td class="nump">$ 4,442,000<span></span>
</td>
<td class="nump">$ 5,260,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term for operating leases</a></td>
<td class="text">52 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate for operating leases</a></td>
<td class="nump">9.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140325105587432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 13, 2020</div></th>
<th class="th"><div>May 25, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Nov. 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abeo_GainOnSettlementOfRelatedParty', window );">[custom:GainOnSettlementOfRelatedParty]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,743,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,743,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=abeo_REGENXBIOMember', window );">REGENXBIO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain loss on payments for settlement</a></td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=abeo_REGENXBIOMember', window );">REGENXBIO [Member] | Subsequent Event [Member] | Settlement Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SettlementLiabilitiesCurrent', window );">Settlement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=abeo_REGENXBIOMember', window );">REGENXBIO [Member] | Subsequent Event [Member] | Settlement Agreement [Member] | One Business Day [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SettlementLiabilitiesCurrent', window );">Settlement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=abeo_REGENXBIOMember', window );">REGENXBIO [Member] | Subsequent Event [Member] | Settlement Agreement [Member] | First Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SettlementLiabilitiesCurrent', window );">Settlement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=abeo_REGENXBIOMember', window );">REGENXBIO [Member] | Subsequent Event [Member] | Settlement Agreement [Member] | Third Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SettlementLiabilitiesCurrent', window );">Settlement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abeo_GainOnSettlementOfRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abeo_GainOnSettlementOfRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abeo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SettlementLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SettlementLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=abeo_REGENXBIOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=abeo_REGENXBIOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abeo_SettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abeo_SettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=abeo_OneBusinessDayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=abeo_OneBusinessDayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=abeo_FirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=abeo_FirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=abeo_ThirdAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=abeo_ThirdAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>51
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M5?NXHT2[8 3T]UO.U>N+N?4^_9=C]1]02P,$%     @ $'AO4V7.)Q)V @
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M" (GQ07L5I6 (LL;>89RZ=M+)AHA&[<[_%.X?&3$V3-$/.9R+S>I6V^^J;0
ME[K9^,I<I7!8Y960:R>3@9V7K1\G",SWL?6)X1"2D*@LI/TK<R\DZ>AQ)'2]
M&<UYA'2&&%N)"!!:,[+S8T@_]+#4$22+CGT>Y[X7OM2M?'\7&A:3PKMQ:"GW
M\\@+[+XY09',QY)&D*#B1EC6"#2$KNW8B_>2E[HU[S57>=JJ_;Q8F\.^(8'
MYD2@ZDO3ID'YX)70>HX.A^6]]+HSS<,?/64(MXI/Z4%AP2DS*"H*>EC9*V'J
MEL*?FALE((-O8)=>"%*MRSN@1,Z/6%%$KK72P%Y>+<A//\2,TE_,3=4QI2AY
MMHQ-HB3QH#&<$H8@642#)/9/.4.0(1O%84Q/><-\CI+ ]Y,>ZO8RFB;.T^A[
MO6QKY^!2J.V@PQ>FM,Y<QU2VUY#,K2$G2UXMC&>RKFK!B_P;S-8"E(5JPPAU
M1FI1--=76L(\\KPP>^0Y[)'GBL-FF8D[#1HD7=>YSG$9VHTA/.GO)Q.$H,[I
ML5#NKG=P=Z?+'8/U=SBVUY[,K3U?RQK*NB*0<2VJ])[ X;9217?>R_Y9*]W<
M\:%,('K0/L)/W"-X@F)X7+S9,\0[)G,O8IE;Q![?>O9M')V3DXUCA*AX%.DC
MN\$40YJ-PW8ZPZ"P5\>)74W#@TOC4L!1U]S6*UC'ZTJW=X*[I[M?!%XU]^ G
MSZ_IQ80BSZ?T8M;>]^_=MS\_O(.3-:Q;4H@YA(+V#;->MS?Z[0<M5\V5]9W4
M6I;-VZ7@F:@- +Z?2ZD?/I@ N]]5QO\"4$L#!!0    ( !!X;U-!"G>A$@D
M '-!   8    >&PO=V]R:W-H965T<R]S:&5E=#4N>&ULM5QM;]LX$OXK@G'
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M'XNB_GG1O.1^_#L+=_\'4$L#!!0    ( !!X;U,Q8Q)-J <  "LD   8
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MM]=:O1!MI4&;_=!$OUD-\9*5391'H^%;">O,[5Q5.1R[R E\JE4A<V[@XM'
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M%\=P7<+M9['G Z@7S,VB>(HXX<J-WU"@<R\Z@A;Z&=JWD[JQDX"V<]=8K<;
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ME74@^UI*<Q!L@N:O8_('4$L#!!0    ( !!X;U- $SYN 0D   D4   8
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&ULI5AM;]LX$O[N7S'P%8==P'4L.TF3
M-@F@O+3U(76".NWNWN$^T!)C\2J)*DG%]?[Z?8:49*5)NQ\.31.1$N?EF9EG
M1CK9://%9E(Z^E;DI3T=9LY5K_?V;)+)0MBQKF2)._?:%,)A:=9[MC)2I/Y0
MD>]-)Y/#O4*H<GAVXO=NS=F)KEVN2GEKR-9%(<SV7.9Z<SJ,ANW&1[7.'&_L
MG9U48BV7TGVJ;@U6>YV45!6RM$J79.3]Z3".7I_O\_/^@<]*;FSOFMB3E=9?
M>#%/3X<3-DCF,G$L0>#/@[R0><Z"8,;71N:P4\D'^]>M]+?>=_BR$E9>Z/PW
ME;KL='@TI%3>BSIW'_7FO6S\.6!YB<ZM_TV;\.S!;$A);9TNFL.PH%!E^"N^
M-3CT#AQ-?G!@VAR8>KN#(F_EI7#B[,3H#1E^&M+XPKOJ3\,X57)0EL[@KL(Y
M=W8]O[A:+*\NZ>[JXOWBYOKFW1\G>PZ"^?9>T@@Y#T*F/Q!R3!]TZ3)+5V4J
MT\?G]V!09]6TM>I\^E.!2UF-:389T70RC7XB;]9Y.?/R9C^0]T[K=*/RG$29
MTKQTHERK52XIME8Z2Y?*)KFVM9'TGWAEG4&N_/<G:O<[M?M>[?[_!^Y/A7!5
MOK:52.3I$&5GI7F0P[/%S=W58$;__,?1-(K>T#.*Z*8<+/2#+%;2T#XC&1V-
M:"-)EDX:F9(JG29!N4I08I+$VDB):G-(0)?1QZMW5XO?S^<W@"L9TR^L:3IY
MTVW[=?3F5X(0O7*H?C)< )8W1$GR6Y+7%@4W0%7F #^5G:I?;+WZ'ZJ2'TVD
M\8=+7;[LSK2BX.^#TK7-M[0V G:G!!JB#[=+FL_G\:^C8.M.,00W2D:\?&1M
M].J-'2SBSQ3'GX_I ?HABL6M92G)9=*(2DGKMQSXS:ERW:D:M5?G([JX7D2<
M,E(P;$@H;,S:C3%=:#!6"FF>=;RTK/.H<6-0HU#"#8T[JA1Y+P"J! XI.RLE
MN^5$SK:\H.AH@CA2U/SXQ>&$///05@IC^<:,CBC"?]STOVZ-8B,TJQO$E5$Y
M1;ZR)J OD7*^-8FQ!@VGO= C+BE*H[9,P9:7B*QP3A:5#YX!<FOME' >0+J'
M(V6BX Q2K+"D[_UVY]F(5C7R"SF!#*2Z%%R#7HY(,B][]R0#"Z-2E2(W'"CO
M2]#QX@@TF.>,;26V'J^TEK3:TB/7QLC_=N=5V!KU/+,X-Z@M\G]C%!R"HVAV
M9=K%JZ<&41BQ+F\M)QSC0-'!RU1L0='PI)* ."5Q#[?A3"(5\&F<;^3F$EK,
MF.ZR71TP2$",\P%J/D#:M+5TD\$D/MZH:33(;Y5"[8[I-TE)DV>(&#]HG7"U
MAUS7YE'8OJMGQ:H,\/89(!B#2@,!A#$?J#)5B>#*@"!55$*9)B71/Q-M4L0W
M@$#Q\H)FAY.7T>3E[.#E- )A3\?'#+OWY*!Q!;%&7N2PDN-K5LHUE9'D0A5!
M%-L?%W QP3-Q[QGPLT8^^>N6@N(X[LA'Y+E<<VVX3+B>C^C6D(:[6UKYY +$
MKH?\KM:JKCB:8/A1 0&S4GZ!9"1BH:% ,T$0QWYML8>PPO[&2J_< PE^QC3
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M\W-G-GXZ0(+53MK!2KJ-;-IJ)4!^TC:C5J!!'&.:8Q4 ! 9ZGNSC#\B^"W)
M6R2A&N=/NR2+?<X)WQ>]OSYSP?<]3T2@?4Z&%W@-XB'N /\.QZ_\?TSVW&(C
MWV+Y-XM*OM8\&E"\DKH4/&=@GI6U4XFEZ^N+4<-//G][X_EN&,F,KM<9+;RO
M?EZ_R%2> L.NH-]K6RDVK!TFS]'](X^+OYS"#^>[*JK\7F-Z:@A//N#MO_(P
M\V0=6EOH<P@#+SQ82U$R[X$D:+DM4Z-1/G?;"AW+Z_"7YX]G*&4':- (YI]<
M\@\-4^7J7K:EU#Z))7"\#BN, S+)2IWK]39,4F@?[0E8GNL-K'U-RXOW5Y>?
MKJ_HYNUS+UF#73]KWU9WI#-K1M%!JY-Z.M'.1]'!X6B"*;YW/;B6UG(2U46=
M\V1(C7<A U_MS_R)P_;IIY)'5*(@\:XPVH]FC?AH=#"9^&M -Q!KI-V:LQ?5
MK(JG6C!E>L0X0&KWLBS"RS(J!"]LO@M[Q)Z! %S"%.YAM(]!C#_<?+R;_SN^
MF]\LZ.KW6T:4WMY\I/GB+EZ\FY_CL7BYO+I;-I--4,<MZ 73.'O-_$(1QOIF
M,>LO]ON+@V[!]2##@'X<!?#N?(WUD8I[*/!(GC\3.*:\UA(Z\L*IB4HTWJ?G
MOAKL]3[/H FL_4<H&R:;\*6FV^V^<\7A\\[N\?"1#"2+OF#Q.G&/HY/QJX-A
M>+5L%TY7_F//2F-$*OPEIAC QP_@_KW&K-\L6$'W]>_L+U!+ P04    "  0
M>&]3&1C=(3 "  "M!   &0   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6R=
M5$V/VC 0O>^O&%D]MB0$MDL1B00+52LM"UKZH:KJP20#L=:Q4]O9P+]?VPDI
ME0J'7F+/>-[SF\F,)[54SSI'-' HN- QR8TIQT&@TQP+JGNR1&%/=E(5U%A3
M[0-=*J29!Q4\B,+P?5!0)D@R\;ZU2B:R,IP)7"O055%0=9PAEW5,^N3D>&+[
MW#A'D$Q*NL<-FJ_E6EDKZ%@R5J#03 I0N(O)M#^>#5V\#_C&L-9G>W"9;*5\
M=L;G+":A$X0<4^,8J%U>\!XY=T16QN^6DW17.N#Y_L3^T>=N<]E2C?>2?V>9
MR6,R(I#ACE;</,GZ$[;YW#J^5'+MOU WL=$=@;321A8MV"HHF&A6>FCK< 88
MA1< 40N(O.[F(J]R3@U-)DK6H%RT97,;GZI'6W%,N)^R,<J>,HLSR<-J^@CK
MZ8_I[&$Q"8QE=/X@;=&S!AU=0'^ I10FU[ 0&69_XP.KI),3G>3,HJN$&RQ[
M, C?0A1&_2M\@RZ]@><;7.";X]; G.F42UTIA)_3K3;*ML*O*^3#CGSHR8?_
M6;NK:#=M8UW2%&-BQTFC>D&2/*Z^+&Z&\ [.N6$E;I;T")$OBRU.C78>4K3M
MG &75$"I9(J8:6 "3(Y "UD) W('M+1G!V;;%_D1WD"_-X)_I1Z<M5"!:N\'
M14/J>)INZKS=+$Z;%OP3W@SRDJH]$QHX[BPT[-W=$E#-<#2&D:5OR*TTMKW]
M-K?O"2H78,]W4IJ3X2[H7JCD%5!+ P04    "  0>&]3EGACV;H&  ![$
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6RU6%UOVSH2?=>O('PO+EK
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M$,8U[;>#R&7:N<0"M<BL#I%2<4B.'U<YQ/U*-(Q">_7;7AA9RFL/W<"*6]^
MLKZITR)1.76[4MB&@5^91I!%DFW8+%D0-_(.Q7+WE,$%T7 'U-\!#=K#N%DG
M%)'=%;Z@@Z61U$_0>F\AI(9'D6T0U )0D$\J2""V0J= !+.ES$\,2\I7 YN2
M(?#Z62:2A\XL6:D,RT:2U54VY"K%K$N;,C-WT40M"_F[O74J75;S.RC*U[U"
M;A#WV=,!%'8^]\ .9S (8[2\WU0HT*P4F?*(5<9P$LL$@9PI5>K\M*P"2=KX
MZ2/[AW163W_NPOR%G=8L#HS2:T5(:,GZ4F5TR+"L*.F4J;+^R/GQNW@PC#_
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M,].AQT%EN!4:!<8MP !=//(]"UW:];QD=>^DNKF#ZS+%[F/<6)1RF7G(G%<
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M["F1,)]YHL!'^1^5BE6S"I,8LK3$P!<*HP'[VV= OA6N#6M6:FHEDE:@T$
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M%@Y8"/BC$0P-LHU*N<[\56ZO*3&^JHRZ;_1B[ '45EVY1LU)=FRXOUZ-1_%
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M(03B_&30$6'@;663\'1F.%^]2&LU.):*E'+HF<++JSG7H+4_%.47/4P^47+
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M,BJK0/<;2:UV/%@'S3,_^A=02P,$%     @ $'AO4Z(-IW6J @  C@4  !D
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M.)(OX!GP%G1=PZ?G*%*'MWM.R44"=D=S\6'TH-=!)J(:DRA_;L_)V C=AC5
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MSV!4=3A[!*!'4=?>V<:H,<L+V!+LVHIT'(5@W3LAO;?M0-XS"Z$"]IZV&]6
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MY['K]((@T&(\'Q;QO6'/"P:!VWUK%UU*B#XG?)-II\VT<S;31++T"6:EUE;
M]RG)'PD_)V&W)>[^3)7MM6'UOE;9WGM]>YV..S@J6/C>KAOXKMOWCPI[(1_Z
MG.]-GOTVS_[9/!=$2$Y3J82N2WQ!:0<M]^!G*JWK_+B"G*\5M\$=JNP-^@//
M"XZJ>\*P[_8]_[BZEQ*BSPGK7.V#FS<G?&M:'@$IJPI9'Z?M:MM634PS<;1^
MXUZ'[HGU2+=AYJ;_05_W<%/,MU3]_!G9*%?.54\%R^NVJ)Y(5II[_Y%)U468
MX4ZUDH1K _5]PYA\G6@';7,Z_@]02P,$%     @ $'AO4P4H<4DC P  U <
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M ?0/@+XU6BNSMFZ)(O.IX'L09K6.9AIV;RQ:NZ',G&*LA)ZE&J?FD?^X?EC
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MZ<RRS4P_NRC, CV_X5R]=PQ!\Y#/_P!02P,$%     @ $'AO4R@X!AE" @
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MHY+!^26QTH7W%1M42^<&4X7D+6ZYH,\%:)M [V=*X79C&U0?H,Y?4$L#!!0
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M9[)D[$5/QDG/<G1 0"&6V@-6GQT,@%+M2(7QI_1I54@M/!R_>[\SN:M<EEC
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M NQYJ6Q?.\>-6?^32/\"4$L#!!0    ( !!X;U-*AFY[E@0  &P?   9
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M=4_?/V%#07R6%,2&@KAP"MH5CVB4 H2VJ\[]E+0S],/;Z*#-%#8@Q6<)4FQ
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MJB>XSXK;J&+"Z3:_;EE0SFF2#S<$AX1)@'B^HI0?)C) =2<X^@=02P,$%
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M,;,A-,5<=.G68#D%'"I0FABV:7:,%,>9-AJHL24=#<B.)W$&2XK8+DTQ?9U
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MC FOTC4F<F5!64R$'+*ER=<,2:!!<60ZEM4P8Q(F1J^CYZY9KT,W(@H3O&;
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MO_0E$2(#,*M' %8"L/X'V$< =@*PRUJH)H!J64 M =3* NH)H%X6T$@ C;*
M9@)H1M&-PQ'%LD<E[;0XVQ.N=B.;&D0)$:$QA(ZO<G<N.:XZB).=[G0\'MV-
M^Y.[.;F:]$AW.KD;30;]27?4GY.S'DCJN(),*.=49=DY^4'NYSUR]NV\I4MT
M0-'HR\38=6S,.F+L9^A6B&E_)Y9A&3GP;C%\3 _$JAU%]XK1<P@JQ#8BN)D#
M[Y>'YUF_.<WZX#3KPV+XA.U0>"O/NHX)DV:-E6:-%?%5C_ ]Q)EY.<#B./6Q
MP$D7L*#)Z?H67"IA-:-<'A[S@A03UR-B55AWG7JC:AL&GFJ7C4:A ZJB7XJ
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M_FO.\HL51Q?_2G+S7^50L%=C>\2]=I'G;T%D_!9$OLZ>#-MC9^=LVSO9>FL
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MNCW/RGRC2+\97_:OKOM)]OZQ+'W=%M=!DQ6GM?;3_P2?_P%02P,$%     @
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MZ\;MA^7SYN0;'W"V<.:[_P502P,$%     @ $'AO4^N(NN65 0  @A8  !,
M  !;0V]N=&5N=%]4>7!E<UTN>&ULS9C-;L(P$(1?)<H5$6.[I3\"+FVO+8>^
M@)ML2$026[:A\/9UPH_4BD8@*G4NL1+OSHR]TG?(Y'UKR$6;NFK<-"Z\-X^,
MN;2@6KE$&VK"3JYMK7QXM0MF5+I4"V)B-!JS5#>>&C_TK48\FSQ3KE:5CUXV
MX;,K=3.-+54NCIYVA:W7-%;&5&6J?-AGZR;[X3+<.R2ALZMQ16G<(!3$[*1#
MN_.[P;[O;4W6EAE%<V7]JZI#%=M4S/EM12[IESB14>=YF5*FTU4=6A)G+*G,
M%42^KI*=Z*#?V8<;IMV37^W?R?09ALJYU<:%B5FZW.XPDK9[:((065_V'_'H
M&*2O/A^UT\XH.],[7.^GMLMN'HYUR_5W_'W&1_T+<PB0'!(DQPU(CEN0'&.0
M''<@.>Y!<CR Y. CE" H1.4H2.4H3.4H4.4H5.4H6.4H7.4H8.4H9!4H9!4H
M9!4H9!4H9!4H9!4H9!4H9!4H9!4H9!4H9)4H9)4H9)4H9)4H9)4H9)4H9)7_
M2=8/K9=__5>T79-:E<W!GW6_GF=?4$L! A0#%     @ $'AO4P=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    "  0>&]3K<7GJNX    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    "  0>&]3F5R<(Q &  "<)P  $P
M        @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( !!X
M;U.VL6KA2P4   06   8              " @0T(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    "  0>&]3(2-%_0,&  #Q&   &
M        @(&.#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%
M  @ $'AO4V7.)Q)V @  G08  !@              ("!QQ,  'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( !!X;U-QU=!-%@8  &,9   8
M              " @7,6  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"
M% ,4    "  0>&]300IWH1()  !S00  &               @(&_'   >&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ $'AO4S%C$DVH!P
M*R0  !@              ("!!R8  'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+ 0(4 Q0    ( !!X;U/FHM3(S \  )$G   8              " @>4M
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  0>&]3ML$I
M _P"  !&!@  &               @('G/0  >&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L! A0#%     @ $'AO4T 3/FX!"0  "10  !@
M ("!&4$  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( !!X
M;U,9&-TA, (  *T$   9              " @5!*  !X;"]W;W)K<VAE971S
M+W-H965T,3 N>&UL4$L! A0#%     @ $'AO4Y9X8]FZ!@  >Q   !D
M         ("!MTP  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
M    "  0>&]3^ASZ5N(&   X$@  &0              @(&H4P  >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( !!X;U-:$),%*0@  )H2
M   9              " @<%:  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL
M4$L! A0#%     @ $'AO4S2T*'6 $   &RP  !D              ("!(6,
M 'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  0>&]3]\3>
MVK<#  #R!P  &0              @('8<P  >&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+ 0(4 Q0    ( !!X;U.B#:=UJ@(  (X%   9
M  " @<9W  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @
M$'AO4PQ)*,XM P  8@<  !D              ("!IWH  'AL+W=O<FMS:&5E
M=',O<VAE970Q-RYX;6Q02P$"% ,4    "  0>&]3A^LNADX#  #E!P  &0
M            @($+?@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4
M Q0    ( !!X;U.9.G/E; 4  !H1   9              " @9"!  !X;"]W
M;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ $'AO4X??/W,C!
MT0D  !D              ("!,X<  'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"% ,4    "  0>&]3XY37%SD#  "H"@  &0              @(&-
MBP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( !!X;U,%
M*'%)(P,  -0'   9              " @?V.  !X;"]W;W)K<VAE971S+W-H
M965T,C(N>&UL4$L! A0#%     @ $'AO4R@X!AE" @  K@0  !D
M     ("!5Y(  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !!X;U, O&W8#P(  # $   9              "
M@4ZE  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ $'AO
M4TJ&;GN6!   ;!\  !D              ("!E*<  'AL+W=O<FMS:&5E=',O
M<VAE970R.2YX;6Q02P$"% ,4    "  0>&]3 * WV#<$   ?%   &0
M        @(%AK   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0
M   ( !!X;U-\0"BN(P,  -X*   9              " @<^P  !X;"]W;W)K
M<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ $'AO4T6M>'WX @  S0@
M !D              ("!*;0  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q0
M2P$"% ,4    "  0>&]395=L+EX#  """@  &0              @(%8MP
M>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( !!X;U-VAU3<
MS0(  (T(   9              " @>VZ  !X;"]W;W)K<VAE971S+W-H965T
M,S0N>&UL4$L! A0#%     @ $'AO4R17C\-^ P  '0L  !D
M ("!\;T  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  0
M>&]32@S-@$4#  "$#   &0              @(&FP0  >&PO=V]R:W-H965T
M<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( !!X;U,.8)5M&@,  &81   -
M          "  2+%  !X;"]S='EL97,N>&UL4$L! A0#%     @ $'AO4Y>*
MNQS     $P(   L              ( !9\@  %]R96QS+RYR96QS4$L! A0#
M%     @ $'AO4[G=@<;) P  JQ@   \              ( !4,D  'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( !!X;U/6^OFQ> $   ,6   :
M      "  4;-  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( !!X;U/KB+KEE0$  ((6   3              "  ?;.  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     L "P ZPL  +S0      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>134</ContextCount>
  <ElementCount>267</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>33</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPolicies</Role>
      <ShortName>NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - SHORT-TERM INVESTMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/Short-termInvestments</Role>
      <ShortName>SHORT-TERM INVESTMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - LICENSED TECHNOLOGY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/LicensedTechnology</Role>
      <ShortName>LICENSED TECHNOLOGY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - LOAN PAYABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/LoanPayable</Role>
      <ShortName>LOAN PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/FairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/Stock-basedCompensation</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesPolicies</Role>
      <ShortName>NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesTables</Role>
      <ShortName>NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - SHORT-TERM INVESTMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/Short-termInvestmentsTables</Role>
      <ShortName>SHORT-TERM INVESTMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/Short-termInvestments</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - LICENSED TECHNOLOGY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/LicensedTechnologyTables</Role>
      <ShortName>LICENSED TECHNOLOGY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/LicensedTechnology</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/FairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/FairValueMeasurements</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/Stock-basedCompensationTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/Stock-basedCompensation</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - SCHEDULE OF AVAILABLE-FOR-SALE INVESTMENTS HELD (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfAvailable-for-saleInvestmentsHeldDetails</Role>
      <ShortName>SCHEDULE OF AVAILABLE-FOR-SALE INVESTMENTS HELD (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - SHORT-TERM INVESTMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/Short-termInvestmentsDetailsNarrative</Role>
      <ShortName>SHORT-TERM INVESTMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/Short-termInvestmentsTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - SCHEDULE OF LICENSED TECHNOLOGY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfLicensedTechnologyDetails</Role>
      <ShortName>SCHEDULE OF LICENSED TECHNOLOGY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfAmortizationExpenseForIntangibleAssetsDetails</Role>
      <ShortName>SCHEDULE OF AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - LICENSED TECHNOLOGY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative</Role>
      <ShortName>LICENSED TECHNOLOGY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/LicensedTechnologyTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - LOAN PAYABLE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/LoanPayableDetailsNarrative</Role>
      <ShortName>LOAN PAYABLE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/LoanPayable</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails</Role>
      <ShortName>SCHEDULE OF STOCK BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - SCHEDULE OF WEIGHTED-AVERAGE ASSUMPTIONS TO ESTIMATE THE FAIR VALUE OF THE OPTIONS GRANTED (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfWeighted-averageAssumptionsToEstimateFairValueOfOptionsGrantedDetails</Role>
      <ShortName>SCHEDULE OF WEIGHTED-AVERAGE ASSUMPTIONS TO ESTIMATE THE FAIR VALUE OF THE OPTIONS GRANTED (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - SCHEDULE OF OPTIONS ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfOptionsActivityDetails</Role>
      <ShortName>SCHEDULE OF OPTIONS ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - SUMMARY OF RESTRICTED COMMON STOCK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/SummaryOfRestrictedCommonStockDetails</Role>
      <ShortName>SUMMARY OF RESTRICTED COMMON STOCK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - SCHEDULE OF COMPONENTS OF LEASE COST (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails</Role>
      <ShortName>SCHEDULE OF COMPONENTS OF LEASE COST (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails</Role>
      <ShortName>SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://abeonatherapeutics.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="form10-q.htm">form10-q.htm</File>
    <File>abeo-20210930.xsd</File>
    <File>abeo-20210930_cal.xml</File>
    <File>abeo-20210930_def.xml</File>
    <File>abeo-20210930_lab.xml</File>
    <File>abeo-20210930_pre.xml</File>
    <File>ex10-1.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10q_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>56
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10-q.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "contextCount": 134,
   "dts": {
    "calculationLink": {
     "local": [
      "abeo-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "abeo-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "abeo-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abeo-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "abeo-20210930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 332,
   "entityCount": 1,
   "hidden": {
    "http://abeonatherapeutics.com/20210930": 23,
    "http://fasb.org/us-gaap/2021-01-31": 98,
    "http://xbrl.sec.gov/dei/2021": 4,
    "total": 125
   },
   "keyCustom": 18,
   "keyStandard": 249,
   "memberCustom": 15,
   "memberStandard": 17,
   "nsprefix": "abeo",
   "nsuri": "http://abeonatherapeutics.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://abeonatherapeutics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - LOAN PAYABLE",
     "role": "http://abeonatherapeutics.com/role/LoanPayable",
     "shortName": "LOAN PAYABLE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - FAIR VALUE MEASUREMENTS",
     "role": "http://abeonatherapeutics.com/role/FairValueMeasurements",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://abeonatherapeutics.com/role/Stock-basedCompensation",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://abeonatherapeutics.com/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abeo:BackgroundPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesPolicies",
     "shortName": "NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abeo:BackgroundPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesTables",
     "shortName": "NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - SHORT-TERM INVESTMENTS (Tables)",
     "role": "http://abeonatherapeutics.com/role/Short-termInvestmentsTables",
     "shortName": "SHORT-TERM INVESTMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - LICENSED TECHNOLOGY (Tables)",
     "role": "http://abeonatherapeutics.com/role/LicensedTechnologyTables",
     "shortName": "LICENSED TECHNOLOGY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "role": "http://abeonatherapeutics.com/role/FairValueMeasurementsTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "role": "http://abeonatherapeutics.com/role/Stock-basedCompensationTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://abeonatherapeutics.com/role/BalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "role": "http://abeonatherapeutics.com/role/CommitmentsAndContingenciesTables",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-07-012021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)",
     "role": "http://abeonatherapeutics.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "shortName": "SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-07-012021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "role": "http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - SCHEDULE OF AVAILABLE-FOR-SALE INVESTMENTS HELD (Details)",
     "role": "http://abeonatherapeutics.com/role/ScheduleOfAvailable-for-saleInvestmentsHeldDetails",
     "shortName": "SCHEDULE OF AVAILABLE-FOR-SALE INVESTMENTS HELD (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - SHORT-TERM INVESTMENTS (Details Narrative)",
     "role": "http://abeonatherapeutics.com/role/Short-termInvestmentsDetailsNarrative",
     "shortName": "SHORT-TERM INVESTMENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - SCHEDULE OF LICENSED TECHNOLOGY (Details)",
     "role": "http://abeonatherapeutics.com/role/ScheduleOfLicensedTechnologyDetails",
     "shortName": "SCHEDULE OF LICENSED TECHNOLOGY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - SCHEDULE OF AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS (Details)",
     "role": "http://abeonatherapeutics.com/role/ScheduleOfAmortizationExpenseForIntangibleAssetsDetails",
     "shortName": "SCHEDULE OF AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2020-11-032020-11-04",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsForRoyalties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - LICENSED TECHNOLOGY (Details Narrative)",
     "role": "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative",
     "shortName": "LICENSED TECHNOLOGY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2020-11-032020-11-04",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsForRoyalties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2020-05-012020-05-02_custom_PaycheckProtectionProgramMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromNotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - LOAN PAYABLE (Details Narrative)",
     "role": "http://abeonatherapeutics.com/role/LoanPayableDetailsNarrative",
     "shortName": "LOAN PAYABLE (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2020-05-012020-05-02_custom_PaycheckProtectionProgramMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromNotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-09-30_custom_ShortTermInvestmentMember_us-gaap_FairValueMeasurementsRecurringMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS (Details)",
     "role": "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails",
     "shortName": "SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-09-30_custom_ShortTermInvestmentMember_us-gaap_FairValueMeasurementsRecurringMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://abeonatherapeutics.com/role/BalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION (Details)",
     "role": "http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails",
     "shortName": "SCHEDULE OF STOCK BASED COMPENSATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-07-012021-09-30_us-gaap_EmployeeStockOptionMember_us-gaap_ResearchAndDevelopmentExpenseMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-07-012021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - SCHEDULE OF WEIGHTED-AVERAGE ASSUMPTIONS TO ESTIMATE THE FAIR VALUE OF THE OPTIONS GRANTED (Details)",
     "role": "http://abeonatherapeutics.com/role/ScheduleOfWeighted-averageAssumptionsToEstimateFairValueOfOptionsGrantedDetails",
     "shortName": "SCHEDULE OF WEIGHTED-AVERAGE ASSUMPTIONS TO ESTIMATE THE FAIR VALUE OF THE OPTIONS GRANTED (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-07-012021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-07-012021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - SCHEDULE OF OPTIONS ACTIVITY (Details)",
     "role": "http://abeonatherapeutics.com/role/ScheduleOfOptionsActivityDetails",
     "shortName": "SCHEDULE OF OPTIONS ACTIVITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-07-012021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-07-012021-09-30_us-gaap_RestrictedStockMember16575765",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - SUMMARY OF RESTRICTED COMMON STOCK (Details)",
     "role": "http://abeonatherapeutics.com/role/SummaryOfRestrictedCommonStockDetails",
     "shortName": "SUMMARY OF RESTRICTED COMMON STOCK (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-07-012021-09-30_us-gaap_RestrictedStockMember16575765",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-07-012021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - SCHEDULE OF COMPONENTS OF LEASE COST (Details)",
     "role": "http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails",
     "shortName": "SCHEDULE OF COMPONENTS OF LEASE COST (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-07-012021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "abeo:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES (Details)",
     "role": "http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails",
     "shortName": "SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "abeo:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-07-012021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "abeo:GainOnSettlementOfRelatedParty",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "role": "http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2020-07-012020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "role": "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2020-07-012020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "role": "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-07-012021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://abeonatherapeutics.com/role/StatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2020-01-012020-09-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:InterestExpenseOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPolicies",
     "shortName": "NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - SHORT-TERM INVESTMENTS",
     "role": "http://abeonatherapeutics.com/role/Short-termInvestments",
     "shortName": "SHORT-TERM INVESTMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - LICENSED TECHNOLOGY",
     "role": "http://abeonatherapeutics.com/role/LicensedTechnology",
     "shortName": "LICENSED TECHNOLOGY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 33,
   "tag": {
    "abeo_AbeonaTherapeuticsLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Abeona Therapeutics Llc [Member]",
        "label": "Abeona Therapeutics LLC [Member]"
       }
      }
     },
     "localname": "AbeonaTherapeuticsLlcMember",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "abeo_AccretionAndInterestOnShorttermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion and interest on short term investments.",
        "label": "AccretionAndInterestOnShorttermInvestments",
        "negatedLabel": "Accretion and interest on short-term investments"
       }
      }
     },
     "localname": "AccretionAndInterestOnShorttermInvestments",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abeo_AllocatedShareBasedCompensationExpenseRestrictedStock": {
     "auth_ref": [],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allocated share based compensation expense restricted stock.",
        "label": "AllocatedShareBasedCompensationExpenseRestrictedStock",
        "verboseLabel": "Restricted stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseRestrictedStock",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abeo_AmendedAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Agreements [Member]",
        "label": "Amended Agreements [Member]"
       }
      }
     },
     "localname": "AmendedAgreementMember",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "abeo_AprilOneTwentyTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "April One Twenty Twenty [Member]",
        "label": "April One Twenty Twenty [Member]"
       }
      }
     },
     "localname": "AprilOneTwentyTwentyMember",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "abeo_BackgroundPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Background [PolicyText Block]",
        "label": "Background"
       }
      }
     },
     "localname": "BackgroundPolicyTextBlock",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abeo_FairValueDisclosureOfGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value disclosure of gain loss.",
        "label": "Fair value disclosure of gain loss"
       }
      }
     },
     "localname": "FairValueDisclosureOfGainLoss",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abeo_FirstAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Anniversary [Member]"
       }
      }
     },
     "localname": "FirstAnniversaryMember",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "abeo_GainOnSettlementOfRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on settlement with licensor",
        "negatedLabel": "Non-cash gain on settlement with licensor",
        "verboseLabel": "[custom:GainOnSettlementOfRelatedParty]"
       }
      }
     },
     "localname": "GainOnSettlementOfRelatedParty",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative",
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows",
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abeo_IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease In accounts payable And accrued a nd lease liabilities.",
        "label": "IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities",
        "negatedLabel": "Accounts payable, accrued expenses and lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedAndLeaseLiabilities",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abeo_IncreaseDecreaseInPayableToLicensor": {
     "auth_ref": [],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in payable to licenser.",
        "label": "Change in payable to licensor"
       }
      }
     },
     "localname": "IncreaseDecreaseInPayableToLicensor",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abeo_InterestAndMiscellaneousIncome": {
     "auth_ref": [],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest and Miscellaneous Income.",
        "label": "Interest and miscellaneous income"
       }
      }
     },
     "localname": "InterestAndMiscellaneousIncome",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abeo_LicensedTechnologyNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensed Technology Net [Member]",
        "label": "Licensed Technology Net [Member]"
       }
      }
     },
     "localname": "LicensedTechnologyNetMember",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abeo_NetCashProvidedByUsedInOperatingActivity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net cash provided by used in operating activities.",
        "label": "[custom:NetCashProvidedByUsedInOperatingActivity]"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivity",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abeo_OneBusinessDayMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "One Business Day [Member]"
       }
      }
     },
     "localname": "OneBusinessDayMember",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "abeo_OriginalLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Original License Agreements [Member]",
        "label": "Original License Agreement [Member]"
       }
      }
     },
     "localname": "OriginalLicenseAgreementMember",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "abeo_OtherAssetsAndRestrictedCash": {
     "auth_ref": [],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other assets and restricted cash.",
        "label": "Other assets and restricted cash"
       }
      }
     },
     "localname": "OtherAssetsAndRestrictedCash",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abeo_PaycheckProtectionProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck Protection Program [Member]",
        "label": "Paycheck Protection Program [Member]"
       }
      }
     },
     "localname": "PaycheckProtectionProgramMember",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/LoanPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "abeo_PaymentForExecutionOfContracts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment on Execution of Contracts.",
        "label": "Payment on execution of contracts"
       }
      }
     },
     "localname": "PaymentForExecutionOfContracts",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abeo_PaymentsForMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for milestone.",
        "label": "Milestone payment"
       }
      }
     },
     "localname": "PaymentsForMilestone",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abeo_PppLoanPayableForgivenessIncome": {
     "auth_ref": [],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ppp Loan Payable Forgiveness Income.",
        "label": "PPP loan payable forgiveness income",
        "negatedLabel": "Non-cash PPP loan payable forgiveness income"
       }
      }
     },
     "localname": "PppLoanPayableForgivenessIncome",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows",
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abeo_PreFundedWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-Funded Warrants [Member]",
        "label": "Pre-Funded Warrants [Member]"
       }
      }
     },
     "localname": "PreFundedWarrantMember",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "abeo_REGENXBIOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "REGENXBIO [Member]",
        "label": "REGENXBIO [Member]"
       }
      }
     },
     "localname": "REGENXBIOMember",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "abeo_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental cash flow information related to leases [TableTextBlock]",
        "label": "SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abeo_SettlementAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement Agreement [Member]"
       }
      }
     },
     "localname": "SettlementAgreementMember",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cancellation of restricted shares awards.",
        "label": "Cancellation of restricted share awards, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeited",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "abeo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options intrinsic value forfeited in Period.",
        "label": "Cancellation of restricted share awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIntrinsicValueForfeitedInPeriod",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abeo_ShortTermInvestmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short Term Investment [Member]",
        "label": "Short Term Investment [Member]"
       }
      }
     },
     "localname": "ShortTermInvestmentMember",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abeo_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period Issuance of common stock in connection with restricted share awards, net of cancellations, shares.",
        "label": "Issuance of common stock in connection with restricted share awards, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "abeo_StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value share issuance of common stock in connection with restricted share awards net of cancellations.",
        "label": "Issuance of common stock in connection with restricted share awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareIssuanceOfCommonStockInConnectionWithRestrictedShareAwardsNetOfCancellations",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abeo_StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Option-Based Compensation Expense Included in Operating Expense [Member]",
        "label": "Stock Option-Based Compensation Expense Included in Operating Expense [Member]"
       }
      }
     },
     "localname": "StockOptionBasedCompensationExpenseIncludedInOperatingExpenseMember",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abeo_StockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options [Member]",
        "label": "Stock Options [Member]"
       }
      }
     },
     "localname": "StockOptionsMember",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abeo_ThirdAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third Anniversary [Member]"
       }
      }
     },
     "localname": "ThirdAnniversaryMember",
     "nsuri": "http://abeonatherapeutics.com/20210930",
     "presentation": [
      "http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r390",
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Series [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://abeonatherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r179",
      "r208",
      "r223",
      "r226",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r364",
      "r365",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r179",
      "r208",
      "r213",
      "r223",
      "r226",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r364",
      "r365",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r179",
      "r208",
      "r213",
      "r223",
      "r226",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r364",
      "r365",
      "r378",
      "r379"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r91",
      "r95",
      "r224"
     ],
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r91",
      "r95",
      "r159",
      "r224",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r27",
      "r316"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r18",
      "r40",
      "r41",
      "r42",
      "r355",
      "r370",
      "r371"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r39",
      "r42",
      "r49",
      "r50",
      "r51",
      "r83",
      "r84",
      "r85",
      "r271",
      "r366",
      "r367",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r250",
      "r251",
      "r252",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.",
        "label": "Restricted stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r227",
      "r229",
      "r256",
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock option-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r229",
      "r247",
      "r255"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Total stock-based compensation expense",
        "verboseLabel": "Stock option-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails",
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r71",
      "r139",
      "r144"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Total"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r79",
      "r113",
      "r116",
      "r122",
      "r134",
      "r163",
      "r164",
      "r165",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r174",
      "r175",
      "r268",
      "r272",
      "r287",
      "r314",
      "r316",
      "r336",
      "r353"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r36",
      "r79",
      "r134",
      "r163",
      "r164",
      "r165",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r174",
      "r175",
      "r268",
      "r272",
      "r287",
      "r314",
      "r316"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Fair value disclosure of assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNet": {
     "auth_ref": [
      "r2",
      "r372",
      "r373",
      "r374",
      "r375"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net assets (liabilities).",
        "label": "Net Assets"
       }
      }
     },
     "localname": "AssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r129",
      "r136"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Amortized cost of available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/Short-termInvestmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r128",
      "r130",
      "r136",
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "U.S. government and agency securities and treasuries"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAvailable-for-saleInvestmentsHeldDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r230",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r230",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails",
      "http://abeonatherapeutics.com/role/Stock-basedCompensationTables",
      "http://abeonatherapeutics.com/role/SummaryOfRestrictedCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r222",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r222",
      "r225",
      "r262",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r25",
      "r73"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets",
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r7",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r7",
      "r74",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r66",
      "r73",
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r66",
      "r73",
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r66",
      "r288"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase/(decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Warrants converted to shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r34",
      "r158",
      "r344",
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r162",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r83",
      "r84",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15",
      "r316"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock - $0.01 par value; authorized 200,000,000 shares; \u00a0issued and outstanding 101,867,539 at September 30, 2021; issued and outstanding 96,131,678 at December 31, 2020;"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r45",
      "r47",
      "r48",
      "r56",
      "r347",
      "r363"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": {
     "auth_ref": [
      "r152",
      "r153",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.",
        "label": "Uses and Sources of Liquidity"
       }
      }
     },
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r77",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r193",
      "r200",
      "r201",
      "r202",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "LOAN PAYABLE"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LoanPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r10",
      "r12",
      "r13",
      "r78",
      "r81",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r183",
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r203",
      "r204",
      "r205",
      "r206",
      "r300",
      "r337",
      "r338",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LoanPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r176",
      "r203",
      "r204",
      "r298",
      "r300",
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Annual fees"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r32",
      "r78",
      "r81",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r183",
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r203",
      "r204",
      "r205",
      "r206",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LoanPayableDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "auth_ref": [
      "r131"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Realized gains or losses on sale or maturity of available-for-sale debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/Short-termInvestmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "SCHEDULE OF AVAILABLE-FOR-SALE INVESTMENTS HELD"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/Short-termInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract liability"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r71",
      "r112"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows",
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/Stock-basedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r27",
      "r80",
      "r166",
      "r168",
      "r169",
      "r173",
      "r174",
      "r175",
      "r313"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Current portion of payable to licensor",
        "verboseLabel": "Due to licensor current"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets",
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesNoncurrent": {
     "auth_ref": [
      "r33",
      "r80",
      "r166",
      "r168",
      "r169",
      "r173",
      "r174",
      "r175",
      "r313"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.",
        "label": "Payable to licensor"
       }
      }
     },
     "localname": "DueToRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Basic and diluted loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r98",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r49",
      "r50",
      "r51",
      "r83",
      "r84",
      "r85",
      "r87",
      "r92",
      "r94",
      "r100",
      "r135",
      "r209",
      "r210",
      "r250",
      "r251",
      "r252",
      "r260",
      "r261",
      "r275",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r366",
      "r367",
      "r368",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r26",
      "r65",
      "r133",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Short-term Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset."
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r277",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r191",
      "r203",
      "r204",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r278",
      "r319",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r277",
      "r278",
      "r280",
      "r281",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r191",
      "r214",
      "r215",
      "r220",
      "r221",
      "r278",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r191",
      "r203",
      "r204",
      "r214",
      "r215",
      "r220",
      "r221",
      "r278",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r191",
      "r203",
      "r204",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r278",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r191",
      "r203",
      "r204",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r319",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r277",
      "r278",
      "r280",
      "r281",
      "r283",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r284",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-lived intangible asset, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfLicensedTechnologyDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Less accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfLicensedTechnologyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfAmortizationExpenseForIntangibleAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfAmortizationExpenseForIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfAmortizationExpenseForIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "2021, remainder"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "SCHEDULE OF AMORTIZATION EXPENSE FOR INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfAmortizationExpenseForIntangibleAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfAmortizationExpenseForIntangibleAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r145"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfAmortizationExpenseForIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAmortizationExpenseForIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r143",
      "r332"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfLicensedTechnologyDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Licensed technology"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfLicensedTechnologyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r143",
      "r331"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://abeonatherapeutics.com/role/ScheduleOfAmortizationExpenseForIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://abeonatherapeutics.com/role/ScheduleOfLicensedTechnologyDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Licensed technology, net",
        "totalLabel": "Licensed technology, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets",
      "http://abeonatherapeutics.com/role/ScheduleOfAmortizationExpenseForIntangibleAssetsDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfLicensedTechnologyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r158"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain loss on payments for settlement"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r137",
      "r138",
      "r316",
      "r335"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill [Member]"
       }
      }
     },
     "localname": "GoodwillMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNon-recurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r150",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedLabel": "Receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r141",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r141",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "LICENSED TECHNOLOGY"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnology"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r53",
      "r111",
      "r297",
      "r299",
      "r348"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseOther": {
     "auth_ref": [],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense classified as other.",
        "label": "Non-cash interest expense"
       }
      }
     },
     "localname": "InterestExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r64",
      "r67",
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r343",
      "r360"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r132",
      "r333",
      "r349",
      "r376",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "SHORT-TERM INVESTMENTS"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/Short-termInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "SCHEDULE OF COMPONENTS OF LEASE COST"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Total undiscounted operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "verboseLabel": "2021, remainder"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r29",
      "r79",
      "r117",
      "r134",
      "r163",
      "r164",
      "r165",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r174",
      "r175",
      "r269",
      "r272",
      "r273",
      "r287",
      "r314",
      "r315"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r79",
      "r134",
      "r287",
      "r316",
      "r339",
      "r357"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r31",
      "r79",
      "r134",
      "r163",
      "r164",
      "r165",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r174",
      "r175",
      "r269",
      "r272",
      "r273",
      "r287",
      "r314",
      "r315",
      "r316"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.",
        "label": "Current portion of PPP loan payable"
       }
      }
     },
     "localname": "LoansPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermLoansPayable": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "PPP loan payable"
       }
      }
     },
     "localname": "LongTermLoansPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r158"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss contingency accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencySettlementAgreementTerms": {
     "auth_ref": [
      "r158",
      "r160",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the terms of a settlement agreement which resolved the legal matter, including the nature of the consideration, timing of payment, and the nature of rights obtained or lost (for example, but not limited to, patent, trademark, copyright, license and franchise rights).",
        "label": "Settlement agreement financial terms, description"
       }
      }
     },
     "localname": "LossContingencySettlementAgreementTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in)/investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r66",
      "r69",
      "r72"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r43",
      "r46",
      "r51",
      "r54",
      "r72",
      "r79",
      "r86",
      "r88",
      "r89",
      "r90",
      "r91",
      "r93",
      "r94",
      "r96",
      "r113",
      "r115",
      "r118",
      "r121",
      "r123",
      "r134",
      "r163",
      "r164",
      "r165",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r174",
      "r175",
      "r276",
      "r287",
      "r345",
      "r361"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows",
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r113",
      "r115",
      "r118",
      "r121",
      "r123"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r305",
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r303"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r303"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Current portion of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets",
      "http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r303"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Long-term lease liabilities",
        "verboseLabel": "Long-term lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets",
      "http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right-of-use lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Amortization of right-of-use lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r309",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted-average discount rate for operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r308",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted-average remaining lease term for operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r3",
      "r82",
      "r108",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent": {
     "auth_ref": [
      "r266",
      "r267",
      "r270"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r37",
      "r38",
      "r40"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Change in unrealized gains/(losses) related to available-for-sale debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r44",
      "r47",
      "r49",
      "r50",
      "r52",
      "r55",
      "r209",
      "r289",
      "r294",
      "r295",
      "r346",
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income/(loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Licensed technology impairment charge",
        "verboseLabel": "Non-cash licensed technology impairment charge"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperating",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative",
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows",
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Royalties payments"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r23",
      "r24"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from open market sales of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from loan"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LoanPayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from loan payable"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r62",
      "r249"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProgramRightsObligationsCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations related to rights to programming, including, but not limited to, feature films and episodic series, acquired under license agreements that will be paid within the next twelve months.",
        "label": "License to be paid"
       }
      }
     },
     "localname": "ProgramRightsObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r8",
      "r9",
      "r149",
      "r316",
      "r350",
      "r358"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r259",
      "r329",
      "r380"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r7",
      "r73",
      "r76",
      "r334",
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "periodEndLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails",
      "http://abeonatherapeutics.com/role/Stock-basedCompensationTables",
      "http://abeonatherapeutics.com/role/SummaryOfRestrictedCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r210",
      "r253",
      "r316",
      "r356",
      "r369",
      "r371"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r83",
      "r84",
      "r85",
      "r87",
      "r92",
      "r94",
      "r135",
      "r250",
      "r251",
      "r252",
      "r260",
      "r261",
      "r275",
      "r366",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r109",
      "r110",
      "r114",
      "r119",
      "r120",
      "r124",
      "r125",
      "r126",
      "r211",
      "r212",
      "r330"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty fees"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesDetailsNarrative",
      "http://abeonatherapeutics.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r229",
      "r246",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "SCHEDULE OF STOCK BASED COMPENSATION"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r277",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING AND NON-RECURRING BASIS"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r140",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "SCHEDULE OF LICENSED TECHNOLOGY"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r146",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r230",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails",
      "http://abeonatherapeutics.com/role/Stock-basedCompensationTables",
      "http://abeonatherapeutics.com/role/SummaryOfRestrictedCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r232",
      "r237",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "SCHEDULE OF OPTIONS ACTIVITY"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "SCHEDULE OF WEIGHTED-AVERAGE ASSUMPTIONS TO ESTIMATE THE FAIR VALUE OF THE OPTIONS GRANTED"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "SUMMARY OF RESTRICTED COMMON STOCK"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LoanPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SettlementLiabilitiesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers.",
        "label": "Settlement amount"
       }
      }
     },
     "localname": "SettlementLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Restricted common stock forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfRestrictedCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Grant date fair value-forfeited awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfRestrictedCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Restricted common stock granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfRestrictedCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Grant date fair value-granted awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfRestrictedCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "verboseLabel": "Weighted-average:"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/SummaryOfRestrictedCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfWeighted-averageAssumptionsToEstimateFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfWeighted-averageAssumptionsToEstimateFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfWeighted-averageAssumptionsToEstimateFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails",
      "http://abeonatherapeutics.com/role/Stock-basedCompensationTables",
      "http://abeonatherapeutics.com/role/SummaryOfRestrictedCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average:"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r228",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfStockBasedCompensationDetails",
      "http://abeonatherapeutics.com/role/Stock-basedCompensationTables",
      "http://abeonatherapeutics.com/role/SummaryOfRestrictedCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r241",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfWeighted-averageAssumptionsToEstimateFairValueOfOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/LoanPayableDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r11",
      "r340",
      "r341",
      "r352"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r306",
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r35",
      "r49",
      "r50",
      "r51",
      "r83",
      "r84",
      "r85",
      "r87",
      "r92",
      "r94",
      "r100",
      "r135",
      "r209",
      "r210",
      "r250",
      "r251",
      "r252",
      "r260",
      "r261",
      "r275",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r366",
      "r367",
      "r368",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r100",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Common stock issued for cash under open market sale agreement, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r209",
      "r210",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Common stock issued for cash exercise of options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Common stock issued for cash under open market sale agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r35",
      "r209",
      "r210"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Common stock issued for cash exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r19",
      "r20",
      "r79",
      "r127",
      "r134",
      "r287",
      "r316"
     ],
     "calculation": {
      "http://abeonatherapeutics.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets",
      "http://abeonatherapeutics.com/role/StatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r296",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r296",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r296",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://abeonatherapeutics.com/role/LicensedTechnologyDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/NatureOfOperationsAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r307",
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/ScheduleOfComponentsOfLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted average number of common shares outstanding \u2013 basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://abeonatherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=77885760&loc=SL35686385-199418"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.23)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262037&loc=d3e9915-115836"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604008-122996"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874367-224272"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874367-224272"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r381": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r382": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r383": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r384": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r385": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r386": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r387": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r388": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r389": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r390": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r391": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r392": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r393": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r394": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r395": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r396": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r397": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r398": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r399": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r400": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>57
<FILENAME>0001493152-21-028506-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-21-028506-xbrl.zip
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MN.=3![QO&EDF ?7"-U>U'K@X&];]-J8^ "=W58]/F\#'_P)02P,$%     @
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MH)AG*NXT$ZV&E5C72:&BY<FWZ][87F &,Q3'Z8E@<GQ[76BK2I.07DV=1,\
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MG$RW^%>:<A8))=]>8] [5J9JR\XBI.3PZ^Q[MY0P##V#FK>EH(!I[CL6CK-
M;N*#P5.!&M?S$W+?X^8 ?GJG%W+3.[^6JR2VT[Q^?JTY+$#HIN$!N>[<K^%
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M+!.Z&P  LXX! !4   !A8F5O+3(P,C$P.3,P7V1E9BYX;6SM7>MOXSB2_W[
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MFDD#]Q&8?SG!Q5$_%^=GG]Z>X5[^5BJ4K!Z0-L<^5L83[?39%%PZ 9;;]!Z
M).914EFX58K&3@1"5 X5<8):Y%76;)I6/ K!$O436W/K 5L.I&^Q'GK86D3@
M'H2Q_P@&,.:*MGY+;?(R3:#[_1X&'C)UQA^IGZSJT$^OW2;-?2>^OP[@CUJB
MWJO4-(4C9*8CL(/IU%^$_API9ICHK@O3,$$SUQ@&ONL#+OF'M]BX].]AE/02
M$"W-\!'$"9$I5_JL2DU3./!=-'" 9P/W/H0!7'#UF%ZC<=J@$XZ=E7.'F^,0
MM5^T:6JN'3\B:XDA<&*D7T)8,BLU/]:15>GA:9C81(02T7[^:&=6:YI*U,?2
MSY2:&&\R$-'B5&!@"U25;YW:LU)M6ZOZ%-EXP+7 :;G=3JRR&"L"5=NWT&*D
M\NIU8A_%2!6HVI&M%-0"D<H=VDTQJH4;:%S6:+/II0&R #KJT_,#]/LCF (W
MC?P$]6X\N4'J >\Z@DLLSS0AXK3FAA.%B,9X#*+I/=JM7('$\0,^/"WU)]_>
MY@2-G A7>.0NBYKKH46=>$0=8OWKS6'4BYT %$SK5Q!X]5&OV6(G\TM=Z&HU
MTAXZ^[-(;3BX3;2H6TLD1/]/HOK&$S;4X!I&9I@XX<)'"J+',=A(M8:"'=)L
M^^N"NBHFWD*+.[O:1/.KMJ=/FX5*AC RI@/?N?,#,JWDBQ?/"B=XJHF0544%
M1C#L1>N_+YW8KZ]N;?3:GHS(XNAR=VU4FVFA9MKCXE?@+^X3X/6<1U1P@46?
M+A_(%&I#(T[\I9. #3!XAB6_W41H5@7UIZQ&NVM/*GFWNHN&FY_4GPK8]1NG
M.UTNG6AES2=H_HQ\-R&ZM(0AT2U1XNLTTI[D\2" 8>:2': A#_HP3FK+7Z25
M%BU#^H#:Q L9)UB[E7'$+EJ2L3T! 5)RSX:$LOIF\EG-=[A;JSOC'= 4BQLG
M<M<,514NTD*)^:U#CSC8]YZ0>(^:B-ST#O0\?XD#,=A]F'=4E-BF%3],3E'1
MT[S,:64#[=.]Z:SGP:7CUR1ZOW8'%).>>DNPO,,ASUKDEJNV3ZL3!/4H)!7:
MIRN$B5Z7M'6=3G42S)TT2 Y6RG7U,LWH:S_TL44<H#]+=(.G!(0>\-:4XP;K
M1^D3/\'5\M,6YUH/'\U(L?U"'_.2[9-4'8DOD7:!Z-F$.@EMJ">\(<*?8ACX
M'IXPM+PE;=U4Q[17A^E+C+P]A!'MIU++?^^"L0-B^"5&WXDQNNU&@W-MVY'F
MA)Y6ZDK#?6D_W89.ZOFH:N=28)P$*''^_A#.BXW_M_, XW]H61\ECG-^UQP'
MT"VQ&>!#0C#:MV;QV@S-G?B.V*(T[BT<Y^$4+U].09#$ZV_(@J9W=IX?"_I;
M_O5L0RX2+C#1QPWN 1)@0#J?Y86KRIZJ0+M=C#HSZ,[+[=*\U3 ]6E.?&W/!
M&3.;03Z[:&6(=-+(UL!H%@(+_&%-V3R"2ZY <^%!)@=%"2-"3C08(0W[<G)^
MMJ4E@$@WOYPD45K!LA28,LW?[H#T)U]$VZJK-0IBY>*7!UH9"PI@+)XK\).+
MU ZQ5_F:FH80I7BCR.RO\'FP,"4.11B@H7-Q=OSPS,XKF&@*H?5R][GF\+D0
M$B9I*+Z5C&+!=S7,-X(T!/>*SAH'K[PCI0##'B>03[.B]D[W/"(X)Q@[OF>&
M?>?!3YR !PNS6@L#K'&,^ Q0 9.,V 2[VT+@K<\)\*"J+C^KLN2*8<2@G#H_
MR1Y.KILN4^+CM?"^J[3/,T.T^P+<H27:Q*S*C"L&83UFJ/.59%3I^^.J-?MN
MV=D'.3C5V%I5DJSHC$4.1<56FI![8\@N,+#8+:H^%)444ZV=[+7#O]/UZ5-(
MF5 )0WN'%"< J5GL)V *HD??!6,0^="; !<N,B1(A)FU_&BW9^7UI!,!4,WQ
MD:C=WL&-;?2<F+Q;Q'#,E4<#6M@,(2]'*1N4!TU'WQVHH_N1;_S-K)IL/8J<
M<$%D<[G:%AD[*_R5_L.)O&P^-4/$7YIYV_$RR+YWPOP8BADBSM%RR"7C[AI&
M<X ]XF:8\5NA?9@@:?2HJX3RQ4+3Q??'HHL;MCK7NDW/?U7]*@N IDD?%-@'
MF7&< N\JQ8<Z,^4G0X+\EC-C/('(]>-*/2KN.>HTI:YB/(LC&M(_*XETMCUI
M!FI&6\>*-8\E&M@?&YX@6)J(2<2_X4,8Y"SFVE6-EF@P#(&+Z?[53^X+:S)<
MAYBQ> 02?!L?U0V"[#@#;:KHD@9U]46.*&AZ]JD3/<M&@3P=:[[_H]2OEL3
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M8HQJB!L^4*8O23A:#)#JPK/W1PL$@R$: .\;!F *DB2S!F(84,O/SB6]L]8
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ME?0GR<'I]1C4W3]2/\XDR=S<4RL<Z3*)QQ8-N8_JX88_1H"[?Q2H*F>SS\.
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M[1/:ZU'.)I"/.=.$-"YQ]?:2+T?'5-[+JJ*'G6Z)*UZ09^<1I967M UNW1A
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MKJ2N[ 5I%XCXT$Z3Y=_C?^Z<&*!O_A]02P,$%     @ $'AO4^S&NCB*10
M*,L# !4   !A8F5O+3(P,C$P.3,P7VQA8BYX;6SE??MSXS:6[N^WZOX/N)E;
MNTF5G7[MS&Z2F=V2;;FC&MORVNID9E.W4C0)2=Q0I )2;GO_^@N ;^)!4**
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MY5BNZ<]D;ZYI9&T31 FW2Q)!$!115.B49,D52LYP%:>$^3OVB!E=&I)NR")
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M.:_Y/F3=*J]^7TX)@/0=ZKVP3RE>[J*;<#E\"[2I"F.O4W3&;%.SUG/.N#W
M=DEXW5SXAO7"UV/:9VC']>DHMX3ROND]25;$V_ [:>G\*0I7?&>V.Q/ISM3[
MM*RN?<Q<:"V#]"I@F&B&4Q&XR.933ZPW# ,@9*.M"=,BRFBOSK8["R\F<7!'
M:UE+."--N[N&QJZT-PE[U<"0SQRKN 68:[*1F*D"H1^[%<,6BV',;RM.?)_0
M2>(DN_0(>:4_Y.]A*0K#4-=JBM,A[K02GIHH@J'A$+32E\7]6IE%WC-M((1L
MS&YO\,J+'G&6Y8DP#78:10U'&XXJZ(I]QZXX&*+U8U3L+*5HR:[1,1V4UDI
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M;P_%7./!54;HJ1V,"=^9TT(42I1K L57RUFUE)Q30\HX3) M%M_#%E! M1Q
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MIPQL00<HZ!HC6Z6DZ@'_99]'GN2_29$O:0VN3J 1=B&1NLIN[$K/SOC+0D2
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M+# 3:HZE.Q#E5,;#45";*#J.0[9:;[O_4:/XD>H_^H_5P%^C%%:1O%080'M
MR<FDI#*J%V!M[C :(KHLIJSTX7A!X6//$T79'56Y1U4?27NTRBE]%35Q-L2
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M&%$]VWD\;"M1Q\</;>9VVYR:;@I\HWR@F=/'MNC9U2(@5R'=B#([SQ?DN=*
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MI9=)#V==V6_&:<O;J36BH[Q=^AA[Z5-W]64O4[<2R984.X)^#2CA[%YU,Z4
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MCJX-%M,NXY/H:+6DY^^7\7&:/(E>DR:6I7Y=8 'OM7*5]E?X9IM W0*2OUM
M\OV; $@^<$[/Y\&1CSSL:8M&OHF&M*"1@]?(]IK?#D^B?35S]Q=%DROH//33
MV,[TOE@W["7XRY46H$FXR2(U3XN,;AF7:=:]PW@4W,+5I_1N!FL9><($*<[
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MXY1>DA28BB:8,BTIXA9>0;;4(8>T?=CO;XU]/%H_^!<Z>.$ %Y!*CD6;%Z1
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M067.M+<W"3PL_WL+O7:3"Z_J9+D[#7TCI0+E:,G4!,B#@#K=<:6*\%">1QH
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MTUC?GVAR9E-(RC9TJ;8Z [V\.@DM:=PF$:M/DIKGL%J_X."B/-7VF&S\,7F
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M@O=I#= >+BX8/G*+4S,E4T&$GC=B.PNTE3V;+WM^W(L8GAGVQ;5MYMHJLR6
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M7*3W=VO 4 ;HB(-<VR+"" OP!1A/$2Y\WEI0K<3_<FV-C:@40U48PVC"K@E
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MQE\C3)]2"4,,W*:A8TYF#HJJ<(%"156XJ K?T;_M9TA&U1@)V*2S)#J:<J0
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M)FQ-#\?4_[34H;/4OB)B6YVXE_;VC;TV8'YM=JQ\@?.4/K&>.5@6I@&EI>Z
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M+:SO:[,)12/DE:4"Q*UPOB1FL2+=ZTPP%ZR@]Q5C>^6.9?BI/Z1[4[!#E.G
M_9J2VI#(]]XXW;Z\%A1-/0K67W+]7PSF ^_A;DV,8)T)$D^&**D05JV 5F%K
MP3H.!-8JWH>^:B[7:'9<4.LJ/NJ2FO@^KR&1,!)P$3UH>(T %1K640>I#UA
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MIMU.)<6;4)4D;D(%A3VTO[YQE[;&7>GNZ(GK_[L78DTW9:W9?&A=37$6NYK
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M^OJ#5'MV6X/C>W?G)\NY$IO8@;#QXC/Z:+Q8!&QNZ7U%VMXAP;GQ9$$3NI6
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M[#7B7(ZK);N?Q)H\> +H$7TN'9Z5JU=C.5/6B$KY.%@ZP=I$T7CI#/3#!.Z
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MM<"PPWI3Y0L>;'I^;8**P]K3:_3(Z8G4QG:/DH:^1T'3+:P[;1"P1ZE6TC7
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M&(!6&Q1<4RAK[7/ALZ5W">T_-E2LGJ#;H ?;+5.1%<E0< 24&_'HUR&)T)]
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M128&IZ2GO^WEPO>:X\?>CY>K>.WW37U'"4!;E9I8 O"R:_7Z6;%]#QIIW?5
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M)TF'V&#,MW2\;78Z+4N>">;W$>M.RZ%YO929OEE@;9<QXI1U\J134BSJ<,
M.KQ%QK&!'*<G@=OL]V1A.!/>68 >CP'?8KMMV)(J6@7),+"))^VL-R'D>-3C
M?AE"LA%[;3UTVZT7GR*$'9K:WMIHQ"XL;AD&0Y%D46SE>SH%9B6'P#'LOR0.
MZ]RD&U G%M"3_FI"[+I1AWN(A\;SGZXI:I>WSYGIVSX6J*'B4(+I+6T%R31-
ME:7A@.^.BA"2S9'0$7X\Z*;/B<B<E.B2Y!$X&"8(4#):BL7C55K$&J),M'PR
M"D?R+@ZQHZY.8UA:1-6'A]*7]/T"M]SD.3;G3]]N#06C@G0D\NG)Y*$N$TG&
M5N"1A<'24[+- [&+Q08Q^J:C6&'=.U>Q6I4'GP8U^^$U<_^8\BY&O0_Z'"8@
M+."4PQ 4](,#P60O[3:$CXII8(FHIX'-9:2%@GX>,3Y]HXZBKM0E?CC3IHDF
M?,E$.PG_B1QA6:0_L)CG7R-=W5+P@H#=#TRL,N":O&7C=<#I">4V6W,T!(-(
M8+'@X),WZD/:Y9 V?>Q+S^PC_YL-M(NG54#J$.._R3C1][XK?GCO],0V!4D8
M&@HL"99*^OA-)RK-]YT. <PY"@TZ2I 20BQU)DLCO/AV.B'R@ %0@PALK;-\
M/JX*M"?&A-_8=RER>@+?N8'AXLY<ASTN:OAW^"?(ZT QB$P[0+9Y.!UWQ&%+
M=9M27;>-B9V;"EQ4\%,&4)RI;T@$MUODZ8FBR4I;P@A -'Y S"F&<QL-Z@4H
M>%1?HT.*]8*02+/NTJFS>.Q\CI-2J,&$?$-9:"7R[SCZ'=4,N?XAO* "XA!P
M)A#S](2\M@FAK=#QL(-A^1L<-)XB&ACPX\J*&H8V8C()&)T\3*[&6M%K75 $
M4EP1\&=2)# =1KT;7I?O'E[-CG?V@M%ZUI;,GC-=6!9I]S1=U;LC_]K;/1"2
M2VWC13-;7G4U$3[]Y2RUP#,5/\\M/54U9]TS:_3'T,\V4.00=%)CWN6LG#E^
M_(4G-E3T9\V6W['HL>?W1GM^YXX]O]^GY_=;&/D <Q%F9$J-'^PI?K*C]@.J
M$KJPI@R,MBHI?7:RHLP4Z1F*#D7?,V!AZJ!BT9^=W -1%-VL TE5,<BCRPY5
M[\SOHW^2=8-N474+=8[ TU48N#HX5T\<F]HDY!F&CN E-\:0X!DEH#;419L*
M#Q55XM.D7Z>:!6^&#6?Y3,Z!.RFPE^B<Z(4EU0U1Y9MR]80)^/ [59U4-AYM
MV- KBL5]_IX>/&'NI^));@RDXJG5C8%A_O7Q9S;7*G9=I0#GP/IH^^Q/NAC/
M+E^F"H1:QSP#';2RI/M3:HOF]W)_+K^78/YSBIVA KB;]*0#N6C0CS!043E'
MQQ2[NZ8N^//3$P_1KGL0M=U9-J*Z/.,R@2:N$X/]@:/8M1ZXEKDP@V376+J]
M;T3ODT_E/Y7.WP(/NN'.1COE"GRN%:-KH\ABT6:PJX"6<T&<%* ](E&-DT>8
M28)E*"T;[T/I)J,*"K+2?44W3.I3QFIH@NX815D*'?9SCF5W4F/RV@;9&4NP
MWT28\'3'[V#I'D1O1WIAEM.$N074UPC;/5>\#UCX,Q>&LPAF-1C\T#69]>A^
M5,*K6"2*]ZT9%&??A.),+,Y1G(DE5D;QH'W9DW/YA/GC>:LHSIS%XNY/B?=
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M.G0JICT8Z(:U9%V4X@P. 3.*L/&<G9F^T6[K_8%*+/:N6T(DGG,/'B2ZCJ3
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MD;?MH7YE^@N3.=.7+)P:KN^>P;$^6WOJLU]=GE:G5U[#A#8]5^N>2:0(_X$
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M\USR TJ/'>S%YL_4^'GJ(TKRW?#%%L[5Y)$SUN6,#9^ML?/<.MD12WLW+8K
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MC6&)03L3IDMS5K'QMS[ (B^FW\S>6WUR16II&>4\R3=P]DP+CMN6P  RA3&
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MX,!;KM\9%VB-6>4*DANCQ</Q(N[AA75%TR1UE*NI*)  ($JS&%GLT_**N#'
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M%>GO7H9+463L3E0?2!;[#R6\W(_-]8XY.@U^Z#2</U8#B4U9X$8*;[!(1#:
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M1164MH11ST(&@UU"-/IIKF(_8B#KN5,(S\YS.:NGVT_HFU<C)!Q6PI*'L_0
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M#\??2+G1;MV"<\.[/\H-4^A[ \X-[QXI-U /W9ASP[L_RHUVZQ:<&]Z]4FZ
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M7(XPVY5AFV)2?[R"FJ&T$P)I!8[0..HC#J^;&L?0)Z9NE\15>WH?)X1<P=F
M 6U3MJSCI97:-1-2BGEM*:YR\L?GH.V%K(T!K'V<GB.1'IF/"XBM6"X5';UA
M<G&$ L3.>=PP-(F-94VKK(G\:"VI^*B<5ZP0UFX$:+NS9<-,?+Q\"KIG=XQ&
M^D39FN]Z'5Z'8G9U.R$\CWEZ?X'YO?B"2NB8JL15']S,6]ULKC!9?3'A61R3
M7-ZR_E6KIKKB)T&;FG;.GB73K1Q1<L@&NNI1ZWG_Q6_/&K/^-+_5RZ^C-6P^
M?W-Y^+;\Q;/K0%3&0>>*5R[=@'.>L.B12\4#HQ6I:,*R=)7ZT2SSER-Y%[9?
M1+M6:+O=FO_&_@XF;JT>_\./=9X[]$7C*;#&N' O-B%'GK;OFZJTZ0X+4?C?
M,K'G.E?D("N0/.M-]@XB[<ZG+KGE._G1+*P.?);7O]V!#X)(OQRI/>!-M8BU
ML(]%V9PYW*NVQ;\TY0QF$KJQ!_#BOY6&<P,1"P%=$(USS@B!WG.&SM_@G@,N
MW][,MWJ?6S7T\O&97(Q"X P,]S+\"T/-;-5/O![H&*TM>?TK'&)M%-#]2<&I
M.>W-C>G@A5XH?81,G."H]JVJ\6\\327P0":CV"X89@2^$0XF1G'!R'02>\)]
MDDS_D3.MS;U+%L/2J?8\T,=5\#_-&&W"^0(B\'\+B,+V4^H@1P18X(%V\0='
M&B=#YO*UXDO#FS"6/7<H*:FVPX>LUJY+/X-,X($T0ATE-:^J[MEM!3V-G:O@
M@53:CZ/ S/O#1/A.=C#P?JY6'IX %M^TBT *HYT9Y"3C-!,+!E4PKLJ^ H7M
M5HY+6(IZIH,A8RZ;FH:(7XOVMKF+4B$!FMJKCTV:/HK@T082^C(VF60IU7W1
M&E=]/J+-+TET7[US=N>]VG?00.Y7'H@.0TY9,.\",W@4BS* NUM!7R5UK@D
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MD,^IEY-/#,G>O/)+W;SF5&'G57:(8TO3]^IJVGK:%,[(J#%SH=NIU8%ELSJ
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M'\+6(^M"C9[\*DN^;H#T:\1=C<DJ5SCF$+930;5;VJY2/<*9Z&(OUDL;+[#
MA+ZVPN#!E;HJJ,D+T1EI1^=?VNW,AQ[NASH],-NYRTS43N[*V]D][QM]P910
MM??ALP?[PK(C'WY[C/$J"G,+2.RX?(1M_<A/Y]>5QF)?,:,*6Z'$;O^:\-$2
M<9,3SHEQQ7&_M9W1KY,/)!NI9793;D8TL(]K2+G5@05M*LYMO(P(-#M7JEX2
M_/YBC:A3L&C%F0H3V:_^""%9)_CYL*1C'[UIVCBF%SBM5Y@&(SSB@1"X*:/S
MG%QL("&5!R+N::%DN?3&P+LR0G90U[L*#3:S'U<MG>Y6-_B,/B0Z-;MD;U#R
MJNG5Q%Q;R;=TM]C8Z >:0;Z'8PZC]*\%9+^;?WQ;'=6&"<CLNGSXDJ=W=IVV
M4D:MJ.(-*Q/GB*I#;K7.LJ-+%Q,U#IU:70_J>GSMA&690-; ,65ZY_SO4$F9
MG+XKU;K9I2K""16Z0/$9FDU)\'"6\N$26U'78$>GS!=Y3=M>JWMY("P/I(;D
M:N403W-X('8D"2CD!O$K!$U8(GCC!E:&1']%YW?S>L]YH-3[D+W8H7JV(P_4
M2>N$L^L(X_R%OFTW^ T\MA!+L7'@@8:D #+[/#:>!]JX>13'UO@$_?T9:P^^
MGL+G6& 9RS".>P9>XX%HM3Q0]\0ZC >2.H#>Q[_>'RCA@9+Z$DF_?6S99]+H
M"=RL'&H45T%=F@>:CP0SC'R/8X=( U!ZF18/]",52O5G*_ ON_N0!Z*HA_%
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M76ZH3!ZB-;)9<@ZQJB/X?2T)3NSK]8'/05?V$U#+S$1E6#PZCH8$=; BT7X
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M]CN<1Z2Y2IPJQ@0HF&LF, 2[H#LQJFA-((DA3.GKE!_;^+,MFK:;K]:ILU8
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MZ7L."%*:<@&O.30/)+>/SJ_$B):'&(%<T0SZA"/006=14S)6,?N"27M(H61
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M\2>%SSZD-+* Y6G6'VSUB78EM.=$^\'3] PO8(S^:ZUS]@"0$C",5N4?UTN
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M_D)';R<[DT6'VL?SG.>CKF9EN=DN- 7>LIT[U@Y<.B@8^SOD']FT&4B0&"^
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MW@?1XDWF8T0OQ,=YX! QNGD85RV<2C]VGO< !V03'Q)N 8Z0F# &[W>_>B&
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MX >ZK)#]2+[NVS30R1. *XG%_FL>;C?V#XJ=K$AY5G#01T1N>9 6#Z -7U<
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M.Y@ _JZH+,SAE X'UC50@E%#T.;'.40K8TI'MSUNFQ<'20)KX)>"#E"]4#9
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ME+[8Y_@E'SSE%I#$?X38(1#>A^*VXGY=1,5N0%B[1>;$>!N01S P<)ZT]JZ
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M^]UCU]<2BEQ_3J_GY+S^M=>M;>9!]/?HY0,K<HIF5@@;[M]&<4OI1NQA[9@
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M^G*,P(X.G!I+IQG] +'5]$0I-AR@DG42OF.<F4C*$;@\AF-9.5@>6(V7,7S
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M:\%=M;47OJ R35-1QHW3"B(,F;%8-PP?%2OR*S%4$P5&\;:YNB^"O;VOFG4
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M?GXM2:G^]OIIB<5S=[_S!U__<\RG^OM]K.FFH^N>_IO9 :$S-@^:U.Q)RW&
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MWI.@/>#\Y=4P7M*4*].0"&AT+4PHY$E:P^&]\<>84A_!1X^")G4BQLU@C1X
M60/;.>J=Z.$TQ@:M'>2Z)$4-?A7PFHK-32P'%VHNXS:./IPHN)+]RZ1 G7U
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M/BEM?I=?08A4-F!A"^ZD%2W;OQ+OLDD6:Q)$[OGI73?FHVVFAA:QEGVU;!W
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M'\X+:H SEW^EC%+KXYHR?H>#(/O68&/8.V;Y,+75A;U*T8;="$N@M7.GY*7
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M,(D<H;WL2FY.HX-9*/#)'A+%@&PQU25*LYXOA%80ZM\&D[2.872R9E5_9:'
MG/+"K!:]X_^BV'W58]IW[4EW'5Z,WMEQ9_2TS_'''=*;E^_D^U;%UCXL[=QY
M._"U>V,^[^O(Y<3&VR\F[MR&586$6<?E7V4)Z5R%=;JX8J80C'>!KR^?I QP
MZJFIV'7D.1&'9DO+<?!YL>Q 3A:/IU7;<&:G22/FW*5X'C(SYCVP#C)OIYD
M^Y[!EX2Z/V6O0'?L38AX<@?L?4F,O[F"V/6S&.:-6Y2!XFT@;B8'(HI],W!A
M26A14P?^VL_SEMD"W07J&AD:2FMZ F AY&P7M!^WFL$5;(+-/>2U&&<H6>21
M*E:[:,-1IW3A#,IA'%0A&L^E; V""]"9VL >D,.-CO'J7T%<WH/=")CULK=.
MK2!T&SBI@@T-@IOLK75)Z&"X,$1(U_27.0W.O]K::_6HCTDU&)V\!=,\ZQ*C
M59R:$MTZ3Q"O)/_6NSWB;4)T ??N"@*A6..6!$Y[Y0F;VB)MT<E+2;FWP+Q3
MU'0L,G$NM=GGGC$KX.(]<&JV(11WPT:.M70[5GV!=6#GO>A(XYKFP'9#KK[7
M7=P;$^EG'W;NTHZO-:71B_57(EY\E5_\NA3(;-%::$Q_<I2^>_\ZTZUIAR[J
MYWH$TH/Q96[.F[F@N@Q6SEJ); ^<"=5+=90?0*X(E[* W$)>0;0W4Z^+P/'4
M^:J<_8/+WGDG8;HPAW3:SWS05O. Q]'P1Y,!J3,W$M]G\2_TM.VX)\Y<03A-
MO?@U\,;&7.%W^LL;%4T7!R8^#==:;GOW[,+B&G7;?5=W1N=_@:/(&>_("?]D
MO]!S-?BUB.Q9Y%";/=5]X\ED?W;_YMOQ=R1*+8$_FG$9(]G:?J;&3:WHLW_N
MZ9M5Z;&2C++TMT^9?\8]Z;X3\8[6F&K1%SO@=V++($D4N8*@HV0.7@IU1R40
M<G?!2OY3QZ==E7%$AVI?O*2"KDAX5W@V)EQ$U2"B$$Q">H)'2W7 ^RCV(8B6
M(4,J;4Q72NP/#<>QINKV$KC)<Y#Q>\.-0^L=*%DAB951]CG1(43#XY=W9BU/
M?3-;H'TG@14_MHQ_WO++K;_(6R5;57(/_J YW<^^J:#7S'= UC7J_95_8(Q2
M:QQB4K><W'NHQ5\TONO$OAI#[^^O_[9X71AU*=7OQ/V*=;O;8C\>P_\@:,[O
M!]\5)=@2PS'AF64>-8>Z-+T,[O149&2;&YQ(#6BX7!9PQZ(N*_5$PQ]/VO9'
M%69_"$?>YH22WG.4A@\/TD["_B#'_:9X\DOC .N2I//$R"]B6D:QA=L9YK]#
M"Y7;:6_JFM+,[-@H4/XWK0R..>DW<T$V/+9\BK.T=-/R1_R!M]_73^_G?_G1
M:*_]SY=[Q1:U!U"Y[?UQ=0>KW<_?G_)^W'NQYU2%AYI%;$1?Z:_9NT^5NN2@
MI]=7[7YS&?-"]>]/\!YLT-W/<-3!D[H::NZ>7!$X;_K&H\CA4@]I=W_AY4J?
MZJG!&@?FDX&J4P]O6J;,_T_7_O]\_J5G4K]Y8+=2W^>).?)]A*'HLW@>YX<Y
M:B-NYCA$4/S#F% )%MW O'4Z2+FI87(E=]4-?/ U[5G_D6!F>=2@(+)WKL;6
MTKN8&/^\[VL-PZI7K&80GEK&O/O']W/ GENKPL[2_LJ[KI?9$$C2BF!O!6>G
M/[2',283[F8F6MWA^H_QPY\,NX7$F]T9L6PI$P=^.#;8=*Q:NKCJT-\7G8+-
M0&WIU1ZLRJ3#6&'I]$@C*T[N8C3])N=88,#1C?6-1$N_FMA1?5/F32>5_ZR_
M)E_-_RW0I6I-2U'UZ83876&>KV.V>)CNXYWNG!#OW?OF\ONP/EX(]#ZAMW)+
M=-3["7'DGAU/ZZ274\Q.,!I>)%3Q?F#X^\1+6X*X]Z[X<_VOX)+K_ET_U:1]
MR190W-78^U_,^CT1*X@0X9\8W!Z=J.&!+6/>EM4^%L7VZL^ZJMH\4_WZ"XK?
M-2D!MXMM."#S>@"G2]#<&J0_Z!:U6]QY^ R$+0J[5((O'8&CEGV?L;5?/[$U
MWLGOH&QLZ9]_'Q#T:UM?.Q;5_(*99ASPZO,%0L/0S+)CT:R,8( U=F076MUI
M?%#:[D 8K68LX/3(62+%O4<?)G=>JFJOB<(Z*#TA"Q7VT#9=VL+/! [51%2>
MB]/$?EFG^!/JFE$5H4P"%3UZ2_2L6@G4Q$=G>I*GCT!G_R(W?A.(=N8GE@+Z
M/7$MR#:* 2'C2H"-R;:A62R23ZH$7,!FLG8[*42,?*I6H+F[HX9'#E6H#3TF
MH\3E]R!2&\=PMBL#HPUM!H[ )+V;;)-IA<5MO98AW(7-0[$KB*S@K2_@%R0Q
M+6NDC*]4*Z/H#K9FCXP84P4'MMLE,*YCC6%^NQ[%_M]G0PW1B6^Q3Y<$7O)J
MW'EWW1&CV5#)7%L0&E_(':18&I8MYMI8!FU':4[Y!N_NF^\\M^Q7,&O38M?E
MU2]#2JS,W9-<O@W,+=#4X7179JZ[US%.0],>7)1@N,DS+RAM5!+/_:.P;<DW
M<Z%+BT\5)^%.D)"36#5P+%."-B 05;UOO]IC"M*366ZB+CWR[</IN=%&;<V*
M++$;+.RQ#33ZH5@+TY1RJR)/K)=&V3N"FU6[6DZNEVRXWSOMZPE@AYBH- TQ
M1PLX)7],,9/].L"D)F=!:=S?H(M9TKF1R])E86.16#-JNIVJ B2!HR\YVC8<
M%+F4MY?@C.L)MI*GQ:*W^)/9;]I-K'J9_\G<EL_)].75%SA,S+J+#WM^AP.%
M^!N$#8 3V#<S*Q:9E!(ATS:<.G!<)(_G:3'9!<U(7DOHT0&,MMC8KN,K:B,B
M"?5$T4U?-;\# IH%[4J[9N@ 8#GPI3(R.,7^>4\$_.L"+EMKTDX)X0USFVMF
M9Y E!,"Y>:C!$K?&?^HX*4:<V!GJ4=]3PGK^_%C5?=((7TITUSL&[:$;44RX
MHDZJQ\!""Y*G9_CIRHAUG6@%@9Q<\F$PR*4G^[_J6KK-J44DN+SX^3HXRRHL
MGYL07%0UF9\_4JV[E',_#W!=/D)MM9I?0>0*ME!V .$XPPJP0.8-4:]C"!+"
M6@:W;&B>JC4&Z()H+EJ3TI4E5OL"?;F+#H<MQ9W:$E<>23-X<M#!<LIP!=$1
MA!WU22-C#2;SX*P&$#6#A@@B3CI;;9)M*'^(,;U4(].&+2%M84=>-9DC0K6C
M328+6F@\I#JP'>PC4L%<F"-]/)#/K2QU!W.YGDPP/CTN$+6JF>@[DE1^O>S'
M=NF$RO1'-VF^O'@^OL'=5T)HFSTX)IAJ#GOQD2S@]G"E<KV.(92FK67D5\T5
MQ'"-H4#L7-;%%9E]&@3=)61ZVU,WZV;-:Z7VL][+MJVB85F0.9^>P@&S \E9
M'F#*R#P% \XLG2/7^\$Q%3)"+[!/^@_ZD0NTMA*L\.U5F$Z..'Q1++<ZI-(S
MK;;2W8HN6DH$UW&@!V,3Y2U;;P@P  D2*3VT!&:T%L1S21O'R(O"#Y3#T':R
M.1=EP+:7'0=_!^4_X/P'$W<I%D_!"CY5FXSF-7,R9?82*Q5>\+;>!E*& RF%
MM;>7&+QY0*;GHQ0L=CN6T&E6+,=E%[KF=#.E7F3EVC&2PVFSY,S0,I4--JP@
MSI/6*[IPFI^&8ELLQ8ITQF2P.9QD1Y<0-L&A[4O([.HX(ZJF[.20;$T,*<8Z
M6=BE3P94%DBNL!P,)$#8.\(B4W%\\APFM.8%MXSLNQQ@2=TD""J_545.7]ZO
MJ37C5&G'-$^;-XYIWSN!"U>,TML2[*K$CQNDX)>BJT^<7+Y+;\$:%9V5@6.R
M0'"'U@3;:( 55AL]-//U03?+[,%'^!W7'[)K2OQCT<[!);EB3.8 S3Y:8I?&
M15?<8QF+;6^*"3.%]:@;Y -2-Z4>3\7N)\>(2X%+?3/SH\C-]$UPWQ&PZ09[
M^S"1HQT+LW7)^:).6AI[&YG304=1MHZ2Q:/'./TR>_%'9 ?ED!*$V9;D*)QZ
MNQ"MH51YSG"\78Z(HTE&I>&$=(*6-45?:=+.P"VEY,,^@[AS>#5%>\!"2UH.
MI-WN$.H&"K@$$]8OY;)SMT>=X3>@I)5]B&3@!P0U0&^+U\,T<#'P.?BE(C0F
M,E*\RS;()\CK.&*Y+T!>C@NG:XY\))#3)=2V'*V.-ZV47V!:7.(3\C)7]\I?
M@"-<)?82=J5A#Q:(HX]ORVJC;Y0%,T2T-=.WF_W(^4&N??/W:LL"%H*0O 2]
MS-]9S:""43YMUWR%64N^K$C:OS2X9&E%Y3HPOZ2*K71G9\/N1"^X:_L_;>Z+
M.[R[$4^,U^9N7^O*EQ2G_SQL#++IXE><1LKAJ(+QUN6/UM]?-N>W?0>YO^;[
MT(7T&_,,7=A7&@8;1$MPVG!>AT.X;"NNOBF%Y=UT3#$ ;F@2XS;#XZY]0"*I
MFHSW_1[]QS)#BH%W0S@A(Y5B-@H$0\Q\'M*0/">^4BC.8F@-O\_9.R6EK(?-
MP'"A5=/-N7DF9V!K;]Q<YC=@R[]PBSC'I._,0+0238"C_;&-_7,7K<P*CB 9
M__.$[O^NE%K8^[]8>\^H)K[PWS=(4Q BTFM40%1*1)IB2$24*D9L*"TJ(DV*
M% D0$I5>HZ*@($1$1$ (2%-:@%!40$!*- @AB8I29$8ECI"$F]__U5GWG'O7
M?7%7ULZKF;UGSW[*][-GS3R8+X^A4F$/!;8.F[<%+5N<O_WY__1$9"-J9;KA
MWF:96\^.RN6]5]K]KUE+N[++Y0*WA'[T:]W<<*+:_9N*?1';MQV[5BQQY.;N
M'SK$A$;UL279AA3F>.M@_N9OS!U+J,"O3Q>_^)4[=F;OQ+2=FW"_MN'IFCX-
M\RI1[=YF6[7.!XE[9R/TMZF[/WWP[^\)<>)42$,S16JD[K4OZL+5!QR5M[JR
MIIR=(4^PLP:ZAKR!R,Z"#4+?(UL&;[:-2Q;L@ _JGY%HB(]Y+G'G9@&VSC/$
M\(MMPXN TUWJFML/)(?;ONN.3?<,)T.PSN[,@]?>I&@+?5W:NI/;&)(^7L7'
M7CQ-R3WX1D\Q,0-F%W]5R8IIS'LP.)7=<Y%PGUTF]\@\R%'JT/4-X9ZHD^U+
M+_?:OVH^Z;._,W#TW( )X=6M7.'+8X@]J.7;ALHG5>]9GITZ+"AF!631&Z9Z
MW-_ZYJ69?-XX!7O0^='Q\^GB(-N0C5?\,O3]_:Y<U$BY<DA9O5#=_]#>K(C3
M%TQ@2F)P7G+Q:=FJD^?>5V6FY7!#UF$(,?O%NN:%_2?Z% 9+=J>>KI/Q7,KS
ME+@V>)YJ/''$3,O.,N;.UV/A.W(/ZAG(N'K\TD5$N\4:_WJ2<UQ<L=^H\V)A
ME3Q<J?APA&6?&$SAJXFZ^Y-:H;Y/Y7YFG,ZXF.K4DI6$JF7OX%!(_9)"V)KS
MX^O-&]7JCV])V7OCBLR9K/CS3F&\^SF=G%\CI7;ZW;4M256>W8?RPKLR_IG6
M,7^'_KJ3YAZM)U/W96=D<O\!,26_!UO>X]<6U1-UV ^B?&][]IBF<=4VERH\
M9E87O6LC5'[Z=X/=NF(N=F*>B;]R*N&2MLZ,U=FV9DG]5O6&]/Z'O]Y&]G\:
MYX]E/3ARPTU07?[SS%IT^O6['&6WV-!S0U=::S@PM MS'3;P+JN]A?WMW/B7
M@!NP3C7Q&]*';'8]WDQ=JC;S=>*M*6ATYNL/+=7:AN@JY7RA%=9Z.NW\R'UE
M_*6U]DS$;+63H*I\6:%PX.CMSV6/LVL>;TVH//)[Z\=^&O[U713J^L??7^Q>
M.=QP''URPTRJ[ME]>0LY5.E1U'>.\&.579#S]+N-N3IGZK-SWVQR=$0'V]OO
M/DY]!NN95]FCY&F6U]XDI@)PAA[\H^R9)@W4794E_[MPN7K/+G%44$OL-;7V
M^GWF'Z:,@F/$#WI-E3^,#*U$(*^%Z5PND) S<KOQ:X?A;M/L8&?3=%)#P[+A
M(N?WX%I"!?:EJJG@^?[;%<V_31&4UK>_-V'-#-^7*8E11/-(,2V<,MU6K'D*
MP5P:$#QC2S3QUB0*V_YQ#[)3=:Y6_+;/>:IQ=*)A3N;D:B\],^5D?M.@NM%[
MI!;"+-#33F1<^BYJ4H3.<MCWT4/JY>YCI[>&+1ZNM#6L:V^2N>-M.16H]E!L
M4WB/D=&AK74]?CEBX1-&+O^N_!P>^LUD7)KQK%OS"M#+8P1&D]!Z VWQJ-XL
MU<OBZB.B&T=J_+/4VKN2;B?NO4ERJ8D>1/[J% $O7(?I@ -KY0^6LO4DU6^*
MFX2<['*2BPUXH9>R(^7GQ_T%7T*;TF_>$]/O9C]V[2T[*5,Q%.!V2#W1O?;J
MI5\]/\V2>Y=H.S\J1J#_>D:?#:3-%52I="I1IJRO3*_#F"J:J.<U5@DMC+!/
MWR[482E6.L>J[V<<6[I36_5V_[CHFFB-5ZVN6N79\I?K%]="ZL(:DGYK?!;?
MMC/\(<E0K(G0(_;(;,W_^![ML#\\^PRGB<G5SZ6VLDH%%[K>/>"$G[27ENFZ
M]R@QVWF7^-X%C?#9F4]SEK//VYJ,T.-F(<F_8^J]Q!\HG&Z@"TY$WK!]$5AV
M*W/*KL7IR8GFO6;J(71U[L:7*H';98[5;0N\J&:F=^%6U/?'FW.K TM0]/A+
MBHO@=)@5KQ ];%2Q^=2_XK#\KTZZE7JM_*;K1\Y>B9:RJ_R8OME^?N*R8O]5
MMYK'3A*_';[URMJ_UW.Z3#:Y8_TB)S%.U\"B["C,+SOXV)ZGN//\T2%13#_6
MM,>W^4)]2^WMJGYQ[7KGIW1QORMW+24DK?N*Q4U;&S]FBM<G/-FWP>NN\6>%
M^Y<+$=OEWBSN?U^D)%8HJ/9[M;UX2U]L"/B--'!.W#RSZ-6[I$N==VYL0ITB
M-44M%5]L:U3XAPED\9)T%]<R8FD_\S7M-\W52)E5'(7Y:Y]\8V; K";TW-WE
M+=>]X>5[\4.I63_ORW^%Z1S8CRLHL(A7V:/R3<K(8)M>R6]>R)-PR\1<];#"
M$JUKN1ECHJ7"-+ZXE6>VV2C<^?@G[-L(]G;4$2<3[/2)P:<$MNU)/^%HHQ[R
M@=5#YOA.34S 41/0/Y1U3_SWSU_#1R/"Y>9WB9NM^?0'D/:'['T;OLG)X>>3
M:UK9@X>R:\Y<M_PD[R*Q9U.Y]LF1K<_.O(G' ^*/VB>)[Q\GZ?Z]Z63DZ-@I
MX&Y[JV%^0@H_OJ16656?%YQ\XLZ[?Y;E?S_M0)ET.ABYQV[7G?EW)FN>=Q,U
MZ'5U2W^XYV+^PRV#79<2GGRN,\&NEDE=EE#WM;UK(8I(Z["E@SBS=T8<;$.F
M:\>Q=1@(G-Y+CKG_53 FK"?=*49]GMNLT5AR GKU<=35.C<0+WLT=,HOY-GG
MO;M(7PO%C![L5/LB*?M#Y)S]IQM/VOY.D7MUH.DU3+-T+:LVK493HG7#62V%
M VGWY0;XCM&Y;%J/U$F9=5BW,J=VX_#^$6K7O!C[)68S(_)_W_3P8&>8#THM
MO3A^0 NVSPDV*W87CY*9:T-RD3+X 6S^*2 UO>T I]URYM=\=X(#7>/G0XXV
M6G;*H7?H$8-I,_2U+29<RLZF=.^KQ,$TYPRO4VV![&QDGU 5#+NU4A<1A5/#
MD[R!IEJCFLLOVZW=TZ*JBG3=UK2_Z+D$QO .ONT8BD0,2TSIN[T^2OBZ9D!\
MXR,IN$NPX4RK=A7K@@[IY>"S1K_*^55*ND>WU;F&0L\J;9.^#_TN30UU-T,X
M;:_C"X=W4Y%E=U3.G_W ?/>>\8E^,4+CH4Y(1N^W?RF::>$?VUZJ6[HY&"83
M:/NZ&'CRTC%[,TO\<ZRX^X82NWDH@+TG(7 R@C?J=F_[ KOVD]&OJV.*&8/@
M/;-W:H\D4>5[RO/W?-0BJM17"4K3>Z^0SF4!T>'.2GD(.2WS2?W)B.B3B4GQ
M";Z\$DB.O>3?;RW5#AK:CEH@4UIB,BTP(F@+IK_XP;R>+7V#O[L46NA76:CQ
M#G1Z/+]*321H<N14>]%[1OB8BOG5R9MLP<G^<^,OMHW]W,HI*A..D20MVHD#
MW=;(S+!&LKHW:\$C9/A6 U5").\(@>PIFKSK+-0XRJ5L], [X[;R#S:.Z4*)
MLRX_5A Z@3Y:8SFY7*3LPNXHIGUK.6OHET$/"3(PXQ\%F_O784I>_,!"AUJ(
M%0+.[S)?PT@&,UKRD\>XC,45-NY&P4RN<5\9Z#/7U9*:^H<'Y&6#4C$ @\X2
M@^:\0?E4=O6>W_U-0LVQE2*SG@3+_#69A1E9Z U%1:C%#RETO3MP%JJK"(SS
MSVE 9*#-&?YD3A\5,.N-:2H^ "66$$<H\#9/\ I&'E\ZNS1!2=T!%49SLJT'
MV"G-;%)2JFN8+,%RQ.-O'RKQ^Q29V<H+:<SLC1P"J>R/F9W,OSUA,E 7%Y2K
M[@3F,H@*7E#H  >7TDBJ_T?S9? 1\5SDIG-!<>8/QEDG0)/4\H],[YGYZV=_
M,X&Y)3/@5"]1OPT(S>7N?@SZ%$57!_Y=A:?QMW.'I8)4XJ@I?(NGT%B/M?&@
M#Q)H2KO :,!(08ETH=%$@VI?XT7V-,EN8J[6&W-NS"1T'8::$F[2+J%S,*G"
MG76"QX1SJ^5TDOBY(*'6>#1%(E"UH)JV%/MXX/%T *)Q,%]C)XU=9'5F<JX#
M^)F/S.G0A*KL04LR*/6NN]]YDG!4[IZB\?"'@N9%JV=0)B>4!B*\H2)J*JC:
MLYS&4OSYARKC">5W1G8])]@)'A'AQ.&Q'V>+=P#4'DVY.!LS9Q'2'2=XU#K%
MFFL\@6Z(:(852M9I)(K-CQ(_D5[R'[\CFD.6S!ZFQ_14L$=62_%]=ON998(^
MFX1@?A?J@,?+GGE 83T=1I3.#G.@.?,)</QFY3P:F7N88;ZV,BK7UG>$52=X
MCA:;MYPQ*9[BD%-T\]G".\'5T)KKN-ZX>5%D9Y-5@;"$'> +EJ<V>J.'<<"S
M\G78)OG[I*<N)0NK5RA43Y_NBIBR*;KYJ>9NZS#^UG*'#\9M8K%^8+]G?B])
MGN\'</LU=I960OL2?+M-@VF;.K2(0QTZ@#WU(C"_#NO_ )'H,[N:P+E%VFQ[
MC ?8G*K_@>]9PS<$4WOAMR+G1\Y!KU%^SV**MXN0/BX(O0L<[D>D>33W?8>G
M88*JK;IF- 1/=5]"OM="G@7[P*%8$CL>(_4#L='X,E08B>E><A[K7)4O81?Y
M>X,VK-X*BVI/+[2!I>7N9^>_'Q%?D(/S2@44O@-'V["[ -,;MG$&GXD3\1?*
MJDQVZL%.T*]WZ%M[66_L;$7-XM(2(>1Q$:Z[8^<HJQ>M1'$'>CR:$BL"(X)E
M*SP;B\X5\NY#2.7A6TN^8/3[)RP%"]?XP\#1]\FSZS!M*-,%-'G-=EF';0V<
M,1PUG_:W!3I*GZ*I[/,$;4X533$PUX<>SQ8HTIFT= N\49N-G^5SFEX !<"Z
M7NI:A_E7BY\2E+:%Q (T7G!J%Q-YBR!=PH2XW;G!,ZI0)/L;$';#L]?Z&P6\
M]6W "5Q.)>A*YN5B<HB*>'^V'RW=))2/_:_P!W.\I>,./"4AL8M6MY*?&(7X
M-':H"4I\CK-=L^$?A9:X"RZ%[5N#,VG*U+XA.-<RA7EF:::$XVV_^CYLLT'O
MW&OKH:_?6F,YN]O0U?':]UK:&"J'=')CUDX3Q)M;@2N%TCT'M2//0>EL[$;\
M0F<+/"DJ3 EB]?B8 #'D*(KZ@A .6J6V'9B=EO9AK-BH^HP(M?'+YU_2FL8T
ME#^T&50'J5[YP&0,7FT/X_4)'A",GT)<'Q#71Y:"#MI"8:50:P]Z'X/@9U(V
M*X"[C'0@\.^GV/T]<E?&SH&6166!'=L^\,7!#;_HG4++=F!ILD(ZB8]['MBA
MSF!A)RT,95TH.5$D:"<,R$_O$(>:NU@(E$-@%7\K9 -@V8[KL*2[4YS)>M4T
M%EOZ!B8 *S9$_13DHR,HX2MS6.(?H;L(\JF@+7C#;N&NU&XA0D?#.L(S:++@
M#^U3D3*#KX@].L[W9>.V!"/4^'85^"B"'=3(7<Z8V=0!,'C"5"[$OP8N]](:
M8FX1#-BR6&VHJJ\ V;4LBW?GX-(:C'TY]F1V@KC;6 ?:AV .^59 /]]/G06N
MD.-#Q5:61$K#"9!V 9]#T2\(QP%A-G<3*M ?X$RY3&Z?-!]P=>%(KLPE_?E.
M4'ZR\)=Y64>+03A>0":C%'VCGWQG-O)*+E[CL. .I+!@DVI?I;\62"9V]NQ]
M-DT>ZICC^*?X W\S?R*7VA )9:[Q5!?.ORB6UG?,YAIRDOFTS,"I"0)6G' (
MQ"43$'XQ)1]GF/,%RQEMIK[/7*_/Z(ZZKL/Z9L1%#NH'V=$1];0^2J(.$KKS
MG. &]O<B)/FN4"R;FDU$ M-?W]. .;J.!10L\HKD&>WV,91I--?5Q9[2KR&?
M#2QT6K.R4-'L!:ID,&XKP9-=Y1T$0/'OQJJCAFVAB36U7O!@[SI,RLA<#N<*
MD.C(5(H<2A?XM0[#CHZ=&FTDRW_BFPB>D*X@R$39>B@FA-VZ)"M4:#?LM29U
M>KMW^NQN&^7;EBZ@M:QT8(R&C<N,[HBIO=*C'3J")T(XOK27-R,VAL+Q2&HS
MP8K0)<8A$)Z*NCB[,$!18^)W(-)C.L2;P]3PD;;-%(YV*KTBE;P"3[US;,9J
MC+\Y%]_RFP[@B<R%$XE8-KF?G$A3_R/0/0N= 0V[*%O,VTE'QOE.)4%H14:(
M1:%V\.$1OGLE7M%[PKRJ-?++O&6!:K:Y-[9[]7->"(9GWQBFG??,6+]]3#CQ
M"]D#_^C>6VQ2R'$EIY("O.TZB0B0W+.$XV*20U^@9"NA5([[+;2>EW! !?%R
M'98:?;Y##Y_+N?\;7]/??9;GRPDMSI]1'VNSK<!/]A]N9*!<G^.#!LZ/\AVJ
M $.>2>$L?$DLF$.3@FH,( 2;)49P&.,KS@87&A[4]J>C]: JZ<6%4GRF;9VU
M?@[E,>WF58[@T5+;E72=PF?S)_$LC@K-AL5+Z0J_@7BLY+8.8_SHG*O5OK%X
M4/[_MM'TNEU7Z S/$(E4 "Y\BE ,?EH3)O*ZNXD<\MI6@LB *J1[F+#E_]/>
M5K!V94^T#/9PW.8_6I3'7WC_O?D>@)F*=X6DP=99:O=N_B9DICD5X5H>A%!I
MBPGD>+JJT&?AMPB^H'CW.DP:K2+2  7>/RD1A*/ET#J,*YUYM6V[7'M-12DZ
MNSR@V!BT&62<U9  G/[Z"OK[O:MS'!?C;SBNWG!<-,/=S6?587L0S#V_>9,@
MMD\4S_E'H$.T!LOVYX0=P#KL)F$718+O6>:P9LW?-AK&/P"$>7:T,@ABH*[/
M:#1K"[[9 TH&*P_B-N+[Z1X=Z1ARU()AE:MB;XO-X.T$!QDW]FM?TP<=AKV'
M4]P2NW:U..-I+\[T7ME?>4X&7WFZ=C?'\-3;< KS]9*C@8;R-76BYZV^=VI:
MQ#W7H!FSWFL61CK2F[K/Q9X9 E^UU&<'.FQ:<5:[6B]KU-VX^8Q75&GJL_JX
M9>3;P+>DAM&RG$'3CQ:HLSC[^]CG';N$HR25/Q@FTDY01-S"WP[%<H?"3D+:
MU?RP<8(MJ,I%9A!5 UN(A:7XWPZ ^LC51;X!8,9%EU0&J:JV3#0N,_W(QU(,
M+[\ZFA/X^/2KV0;:5%<T)@DM#R8A9"RT'3@L,O$ Q.(% *E=-'E\%7;R*L$%
M3&4ST@B^C_'=WIJ<Y/=%I=\_\'5'J@GB')K:/$8)B<+X18>Q;79P=&?SP'MY
MQ0HM_U1P21AM0@QHR(N'&M?<B#U,1G^[RR%!]@HND:2(LGH23'K)R- =)1[P
M()P!5KYT()OK(0HXU4G4;AGE^['787(S$.58!_"MM()U[AP^;^H0XVI4R"7C
M4\XOYXD(XKMU6 ,BZ7\^*7.339,,C!,IW W"29R2T(HO)TI#[MQLE6^83<3W
M&(4V12K!LEU P;"M1VKX[K.LS="8ZQC*FX/5A/;(Z7J 6#IE8[!9($G.&'4&
MD<A&ZWWH>'OYD;I]SIG47M]]&:_:+#4-<PR54]\'8)&#O_&G07'9!^PZM3;Y
MX.S>L2ZNZ3GYS<5[&@GU!MU?'A+1^S];6BFBO!TO$F4%E[B$,X1^U:3NN:A:
MM8??[H=#09]L\-Q];74?9K6NB"NX2&>^ \[%?E/S4O'M4P+V!USY5Z-K/13Q
M@VUZWD_CG/PQTJ<.A*",J!^ 4!-J$=0%CX5PR)W=5 X6#/=*LQVRB>K\4Y/$
MO004B$CCJSZQ2B<<G94CG04-NLFWA/I 3$XAW5)$;'RK\L\0YBSP-_V/#1QG
MV;&[<;+AV<A/="[XMP<C0S %'#(Z=D LK[&V@[/+D@$:^>E\UYH@N,&GJ&JX
M0U/PD/VO(S=<(L/?AB9Y,IE=%M/3@[<]F'2+'J#7@,Y,34:;"3^PM(DPJ+F7
MM)'O+G*IW8*BQF45PO$C4#*'E$34@PI!."<_C:B-%Z%%\M4H.6E1,NF!9^G(
M G]OHM2?0 N]UL+7'+@BOGVE**PW/,!:CG*K\%#&7Z]7B_R$-7UHK8]'5*AC
MK,."AC/1IB^!_![,9H*S1AA9B"!(CT?9^)X'+FMDS2B+)D9*P6U&;S5I+/M.
M-&@?:XN_Z%LS],)C"C_6C89/7DJ1'/707(>1>V9?6KGOS#,S[?P:[8/#*O3L
M1U&GOD55G#[7UGUZ<D.'1E/8S;*,/C_\54F/<;\";O@#H^.8(M?N^X3M/+P1
M/6T&89,BN^F!OT(*N@F1"GYZ6OLPVJD\L=,^3#N5FO@&7 G?;S2LD)6]9V /
MW??:@ZM(7<%79[6R.:*,@,:W Q79^=WM)#I%C&I.RZ1H$C$$#TAQ%IDHM 1;
M(?SW"+[6.'''9VB@EZ3<=L9O=BEBN2M0Y!12?,N):.Q6?-@A@)03;6S5Y[Z*
MNQDU51VG28:<^ZN@@[SVUG$A@G]FDN\))/99LA2%LH2SXT(9/(,-[_ZX@LV,
MJZ%RQT<)& Y9AB(6O!<?WQWR',+THY7 U*2VHV5X1K\'@EZD2&\)K8J)Y'Y"
M&00_F8\Y07 #?O."!>5"54^1QU$KH=!ECD,6<8N026G\V_-:J!K 0&PF[.;@
M5 BZ@L<KR&RT#GH/0*Q[CO\YQAZ?,9I<)KBSD9F6PJT@.8NO$S4M'Q+6]==J
MU9(:XG?1BKD.>\FX0=3[KD%>@H,XCGLRJ[-CM^ )\: WP?4EE'"M(H Y635+
ME<+'L//IY$3BQ@\H[TK(\QRHFF2"PE7@X]E/T;L9;* YK5$@[MS"*!FM7ID^
M&[+GVRHI/JW62S,IQ0]5\15Z9]ISLEAFO]%?Q5.*6OZK[VM7?A6<!A7S_-P-
M2[OOIABNV:GFN=TG'#'D5GP[U?OVZVF"O/8@-*6.$\/NRPM,HJ+,V1FKWVR3
M<Q3G?[.;/5+\#WP([SHYN =TKDA)\4X=K++>'W=OKT5M'?V4\$/%(J[>O>^
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M3>J&_RPWA): *OSU"6NHOA*ZZ0WAI'!=TF=4-E*GXU*J>-S>.8Q/65/,JY7
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M04])S$AY>;0C7(344B C.6L4Z^4'(6_)J_G=9">@YV6P#I0D6<X['A?W&/^
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MBB 0]>F05"?B%!0GPZM%5W0!Y #H>1+0WY6QK**BF\&S3Y=,[A5?KVYGKQB
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M.3,P7V-A;"YX;6Q02P$"% ,4    "  0>&]3_V8L$[H;  "SC@$ %0
M        @ $Z'P  86)E;RTR,#(Q,#DS,%]D968N>&UL4$L! A0#%     @
M$'AO4^S&NCB*10  *,L# !4              ( !)SL  &%B96\M,C R,3 Y
M,S!?;&%B+GAM;%!+ 0(4 Q0    ( !!X;U,2)JHBT#$  "H2 P 5
M      "  >2   !A8F5O+3(P,C$P.3,P7W!R92YX;6Q02P$"% ,4    "  0
M>&]3X5<=&!A'  !SV0$ "@              @ 'GL@  97@Q,"TQ+FAT;5!+
M 0(4 Q0    ( !!X;U.74I 0? @  +]#   *              "  2?Z  !E
M>#,Q+3$N:'1M4$L! A0#%     @ $'AO4S+N1Z5I"   9T,   H
M     ( !RP(! &5X,S$M,BYH=&U02P$"% ,4    "  0>&]3I?.6 2@%   %
M.   "               @ %<"P$ 97@S,BYH=&U02P$"% ,4    "  0>&]3
M?$Y&UBL( 0"5$ L #               @ &J$ $ 9F]R;3$P+7$N:'1M4$L!
M A0#%     @ $'AO4UF'D^(4: $ M(D!  \              ( !_Q@" &9O
C<FTQ,'%?,# Q+FIP9U!+!08     "P + * "  ! @0,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
